0000899749-19-000048.txt : 20190501 0000899749-19-000048.hdr.sgml : 20190501 20190501165707 ACCESSION NUMBER: 0000899749-19-000048 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 65 CONFORMED PERIOD OF REPORT: 20190331 FILED AS OF DATE: 20190501 DATE AS OF CHANGE: 20190501 FILER: COMPANY DATA: COMPANY CONFORMED NAME: HEALTHCARE REALTY TRUST INC CENTRAL INDEX KEY: 0000899749 STANDARD INDUSTRIAL CLASSIFICATION: REAL ESTATE INVESTMENT TRUSTS [6798] IRS NUMBER: 621507028 STATE OF INCORPORATION: MD FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-11852 FILM NUMBER: 19788370 BUSINESS ADDRESS: STREET 1: 3310 WEST END AVE STREET 2: FOURTH FL SUITE 700 CITY: NASHVILLE STATE: TN ZIP: 37203 BUSINESS PHONE: 6152698175 MAIL ADDRESS: STREET 1: 3310 WEST END AVENUE, SUITE 700 CITY: NASHVILLE STATE: TN ZIP: 37203 10-Q 1 hr-2019331xsinglesourc.htm 10-Q Document
false--12-31Q120192019-03-310000899749falseLarge Accelerated Filerfalse5005000001000000.300.010.013000000003000000001252790001292140001252790001292140000.01100.010.0150000000500000000000 0000899749 2019-01-01 2019-03-31 0000899749 2019-04-26 0000899749 2019-03-31 0000899749 2018-12-31 0000899749 2018-01-01 2018-03-31 0000899749 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-03-31 0000899749 2018-03-31 0000899749 us-gaap:CommonStockMember 2018-01-01 2018-03-31 0000899749 2017-12-31 0000899749 hr:CumulativeDividendsMember 2017-12-31 0000899749 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0000899749 us-gaap:CommonStockMember 2017-12-31 0000899749 us-gaap:AdditionalPaidInCapitalMember 2018-03-31 0000899749 hr:CumulativeNetIncomeMember 2018-03-31 0000899749 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0000899749 hr:CumulativeNetIncomeMember 2018-01-01 2018-03-31 0000899749 hr:CumulativeNetIncomeMember 2017-12-31 0000899749 hr:CumulativeDividendsMember 2018-03-31 0000899749 hr:CumulativeDividendsMember 2018-01-01 2018-03-31 0000899749 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-03-31 0000899749 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-03-31 0000899749 us-gaap:CommonStockMember 2018-03-31 0000899749 us-gaap:CommonStockMember 2019-01-01 2019-03-31 0000899749 us-gaap:CommonStockMember 2019-03-31 0000899749 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0000899749 hr:CumulativeDividendsMember 2019-03-31 0000899749 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-03-31 0000899749 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0000899749 hr:CumulativeNetIncomeMember 2019-01-01 2019-03-31 0000899749 hr:CumulativeDividendsMember 2019-01-01 2019-03-31 0000899749 us-gaap:CommonStockMember 2018-12-31 0000899749 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0000899749 hr:CumulativeNetIncomeMember 2018-12-31 0000899749 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0000899749 hr:CumulativeDividendsMember 2018-12-31 0000899749 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-03-31 0000899749 hr:CumulativeNetIncomeMember 2019-03-31 0000899749 us-gaap:AccountsPayableAndAccruedLiabilitiesMember 2019-01-01 2019-01-01 0000899749 srt:MaximumMember us-gaap:AccountingStandardsUpdate201602Member 2019-03-31 0000899749 srt:WeightedAverageMember us-gaap:AccountingStandardsUpdate201602Member 2019-03-31 0000899749 us-gaap:OtherLiabilitiesMember 2019-01-01 2019-01-01 0000899749 us-gaap:OtherAssetsMember 2019-01-01 2019-01-01 0000899749 srt:MinimumMember us-gaap:AccountingStandardsUpdate201602Member 2018-12-31 0000899749 srt:MinimumMember us-gaap:AccountingStandardsUpdate201602Member 2019-03-31 0000899749 srt:MaximumMember us-gaap:AccountingStandardsUpdate201602Member 2018-12-31 0000899749 hr:RentalLeaseGuarantyMember 2019-01-01 2019-03-31 0000899749 hr:MiscellaneousMember 2019-01-01 2019-03-31 0000899749 hr:RentalLeaseGuarantyMember 2018-01-01 2018-03-31 0000899749 hr:ManagementFeeIncomeMember 2019-01-01 2019-03-31 0000899749 hr:ManagementFeeIncomeMember 2018-01-01 2018-03-31 0000899749 hr:ParkingIncomeMember 2018-01-01 2018-03-31 0000899749 hr:ParkingIncomeMember 2019-01-01 2019-03-31 0000899749 hr:MiscellaneousMember 2018-01-01 2018-03-31 0000899749 hr:RealEstateAcquisitionsMember 2019-03-31 0000899749 hr:RealEstateAcquisitionsMember hr:MedicalOfficeBuildingMember stpr:DC 2019-03-28 0000899749 hr:RealEstateAcquisitionsMember hr:MedicalOfficeBuildingMember stpr:IN 2019-03-28 0000899749 hr:RealEstateAcquisitionsMember hr:MedicalOfficeBuildingMember stpr:DC 2019-03-28 2019-03-28 0000899749 hr:RealEstateAcquisitionsMember hr:MedicalOfficeBuildingMember stpr:IN 2019-03-28 2019-03-28 0000899749 hr:RealEstateAcquisitionsMember hr:MedicalOfficeBuildingMember stpr:DC 2018-05-03 2018-05-03 0000899749 hr:RealEstateAcquisitionsMember 2019-01-01 2019-03-31 0000899749 hr:RealEstateAcquisitionsMember hr:MedicalOfficeBuildingMember stpr:IN 2018-05-21 2018-05-21 0000899749 us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember hr:InpatientRehabMember 2019-03-31 0000899749 us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember hr:InpatientRehabMember 2018-12-31 0000899749 hr:RealEstateDispositionsMember hr:MedicalOfficeBuildingMember stpr:AZ us-gaap:SubsequentEventMember 2019-04-09 0000899749 hr:RealEstateAcquisitionsMember hr:MedicalOfficeBuildingMember stpr:DC 2019-03-31 0000899749 hr:RealEstateAcquisitionsMember hr:MedicalOfficeBuildingMember stpr:GA us-gaap:SubsequentEventMember 2019-04-02 2019-04-02 0000899749 hr:RealEstateDispositionsMember hr:MedicalOfficeBuildingMember stpr:AZ 2019-03-31 0000899749 hr:RealEstateAcquisitionsMember hr:MedicalOfficeBuildingMember stpr:GA us-gaap:SubsequentEventMember 2019-04-02 0000899749 srt:MaximumMember 2018-12-31 0000899749 2018-01-01 2018-12-31 0000899749 srt:MinimumMember 2018-01-01 2018-12-31 0000899749 srt:MaximumMember 2018-01-01 2018-12-31 0000899749 srt:WeightedAverageMember 2018-12-31 0000899749 srt:MinimumMember 2018-12-31 0000899749 srt:WeightedAverageMember us-gaap:AccountingStandardsUpdate201602Member 2019-01-01 2019-03-31 0000899749 2016-01-01 2016-12-31 0000899749 2017-01-01 2017-12-31 0000899749 hr:SeniorNotesdue2023Member us-gaap:SeniorNotesMember 2019-03-31 0000899749 hr:TermLoandue2022Member us-gaap:MediumTermNotesMember 2019-03-31 0000899749 hr:MortgageNotesPayableNetMember us-gaap:MortgagesMember 2018-12-31 0000899749 hr:SeniorNotesdue2025Member us-gaap:SeniorNotesMember 2019-03-31 0000899749 hr:SeniorNotesdue2028Member us-gaap:SeniorNotesMember 2019-03-31 0000899749 hr:TermLoandue2022Member us-gaap:MediumTermNotesMember 2018-12-31 0000899749 hr:MortgageNotesPayableNetMember us-gaap:MortgagesMember 2019-03-31 0000899749 hr:SeniorNotesdue2025Member us-gaap:SeniorNotesMember 2018-12-31 0000899749 hr:UnsecuredCreditFacilityDue2020Member us-gaap:LineOfCreditMember 2018-12-31 0000899749 hr:UnsecuredCreditFacilityDue2020Member us-gaap:LineOfCreditMember 2019-03-31 0000899749 hr:SeniorNotesdue2023Member us-gaap:SeniorNotesMember 2018-12-31 0000899749 hr:SeniorNotesdue2028Member us-gaap:SeniorNotesMember 2018-12-31 0000899749 hr:MortgageNotesPayableNetMember us-gaap:MortgagesMember us-gaap:SubsequentEventMember 2019-04-10 0000899749 hr:TermLoandue2022Member us-gaap:InterestRateSwapMember us-gaap:MediumTermNotesMember 2019-03-31 0000899749 hr:MortgageNotesPayableNetMember us-gaap:MortgagesMember us-gaap:SubsequentEventMember 2019-04-10 2019-04-10 0000899749 hr:SeniorNotesdue2025Member us-gaap:InterestRateSwapMember us-gaap:SeniorNotesMember 2019-01-01 2019-03-31 0000899749 hr:TermLoandue2022Member us-gaap:MediumTermNotesMember 2019-01-01 2019-03-31 0000899749 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-03-31 0000899749 us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-03-31 0000899749 us-gaap:OtherLiabilitiesMember us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-03-31 0000899749 us-gaap:InterestRateContractMember us-gaap:InterestExpenseMember 2018-01-01 2018-03-31 0000899749 us-gaap:InterestRateContractMember us-gaap:InterestExpenseMember 2019-01-01 2019-03-31 0000899749 us-gaap:InterestExpenseMember 2019-01-01 2019-03-31 0000899749 us-gaap:InterestRateContractMember 2019-01-01 2019-03-31 0000899749 us-gaap:InterestExpenseMember 2018-01-01 2018-03-31 0000899749 us-gaap:InterestRateSwapMember 2019-01-01 2019-03-31 0000899749 us-gaap:InterestRateSwapMember us-gaap:InterestExpenseMember 2019-01-01 2019-03-31 0000899749 us-gaap:InterestRateSwapMember us-gaap:InterestExpenseMember 2018-01-01 2018-03-31 0000899749 hr:ActiveInterestRateSwapsMember 2019-03-31 0000899749 hr:SettledInterestRateSwapMember 2019-03-31 0000899749 us-gaap:InterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:SubsequentEventMember 2019-04-12 0000899749 hr:MedicalOfficeBuildingMember stpr:CO 2019-03-31 0000899749 hr:MedicalOfficeBuildingExpansionMember stpr:NC 2019-03-31 0000899749 hr:MedicalOfficeBuildingMember stpr:NC 2019-03-31 0000899749 us-gaap:EmployeeStockMember 2018-01-01 2018-03-31 0000899749 us-gaap:EmployeeStockMember 2018-03-31 0000899749 us-gaap:EmployeeStockMember 2019-01-01 2019-03-31 0000899749 us-gaap:EmployeeStockMember 2018-12-31 0000899749 us-gaap:EmployeeStockMember 2017-12-31 0000899749 us-gaap:EmployeeStockMember 2019-03-31 0000899749 hr:StockIncentivePlanMember 2018-01-01 2018-03-31 0000899749 hr:StockIncentivePlanMember 2019-01-01 2019-03-31 0000899749 hr:StockIncentivePlanMember 2018-03-31 0000899749 hr:StockIncentivePlanMember 2019-03-31 0000899749 hr:StockIncentivePlanMember 2018-12-31 0000899749 hr:StockIncentivePlanMember 2017-12-31 0000899749 hr:AtTheMarketEquityOfferingProgramMember srt:MaximumMember 2019-01-01 2019-03-31 0000899749 us-gaap:SubsequentEventMember 2019-04-30 2019-04-30 0000899749 hr:EquityOfferingMember 2019-03-19 0000899749 hr:AtTheMarketEquityOfferingProgramMember us-gaap:SubsequentEventMember 2019-04-26 0000899749 us-gaap:RestrictedStockMember hr:StockIncentivePlanMember 2019-01-01 2019-03-31 0000899749 us-gaap:RestrictedStockMember hr:StockIncentivePlanMember 2018-01-01 2018-03-31 0000899749 hr:EquityOfferingMember 2019-03-19 2019-03-19 0000899749 hr:AtTheMarketEquityOfferingProgramMember 2019-01-01 2019-03-31 0000899749 hr:AtTheMarketEquityOfferingProgramMember srt:MinimumMember 2019-01-01 2019-03-31 0000899749 hr:AtTheMarketEquityOfferingProgramMember srt:WeightedAverageMember 2019-01-01 2019-03-31 0000899749 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2018-12-31 0000899749 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2018-12-31 0000899749 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2019-03-31 0000899749 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2019-03-31 xbrli:pure iso4217:USD xbrli:shares hr:derivative xbrli:shares hr:swap_agreement hr:Building iso4217:USD utreg:sqft hr:state hr:property hr:Lease

 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
____________________________________________________________
FORM 10-Q
____________________________________________________________
(Mark One)
x
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended: March 31, 2019
OR
o
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from                     to                     
Commission File Number: 001-11852
____________________________________________________________
HEALTHCARE REALTY TRUST INCORPORATED
(Exact name of Registrant as specified in its charter) 
____________________________________________________________
Maryland
 
62 – 1507028
(State or other jurisdiction of
incorporation or organization)
 
(I.R.S. Employer
Identification No.)
 
3310 West End Avenue
 
 
Suite 700
 
 
Nashville, Tennessee 37203
 
 
(Address of principal executive offices)
 
 
 
 
 
(615) 269-8175
 
 
(Registrant’s telephone number, including area code)
 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  x    No  o
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes  x    No  o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated 
filer x
Accelerated 
filer o
Non-accelerated
 filer o
Smaller reporting 
company o
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  o    No  x
 
As of April 26, 2019, the Registrant had 129,214,135 shares of Common Stock outstanding.
 



HEALTHCARE REALTY TRUST INCORPORATED
FORM 10-Q
March 31, 2019

TABLE OF CONTENTS
 



PART I. FINANCIAL INFORMATION

Item 1. Financial Statements
Healthcare Realty Trust Incorporated
Condensed Consolidated Balance Sheets
(Amounts in thousands, except per share data)
 
(Unaudited)
 
 
 
March 31,
2019
 
December 31,
2018
ASSETS
 
 
 
Real estate properties:
 
 
 
Land
$
230,206

 
$
230,206

Buildings, improvements and lease intangibles
3,757,260

 
3,675,415

Personal property
10,739

 
10,696

Construction in progress
40,326

 
33,107

Land held for development
24,647

 
24,647

 
4,063,178

 
3,974,071

Less accumulated depreciation and amortization
(1,035,800
)
 
(1,015,174
)
Total real estate properties, net
3,027,378

 
2,958,897

Cash and cash equivalents
11,313

 
8,381

Assets held for sale, net
10,568

 
9,272

Operating lease right-of-use assets
128,141

 

Financing lease right-of-use assets
9,259

 

Other assets, net
175,864

 
214,697

Total assets
$
3,362,523

 
$
3,191,247

LIABILITIES AND STOCKHOLDERS' EQUITY
 
 
 
Liabilities:
 
 
 
Notes and bonds payable
$
1,343,110

 
$
1,345,984

Accounts payable and accrued liabilities
61,519

 
80,411

Liabilities of properties held for sale
633

 
587

Operating lease liabilities
91,044

 

Financing lease liabilities
14,294

 

Other liabilities
46,144

 
47,623

Total liabilities
1,556,744

 
1,474,605

Commitments and contingencies


 


Stockholders' equity:
 
 
 
Preferred stock, $.01 par value per share; 50,000 shares authorized; none issued and outstanding

 

Common stock, $.01 par value per share; 300,000 shares authorized; 129,214 and 125,279 shares issued and outstanding at March 31, 2019 and December 31, 2018, respectively
1,292

 
1,253

Additional paid-in capital
3,302,814

 
3,180,284

Accumulated other comprehensive loss
(1,611
)
 
(902
)
Cumulative net income attributable to common stockholders
1,093,010

 
1,088,119

Cumulative dividends
(2,589,726
)
 
(2,552,112
)
Total stockholders' equity
1,805,779

 
1,716,642

Total liabilities and stockholders' equity
$
3,362,523

 
$
3,191,247


The accompanying notes, together with the Notes to the Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, are an integral part of these financial statements.

1


Healthcare Realty Trust Incorporated
Condensed Consolidated Statements of Income
For the Three Months Ended March 31, 2019 and 2018
(Amounts in thousands, except per share data)
(Unaudited)
 
 
Three Months Ended March 31,
 
 
2019
 
2018
REVENUES
 
 
 
 
Rental income
 
$
110,696

 
$
110,229

Other operating
 
1,961

 
1,895

 
 
112,657

 
112,124

EXPENSES
 
 
 
 
Property operating
 
42,725

 
41,818

General and administrative
 
8,510

 
9,101

Acquisition and pursuit costs
 
305

 
277

Depreciation and amortization
 
42,662

 
39,573

 
 
94,202

 
90,769

OTHER INCOME (EXPENSE)
 
 
 
 
Gain on sales of real estate assets
 
15

 

Interest expense
 
(13,588
)
 
(12,668
)
Interest and other income, net
 
9

 
493

 
 
(13,564
)
 
(12,175
)
NET INCOME
 
$
4,891

 
$
9,180

Basic earnings per common share
 
$
0.04

 
$
0.07

Diluted earnings per common share
 
$
0.04

 
$
0.07

Weighted average common shares outstanding - basic
 
124,130

 
123,257

Weighted average common shares outstanding - diluted
 
124,232

 
123,348

Dividends declared, per common share, during the period
 
$
0.30

 
$
0.30

The accompanying notes, together with the Notes to the Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, are an integral part of these financial statements.

2


Healthcare Realty Trust Incorporated
Condensed Consolidated Statements of Comprehensive Income
For the Three Months Ended March 31, 2019 and 2018
(Dollars in thousands)
(Unaudited)
 
 
Three Months Ended March 31,
 
 
2019
 
2018
NET INCOME
 
$
4,891

 
$
9,180

Other comprehensive income:
 
 
 
 
Interest rate swaps:
 
 
 
 
Reclassification adjustments for losses included in net income (interest expense)
 
15

 
147

(Losses) gains arising during the period on interest rate swaps
 
(724
)
 
513

Total other comprehensive income (loss)
 
(709
)
 
660

COMPREHENSIVE INCOME
 
$
4,182

 
$
9,840


The accompanying notes, together with the Notes to the Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, are an integral part of these financial statements.

3


Healthcare Realty Trust Incorporated
Condensed Consolidated Statement of Equity
For the Three Months Ended March 31, 2019 and 2018
(Dollars in thousands, except per share data)
(Unaudited)

 
Common
Stock
 
Additional
Paid-In
Capital
 
Accumulated
Other
Comprehensive
Income (Loss)
 
Cumulative
Net
Income
 
Cumulative
Dividends
 
Total
Stockholders’
Equity
Balance at December 31, 2018
$
1,253


$
3,180,284


$
(902
)

$
1,088,119


$
(2,552,112
)

$
1,716,642

Issuance of common stock, net of issuance costs
38

 
120,462

 

 

 

 
120,500

Common stock redemptions

 
(570
)
 

 

 

 
(570
)
Share-based compensation
1

 
2,638

 

 

 

 
2,639

Net income

 

 

 
4,891

 

 
4,891

Reclassification adjustments for losses included in net income (interest expense)


 

 
15

 

 

 
15

Losses arising during the period on interest rate swaps


 

 
(724
)
 

 

 
(724
)
Dividends to common stockholders ($0.30 per share)

 

 

 

 
(37,614
)
 
(37,614
)
Balance at March 31, 2019
$
1,292

 
$
3,302,814

 
$
(1,611
)
 
$
1,093,010

 
$
(2,589,726
)
 
$
1,805,779


 
Common
Stock
 
Additional
Paid-In
Capital
 
Accumulated
Other
Comprehensive
Loss
 
Cumulative
Net
Income
 
Cumulative
Dividends
 
Total
Stockholders’
Equity
Balance at December 31, 2017
$
1,251

 
$
3,173,429

 
$
(1,299
)
 
$
1,018,348

 
$
(2,401,846
)
 
$
1,789,883

Issuance of common stock, net of issuance costs


 
239

 

 

 

 
239

Common stock redemptions

 
(680
)
 

 

 

 
(680
)
Share-based compensation
1

 
2,821

 

 

 

 
2,822

Net income

 

 

 
9,180

 

 
9,180

Reclassification adjustments for losses included in net income (interest expense)


 

 
147

 

 

 
147

Gains arising during the period on interest rate swaps


 

 
513

 

 

 
513

Dividends to common stockholders ($0.30 per share)

 

 

 

 
(37,556
)
 
(37,556
)
Balance at March 31, 2018
$
1,252

 
$
3,175,809

 
$
(639
)
 
$
1,027,528

 
$
(2,439,402
)
 
$
1,764,548


The accompanying notes, together with the Notes to the Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, are an integral part of these financial statements.


4


Healthcare Realty Trust Incorporated
Condensed Consolidated Statements of Cash Flows
For the Three Months Ended March 31, 2019 and 2018
(Dollars in thousands)
(Unaudited)
 
Three Months Ended March 31,
 
2019
 
2018
OPERATING ACTIVITIES
 
 
 
Net income
$
4,891

 
$
9,180

Adjustments to reconcile net income to net cash provided by operating activities:
 
 
 
Depreciation and amortization
42,662

 
39,573

Other amortization
727

 
584

Share-based compensation
2,639

 
2,822

Amortization of straight-line rent receivable (lessor)
(668
)
 
(1,722
)
Amortization of straight-line rent on operating leases (lessee)
390

 
384

Gain on sales of real estate assets
(15
)
 

Equity from unconsolidated joint ventures loss
10

 
10

Distributions from unconsolidated joint ventures
88

 
37

Changes in operating assets and liabilities:
 
 
 
Other assets, including right-of-use-assets
(4,971
)
 
(4,193
)
Accounts payable and accrued liabilities
(10,276
)
 
(6,949
)
Other liabilities
(673
)
 
1,094

Net cash provided by operating activities
34,804

 
40,820

INVESTING ACTIVITIES
 
 
 
Acquisitions of real estate
(91,787
)
 
(1,756
)
Development of real estate
(5,712
)
 
(7,573
)
Additional long-lived assets
(11,741
)
 
(16,764
)
Proceeds from notes receivable repayments

 
5

Net cash used in investing activities
(109,240
)
 
(26,088
)
FINANCING ACTIVITIES
 
 
 
Net (repayments) borrowings on unsecured credit facility
(2,000
)
 
24,000

Repayments of notes and bonds payable
(1,193
)
 
(1,154
)
Dividends paid
(37,614
)
 
(37,556
)
Net proceeds from issuance of common stock
120,617

 
236

Common stock redemptions
(2,442
)
 
(2,633
)
Debt issuance and assumption costs

 
(44
)
Net cash provided by (used in) financing activities
77,368

 
(17,151
)
Increase (decrease) in cash and cash equivalents
2,932

 
(2,419
)
Cash and cash equivalents at beginning of period
8,381

 
6,215

Cash and cash equivalents at end of period
$
11,313

 
$
3,796

 
 
 
 
Supplemental Cash Flow Information:
 
 
 
Interest paid
$
11,071

 
$
3,899

Invoices accrued for construction, tenant improvements and other capitalized costs
$
13,509

 
$
8,592

Capitalized interest
$
307

 
$
186

The accompanying notes, together with the Notes to the Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, are an integral part of these financial statements.

5

Healthcare Realty Trust Incorporated

Notes to the Condensed Consolidated Financial Statements
March 31, 2019
(Unaudited)

Note 1. Summary of Significant Accounting Policies
Business Overview
Healthcare Realty Trust Incorporated (the "Company") is a real estate investment trust ("REIT") that owns, leases, manages, acquires, finances, develops and redevelops income-producing real estate properties associated primarily with the delivery of outpatient healthcare services throughout the United States. As of March 31, 2019, the Company had gross investments of approximately $4.0 billion in 201 real estate properties located in 26 states totaling approximately 15.0 million square feet. The Company provided leasing and property management services to approximately 11.3 million square feet nationwide.

Basis of Presentation
The Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. They do not include all of the information and footnotes required by GAAP for complete financial statements. However, except as disclosed herein, management believes there has been no material change in the information disclosed in the Notes to the Consolidated Financial Statements included in the Annual Report on Form 10-K for the year ended December 31, 2018. All material intercompany transactions and balances have been eliminated in consolidation.

This interim financial information should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2018. Management believes that all adjustments of a normal, recurring nature considered necessary for a fair presentation have been included. In addition, the interim financial information does not necessarily represent or indicate what the operating results will be for the year ending December 31, 2019 for many reasons including, but not limited to, acquisitions, dispositions, capital financing transactions, changes in interest rates and the effects of other trends, risks and uncertainties.

Use of Estimates in the Condensed Consolidated Financial Statements
Preparation of the Condensed Consolidated Financial Statements in accordance with GAAP requires management to make estimates and assumptions that affect amounts reported in the Condensed Consolidated Financial Statements and accompanying notes. Actual results may differ from those estimates.
Revenue from Contracts with Customers (Topic 606)
The Company recognizes certain revenue under the core principle of Topic 606. This requires an entity to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Lease revenue is not within the scope of Topic 606. To achieve the core principle, the Company applies the five step model specified in the guidance.

Revenue that is accounted for under Topic 606 is segregated on the Company’s Condensed Consolidated Statements of Income in the Other operating line item. This line item includes parking income, rental lease guaranty income, management fee income and other miscellaneous income. Below is a detail of the amounts by category:
(in thousands)
 
Three Months Ended March 31,
Type of Revenue
 
2019
 
2018
Parking income
 
$
1,734

 
$
1,626

Rental lease guaranty
 
128

 
175

Management fee income
 
69

 
68

Miscellaneous
 
30

 
26

 
 
$
1,961

 
$
1,895



The Company’s three major types of revenue that are accounted for under Topic 606 that are listed above are all accounted for as the performance obligation is satisfied. The performance obligations that are identified for each of these items are satisfied over time and the Company recognizes revenue monthly based on this principle.

6



New Accounting Pronouncements
Accounting Standards Update No. 2016-02, No. 2018-01 and No. 2018-11
In February 2016, the Financial Accounting Standards Board ("FASB") issued ASU 2016-02, "Leases." In January 2018, FASB issued ASU 2018-01, "Leases - Land Easement Practical Expedient for Transition to Topic 842," in July 2018, FASB issued ASU 2018-10, "Codification Improvements to Topic 842, Leases" and ASU 2018-11, "Leases - Targeted Improvements," and in December 2018, FASB issued ASU 2018-20, “Narrow-Scope Improvements for Lessors.” These accounting standard updates are collectively referred to as "Topic 842."
Topic 842 provides several practical expedients that the Company elected. These are (a) the package of practical expedients offered that allows an entity not to reassess upon adoption (i) whether an expired or existing contract contains a lease, (ii) lease classification related to expired or existing lease arrangements, and (iii) whether costs incurred on expired or existing leases qualify as initial direct costs, (b) the lessor practical expedient not to separate certain non-lease components, such as common area maintenance, from the lease component if (i) the timing and pattern of transfer are the same for the non-lease component and associated lease component, and (ii) the lease component would be classified as an operating lease if accounted for separately and (c) the lessee practical expedient not to separate certain non-lease components from the associated lease component.
For lessees, the new standard establishes a right-of-use ("ROU") model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with the classification affecting the pattern of expense recognition in the income statement. Ground leases executed or assumed prior to the adoption of Topic 842 will continue to be accounted for as operating leases and will not result in a materially different ground lease expense. However, each ground lease executed after the adoption of Topic 842 will be evaluated to determine if it is an operating or finance lease. If the lease is to be accounted for as a finance lease, ground lease expense would be accounted for using the effective interest method instead of the straight-line method over the term of the lease, which would result in higher ground lease expense in the earlier years of a ground lease when compared to the straight-line method. The Company's lease population is primarily ground leases, but also includes management office leases in third party buildings and certain copier and postage machine leases. The Company utilized a third party to assist in determining the discount rate for its ground leases. The terms of the ground leases generally range from 40 to 99 years with a weighted average remaining lease term remaining of 54.9 years, excluding renewal options. The Company's discount rates, which approximates the Company's incremental borrowing rate, ranged from 3.4% for leases expiring in 2019 to 6.2% for leases expiring in 2115. The Company utilized a third party to assist in determining the discount rates. The discount rates consider the general economic environment and factor in various financing and asset specific adjustments so that the discount rate is appropriate for the intended use of the underlying lease. As of January 1, 2019, the Company recognized the present value of its lease payments and a corresponding lease liability of $91.7 million. In addition, the Company reclassified $45.0 million of prepaid ground leases and below-market lease intangibles from the Other assets line item, $1.9 million of above-market lease intangibles from the Other liabilities line and $8.4 million of straight-line rent from the Accounts payable and accrued liabilities line item to the Operating lease right-of-use assets line item on the Condensed Consolidated Balance Sheets.
For lessors, the new standard requires a lessor to classify leases as either sales-type, direct-financing or operating. A lease will be treated as a sale if it is considered to transfer control of the underlying asset to the lessee. A lease will be classified as direct-financing if risks and rewards are conveyed without the transfer of control. Otherwise, the lease is treated as an operating lease. Lessor accounting remains largely unchanged with some exceptions including the concept of separating lease and nonlease components. Nonlease components, such as common area maintenance, are generally accounted for under Topic 606 and separated from the lease payments. However, the Company elected the lessor practical expedient allowing the Company to not separate these components when certain conditions are met. The combined component is accounted for under Topic 842. Lease related receivables, which include accounts receivable and accrued straight-line rent receivables, are reduced for revenue reserves and are recognized as a reduction to rental income. The adoption of Topic 842, where the Company is the lessor, did not have a material impact on the Company's Condensed Consolidated Financial Statements for the three months ended March 31, 2019.
The new standard was effective for the Company on January 1, 2019. Topic 842 provides two transition alternatives. The Company elected to choose the prospective optional transition method available to apply the guidance in Accounting Standards Codification Topic 840 in the comparative periods presented in the year Topic 842 is adopted. Topic 842 includes extensive quantitative and qualitative disclosures as compared to Topic 840, Leases, for both lessees and lessors. See Note 3 for additional disclosures.

7


Accounting Standards Update No. 2016-13 and No. 2018-19
In June 2016, the FASB issued ASU 2016-13, "Measurement of Credit Losses on Financial Instruments." This update is intended to improve financial reporting by requiring timelier recognition of credit losses on loans and other financial instruments that are not accounted for at fair value through net income, including loans held for investment, held-to-maturity debt securities, trade and other receivables, net investment in leases and other such commitments. This update requires that financial statement assets measured at an amortized cost and certain other financial instruments be presented at the net amount expected to be collected, through an allowance for credit losses that is deducted from the amortized cost basis. ASU 2018-19 also clarifies that receivables arising from operating leases are not within the scope of this topic. Instead, impairment of these receivables should be accounted for in accordance with Topic 842, Leases. This standard is effective for annual and interim periods beginning after December 15, 2019 with early adoption permitted. The Company is in the initial stages of evaluating the impact from the adoption of this new standard on the Condensed Consolidated Financial Statements and related notes.

Accounting Standards Update No. 2017-04
In January 2017, the FASB issued ASU 2017-04, "Simplifying the Test for Goodwill Impairment." This update eliminates Step 2 of the goodwill impairment test. As such, an entity will perform its annual, or interim, goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An entity should recognize a goodwill impairment charge for the amount by which the reporting unit's carrying amount exceeds its fair value. This standard is effective for the Company for annual and interim periods beginning after December 15, 2019. The Company does not expect a material impact on the Condensed Consolidated Financial Statements and related notes from the adoption of this standard.

Note 2. Real Estate Investments
2019 Acquisitions
The following table details the Company's acquisitions for the three months ended March 31, 2019:
(Dollars in millions)
Type (1)
 
Date
Acquired
 
Purchase Price

 
Cash
Consideration
(2)

 
Real
Estate

 
Other (3)

 
Square
Footage
(Unaudited)

Washington, D.C. (4)
MOB
 
3/28/19
 
$
46.0

 
$
45.9

 
$
50.2

 
$
(4.3
)
 
158,338

Indianapolis, IN (5)
MOB
 
3/28/19
 
47.0

 
44.8

 
43.7

 
1.1

 
143,499

 
 
 
 
 
$
93.0

 
$
90.7

 
$
93.9

 
$
(3.2
)
 
301,837

______
(1)
MOB = medical office building
(2)
Cash consideration excludes prorations of revenue and expense due to/from seller at the time of the acquisition.
(3)
Includes other assets acquired, liabilities assumed, and intangibles recognized at acquisition.
(4)
Includes two properties. The Company assumed two ground leases in connection with this acquisition that are classified as financing leases. The present value of future lease payments totaling $14.4 million was recorded on the Company's Condensed Consolidated Balance Sheets. In addition, the right-of-use assets were partially offset by $5.2 million of above-market lease intangibles included in Other.
(5)
The Company assumed a prepaid ground lease totaling $0.8 million and recorded a below-market lease intangible totaling $0.9 million in connection with this acquisition that is classified as an operating lease that are included in Other.

Subsequent Acquisition
On April 2, 2019, the Company acquired a 47,963 square foot medical office building in Atlanta, Georgia for a purchase price of $28.0 million.

Subsequent Disposition
On April 9, 2019, the Company disposed of three off-campus medical office buildings and one on-campus medical office building to a single purchaser. The buildings are located in Tucson, Arizona and total 67,345 square feet. The sales price was approximately $13.0 million and as of March 31, 2019, the Company's net investment in the buildings was $6.9 million.





8


Assets Held for Sale
In March 2019, the Company reclassified an inpatient rehabilitation facility to held for sale upon notification that a ground lessor is exercising a purchase option. The purchase price is determined by an appraisal process that is currently underway. The Company expects the purchase price to be greater than the current net investment of approximately $1.3 million. As of March 31, 2019 and December 31, 2018, the Company had two properties and one property, respectively, classified as held for sale.

The table below reflects the assets and liabilities of the properties classified as held for sale as of March 31, 2019 and December 31, 2018:
(Dollars in thousands)
March 31,
2019
 
December 31,
2018
Balance Sheet data:
 
 
 
Land
$
1,125

 
$
1,125

Buildings, improvements and lease intangibles
39,586

 
18,231

 
40,711

 
19,356

Accumulated depreciation
(30,706
)
 
(10,657
)
Real estate assets held for sale, net
10,005

 
8,699

Operating lease right-of-use assets
168

 

Other assets, net
395

 
573

Assets held for sale, net
$
10,568

 
$
9,272

 
 
 
 
Accounts payable and accrued liabilities
$
251

 
$
450

Operating lease liabilities
168

 

Other liabilities
214

 
137

Liabilities of properties held for sale
$
633

 
$
587




Note 3. Leases
Lessor Accounting Under ASC 842
The Company’s properties generally are leased pursuant to non-cancelable, fixed-term operating leases with expiration dates through 2036. Some leases provide for fixed rent renewal terms in addition to market rent renewal terms. Some leases provide the lessee, during the term of the lease, with an option or right of first refusal to purchase the leased property.

The Company's leases typically have escalators that are either based on a stated percentage or an index such as CPI (consumer price index). In addition, most of the Company's leases include nonlease components such as reimbursement of operating expenses as additional rent or include the reimbursement of expected operating expenses as part of the lease payment. The Company elected the practical expedient and adopted an accounting policy to combine lease and nonlease components. Rent escalators based on indices and reimbursements of operating expenses that are not included in the lease rate are considered variable lease payments. Variable payments are recognized in the periods when the information is known. As of March 31, 2019, the Company had one ground lease that is associated with a property under construction where rent has not yet commenced. Lease income for the Company's operating leases recognized for the three months ended March 31, 2019 was $110.7 million.


9


Future lease payments under the non-cancelable operating leases, excluding any reimbursements, as of March 31, 2019 are as follows (in thousands):
2019
$
250,619

2020
294,900

2021
250,050

2022
213,822

2023
175,215

2024 and thereafter
502,647

 
$
1,687,253



Lessor Accounting Under ASC 840
The Company’s properties are generally leased pursuant to non-cancelable, fixed-term operating leases with expiration dates through 2036. Some leases and financial arrangements provide for fixed rent renewal terms in addition to market rent renewal terms. Some leases provide the lessee, during the term of the lease and for a short period thereafter, with an option or a right of first refusal to purchase the leased property. The Company’s portfolio of single-tenant net leases generally requires the lessee to pay minimum rent and all taxes (including property tax), insurance, maintenance and other operating costs associated with the leased property.
Future minimum lease payments under the non-cancelable operating leases, excluding any reimbursements, as of December 31, 2018 are as follows (in thousands):
2019
$
326,441

2020
279,211

2021
235,660

2022
201,072

2023
163,978

2024 and thereafter
476,673

 
$
1,683,035



Lessee Accounting Under ASC 842
As of March 31, 2019, the Company was obligated, as the lessee, under operating lease agreements consisting primarily of the Company’s ground leases. As of March 31, 2019, the Company had 109 properties, excluding one property classified as held for sale, totaling 9.1 million square feet that were held under ground leases with a remaining weighted average term of 54.9 years, excluding renewal options. Including renewal options, the remaining weighted average term would be 70.7 years. Some lease renewal terms are based on fixed rent renewal terms in addition to market rent renewal terms. These ground leases typically have initial terms of 40 to 99 years with expiration dates through 2117. Any increases related to the Company’s ground leases are generally either stated or based on the Consumer Price Index. The Company had 46 prepaid ground leases as of March 31, 2019. The amortization of the prepaid rent, included in the operating lease right-of-use asset represented approximately $0.1 million of the Company’s rental expense for the three months ended March 31, 2019 and March 31, 2018.

The Company’s future lease payments (primarily for its 63 non-prepaid ground leases) as of March 31, 2019 were as follows (in thousands):

 
 
Operating

 
Financing

2019
$
2,948

 
$
626

2020
4,849

 
611

2021
4,879

 
619

2022
4,909

 
628

2023
4,947

 
637

2024 and thereafter
314,406

 
74,766

Total undiscounted lease payments
336,938

 
77,887

Discount
(245,894
)
 
(63,593
)
Lease Liability
$
91,044

 
$
14,294



10



The following table provides a detail of the Company's total lease expense for the three months ended March 31, 2019 (in thousands):
 
 
Operating
 
FInancing
Lease expense
 
 
 
 
Operating lease expense
 
$
1,116

 
$

Variable lease expense
 
740

 

Total lease expense
 
$
1,856

 
$

 
 
 
 
 
Other information
 
 
 
 
Operating cash flows outflows related to operating leases
 
$
2,771

 
$

Right-of-use assets obtained in exchange for new lease liabilities
 
$

 
$
14,294

Weighted-average remaining lease term (excluding renewal options)
 
54.0

 
70.6

Weighted-average discount rate
 
5.5
%
 
5.9
%


Lessee Accounting Under ASC 840

As of December 31, 2018, the Company was obligated under operating lease agreements consisting primarily of the Company’s ground leases. At December 31, 2018, the Company had 107 properties totaling 8.8 million square feet that were held under ground leases with a remaining weighted average term of 53.9 years, excluding renewal options. These ground leases typically have initial terms of 50 to 75 years with one or more renewal options extending the terms to 75 to 100 years, with expiration dates through 2117. Any rental increases related to the Company’s ground leases are generally either stated or based on the Consumer Price Index.

The Company’s future minimum lease payments (primarily for its 60 non-prepaid ground leases) as of December 31, 2018 were as follows (in thousands):  
2019
$
5,288

2020
5,260

2021
5,238

2022
5,207

2023
5,224

2024 and thereafter
323,533

 
$
349,750



11


Note 4. Notes and Bonds Payable
The table below details the Company’s notes and bonds payable. 
 
Maturity
Dates
 
Balance as of
 
Effective Interest Rate as of

(Dollars in thousands)
March 31, 2019

 
December 31, 2018

March 31, 2019

Unsecured Credit Facility
7/20
 
$
260,000

 
$
262,000

 
3.49
%
Unsecured Term Loan Facility, net of issuance costs (1)
12/22
 
149,234

 
149,183

 
3.53
%
Senior Notes due 2023, net of discount and issuance costs
4/23
 
248,223

 
248,117

 
3.95
%
Senior Notes due 2025, net of discount and issuance costs (2)
5/25
 
248,338

 
248,278

 
4.08
%
Senior Notes due 2028, net of discount and issuance costs
1/28
 
295,309

 
295,198

 
3.84
%
Mortgage notes payable, net of discounts and issuance costs and including premiums
7/19-5/40
 
142,006

 
143,208

 
4.79
%
 
 
 
$
1,343,110

 
$
1,345,984

 
 

______
(1)
The effective interest rate includes the impact of interest rate swaps on $25.0 million and $50.0 million of the outstanding balance at a rate of 2.18% and 2.46%, respectively (plus the applicable margin rate, currently 110 basis points).
(2)
The effective interest rate includes the impact of the $1.7 million settlement of a forward-starting interest rate swap that is included in Accumulated other comprehensive income (loss) on the Company's Condensed Consolidated Balance Sheets.

Subsequent Mortgage Note Payable Payoff
On April 10, 2019, the Company repaid in full a mortgage note payable bearing interest at a rate of 5.00% per annum with an outstanding principal of $8.9 million. The mortgage note encumbered a 52,813 square foot property in Washington.



12


Note 5. Derivative Financial Instruments
Risk Management Objective of Using Derivatives
The Company is exposed to certain risks arising from both its business operations and economic conditions. The Company principally manages its exposures to a wide variety of business and operational risks through management of its core business activities. The Company manages economic risks, including interest rate, liquidity, and credit risk, primarily by managing the amount, sources, and duration of its assets and liabilities and the use of derivative financial instruments. Specifically, the Company enters into derivative financial instruments to manage exposures that arise from business activities that result in the
receipt or payment of future known and uncertain cash amounts, the value of which are determined by interest rates. The Company’s derivative financial instruments are used to manage differences in the amount, timing, and duration of the Company’s known or expected cash receipts and its known or expected cash payments principally related to the Company’s borrowings.

Cash Flow Hedges of Interest Rate Risk
The Company’s objectives in using interest rate derivatives are to add stability to interest expense and to manage its exposure to interest rate movements. To accomplish this objective, the Company primarily uses interest rate swaps as part of its interest rate risk management strategy. Interest rate swaps designated as cash flow hedges involve the receipt of variable amounts from a counterparty in exchange for the Company making fixed-rate payments over the life of the agreements without exchange of the underlying notional amount. Such derivatives were used to hedge the variable cash flows associated with existing variable-rate debt.

For derivatives designated and that qualify as cash flow hedges of interest rate risk, the gain or loss on the derivative is recorded in Accumulated Other Comprehensive Income (Loss) and subsequently reclassified into interest expense in the same period(s) during which the hedged transaction affects earnings. Amounts reported in Accumulated other comprehensive income (loss) related to derivatives will be reclassified to interest expense as interest payments are made on the Company’s variable-rate debt.

As of March 31, 2019, the Company had four outstanding interest rate derivatives that were designated as cash flow hedges of interest rate risk:
Derivative Instrument
 
Number of Instruments

 
Notional Amount
(in millions)
Interest rate swaps
 
4

 
$75.0


Tabular Disclosure of Fair Values of Derivative Instruments on the Balance Sheet
The table below presents the fair value of the Company's derivative financial instruments, as well as their classification on the Condensed Consolidated Balance Sheet as of March 31, 2019.
 
Balance at March 31, 2019
(Dollars in thousands)
Balance Sheet Location
 
Fair Value

Derivatives designated as hedging instruments
 
 
 
Interest rate swaps
Other liabilities
 
$
589

Total derivatives designated as hedging instruments
 
 
$
589



Tabular Disclosure of the Effect of Cash Flow Hedge Accounting on Accumulated Other Comprehensive Income (Loss)
The table below presents the effect of cash flow hedge accounting on Accumulated Other Comprehensive Income (Loss) ("OCI") during the three months ended March 31, 2019 and 2018 related to the Company's outstanding interest rate swaps.
 
Amount of Loss Recognized in OCI on Derivative
 
Amount of Loss Reclassified from OCI into Income
(Dollars in thousands)
2019

2019

 
2018

Interest rate products
$
724

Interest expense
$
(27
)
 
$
105

Settled interest rate swaps

Interest expense
42

 
42

 
$
724

Total interest expense
$
15

 
$
147



13


Credit-risk-related Contingent Features
The Company's agreements with each of its derivative counterparties contain a cross-default provision under which the Company could be declared in default of its derivative obligations if repayment of the underlying indebtedness is accelerated by the lender due to the Company's default on the indebtedness.

The Company estimates that $13 thousand related to active interest rate swaps will be reclassified from OCI as a decrease to interest expense over the next 12 months, and that $0.2 million related to settled interest rate swaps will be amortized from OCI as an increase to interest expense over the next 12 months.

Subsequent Activity
On April 12, 2019, the Company entered into two interest rate swaps totaling $50.0 million to hedge the 1-month LIBOR portion of the cost of borrowing under the Company's variable rate debt to a fixed interest rate of 2.334%. These derivatives were used to hedge variable cash flows associated with variable-rate debt.

Note 6. Commitments and Contingencies
Legal Proceedings
The Company is, from time to time, involved in litigation arising in the ordinary course of business. The Company is not aware of any pending or threatened litigation that, if resolved against the Company, would have a material adverse effect on the Company’s consolidated financial position, results of operations or cash flows.

Redevelopment Activity
The Company is redeveloping a medical office building in Charlotte, North Carolina, which includes a 38,000 square foot vertical expansion. As of March 31, 2019, the Company had funded approximately $9.7 million on the redevelopment of this property. The project is expected to be completed in the second quarter of 2019.

Development Activity
The Company began the development of a 151,000 square foot medical office building in Seattle, Washington during 2017. As of March 31, 2019, the Company had funded approximately $30.9 million on the development. The Company expects the project to be completed in the fourth quarter of 2019.
Note 7. Stockholders' Equity

Common Stock    
The following table provides a reconciliation of the beginning and ending shares of common stock outstanding for the three months ended March 31, 2019 and the year ended December 31, 2018:
 
March 31, 2019
 
December 31, 2018
Balance, beginning of period
125,279,455

 
125,131,593

Issuance of common stock
3,889,411

 
26,203

Nonvested share-based awards, net of withheld shares
45,225

 
121,659

Balance, end of period
129,214,091

 
125,279,455



Equity Offering
On March 19, 2019, the Company issued 3,737,500 shares of common stock, par value $0.01 per share, at $31.40 per share in an underwritten public offering pursuant to the Company's existing effective registration statement. The net proceeds of the offering, after underwriting discounts and offering expenses, were approximately $115.8 million.

At-The-Market Equity Offering Program
The Company sold 135,265 shares under the Company's at-the-market equity offering program during the three months ended March 31, 2019. The sales generated $4.3 million in net proceeds at prices to the public ranging from $32.01 to $32.86 (weighted average of $32.36). The Company had 5,733,432 authorized shares remaining available to be sold under the current sales agreements as of April 26, 2019.


14


Common Stock Dividends
During the three months ended March 31, 2019, the Company declared and paid common stock dividends totaling $0.30 per share. On April 30, 2019, the Company declared a quarterly common stock dividend in the amount of $0.30 per share payable on May 30, 2019 to stockholders of record on May 15, 2019.

Earnings Per Common Share
The Company uses the two-class method of computing net earnings per common shares. The Company's nonvested share-based awards are considered participating securities pursuant to the two-class method. The following table sets forth the computation of basic and diluted earnings per common share for the three months ended March 31, 2019 and 2018.
 
Three Months Ended March 31,
(Dollars in thousands, except per share data)
2019
 
2018
Weighted average Common Shares outstanding
 
 
 
Weighted average Common Shares outstanding
125,908,335

 
125,167,128

Nonvested shares
(1,778,700
)
 
(1,909,777
)
Weighted average Common Shares outstanding—Basic
124,129,635

 
123,257,351

Weighted average Common Shares outstanding—Basic
124,129,635

 
123,257,351

Dilutive effect of employee stock purchase plan
102,132

 
90,330

Weighted average Common Shares outstanding—Diluted
124,231,767

 
123,347,681

Net Income
$
4,891

 
$
9,180

Dividends paid on nonvested share-based awards
(536
)
 
(579
)
Net income applicable to common stockholders
$
4,355

 
$
8,601

Basic earnings per common share - Net income
$
0.04

 
$
0.07

Diluted earnings per common share - Net income
$
0.04

 
$
0.07



Incentive Plans
A summary of the activity under the Company's share-based incentive plans for the three months ended March 31, 2019 and 2018 is included in the table below.
 
Three Months Ended March 31,
 
2019
 
2018
Share-based awards, beginning of period
1,769,863

 
1,907,645

Granted
64,771

 
76,762

Vested
(50,507
)
 
(54,065
)
Share-based awards, end of period
1,784,127

 
1,930,342



During the three months ended March 31, 2019 and 2018, the Company withheld 19,546 and 21,196 shares of common stock, respectively, from participants to pay estimated withholding taxes related to shares that vested.

In addition to the share-based incentive plans, the Company maintains the 2000 Employee Stock Purchase Plan (the "Purchase Plan"). A summary of the activity under the Purchase Plan for the three months ended March 31, 2019 and 2018 is included in the table below.
 
Three Months Ended March 31,
 
2019
 
2018
Outstanding and exercisable, beginning of period
328,533

 
318,100

Granted
235,572

 
203,836

Exercised
(14,630
)
 
(8,835
)
Forfeited
(16,625
)
 
(10,580
)
Expired
(142,074
)
 
(135,790
)
Outstanding and exercisable, end of period
390,776

 
366,731




15


Note 8. Fair Value of Financial Instruments
The following methods and assumptions were used to estimate the fair value of each class of financial instrument for which it is practical to estimate that value.

Cash and cash equivalents - The carrying amount approximates fair value due to the short term maturity of these investments.

Borrowings under the unsecured credit facility due 2020 and unsecured term loan facility due 2022 - The carrying amount approximates fair value because the borrowings are based on variable market interest rates.

Senior Notes and Mortgage Notes payable - The fair value of notes and bonds payable is estimated using cash flow analyses, based on the Company’s current interest rates for similar types of borrowing arrangements.

Interest rate swap agreements - Interest rate swap agreements are recorded in other liabilities on the Company's Consolidated Balance Sheets at fair value. Fair value is estimated by utilizing pricing models that consider forward yield curves and discount rates.

The table below details the fair values and carrying values for notes and bonds payable at March 31, 2019 and December 31, 2018.
 
March 31, 2019
 
December 31, 2018
(Dollars in millions)
Carrying Value
 
Fair Value
 
Carrying Value
 
Fair Value
Notes and bonds payable (1)
$
1,343.1

 
$
1,329.8

 
$
1,346.0

 
$
1,326.5


______
(1)
Level 2 – model-derived valuations in which significant inputs and significant value drivers are observable in active markets.



16


Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
Disclosure Regarding Forward-Looking Statements
This report and other materials the Company has filed or may file with the Securities and Exchange Commission, as well as information included in oral statements or other written statements made, or to be made, by management of the Company, contain, or will contain, disclosures that are “forward-looking statements.” Forward-looking statements include all statements that do not relate solely to historical or current facts and can be identified by the use of words such as “may,” “will,” “expect,” “believe,” “anticipate,” “target,” “intend,” “plan,” “estimate,” “project,” “continue,” “should,” “could," "budget" and other comparable terms. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of risks and uncertainties, including the risks described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, that could significantly affect the Company’s current plans and expectations and future financial condition and results.

The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Stockholders and investors are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in the Company’s filings and reports, including, without limitation, estimates and projections regarding the performance of development projects the Company is pursuing.

For a detailed discussion of the Company’s risk factors, please refer to the Company’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2018.

Liquidity and Capital Resources
Sources and Uses of Cash
The Company’s primary sources of cash include rent receipts from its real estate portfolio based on contractual arrangements with its tenants and sponsors, borrowings under the Company's unsecured credit facility due 2020 (the "Unsecured Credit Facility"), proceeds from the sales of real estate properties and proceeds from public or private debt or equity offerings.

The Company expects to continue to meet its liquidity needs, including funding additional investments, paying dividends, and funding debt service, through cash on hand, cash flows from operations, and the cash flow sources described above. The Company had unencumbered real estate assets with a gross book value of approximately $3.7 billion at March 31, 2019, of which a portion could serve as collateral for secured mortgage financing. The Company believes that its liquidity and sources of capital are adequate to satisfy its cash requirements. The Company cannot, however, be certain that these sources of funds will be available at a time and upon terms acceptable to the Company in sufficient amounts to meet its liquidity needs.

Dividends paid by the Company for the three months ended March 31, 2019 were funded from cash flows from operations and the Unsecured Credit Facility, as cash flows from operations were not adequate to fully fund dividends paid at the rate per quarter of $0.30 per common share. The Company expects that additional cash flows from existing properties, acquisitions and developments will generate sufficient cash flows from operations such that dividends for the full year 2019 can be funded by cash flows from operations.
 
Investing Activities
Cash flows used in investing activities for the three months ended March 31, 2019 were approximately $109.2 million. Below is a summary of significant investing activities.
2019 Acquisitions
The following table details the Company's acquisitions for the three months ended March 31, 2019:
(Dollars in millions)
 
Health System Affiliation
 
Date
Acquired
 
Purchase Price

 
Square
Footage

 
Cap Rate

 
Hospital Campus Location (1)
Washington, D.C. (2)
 
Inova Health
 
3/28/19
 
$
46.0

 
158,338

 
5.2
%
 
On
Indianapolis, IN
 
Indiana University Health
 
3/28/19
 
47.0

 
143,499

 
5.1
%
 
On
 
 
 
 
 
 
$
93.0

 
301,837

 
5.2
%
 
 
______
(1)
On = Located on a hospital campus
(2)
Includes two properties.






17


Subsequent Acquisition
On April 2, 2019, the Company acquired a 47,963 square foot medical office building in Atlanta, Georgia for a purchase price of $28.0 million.

Capital Funding
During the three months ended March 31, 2019, the Company funded the following:
$7.3 million toward development and redevelopment of properties;
$2.8 million toward first generation tenant improvements and planned capital expenditures for acquisitions;
$4.3 million toward second generation tenant improvements; and
$3.5 million toward capital expenditures.

Subsequent Disposition
On April 9, 2019, the Company disposed of three off-campus medical office buildings and one on-campus medical office building to a single purchaser. The buildings are located in Tucson, Arizona and total 67,345 square feet. The sales price was approximately $13.0 million and the Company's net investment in the buildings was $6.9 million as of March 31, 2019.

Financing Activities
Cash flows used in financing activities for the three months ended March 31, 2019 were approximately $77.4 million. Inflows from equity related to the Company's common stock issuances and net borrowings totaled $120.6 million, net of issuance costs incurred. Aggregate cash outflows totaled approximately $43.2 million primarily associated with dividends paid to common stockholders. See Notes 4 and 7 to the Condensed Consolidated Financial Statements for more information about capital markets and financing activities.

Common Stock Issuances
The Company sold 135,265 shares under the Company's at-the-market equity offering program during the three months ended March 31, 2019. The sales generated $4.3 million in net proceeds at prices to the public ranging from $32.01 to $32.86 (weighted average of $32.36). The Company had 5,733,432 authorized shares remaining available to be sold under the current sales agreements as of April 26, 2019.

On March 19, 2019, the Company issued 3,737,500 shares of common stock, par value $0.01 per share, at $31.40 per share in an underwritten public offering pursuant to the Company's existing effective registration statement. The net proceeds of the offering, after underwriting discounts and offering expenses, were approximately $115.8 million.

Subsequent Mortgage Note Payable Payoff
On April 10, 2019, the Company repaid in full a mortgage note payable bearing interest at a rate of 5.00% per annum with an outstanding principal of $8.9 million. The mortgage note encumbered a 52,813 square foot property in Washington.

Operating Activities
Cash flows provided by operating activities decreased from $40.8 million for the three months ended March 31, 2018 to $34.8 million for the three months ended March 31, 2019. Items impacting cash flows from operations include, but are not limited to, cash generated from property operations, interest payments and the timing related to the payment of invoices and other expenses and receipts of tenant rent.
The Company may, from time to time, sell additional properties and redeploy cash from property sales into new investments. To the extent revenues related to the properties being sold exceed income from these new investments, the Company's results of operations and cash flows could be adversely affected.

Off-Balance Sheet Arrangements
The Company has no off-balance sheet arrangements that are reasonably likely to have a current or future material effect on the Company’s financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.

New Accounting Pronouncements
See Note 1 to the Company's Condensed Consolidated Financial Statements accompanying this report for information on new accounting standards.


18


Trends and Matters Impacting Operating Results
Management monitors factors and trends important to the Company and the REIT industry to gauge the potential impact on the operations of the Company. In addition to the matters discussed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, below are some of the factors and trends that management believes may impact future operations of the Company.

Expiring Leases
The Company expects that approximately 15% to 20% of the leases in its multi-tenanted portfolio will expire each year in the ordinary course of business. There are 581 leases totaling 2.1 million square feet in the Company's multi-tenant portfolio that will expire during the remainder of 2019. Approximately 95% of the leases expiring in 2019 are located in buildings on or adjacent to hospital campuses, are distributed throughout the portfolio, and are not concentrated with any one tenant, health system or market area. The Company typically expects to retain 75% to 90% of multi-tenant property tenants upon expiration, and the retention ratio for the first three months of the year has been within this range.

Included in the 2019 lease expirations is a lease for a 111,000 square foot fitness center with Baylor Scott & White that recently was extended for 90 days to September 30, 2019. This fitness center is located in a 217,000 square foot on-campus medical office building. The Company and Baylor Scott & White are exploring options, including bringing in a third party operator for the fitness center and converting any remaining space to clinical use.

The Company has two single-tenant net leased, on-campus inpatient rehabilitation facilities with lease terms scheduled to expire in the third quarter of 2019.  The Company received notice that the lessee is exercising its third renewal option related to one of the leases, representing 0.9% of the total cash NOI for the trailing twelve months ended March 31, 2019.  The other lease, representing 0.8% of total cash NOI for the same period, is not expected to be renewed; however, the Company received notice that the the ground lessor is exercising its purchase option. The purchase price is determined by an appraisal process that is currently underway. The Company expects the purchase price to be greater than the current net investment of approximately $1.3 million.
Property Operating Agreement Expirations
On February 28, 2019, the Company’s remaining property operating agreement between the Company and a sponsoring health system expired. This agreement contractually obligated the sponsoring health system to provide to the Company a minimum return on the Company’s investment in the property in exchange for the right to be involved in the operating decisions of the property, including tenancy. If the minimum return was not achieved through normal operations of the property, the Company calculated and accrued to property lease guaranty revenue, each quarter, any shortfalls due from the sponsor under the terms of the property operating agreement. The Company recognized $0.1 million in property lease guaranty revenue during the first quarter of 2019 related to this agreement.

Operating Expenses
The Company has historically experienced increases in property taxes throughout its portfolio as a result of increasing assessments and tax rates levied across the country. The Company continues its efforts to appeal property tax increases and manage the impact of the increases. In addition, the Company has historically incurred variability in portfolio utilities expense based on seasonality, with the first and third quarters usually reflecting greater amounts. The effects of these operating expense increases are mitigated in leases that have provisions for operating expense reimbursement. As of March 31, 2019, leases for 88% of the Company's multi-tenant leased square footage allow for some recovery of operating expenses, with 31% having modified gross lease structures and 57% having net lease structures.

19


Purchase Options
Information about the Company's unexercised purchase options and the amount and basis for determination of the purchase price is detailed in the table below (dollars in thousands):
 
 
Number of Properties
 
Gross Real Estate Investment as of March 31, 2019
Year Exercisable
 
MOB
 
Inpatient
 
Fair Market Value Method (1)

 
Non Fair Market Value Method (2)

 
Total

Current (3)
 
3

 
1

 
$
95,740

 
$

 
$
95,740

2020
 

 

 

 

 

2021
 
1

 

 

 
14,984

 
14,984

2022
 

 

 

 

 

2023
 

 

 

 

 

2024
 

 

 

 

 

2025
 
5

 
1

 
47,620

 
221,929

 
269,549

2026
 

 

 

 

 

2027
 

 

 

 

 

2028
 
1

 

 
43,869

 

 
43,869

2029 and thereafter
 
5

 

 
125,638

 

 
125,638

Total
 
15

 
2

 
$
312,867

 
$
236,913

 
$
549,780

_____
(1)
The purchase option price includes a fair market value component that is determined by an appraisal process.
(2)
Includes properties with stated purchase prices or prices based on fixed capitalization rates. These properties have purchase prices that are on average 17% greater than the Company's current gross investment.
(3)
These purchase options have been exercisable for an average of 10.6 years.

In March 2019, the Company received notice that a ground lessor is exercising a purchase option on a inpatient rehabilitation facility. The purchase price is determined by an appraisal process that is currently underway. The Company expects the purchase price to be greater than the current net investment of approximately $1.3 million.

Non-GAAP Financial Measures and Key Performance Indicators
Management considers certain non-GAAP financial measures and key performance indicators to be useful supplemental measures of the Company's operating performance. A non-GAAP financial measure is generally defined as one that purports to measure financial performance, financial position or cash flows, but excludes or includes amounts that would not be so adjusted in the most comparable measure determined in accordance with generally accepted accounting principles ("GAAP"). Set forth below are descriptions of the non-GAAP financial measures management considers relevant to the Company's business and useful to investors, as well as reconciliations of these measures to the most directly comparable GAAP financial measures.
The non-GAAP financial measures and key performance indicators presented herein are not necessarily identical to those presented by other real estate companies due to the fact that not all real estate companies use the same definitions. These measures should not be considered as alternatives to net income, as indicators of the Company's financial performance, or as alternatives to cash flow from operating activities as measures of the Company's liquidity, nor are these measures necessarily indicative of sufficient cash flow to fund all of the Company's needs. Management believes that in order to facilitate a clear understanding of the Company's historical consolidated operating results, these measures should be examined in conjunction with net income and cash flows from operations as presented in the Consolidated Financial Statements and other financial data included elsewhere in this Quarterly Report on Form 10-Q.
Funds from Operations ("FFO"), Normalized FFO and Funds Available for Distribution ("FAD")
FFO and FFO per share are operating performance measures adopted by the National Association of Real Estate Investment Trusts (“NAREIT”). NAREIT defines FFO as the most commonly accepted and reported measure of a REIT’s operating performance equal to “net income (computed in accordance with GAAP), excluding gains (or losses) from sales of property, plus depreciation and amortization, impairment, and after adjustments for unconsolidated partnerships and joint ventures.”
In addition to FFO, the Company presents Normalized FFO and FAD. Normalized FFO is presented by adding to FFO acquisition-related costs, acceleration of debt issuance costs, debt extinguishment costs and other Company-defined normalizing items to evaluate operating performance. FAD is presented by adding to Normalized FFO non-real estate depreciation and amortization, deferred financing fees amortization, stock-based compensation expense and provision for bad debts, net; and subtracting maintenance capital expenditures, including second generation tenant improvements and leasing commissions paid and straight-line rent income, net of expense. The Company's definition of these terms may not be

20


comparable to that of other real estate companies as they may have different methodologies for computing these amounts. Normalized FFO and FAD should not be considered as an alternative to net income as an indicator of the Company's financial performance or to cash flow from operating activities as an indicator of the Company's liquidity. Normalized FFO and FAD should be reviewed in connection with GAAP financial measures.
Management believes FFO, Normalized FFO, FFO per share, Normalized FFO per share and FAD ("Non-GAAP Measures") provide an understanding of the operating performance of the Company’s properties without giving effect to certain significant non-cash items, primarily depreciation and amortization expense. Historical cost accounting for real estate assets in accordance with GAAP assumes that the value of real estate assets diminishes predictably over time. However, real estate values instead have historically risen or fallen with market conditions. The Company believes that by excluding the effect of depreciation, amortization, impairments and gains or losses from sales of real estate, all of which are based on historical costs and which may be of limited relevance in evaluating current performance, Non-GAAP Measures can facilitate comparisons of operating performance between periods. The Company reports Non-GAAP Measures because these measures are observed by management to also be the predominant measures used by the REIT industry and by industry analysts to evaluate REITs. For these reasons, management deems it appropriate to disclose and discuss these Non-GAAP Measures. However, none of these measures represent cash generated from operating activities determined in accordance with GAAP and are not necessarily indicative of cash available to fund cash needs. Further, these measures should not be considered as an alternative to net income as an indicator of the Company’s operating performance or as an alternative to cash flow from operating activities as a measure of liquidity. The table below reconciles net income to FFO, Normalized FFO and FAD for the three months ended March 31, 2019 and 2018:
 
Three Months Ended March 31,
(Amounts in thousands, except per share data)
2019
 
2018
Net Income
$
4,891

 
$
9,180

Gain on sales of real estate assets
(15
)
 

Real estate depreciation and amortization
43,383

 
40,003

Total adjustments
43,368

 
40,003

FFO Attributable to Common Stockholders
$
48,259

 
$
49,183

Acquisition and pursuit costs (1)
305

 
277

Lease intangible amortization (2)
84

 

Forfeited earnest money received

 
(466
)
Normalized FFO Attributable to Common Stockholders
$
48,648

 
$
48,994

Non-real estate depreciation and amortization
1,465

 
1,466

Provision for bad debt, net
(75
)
 

Straight-line rent, net
(270
)
 
(1,330
)
Stock-based compensation
2,639

 
2,822

Normalized FFO adjusted for non-cash items
$
52,407

 
$
51,952

2nd generation TI
(4,326
)
 
(5,867
)
Leasing commissions paid
(1,483
)
 
(1,851
)
Capital additions
(3,462
)
 
(4,184
)
FAD
$
43,136

 
$
40,050

FFO per Common Share—Diluted
$
0.39

 
$
0.40

Normalized FFO per Common Share—Diluted
$
0.39

 
$
0.40

FFO weighted average common shares outstanding - Diluted (3)
124,928

 
123,984

_____
(1)
Acquisition and pursuit costs include third party and travel costs related to the pursuit of acquisitions and developments.
(2)
The Company adopted the 2018 NAREIT FFO White Paper Restatement during the first quarter of 2019. This amended definition specifically includes the impact of acquisition related market lease intangible amortization in the calculation of NAREIT FFO.  The Company historically included this amortization in the real estate depreciation and amortization line item which is added back in the calculation of NAREIT FFO.  Prior periods were not restated for the adoption.
(3)
Diluted weighted average common shares outstanding for the three months ended March 31, 2019 and 2018 includes the dilutive effect of nonvested share-based awards outstanding of 696,432 and 635,872 respectively.

21


Cash Net Operating Income ("NOI") and Same Store Cash NOI
Cash NOI and Same Store Cash NOI are key performance indicators. Management considers these to be supplemental measures that allow investors, analysts and Company management to measure unlevered property-level operating results. The Company defines Cash NOI as rental income and property lease guaranty income less property operating expenses. Cash NOI excludes non-cash items such as above and below market lease intangibles, straight-line rent, lease inducements, lease terminations, tenant improvement amortization and leasing commission amortization. Cash NOI is historical and not necessarily indicative of future results.
Same Store Cash NOI compares Cash NOI for stabilized properties. Stabilized properties are properties that have been included in operations for the duration of the year-over-year comparison period presented and include redevelopment projects. Accordingly, stabilized properties exclude properties that were recently acquired or disposed of, properties classified as held for sale, and development conversions. In addition, the Company typically excludes properties that meet any of the following Company-defined criteria to be included in the reposition property group:

Properties having less than 60% occupancy that is expected to last at least two quarters;
Properties that experience a loss of occupancy over 30% in a single quarter; or
Properties with negative net operating income that is expected to last at least two quarters.

Any recently acquired property will be included in the same store pool once the Company has owned the property for eight full quarters. Development properties will be included in the same store pool eight full quarters after substantial completion. Any additional square footage created by redevelopment projects at a same store property is included in the same store pool immediately upon completion. Any property included in the reposition property group will be included in the same store analysis once occupancy has increased to 60% or greater with positive net operating income and has remained at that level for eight full quarters.The following table reflects the Company's same store cash NOI for the three months ended March 31, 2019 and 2018.
 
 
 
 
 
Same Store Cash NOI for the
 
 
 
 
 
Three Months Ended March 31,
(Dollars in thousands)
Number of Properties
 
Gross Investment at March 31, 2019
 
2019
 
2018
Multi-tenant Properties
150

 
$
2,894,291

 
$
53,105

 
$
50,792

Single-tenant Net Lease Properties
14

 
463,261

 
10,378

 
10,182

Total
164

 
$
3,357,552

 
$
63,483

 
$
60,974


The following tables reconcile net income to same store NOI and the same store property count to the total owned real estate portfolio for the three months ended March 31, 2019 and 2018:
Reconciliation of Same Store Cash NOI:
 
Three Months Ended March 31,
(Dollars in thousands)
2019
 
2018
Net income
$
4,891

 
$
9,180

Other (income) expense
13,564

 
12,175

General and administrative expense
8,510

 
9,101

Depreciation and amortization expense
42,662

 
39,573

Other expenses (1)
2,159

 
1,968

Straight-line rent revenue
(668
)
 
(1,722
)
Other revenue (2)
(1,350
)
 
(1,438
)
Cash NOI
69,768

 
68,837

Cash NOI not included in same store
(6,285
)
 
(7,863
)
Same store cash NOI
$
63,483

 
$
60,974

_____
(1)
Includes acquisition and pursuit costs, bad debt, above and below market ground lease intangible amortization, leasing commission amortization and ground lease straight-line rent expense.
(2)
Includes management fee income, interest, mortgage interest income, above and below market lease intangible amortization, lease inducement amortization, lease terminations and tenant improvement overage amortization.

22


Reconciliation of Same Store Property Count:
 
Property Count as of March 31, 2019
Same Store Properties
164

Acquisitions
24

Development Conversion
1

Reposition
12

Total Owned Real Estate Properties
201


Results of Operations
Three Months Ended March 31, 2019 Compared to Three Months Ended March 31, 2018
The Company’s results of operations for the three months ended March 31, 2019 compared to the same period in 2018 were impacted by acquisitions, developments, dispositions, gains, impairments recorded and capital markets transactions.

Revenues
Total revenues increased $0.5 million, or 0.5%, to approximately $112.7 million for the three months ended March 31, 2019 compared to $112.1 million in the prior year period. This increase is comprised of the following:
 
Three Months Ended March 31,
 
Change
(Dollars in thousands)
2019
 
2018
 
$
 
%
Property operating
$
98,982

 
$
95,294

 
$
3,688

 
3.9
 %
Single-tenant net lease
11,046

 
13,213

 
(2,167
)
 
(16.4
)%
Straight-line rent
668

 
1,722

 
(1,054
)
 
(61.2
)%
Rental income
110,696

 
110,229

 
467

 
0.4
 %
Other operating
1,961

 
1,895

 
66

 
3.5
 %
Total Revenues
$
112,657

 
$
112,124

 
$
533

 
0.5
 %

Property operating revenue increased $3.7 million, or 3.9%, from the prior year period primarily as a result of the following activity:

Acquisitions in 2018 and 2019 contributed $2.5 million.
Leasing activity, including contractual rent increases, contributed $2.4 million.
The conversion of one property in 2018 to single-tenant net lease resulted in a decrease of $0.2 million.
Dispositions in 2017 and 2018 resulted in a decrease of $1.0 million.

Single-tenant net lease revenue decreased $2.2 million, or 16.4%, from the prior year period primarily as a result of the following activity:

Dispositions in 2018 resulted in a decrease of $2.5 million.
Leasing activity including contractual rent increases contributed $0.2 million.
The conversion of one property in 2018 from multi-tenant resulted in an increase of $0.1 million.

Straight-line rent revenue decreased $1.1 million, or 61.2%, from the prior year period primarily as a result of net leasing activity and contractual rent increases.
    
Expenses
Property operating expenses increased $0.9 million, or 2.2%, for the three months ended March 31, 2019 compared to the prior year period primarily as a result of the following activity:

Acquisitions in 2018 and 2019 resulted in an increase of $1.3 million.

23


Portfolio property tax increases of $0.6 million.
Utilities expense decreases of $0.4 million.
Dispositions in 2018 resulted in a decrease of $0.6 million.

General and administrative expenses decreased approximately $0.6 million, or 6.5%, for the three months ended March 31, 2019 compared to the prior year period primarily as a result of the following:
Performance-based compensation expense resulted in a decrease of $0.2 million.
Office rent decrease of $0.2 million due to the acquisition of the Company's headquarters.
Other net decreases, including telecommunication lines, travel and other administrative, of $0.4 million.
Compensation expense increased $0.3 million.

Depreciation and amortization expense increased $3.1 million, or 7.8%, for the three months ended March 31, 2019 compared to the prior year period primarily as a result of the following activity:
Acquisitions in 2018 resulted in an increase of $2.1 million.
Various building and tenant improvement expenditures resulted in an increase of $2.9 million.
Dispositions in 2018 resulted in a decrease of $0.6 million.
Assets that became fully depreciated resulted in a decrease of $1.3 million.

Other income (expense)
Interest expense increased $0.9 million, or 7.3%, for the three months ended March 31, 2019 compared to the prior year period. The components of interest expense are as follows:
 
Three Months Ended March 31,
 
Change
(Dollars in thousands)
2019
 
2018
 
$
 
%
Contractual interest
$
13,193

 
$
12,208

 
$
985

 
8.1
 %
Net discount/premium accretion
52

 
(1
)
 
53

 
(5,300.0
)%
Deferred financing costs amortization
608

 
605

 
3

 
0.5
 %
Interest rate swap amortization
42

 
42

 

 
 %
Interest cost capitalization
(307
)
 
(186
)
 
(121
)
 
65.1
 %
Total interest expense
$
13,588

 
$
12,668

 
$
920

 
7.3
 %

Contractual interest expense increased $1.0 million, or 8.1%, primarily due to the following activity:
The Unsecured Credit Facility balance and interest rate increases accounted for an increase of approximately $1.0 million.
The Company's unsecured term loan due 2022 interest rate increase accounted for an increase of $0.2 million.
Mortgage notes assumed upon 2018 acquisitions of real estate properties accounted for an increase of $0.1 million.
Mortgage notes repayments accounted for a decrease of approximately $0.3 million.



24


Item 3. Quantitative and Qualitative Disclosures about Market Risk
The Company is exposed to market risk in the form of changing interest rates on its debt and mortgage notes. Management uses regular monitoring of market conditions and analysis techniques to manage this risk. During the three months ended March 31, 2019, there were no material changes in the quantitative and qualitative disclosures about market risks presented in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018.

Item 4. Controls and Procedures
Disclosure Controls and Procedures
The Company’s management, with the participation of the Company’s Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the Company’s disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), as of the end of the period covered by this report. Based on this evaluation, the Company’s Chief Executive Officer and Chief Financial Officer have concluded that, as of the end of such period, the Company’s disclosure controls and procedures were effective in recording, processing, summarizing and reporting, on a timely basis, information required to be disclosed by the Company in the reports it files or submits under the Exchange Act.
Changes in Internal Control over Financial Reporting
There have not been any changes in the Company’s internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the fiscal quarter to which this report relates that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.


25


PART II—OTHER INFORMATION

Item 1. Legal Proceedings
The Company is, from time to time, involved in litigation arising in the ordinary course of business. The Company is not aware of any pending or threatened litigation that, if resolved against the Company, would have a material adverse effect on the Company’s consolidated financial position, results of operations or cash flows.

Item 1A. Risk Factors
In addition to the other information set forth in this report, an investor should carefully consider the factors discussed in Part I, “Item 1A. Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, which could materially affect the Company’s business, financial condition or future results. The risks, as described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, are not the only risks facing the Company. Additional risks and uncertainties not currently known to management or that management currently deems immaterial also may materially, adversely affect the Company’s business, financial condition, operating results or cash flows.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

During the three months ended March 31, 2019, the Company withheld shares of Company common stock to satisfy employee tax withholding obligations payable upon the vesting of nonvested stock, as follows:
Period
Total Number of Shares Purchased
Average Price Paid per Share
Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs
Maximum Number of Shares that May Yet Be Purchased Under the Plans or Programs
January 1 - January 31
10,947

$
28.28



February 1 - February 28
7,649

31.69



March 1 - March 31
950

31.60



Total
19,546

 
 
 

Authorized Repurchases of Equity Securities by the Issuer
On April 30, 2019, the Company’s Board of Directors authorized the repurchase of up to $50 million of outstanding shares of the Company’s common stock either in the open market or through privately negotiated transactions, subject to market conditions, regulatory constraints, and other customary conditions. The Company is not obligated under this authorization to repurchase any specific number of shares. This authorization supersedes all previous stock repurchase authorizations. As of the date of this report, the Company has not repurchased any shares of its common stock under this authorization.

26


Item 6. Exhibits
Exhibit
 
Description
 
 
 
 
 
 
 
 
 
 
 
 
Exhibit 4.1
 
Specimen Stock Certificate (4)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Exhibit 101.INS
 
The instance document does not appear in the interactive data file because its XBRL tags are embedded within the Inline XBRL document.
 
 
 
Exhibit 101.SCH
 
XBRL Taxonomy Extension Schema Document (furnished electronically herewith)
 
 
 
Exhibit 101.CAL
 
XBRL Taxonomy Extension Calculation Linkbase Document (furnished electronically herewith)
 
 
 
Exhibit 101.LAB
 
XBRL Taxonomy Extension Labels Linkbase Document (furnished electronically herewith)
 
 
 
Exhibit 101.DEF
 
XBRL Taxonomy Extension Definition Linkbase Document (furnished electronically herewith)
 
 
 
Exhibit 101.PRE
 
XBRL Taxonomy Extension Presentation Linkbase Document (furnished electronically herewith)
_______________
(1)
Filed as an exhibit to the Company's Form 8-K filed March 18, 2019 and hereby incorporated by reference.
(2)
Filed as an exhibit to the Company's Form 8-K filed May 5, 2017 and hereby incorporated by reference.
(3)
Filed as an exhibit to the Company's Form 10-Q for the quarter ended June 30, 2015 and hereby incorporated by reference.
(4)
Filed as an exhibit to the Company’s Registration Statement on Form S-11 (Registration No. 33-60506) filed April 2, 1993 and hereby incorporated by reference.
(5)
Filed as an exhibit to the Company's Form 8-K filed May 17, 2001 and hereby incorporated as reference.
(6)
Filed as an exhibit to the Company's Form 8-K filed March 26, 2013 and hereby incorporated by reference.
(7)
Filed as an exhibit to the Company's Form 8-K filed April 24, 2015 and hereby incorporated by reference.
(8)
Filed as an exhibit to the Company’s Form 8-K filed December 11, 2017 and hereby incorporated by reference.




27



SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
 
 
HEALTHCARE REALTY TRUST INCORPORATED
 
 
 
 
 
 
By:
/s/ J. CHRISTOPHER DOUGLAS
 
 
 
J. Christopher Douglas
Executive Vice President and Chief Financial Officer
 
 
 
 
Date:
May 1, 2019
 
 



28
EX-31.1 2 hr-2019331xex311.htm EXHIBIT 31.1 Exhibit


CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302

Exhibit 31.1
Healthcare Realty Trust Incorporated
Quarterly Certification
Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, Todd J. Meredith, certify that:
1.
I have reviewed this quarterly report on Form 10-Q of Healthcare Realty Trust Incorporated;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a.
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.
The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a.
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b.
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date:
May 1, 2019
 
 
 
/s/ TODD J. MEREDITH
 
 
Todd J. Meredith
 
 
President and Chief Executive Officer



EX-31.2 3 hr-2019331xex312.htm EXHIBIT 31.2 Exhibit


CERTIFICATION OF THE CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302
Exhibit 31.2
Healthcare Realty Trust Incorporated
Quarterly Certification
Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
I, J. Christopher Douglas, certify that:
1.
I have reviewed this quarterly report on Form 10-Q of Healthcare Realty Trust Incorporated;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a.
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.
The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a.
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b.
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.


 

Date:
May 1, 2019
 
 
 
/s/ J. CHRISTOPHER DOUGLAS
 
 
J. Christopher Douglas
 
 
Executive Vice President and Chief Financial Officer



EX-32 4 hr-2019331xex32.htm EXHIBIT 32 Exhibit


CERTIFICATIONS PURSUANT TO 18 U.S.C. SECTION 1350 SECTION 906
Exhibit 32
Healthcare Realty Trust Incorporated
Certification Pursuant to
18 U.S.C. Section 1350,
as Adopted Pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002

In connection with the Quarterly Report of Healthcare Realty Trust Incorporated (the “Company”) on Form 10-Q for the quarter ended March 31, 2019, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Todd J. Meredith, President and Chief Executive Officer of the Company, and I, J. Christopher Douglas, Executive Vice President and Chief Financial Officer of the Company, each certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
1.
The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2.
Information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.



Date:
May 1, 2019
 
 
 
/s/ TODD J. MEREDITH
 
 
Todd J. Meredith
 
 
President and Chief Executive Officer
 
 
 
 
 
/s/ J. CHRISTOPHER DOUGLAS
 
 
J. Christopher Douglas
 
 
Executive Vice President and Chief Financial Officer



EX-101.SCH 5 hr-20190331.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2106100 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 2406401 - Disclosure - Commitments and Contingencies - Construction Activity (Details) link:presentationLink link:calculationLink link:definitionLink 1001501 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - Condensed Consolidated Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 1004001 - Statement - Condensed Consolidated Statement of Equity (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1004000 - Statement - Condensed Consolidated Statement of Equity (Unaudited) Statement link:presentationLink link:calculationLink link:definitionLink 1005000 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 1003000 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited) link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - Condensed Consolidated Statements of Income (Unaudited) link:presentationLink link:calculationLink link:definitionLink 2105100 - Disclosure - Derivative Financial Instruments link:presentationLink link:calculationLink link:definitionLink 2405405 - Disclosure - Derivative Financial Instruments - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2405402 - Disclosure - Derivative Financial Instruments - Derivative Instruments Designated as Cash Flow Hedges (Details) link:presentationLink link:calculationLink link:definitionLink 2405404 - Disclosure - Derivative Financial Instruments - Effect of Cash Flow Hedging on AOCI (Details) link:presentationLink link:calculationLink link:definitionLink 2405403 - Disclosure - Derivative Financial Instruments - Fair Value of Derivative Instruments on the Balance Sheet (Details) link:presentationLink link:calculationLink link:definitionLink 2305301 - Disclosure - Derivative Financial Instruments (Tables) link:presentationLink link:calculationLink link:definitionLink 0001000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 2109100 - Disclosure - Fair Value of Financial Instruments link:presentationLink link:calculationLink link:definitionLink 2409402 - Disclosure - Fair Value of Financial Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 2309301 - Disclosure - Fair Value of Financial Instruments (Tables) link:presentationLink link:calculationLink link:definitionLink 2103100 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 2403404 - Disclosure - Leases - Future Lease Payments Receivable under ASC 840 (Details) link:presentationLink link:calculationLink link:definitionLink 2403406 - Disclosure - Leases - Future Minimum Lease Payments (Details) link:presentationLink link:calculationLink link:definitionLink 2403406 - Disclosure - Leases - Future Minimum Lease Payments (Details) link:presentationLink link:calculationLink link:definitionLink 2403408 - Disclosure - Leases - Future Minimum Lease Payments under ASC 840 (Details) link:presentationLink link:calculationLink link:definitionLink 2403405 - Disclosure - Leases - Ground Leases (Details) link:presentationLink link:calculationLink link:definitionLink 2403407 - Disclosure - Leases - Lease Cost (Details) link:presentationLink link:calculationLink link:definitionLink 2403402 - Disclosure - Leases - Lease Income (Details) link:presentationLink link:calculationLink link:definitionLink 2403403 - Disclosure - Leases - Lessor Accounting (Details) link:presentationLink link:calculationLink link:definitionLink 2303301 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 2104100 - Disclosure - Notes and Bonds Payable link:presentationLink link:calculationLink link:definitionLink 2404402 - Disclosure - Notes and Bonds Payable (Details) link:presentationLink link:calculationLink link:definitionLink 2304301 - Disclosure - Notes and Bonds Payable (Tables) link:presentationLink link:calculationLink link:definitionLink 2102100 - Disclosure - Real Estate Investments link:presentationLink link:calculationLink link:definitionLink 2402402 - Disclosure - Real Estate Investments - Acquisitions and dispositions (Details) link:presentationLink link:calculationLink link:definitionLink 2402404 - Disclosure - Real Estate Investments - Assets Held for Sale (Details) link:presentationLink link:calculationLink link:definitionLink 2402405 - Disclosure - Real Estate Investments - Discontinued Operations and Assets Held for Sale - Balance Sheet (Details) link:presentationLink link:calculationLink link:definitionLink 2302301 - Disclosure - Real Estate Investments (Tables) link:presentationLink link:calculationLink link:definitionLink 2108100 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 2408406 - Disclosure - Stockholders' Equity - Computation of basic and diluted earnings (loss) per common share (Details) link:presentationLink link:calculationLink link:definitionLink 2408402 - Disclosure - Stockholders' Equity - Reconciliation of beginning and ending common stock outstanding (Details) link:presentationLink link:calculationLink link:definitionLink 2408403 - Disclosure - Stockholders' Equity (Stock Transactions - Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2408408 - Disclosure - Stockholders' Equity - Summary of activity under Employee Stock Purchase Plan (Details) link:presentationLink link:calculationLink link:definitionLink 2408407 - Disclosure - Stockholders' Equity - Summary of activity under stock-based incentive plans (Details) link:presentationLink link:calculationLink link:definitionLink 2308301 - Disclosure - Stockholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 2101100 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 2401403 - Disclosure - Summary of Significant Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 2401405 - Disclosure - Summary of Significant Accounting Policies - Impact of Adoption of New Accounting Standard (Details) link:presentationLink link:calculationLink link:definitionLink 2201201 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 2401404 - Disclosure - Summary of Significant Accounting Policies - Revenue Recognition (Details) link:presentationLink link:calculationLink link:definitionLink 2301302 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 6 hr-20190331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 7 hr-20190331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 8 hr-20190331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Statement of Comprehensive Income [Abstract] NET INCOME Net Income (Loss) Attributable to Parent Other comprehensive income: Other Comprehensive Income (Loss), Net of Tax [Abstract] Interest rate swaps: Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax [Abstract] Reclassification adjustments for losses included in net income (interest expense) Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax (Losses) gains arising during the period on interest rate swaps Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Net of Tax Total other comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax COMPREHENSIVE INCOME Comprehensive Income (Loss), Net of Tax, Attributable to Parent Debt Disclosure [Abstract] Notes and Bonds Payable Debt Disclosure [Text Block] Statement of Financial Position [Abstract] Preferred stock, par value (dollars per share) Preferred Stock, Par or Stated Value Per Share Preferred stock, authorized shares Preferred Stock, Shares Authorized Preferred stock, issued shares Preferred Stock, Shares Issued Preferred stock, outstanding shares Preferred Stock, Shares Outstanding Common stock, par value (dollars per share) Common Stock, Par or Stated Value Per Share Common stock, authorized shares Common Stock, Shares Authorized Common stock, issued shares Common Stock, Shares, Issued Common stock, outstanding shares Common Stock, Shares, Outstanding Statement of Stockholders' Equity [Abstract] Statement [Table] Statement [Table] Equity Components [Axis] Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Common Stock Common Stock [Member] Additional Paid-in Capital Additional Paid-in Capital [Member] Accumulated Other Comprehensive Income (Loss) AOCI Attributable to Parent [Member] Cumulative Net Income Cumulative Net Income [Member] Cumulative Net Income [Member]. Cumulative Dividends Cumulative Dividends [Member] Cumulative Dividends [Member]. Statement [Line Items] Statement [Line Items] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Beginning balance Stockholders' Equity Attributable to Parent Issuance of common stock, net of issuance costs Stock Issued During Period, Value, New Issues Common stock redemptions Stock Repurchased and Retired During Period, Value Share-based compensation Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition Net income Reclassification adjustments for losses included in net income (interest expense) Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, Net of Tax Gains (losses) arising during the period on interest rate swaps Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), after Adjustments and Tax Dividends to common stockholders ($0.30 per share) Dividends, Common Stock, Cash Ending balance Leases [Abstract] 2019 Operating Leases, Future Minimum Payments Receivable, Current 2020 Operating Leases, Future Minimum Payments Receivable, in Two Years 2021 Operating Leases, Future Minimum Payments Receivable, in Three Years 2022 Operating Leases, Future Minimum Payments Receivable, in Four Years 2023 Operating Leases, Future Minimum Payments Receivable, in Five Years 2024 and thereafter Operating Leases, Future Minimum Payments Receivable, Thereafter Total Operating Leases, Future Minimum Payments Receivable Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative [Table] Derivative [Table] Income Statement Location [Axis] Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Interest Expense Interest Expense [Member] Derivative Instrument [Axis] Derivative Instrument [Axis] Derivative Contract [Domain] Derivative Contract [Domain] Interest Rate Products Interest Rate Contract [Member] Settled Interest Rate Swaps Interest Rate Swap [Member] Derivative [Line Items] Derivative [Line Items] Amount of Loss Recognized in OCI on Derivative Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax Amount of Loss Reclassified from OCI into Income Income Statement [Abstract] REVENUES Revenues [Abstract] Rental income Operating Leases, Income Statement, Lease Revenue Other operating Revenue from Contract with Customer, Excluding Assessed Tax Revenues Revenues EXPENSES Operating Expenses [Abstract] Property operating Direct Costs of Leased and Rented Property or Equipment General and administrative General and Administrative Expense Acquisition and pursuit costs Acquisition Costs, Period Cost Depreciation and amortization Depreciation, Depletion and Amortization, Nonproduction Total Expenses Operating Expenses OTHER INCOME (EXPENSE) Nonoperating Income (Expense) [Abstract] Gain on sales of real estate assets Gains (Losses) on Sales of Investment Real Estate Interest expense Interest Expense Interest and other income, net Other Nonoperating Income Total other income (expense) Nonoperating Income (Expense) NET INCOME Basic earnings per common share (in dollars per share) Earnings Per Share, Basic Diluted earnings per common share (in dollars per share) Earnings Per Share, Diluted Weighted average common shares outstanding - basic (in shares) Weighted Average Number of Shares Outstanding, Basic Weighted average common shares outstanding - diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Dividends declared, per common share, during the period (in dollars per share) Common Stock, Dividends, Per Share, Declared ASSETS Assets [Abstract] Real estate properties: Real Estate Investment Property, Net [Abstract] Land Land Buildings, improvements and lease intangibles Investment Building and Building Improvements Personal property Personal Property Personal property. Construction in progress Development in Process Land held for development Land Available for Development Real estate properties, Total Real Estate Investment Property, at Cost Less accumulated depreciation and amortization Real Estate Investment Property, Accumulated Depreciation Total real estate properties, net Real Estate Investment Property, Net Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Assets held for sale, net Assets Held-for-sale and Discontinued Operations Net Assets held for sale and discontinued operations, net. Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Financing lease right-of-use assets Finance Lease, Right-of-Use Asset Other assets, net Other Assets Total assets Assets LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities and Equity [Abstract] Liabilities: Liabilities [Abstract] Notes and bonds payable Long-term Debt Accounts payable and accrued liabilities Accounts Payable and Accrued Liabilities Liabilities of properties held for sale Disposal Group, Including Discontinued Operation, Liabilities Operating lease liabilities Operating Lease, Liability Financing lease liabilities Finance Lease, Liability Other liabilities Other Liabilities Total liabilities Liabilities Commitments and contingencies Commitments and Contingencies Stockholders' equity: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] Preferred stock, $.01 par value per share; 50,000 shares authorized; none issued and outstanding Preferred Stock, Value, Issued Common stock, $.01 par value per share; 300,000 shares authorized; 129,214 and 125,279 shares issued and outstanding at March 31, 2019 and December 31, 2018, respectively Common Stock, Value, Issued Additional paid-in capital Additional Paid in Capital, Common Stock Accumulated other comprehensive loss Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax Cumulative net income attributable to common stockholders Cumulative Net Income Attributable to Common Stockholders Cumulative net income attributable to common stockholders. Cumulative dividends Cumulative Dividends Total stockholders' equity Total liabilities and stockholders' equity Liabilities and Equity Business Combinations [Abstract] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Table] Disposal Groups, Including Discontinued Operations [Table] Disposal Group Name [Axis] Disposal Group Name [Axis] Disposal Group Name [Domain] Disposal Group Name [Domain] Inpatient Rehabilitation Facility Inpatient Rehab [Member] Inpatient rehab. Disposal Group Classification [Axis] Disposal Group Classification [Axis] Disposal Group Classification [Domain] Disposal Group Classification [Domain] Disposal Group, Held-for-sale, Not Discontinued Operations Disposal Group, Held-for-sale, Not Discontinued Operations [Member] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Asset Dispositions and Potential Dispositions Assets and Liabilities Related to Held for Sale and Discontinued Operations [Abstract] Assets and liabilities related to held for sale and discontinued operations. Balance Sheet data (as of the period ended): Investment Building and Building Improvements Accumulated depreciation Operating lease right-of-use assets Disposal Group, Including Discontinued Operation, Operating Lease, Right-of-Use Assets Disposal Group, Including Discontinued Operation, Operating Lease, Right-of-Use Assets Other assets, net Disposal Group, Including Discontinued Operation, Other Assets Assets held for sale, net Disposal Group, Including Discontinued Operation, Assets Accounts payable and accrued liabilities Disposal Group, Including Discontinued Operation, Accounts Payable and Accrued Liabilities Operating lease liabilities Disposal Group, Including Discontinued Operation, Operating Lease Liabilities Disposal Group, Including Discontinued Operation, Operating Lease Liabilities Other liabilities Disposal Group, Including Discontinued Operation, Other Liabilities Liabilities of properties held for sale Statement of Cash Flows [Abstract] OPERATING ACTIVITIES Net Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net income to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Depreciation and amortization Depreciation, Depletion and Amortization Other amortization Amortization of Other Deferred Charges Share-based compensation Share-based Compensation Amortization of straight-line rent receivable (lessor) Straight-line Rent Receivable Straight-line rent receivable. Amortization of straight-line rent on operating leases (lessee) Straight-line Rent Liability Straight-line rent liability. Gain on sales of real estate assets Gains (Losses) on Sales of Investment Real Estate, Including Discontinued Operation Gains (Losses) on Sales of Investment Real Estate, Including Discontinued Operation Equity from unconsolidated joint ventures loss Income (Loss) from Equity Method Investments Distributions from unconsolidated joint ventures Proceeds from Equity Method Investment, Distribution Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Other assets, including right-of-use-assets Increase (Decrease) in Other Operating Assets Accounts payable and accrued liabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities Other liabilities Increase (Decrease) in Other Operating Liabilities Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities INVESTING ACTIVITIES Net Cash Provided by (Used in) Investing Activities [Abstract] Acquisitions of real estate Payments to Acquire Real Estate Development of real estate Payments to Develop Real Estate Assets Additional long-lived assets Payments for Capital Improvements Proceeds from notes receivable repayments Proceeds from Sale and Collection of Notes Receivable Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities FINANCING ACTIVITIES Net Cash Provided by (Used in) Financing Activities [Abstract] Net (repayments) borrowings on unsecured credit facility Proceeds from (Repayments of) Lines of Credit Repayments on notes and bonds payable Repayments of Debt Dividends paid Payments of Ordinary Dividends, Common Stock Net proceeds from issuance of common stock Proceeds from Issuance of Common Stock Common stock redemptions Payments for Repurchase of Common Stock Debt issuance and assumption costs Payments of Debt Issuance Costs Net cash provided by (used in) financing activities Net Cash Provided by (Used in) Financing Activities Increase (decrease) in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect Cash and cash equivalents at beginning of period Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Cash and cash equivalents at end of period Supplemental Cash Flow Information: Supplemental Cash Flow Information [Abstract] Interest paid Interest Paid, Including Capitalized Interest, Operating and Investing Activities Invoices accrued for construction, tenant improvements and other capitalized costs Capital Expenditures Incurred but Not yet Paid Capitalized interest Interest Paid, Capitalized, Investing Activities Accounting Policies [Abstract] Business Overview Nature of Operations [Policy Text Block] Nature Of Operations Policy. Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Use of Estimates in the Condensed Consolidated Financial Statements Use of Estimates, Policy [Policy Text Block] Revenue from Contracts with Customers (Topic 606) Revenue from Contract with Customer [Text Block] New Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Dividend per share to common Stockholders (in dollars per share) Common Stock, Dividends, Per Share, Cash Paid Derivative Instruments, Gain (Loss) [Table] Derivative Instruments, Gain (Loss) [Table] Hedging Relationship [Axis] Hedging Relationship [Axis] Hedging Relationship [Domain] Hedging Relationship [Domain] Cash Flow Hedging Cash Flow Hedging [Member] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Subsequent Event Subsequent Event [Member] Active Interest Rate Swap Active Interest Rate Swaps [Member] Active Interest Rate Swaps [Member] Settled Interest Rate Swap Settled Interest Rate Swap [Member] Settled Interest Rate Swap [Member] Derivative Instruments, Gain (Loss) [Line Items] Derivative Instruments, Gain (Loss) [Line Items] Interest rate cash flow hedge gain (loss) to be reclassified to interest expense during the next 12 months Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net Number of instruments Number of Interest Rate Derivatives Held Notional amount Derivative, Notional Amount Derivative, fixed interest rate (percent) Derivative, Fixed Interest Rate Balance Sheet Location [Axis] Balance Sheet Location [Axis] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Other liabilities Other Liabilities [Member] Hedging Designation [Axis] Hedging Designation [Axis] Hedging Designation [Domain] Hedging Designation [Domain] Designated as Hedging Instrument Designated as Hedging Instrument [Member] Interest Rate Swap Liability derivatives Derivative Liability, Fair Value, Gross Liability Derivative Financial Instruments Derivative Instruments and Hedging Activities Disclosure [Text Block] Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Adjustments for New Accounting Pronouncements [Axis] Adjustments for New Accounting Pronouncements [Axis] Type of Adoption [Domain] Type of Adoption [Domain] Accounting Standards Update 2016-02 Accounting Standards Update 2016-02 [Member] Range [Axis] Range [Axis] Range [Domain] Range [Domain] Weighted Average Remaining Term Weighted Average [Member] Minimum Minimum [Member] Maximum Maximum [Member] Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Number of properties subject to ground leases Number of Properties Subject to Ground Leases Square feet subject to ground leases Square Feet Subject to Ground Leases Square Feet Subject to Ground Leases Ground lease, initial term Lessee, Operating Lease, Term of Contract Term of lease, including renewals Lessee, Operating Lease, Term of Contract, Including Renewals Lessee, Operating Lease, Term of Contract, Including Renewals Number of prepaid ground leases Number of Ground Leases Prepaid Number of Ground Leases Prepaid Amortization of prepaid rent Amortization of Prepaid Rent Amortization of Prepaid Rent Number of non-prepaid ground leases Number of Ground Leases, Excluding Prepaid Leases Number of Ground Leases, Excluding Prepaid Leases Disaggregation of revenue Disaggregation of Revenue [Table Text Block] Equity [Abstract] Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Weighted Average Sale of Stock [Axis] Sale of Stock [Axis] Sale of Stock [Domain] Sale of Stock [Domain] Equity Offering Equity Offering [Member] Equity Offering [Member] Stock Issuance Program [Axis] Stock Issuance Program [Axis] Stock Issuance Program [Axis] Stock Issuance Program [Domain] Stock Issuance Program [Domain] [Domain] for Stock Issuance Program [Axis] At The Market Equity Offering Program At The Market Equity Offering Program [Member] At The Market Equity Offering Program [Member] Class of Stock [Line Items] Class of Stock [Line Items] Issuance of common stock (shares) Stock Issued During Period, Shares, New Issues Shares Issued, Price Per Share Shares Issued, Price Per Share Proceeds from Issuance of Common Stock Shares Issued During Period, Price Per Share Shares Issued During Period, Price Per Share Shares Issued During Period, Price Per Share Number of authorized shares remaining under offering program (shares) Number of Authorized Shares Remaining Under Offering Program Number of Authorized Shares Remaining Under Offering Program Dividends declared per common share, during the period (in dollars per share) Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Plan Name [Axis] Plan Name [Axis] Plan Name [Domain] Plan Name [Domain] Stock Incentive Plan Stock Incentive Plan [Member] Stock Incentive Plan [Member] Award Type [Axis] Award Type [Axis] Award Type [Domain] Equity Award [Domain] Restricted Stock Restricted Stock [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Summary of the activity under the incentive plans Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Share-based awards, beginning of period Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Granted (shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Vested (shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Share-based awards, end of period Shares withheld to pay estimated withholding taxes Shares Paid for Tax Withholding for Share Based Compensation Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) [Table Text Block] Schedule of Derivative Instruments in Statement of Financial Position, Fair Value Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block] Schedule of Derivative Instruments, Effect on Other Comprehensive Income (Loss) Schedule of Derivative Instruments, Effect on Other Comprehensive Income (Loss) [Table Text Block] Reconciliation of the beginning and ending common stock outstanding Reconciliation of Beginning and Ending Common Stock Outstanding [Roll Forward] Reconciliation of the beginning and ending common stock outstanding. Balance, beginning of period Issuance of common stock Nonvested share-based awards, net of withheld shares Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Balance, end of period Net investment in property held for sale Real Estate Held-for-sale Number of properties held for sale Number of Properties Held for Sale Number of properties held for sale. Operating Operating Lease Liabilities, Payments Due [Abstract] 2019 Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year 2020 Lessee, Operating Lease, Liability, Payments, Due Year Two 2021 Lessee, Operating Lease, Liability, Payments, Due Year Three 2022 Lessee, Operating Lease, Liability, Payments, Due Year Four 2023 Lessee, Operating Lease, Liability, Payments, Due Year Five 2024 and thereafter Lessee, Operating Lease, Liability, Payments, Due after Year Five Total undiscounted lease payments Lessee, Operating Lease, Liability, Payments, Due Discount Lessee, Operating Lease, Liability, Undiscounted Excess Amount Lease Liability Financing Finance Lease Liabilities, Payments, Due [Abstract] 2019 Finance Lease, Liability, Payments, Remainder of Fiscal Year 2020 Finance Lease, Liability, Payments, Due Year Two 2021 Finance Lease, Liability, Payments, Due Year Three 2022 Finance Lease, Liability, Payments, Due Year Four 2023 Finance Lease, Liability, Payments, Due Year Five 2024 and thereafter Finance Lease, Liability, Payments, Due after Year Five Total undiscounted lease payments Finance Lease, Liability, Payments, Due Discount Finance Lease, Liability, Undiscounted Excess Amount Lease Liability Leases Operating and Finance Leases [Text Block] Operating and Finance Leases [Text Block] Future Minimum Lease Payments Receivable Lessor, Operating Lease, Payments to be Received, Maturity [Table Text Block] Future Minimum Lease Payments Receivable under ASC 840 Future Minimum Lease Payments Receivable under ASC 840 [Table Text Block] Future Minimum Lease Payments Receivable under ASC 840 [Table Text Block] Future Minimum Operating Lease Payments Lessee, Operating Lease, Liability, Maturity [Table Text Block] Future Minimum Financing Lease Payments Finance Lease, Liability, Maturity [Table Text Block] Lease Cost Lease, Cost [Table Text Block] Future Minimum Lease Payments under ASC 840 Contractual Obligation, Fiscal Year Maturity Schedule [Table Text Block] Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Line of Credit Line of Credit [Member] Medium-term Notes Medium-term Notes [Member] Senior Notes Senior Notes [Member] Mortgages Mortgages [Member] Debt Instrument [Axis] Debt Instrument [Axis] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Unsecured Credit Facility Unsecured Credit Facility Due 2020 [Member] Unsecured Credit Facility Due 2020 [Member] Unsecured Term Loan Facility, net of issuance costs (1) Term Loan due 2022 [Member] Term Loan due 2022 [Member] Senior Notes due 2023, net of discount and issuance costs Senior Notes due 2023 [Member] Senior Notes due 2023 [Member] Senior Notes due 2025, net of discount and issuance costs (2) Senior Notes due 2025 [Member] Senior Notes due 2025 [Member] Senior Notes due 2028, net of discount and issuance costs Senior Notes due 2028 [Member] Senior Notes due 2028 [Member] Mortgage notes payable, net of discounts and issuance costs and including premiums Mortgage Notes Payable, Net [Member] Mortgage Notes Payable, Net [Member] Debt Instrument [Line Items] Debt Instrument [Line Items] Effective interest rate (percent) Debt Instrument, Interest Rate, Effective Percentage Basis spread on variable rate (percent) Debt Instrument, Basis Spread on Variable Rate Loss on forward starting interest rate swap agreement recognized in OCI Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, before Tax Extinguishment of Debt, Amount Extinguishment of Debt, Amount Area of Real Estate Property Area of Real Estate Property Weighted average Common Shares outstanding Weighted Average Number of Shares Outstanding, Diluted [Abstract] Weighted average Common Shares outstanding Weighted Average Number of Shares Issued, Basic Nonvested shares Weighted Average Number of Shares, Restricted Stock Weighted average Common Shares—Basic Dilutive effect of employee stock purchase plan Incremental Common Shares Attributable to Dilutive Effect of Employee Stock Purchase Plan Incremental common shares attributable to dilutive effect of employee stock purchase plan. Weighted average Common Shares outstanding—Diluted Net Income Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent Dividends paid on nonvested share-based awards Dividends, Share-based Compensation Net income applicable to common stockholders Net Income (Loss) from Continuing Operations Available to Common Stockholders, Basic Net Income (Loss) from Continuing Operations Available to Common Stockholders, Basic Stockholders' Equity Stockholders' Equity Note Disclosure [Text Block] Employee Stock Purchase Plan Employee Stock [Member] Summary of the Employee Stock Purchase Plan activity Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Outstanding and exercisable, beginning of period (shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Granted (shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Exercised (shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Forfeited (shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Expired (shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period Outstanding and exercisable, end of period (shares) Future Lease Payments Receivable [Abstract] Lessor, Operating Lease, Payments, Fiscal Year Maturity [Abstract] 2019 Lessor, Operating Lease, Payments to be Received, Remainder of Fiscal Year 2020 Lessor, Operating Lease, Payments to be Received, Two Years 2021 Lessor, Operating Lease, Payments to be Received, Three Years 2022 Lessor, Operating Lease, Payments to be Received, Four Years 2023 Lessor, Operating Lease, Payments to be Received, Five Years 2024 and thereafter Lessor, Operating Lease, Payments to be Received, Thereafter Total Lessor, Operating Lease, Payments to be Received Real Estate Investments Acquisitions and Dispositions [Text Block] Acquisitions and dispositions. Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Product and Service [Axis] Product and Service [Axis] Product and Service [Domain] Product and Service [Domain] Parking Income Parking Income [Member] Parking Income [Member] Rental Lease Guaranty Rental Lease Guaranty [Member] Rental Lease Guaranty [Member] Management Fee Income Management Fee Income [Member] Management Fee Income [Member] Miscellaneous Miscellaneous [Member] Miscellaneous [Member] Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Real Estate, Type of Property [Axis] Real Estate, Type of Property [Axis] Real Estate [Domain] Real Estate [Domain] Medical Office Building Medical Office Building [Member] Medical Office Building [Member] Geographical [Axis] Geographical [Axis] Geographical [Domain] Geographical [Domain] Washington, D.C. (4) DISTRICT OF COLUMBIA Indianapolis, IN (5) INDIANA Atlanta, Georgia GEORGIA Tucson, Arizona ARIZONA Real Estate Acquisitions and Mortgage Note Financing [Axis] Real Estate Acquisitions and Mortgage Note Financing [Axis] Real Estate Acquisitions and Mortgage Note Financing. Real Estate Acquisitions and Mortgage Note Financing [Domain] Real Estate Acquisitions and Mortgage Note Financing [Domain] Real Estate Acquisitions and Mortgage Note Financing. Real Estate Acquisition Real Estate Acquisitions [Member] Real estate acquisitions. Real Estate Dispositions Real Estate Dispositions [Member] Real Estate Dispositions [Member] Business Acquisition [Line Items] Business Acquisition [Line Items] Number of properties acquired Number of Properties Acquired Number of Properties Acquired Date Acquired Business Acquisition, Effective Date of Acquisition Purchase price Business Combination, Consideration Transferred Cash consideration Payments to Acquire Businesses, Gross Real Estate Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Real Property Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Real Property Other Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Fair Value Adjustments and Other Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Fair Value Adjustments and Other Square footage Business Acquisition Purchase Price Allocation Square Footage Business Acquisition Purchase Price Allocation Square Footage. Number of Off-campus Buildings Number of Off-campus Buildings Number of Off-campus Buildings Number of On-campus Buildings Number of On-campus Buildings Number of On-campus Buildings Sales price Disposition Sales Price Disposition Sales Price Net Real Estate Investment Real Estate Investment Net Disposed of During Period Real estate investment net disposed of during the Period. Above-market lease intangibles Finite-Lived Intangible Asset, Off-market Lease, Favorable, Gross Prepaid ground leases Ground Leases, Net Below-market lease intangible Below Market Lease, Net 2019 Operating Leases, Future Minimum Payments Due, Next Twelve Months 2020 Operating Leases, Future Minimum Payments, Due in Two Years 2021 Operating Leases, Future Minimum Payments, Due in Three Years 2022 Operating Leases, Future Minimum Payments, Due in Four Years 2023 Operating Leases, Future Minimum Payments, Due in Five Years 2024 and thereafter Operating Leases, Future Minimum Payments, Due Thereafter Total Operating Leases, Future Minimum Payments Due Reconciliation of beginning and ending common stock outstanding Reconciliation of Beginning and Ending Common Stock Outstanding [Table Text Block] Reconciliation of beginning and ending common stock outstanding. Earnings (loss) per share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Summary of the activity under the Incentive Plan Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block] Summary of employee stock purchase plan activity Schedule of Share-based Compensation, Employee Stock Purchase Plan, Activity [Table Text Block] Summary of acquisitions Schedule of Business Acquisitions, by Acquisition [Table Text Block] Assets held for sale Disposal Groups, Including Discontinued Operations [Table Text Block] Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] New Accounting Pronouncements or Change in Accounting Principle [Table] New Accounting Pronouncements or Change in Accounting Principle [Table] Other Assets Other Assets [Member] Accounts Payable and Accrued Liabilities Accounts Payable and Accrued Liabilities [Member] New Accounting Pronouncements or Change in Accounting Principle [Line Items] New Accounting Pronouncements or Change in Accounting Principle [Line Items] Weighted-average remaining lease term - operating leases Operating Lease, Weighted Average Remaining Lease Term Ground lease, discount rate (percent) Lessee, Operating Lease, Discount Rate Transfers to operating lease, right-of-use assets Transfers to Operating Lease, Right-of-use Assets Transfers to Operating Lease, Right-of-use Assets Fair Value Disclosures [Abstract] Measurement Basis [Axis] Measurement Basis [Axis] Fair Value Measurement [Domain] Fair Value Measurement [Domain] Portion at Fair Value Measurement [Member] Portion at Fair Value Measurement [Member] Carrying Value Reported Value Measurement [Member] Fair Value Estimate of Fair Value Measurement [Member] Notes and bonds payable Debt Instrument, Fair Value Disclosure Document and Entity Information [Abstract] Document and Entity Information. Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Document Type Document Type Document Period End Date Document Period End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Amendment Flag Amendment Flag Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Entity Emerging Growth Company Entity Emerging Growth Company Entity Small Business Entity Small Business Business Overview: Business Overview [Abstract] Business Overview [Abstract] Gross investment amount, total Investment in Real Estate Properties and Mortgage Notes Investment in real estate properties and mortgage notes. Number of real estate properties Number of Real Estate Investments Number of real estate investments. Number of states that the Company owns real estate in, whole units Real Estate Investments Property Owned in Number of States Real estate investments property owned in number of states. Square footage of owned real estate properties Approximate square feet for which Nationwide property management services provided by company Approximate Square Feet Provided by Company Approximate square feet for which Nationwide property management services provided by company Other Commitments [Table] Other Commitments [Table] Medical Office Building Expansion Medical Office Building Expansion [Member] Medical Office Building Expansion [Member] NORTH CAROLINA NORTH CAROLINA COLORADO COLORADO Other Commitments [Line Items] Other Commitments [Line Items] Approximate Square Feet Total amount funded Construction Activity, Total Amount Funded Construction Activity, Total Amount Funded Fair Value of Financial Instruments Fair Value Disclosures [Text Block] Lease expense Lease, Cost [Abstract] Operating lease expense Operating Lease, Cost Variable lease expense Variable Lease, Cost Total lease expense Lease, Cost Other information Leases, Operating [Abstract] Operating cash flows outflows related to operating leases Operating Lease, Payments Right-of-use assets obtained in exchange for new operating lease liabilities Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Right-of-use assets obtained in exchange for new finance lease liabilities Right-of-Use Asset Obtained in Exchange for Finance Lease Liability Weighted-average remaining lease term - finance leases Finance Lease, Weighted Average Remaining Lease Term Weighted-average discount rate - operating leases (percent) Operating Lease, Weighted Average Discount Rate, Percent Weighted-average discount rate - finance leases (percent) Finance Lease, Weighted Average Discount Rate, Percent Fair value and carrying values for notes and bonds payable, mortgage notes receivable, and notes receivable Fair Value, by Balance Sheet Grouping [Table Text Block] Schedule of Debt Schedule of Debt [Table Text Block] EX-101.PRE 9 hr-20190331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 10 hr-2019331xsinglesourc_htm.xml IDEA: XBRL DOCUMENT 0000899749 2019-01-01 2019-03-31 0000899749 2019-04-26 0000899749 2019-03-31 0000899749 2018-12-31 0000899749 2018-01-01 2018-03-31 0000899749 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-03-31 0000899749 2018-03-31 0000899749 us-gaap:CommonStockMember 2018-01-01 2018-03-31 0000899749 2017-12-31 0000899749 hr:CumulativeDividendsMember 2017-12-31 0000899749 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0000899749 us-gaap:CommonStockMember 2017-12-31 0000899749 us-gaap:AdditionalPaidInCapitalMember 2018-03-31 0000899749 hr:CumulativeNetIncomeMember 2018-03-31 0000899749 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0000899749 hr:CumulativeNetIncomeMember 2018-01-01 2018-03-31 0000899749 hr:CumulativeNetIncomeMember 2017-12-31 0000899749 hr:CumulativeDividendsMember 2018-03-31 0000899749 hr:CumulativeDividendsMember 2018-01-01 2018-03-31 0000899749 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-03-31 0000899749 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-03-31 0000899749 us-gaap:CommonStockMember 2018-03-31 0000899749 us-gaap:CommonStockMember 2019-01-01 2019-03-31 0000899749 us-gaap:CommonStockMember 2019-03-31 0000899749 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0000899749 hr:CumulativeDividendsMember 2019-03-31 0000899749 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-03-31 0000899749 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0000899749 hr:CumulativeNetIncomeMember 2019-01-01 2019-03-31 0000899749 hr:CumulativeDividendsMember 2019-01-01 2019-03-31 0000899749 us-gaap:CommonStockMember 2018-12-31 0000899749 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0000899749 hr:CumulativeNetIncomeMember 2018-12-31 0000899749 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0000899749 hr:CumulativeDividendsMember 2018-12-31 0000899749 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-03-31 0000899749 hr:CumulativeNetIncomeMember 2019-03-31 0000899749 us-gaap:AccountsPayableAndAccruedLiabilitiesMember 2019-01-01 2019-01-01 0000899749 srt:MaximumMember us-gaap:AccountingStandardsUpdate201602Member 2019-03-31 0000899749 srt:WeightedAverageMember us-gaap:AccountingStandardsUpdate201602Member 2019-03-31 0000899749 us-gaap:OtherLiabilitiesMember 2019-01-01 2019-01-01 0000899749 us-gaap:OtherAssetsMember 2019-01-01 2019-01-01 0000899749 srt:MinimumMember us-gaap:AccountingStandardsUpdate201602Member 2018-12-31 0000899749 srt:MinimumMember us-gaap:AccountingStandardsUpdate201602Member 2019-03-31 0000899749 srt:MaximumMember us-gaap:AccountingStandardsUpdate201602Member 2018-12-31 0000899749 hr:RentalLeaseGuarantyMember 2019-01-01 2019-03-31 0000899749 hr:MiscellaneousMember 2019-01-01 2019-03-31 0000899749 hr:RentalLeaseGuarantyMember 2018-01-01 2018-03-31 0000899749 hr:ManagementFeeIncomeMember 2019-01-01 2019-03-31 0000899749 hr:ManagementFeeIncomeMember 2018-01-01 2018-03-31 0000899749 hr:ParkingIncomeMember 2018-01-01 2018-03-31 0000899749 hr:ParkingIncomeMember 2019-01-01 2019-03-31 0000899749 hr:MiscellaneousMember 2018-01-01 2018-03-31 0000899749 hr:RealEstateAcquisitionsMember 2019-03-31 0000899749 hr:MedicalOfficeBuildingMember stpr:DC hr:RealEstateAcquisitionsMember 2019-03-28 0000899749 hr:MedicalOfficeBuildingMember stpr:IN hr:RealEstateAcquisitionsMember 2019-03-28 0000899749 hr:MedicalOfficeBuildingMember stpr:DC hr:RealEstateAcquisitionsMember 2019-03-28 2019-03-28 0000899749 hr:MedicalOfficeBuildingMember stpr:IN hr:RealEstateAcquisitionsMember 2019-03-28 2019-03-28 0000899749 hr:MedicalOfficeBuildingMember stpr:DC hr:RealEstateAcquisitionsMember 2018-05-03 2018-05-03 0000899749 hr:RealEstateAcquisitionsMember 2019-01-01 2019-03-31 0000899749 hr:MedicalOfficeBuildingMember stpr:IN hr:RealEstateAcquisitionsMember 2018-05-21 2018-05-21 0000899749 us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember hr:InpatientRehabMember 2019-03-31 0000899749 us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember hr:InpatientRehabMember 2018-12-31 0000899749 hr:MedicalOfficeBuildingMember stpr:AZ us-gaap:SubsequentEventMember hr:RealEstateDispositionsMember 2019-04-09 0000899749 hr:MedicalOfficeBuildingMember stpr:DC hr:RealEstateAcquisitionsMember 2019-03-31 0000899749 hr:MedicalOfficeBuildingMember stpr:GA us-gaap:SubsequentEventMember hr:RealEstateAcquisitionsMember 2019-04-02 2019-04-02 0000899749 hr:MedicalOfficeBuildingMember stpr:AZ hr:RealEstateDispositionsMember 2019-03-31 0000899749 hr:MedicalOfficeBuildingMember stpr:GA us-gaap:SubsequentEventMember hr:RealEstateAcquisitionsMember 2019-04-02 0000899749 srt:MaximumMember 2018-12-31 0000899749 2018-01-01 2018-12-31 0000899749 srt:MinimumMember 2018-01-01 2018-12-31 0000899749 srt:MaximumMember 2018-01-01 2018-12-31 0000899749 srt:WeightedAverageMember 2018-12-31 0000899749 srt:MinimumMember 2018-12-31 0000899749 srt:WeightedAverageMember us-gaap:AccountingStandardsUpdate201602Member 2019-01-01 2019-03-31 0000899749 2016-01-01 2016-12-31 0000899749 2017-01-01 2017-12-31 0000899749 hr:SeniorNotesdue2023Member us-gaap:SeniorNotesMember 2019-03-31 0000899749 hr:TermLoandue2022Member us-gaap:MediumTermNotesMember 2019-03-31 0000899749 hr:MortgageNotesPayableNetMember us-gaap:MortgagesMember 2018-12-31 0000899749 hr:SeniorNotesdue2025Member us-gaap:SeniorNotesMember 2019-03-31 0000899749 hr:SeniorNotesdue2028Member us-gaap:SeniorNotesMember 2019-03-31 0000899749 hr:TermLoandue2022Member us-gaap:MediumTermNotesMember 2018-12-31 0000899749 hr:MortgageNotesPayableNetMember us-gaap:MortgagesMember 2019-03-31 0000899749 hr:SeniorNotesdue2025Member us-gaap:SeniorNotesMember 2018-12-31 0000899749 hr:UnsecuredCreditFacilityDue2020Member us-gaap:LineOfCreditMember 2018-12-31 0000899749 hr:UnsecuredCreditFacilityDue2020Member us-gaap:LineOfCreditMember 2019-03-31 0000899749 hr:SeniorNotesdue2023Member us-gaap:SeniorNotesMember 2018-12-31 0000899749 hr:SeniorNotesdue2028Member us-gaap:SeniorNotesMember 2018-12-31 0000899749 hr:MortgageNotesPayableNetMember us-gaap:MortgagesMember us-gaap:SubsequentEventMember 2019-04-10 0000899749 hr:TermLoandue2022Member us-gaap:InterestRateSwapMember us-gaap:MediumTermNotesMember 2019-03-31 0000899749 hr:MortgageNotesPayableNetMember us-gaap:MortgagesMember us-gaap:SubsequentEventMember 2019-04-10 2019-04-10 0000899749 hr:SeniorNotesdue2025Member us-gaap:InterestRateSwapMember us-gaap:SeniorNotesMember 2019-01-01 2019-03-31 0000899749 hr:TermLoandue2022Member us-gaap:MediumTermNotesMember 2019-01-01 2019-03-31 0000899749 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-03-31 0000899749 us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-03-31 0000899749 us-gaap:OtherLiabilitiesMember us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-03-31 0000899749 us-gaap:InterestRateContractMember us-gaap:InterestExpenseMember 2018-01-01 2018-03-31 0000899749 us-gaap:InterestRateContractMember us-gaap:InterestExpenseMember 2019-01-01 2019-03-31 0000899749 us-gaap:InterestExpenseMember 2019-01-01 2019-03-31 0000899749 us-gaap:InterestRateContractMember 2019-01-01 2019-03-31 0000899749 us-gaap:InterestExpenseMember 2018-01-01 2018-03-31 0000899749 us-gaap:InterestRateSwapMember 2019-01-01 2019-03-31 0000899749 us-gaap:InterestRateSwapMember us-gaap:InterestExpenseMember 2019-01-01 2019-03-31 0000899749 us-gaap:InterestRateSwapMember us-gaap:InterestExpenseMember 2018-01-01 2018-03-31 0000899749 hr:ActiveInterestRateSwapsMember 2019-03-31 0000899749 hr:SettledInterestRateSwapMember 2019-03-31 0000899749 us-gaap:InterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:SubsequentEventMember 2019-04-12 0000899749 hr:MedicalOfficeBuildingMember stpr:CO 2019-03-31 0000899749 hr:MedicalOfficeBuildingExpansionMember stpr:NC 2019-03-31 0000899749 hr:MedicalOfficeBuildingMember stpr:NC 2019-03-31 0000899749 us-gaap:EmployeeStockMember 2018-01-01 2018-03-31 0000899749 us-gaap:EmployeeStockMember 2018-03-31 0000899749 us-gaap:EmployeeStockMember 2019-01-01 2019-03-31 0000899749 us-gaap:EmployeeStockMember 2018-12-31 0000899749 us-gaap:EmployeeStockMember 2017-12-31 0000899749 us-gaap:EmployeeStockMember 2019-03-31 0000899749 hr:StockIncentivePlanMember 2018-01-01 2018-03-31 0000899749 hr:StockIncentivePlanMember 2019-01-01 2019-03-31 0000899749 hr:StockIncentivePlanMember 2018-03-31 0000899749 hr:StockIncentivePlanMember 2019-03-31 0000899749 hr:StockIncentivePlanMember 2018-12-31 0000899749 hr:StockIncentivePlanMember 2017-12-31 0000899749 srt:MaximumMember hr:AtTheMarketEquityOfferingProgramMember 2019-01-01 2019-03-31 0000899749 us-gaap:SubsequentEventMember 2019-04-30 2019-04-30 0000899749 hr:EquityOfferingMember 2019-03-19 0000899749 us-gaap:SubsequentEventMember hr:AtTheMarketEquityOfferingProgramMember 2019-04-26 0000899749 us-gaap:RestrictedStockMember hr:StockIncentivePlanMember 2019-01-01 2019-03-31 0000899749 us-gaap:RestrictedStockMember hr:StockIncentivePlanMember 2018-01-01 2018-03-31 0000899749 hr:EquityOfferingMember 2019-03-19 2019-03-19 0000899749 hr:AtTheMarketEquityOfferingProgramMember 2019-01-01 2019-03-31 0000899749 srt:MinimumMember hr:AtTheMarketEquityOfferingProgramMember 2019-01-01 2019-03-31 0000899749 srt:WeightedAverageMember hr:AtTheMarketEquityOfferingProgramMember 2019-01-01 2019-03-31 0000899749 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2018-12-31 0000899749 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2018-12-31 0000899749 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2019-03-31 0000899749 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2019-03-31 pure iso4217:USD shares hr:derivative shares hr:swap_agreement hr:Building iso4217:USD utreg:sqft hr:state hr:property hr:Lease false --12-31 Q1 2019 2019-03-31 0000899749 false Large Accelerated Filer false 500 500000 100000 0.30 0.01 0.01 300000000 300000000 125279000 129214000 125279000 129214000 0.0110 0.01 0.01 50000000 50000000 0 0 0 0 10-Q HEALTHCARE REALTY TRUST INCORPORATED 129214135 230206000 230206000 3757260000 3675415000 10739000 10696000 40326000 33107000 24647000 24647000 4063178000 3974071000 1035800000 1015174000 3027378000 2958897000 11313000 8381000 10568000 9272000 128141000 9259000 175864000 214697000 3362523000 3191247000 1343110000 1345984000 61519000 80411000 633000 587000 91044000 14294000 46144000 47623000 1556744000 1474605000 0 0 1292000 1253000 3302814000 3180284000 1611000 902000 1093010000 1088119000 2589726000 2552112000 1805779000 1716642000 3362523000 3191247000 110696000 110229000 1961000 1895000 112657000 112124000 42725000 41818000 8510000 9101000 305000 277000 42662000 39573000 94202000 90769000 15000 13588000 12668000 9000 493000 -13564000 -12175000 4891000 9180000 0.04 0.07 0.04 0.07 124130000 123257000 124232000 123348000 0.30 0.30 4891000 9180000 -15000 -147000 -724000 513000 -709000 660000 4182000 9840000 1253000 3180284000 -902000 1088119000 -2552112000 1716642000 38000 120462000 120500000 570000 570000 1000 2638000 2639000 4891000 4891000 -15000 -15000 -724000 -724000 37614000 37614000 1292000 3302814000 -1611000 1093010000 -2589726000 1805779000 1251000 3173429000 -1299000 1018348000 -2401846000 1789883000 239000 239000 680000 680000 1000 2821000 2822000 9180000 9180000 -147000 -147000 513000 513000 37556000 37556000 1252000 3175809000 -639000 1027528000 -2439402000 1764548000 4891000 9180000 42662000 39573000 727000 584000 2639000 2822000 668000 1722000 390000 384000 15000 -10000 -10000 88000 37000 4971000 4193000 -10276000 -6949000 -673000 1094000 34804000 40820000 91787000 1756000 5712000 7573000 11741000 16764000 0 5000 -109240000 -26088000 -2000000 24000000 1193000 1154000 37614000 37556000 120617000 236000 2442000 2633000 44000 77368000 -17151000 2932000 -2419000 8381000 6215000 11313000 3796000 11071000 3899000 13509000 8592000 307000 186000 Business Overview<span style="font-family:inherit;font-size:10pt;">Healthcare Realty Trust Incorporated (the "Company") is a real estate investment trust ("REIT") that owns, leases, manages, acquires, finances, develops and redevelops income-producing real estate properties associated primarily with the delivery of outpatient healthcare services throughout the United States. As of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company had gross investments of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$4.0 billion</span></span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;"><span>201</span></span><span style="font-family:inherit;font-size:10pt;"> real estate properties located in </span><span style="font-family:inherit;font-size:10pt;"><span>26</span></span><span style="font-family:inherit;font-size:10pt;"> states totaling approximately </span><span style="font-family:inherit;font-size:10pt;"><span>15.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> square feet. The Company provided leasing and property management services to approximately </span><span style="font-family:inherit;font-size:10pt;"><span>11.3 million</span></span> square feet nationwide. Business Overview<div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Healthcare Realty Trust Incorporated (the "Company") is a real estate investment trust ("REIT") that owns, leases, manages, acquires, finances, develops and redevelops income-producing real estate properties associated primarily with the delivery of outpatient healthcare services throughout the United States. As of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company had gross investments of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$4.0 billion</span></span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;"><span>201</span></span><span style="font-family:inherit;font-size:10pt;"> real estate properties located in </span><span style="font-family:inherit;font-size:10pt;"><span>26</span></span><span style="font-family:inherit;font-size:10pt;"> states totaling approximately </span><span style="font-family:inherit;font-size:10pt;"><span>15.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> square feet. The Company provided leasing and property management services to approximately </span><span style="font-family:inherit;font-size:10pt;"><span>11.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> square feet nationwide.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:9pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:9pt;font-weight:bold;">Basis of Presentation</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. They do not include all of the information and footnotes required by GAAP for complete financial statements. However, except as disclosed herein, management believes there has been no material change in the information disclosed in the Notes to the Consolidated Financial Statements included in the Annual Report on Form 10-K for the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">. All material intercompany transactions and balances have been eliminated in consolidation.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">This interim financial information should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">. Management believes that all adjustments of a normal, recurring nature considered necessary for a fair presentation have been included. In addition, the interim financial information does not necessarily represent or indicate what the operating results will be for the year ending </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> for many reasons including, but not limited to, acquisitions, dispositions, capital financing transactions, changes in interest rates and the effects of other trends, risks and uncertainties.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:9pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:9pt;font-weight:bold;">Use of Estimates in the Condensed Consolidated Financial Statements</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Preparation of the Condensed Consolidated Financial Statements in accordance with GAAP requires management to make estimates and assumptions that affect amounts reported in the Condensed Consolidated Financial Statements and accompanying notes. Actual results may differ from those estimates.</span></div><div style="line-height:120%;padding-bottom:4px;padding-top:12px;font-size:9pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:9pt;font-weight:bold;">Revenue from Contracts with Customers (Topic 606)</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company recognizes certain revenue under the core principle of Topic 606. This requires an entity to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Lease revenue is not within the scope of Topic 606. To achieve the core principle, the Company applies the five step model specified in the guidance. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenue that is accounted for under Topic 606 is segregated on the Company’s Condensed Consolidated Statements of Income in the Other operating line item. This line item includes parking income, rental lease guaranty income, management fee income and other miscellaneous income. Below is a detail of the amounts by category:</span></div><div style="line-height:120%;padding-bottom:4px;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:73.6328125%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:62%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Three Months Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Type of Revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Parking income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,734</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,626</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Rental lease guaranty</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>128</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>175</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Management fee income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>69</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>68</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Miscellaneous</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>30</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>26</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,961</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,895</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company’s three major types of revenue that are accounted for under Topic 606 that are listed above are all accounted for as the performance obligation is satisfied. The performance obligations that are identified for each of these items are satisfied over time and the Company recognizes revenue monthly based on this principle. </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:9pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:9pt;font-weight:bold;">New Accounting Pronouncements</span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:8pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:8pt;font-style:italic;font-weight:bold;">Accounting Standards Update No. 2016-02, No. 2018-01 and No. 2018-11</span></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2016, the Financial Accounting Standards Board ("FASB") issued ASU 2016-02, "Leases." In January 2018, FASB issued ASU 2018-01, "Leases - Land Easement Practical Expedient for Transition to Topic 842," in July 2018, FASB issued ASU 2018-10, "Codification Improvements to Topic 842, Leases" and ASU 2018-11, "Leases - Targeted Improvements," and in December 2018, FASB issued ASU 2018-20, “Narrow-Scope Improvements for Lessors.” These accounting standard updates are collectively referred to as "Topic 842." </span></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Topic 842 provides several practical expedients that the Company elected. These are (a) the package of practical expedients offered that allows an entity not to reassess upon adoption (i) whether an expired or existing contract contains a lease, (ii) lease classification related to expired or existing lease arrangements, and (iii) whether costs incurred on expired or existing leases qualify as initial direct costs, (b) the lessor practical expedient not to separate certain non-lease components, such as common area maintenance, from the lease component if (i) the timing and pattern of transfer are the same for the non-lease component and associated lease component, and (ii) the lease component would be classified as an operating lease if accounted for separately and (c) the lessee practical expedient not to separate certain non-lease components from the associated lease component.</span></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For lessees, the new standard establishes a right-of-use ("ROU") model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with the classification affecting the pattern of expense recognition in the income statement. Ground leases executed or assumed prior to the adoption of Topic 842 will continue to be accounted for as operating leases and will not result in a materially different ground lease expense. However, each ground lease executed after the adoption of Topic 842 will be evaluated to determine if it is an operating or finance lease. If the lease is to be accounted for as a finance lease, ground lease expense would be accounted for using the effective interest method instead of the straight-line method over the term of the lease, which would result in higher ground lease expense in the earlier years of a ground lease when compared to the straight-line method. The Company's lease population is primarily ground leases, but also includes management office leases in third party buildings and certain copier and postage machine leases. The Company utilized a third party to assist in determining the discount rate for its ground leases. The terms of the ground leases generally range from </span><span style="font-family:inherit;font-size:10pt;"><span>40</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>99</span></span><span style="font-family:inherit;font-size:10pt;"> years with a weighted average remaining lease term remaining of </span><span style="font-family:inherit;font-size:10pt;"><span>54.9 years</span></span><span style="font-family:inherit;font-size:10pt;">, excluding renewal options. The Company's discount rates, which approximates the Company's incremental borrowing rate, ranged from </span><span style="font-family:inherit;font-size:10pt;"><span>3.4%</span></span><span style="font-family:inherit;font-size:10pt;"> for leases expiring in 2019 to </span><span style="font-family:inherit;font-size:10pt;"><span>6.2%</span></span><span style="font-family:inherit;font-size:10pt;"> for leases expiring in 2115. The Company utilized a third party to assist in determining the discount rates. The discount rates consider the general economic environment and factor in various financing and asset specific adjustments so that the discount rate is appropriate for the intended use of the underlying lease. As of January 1, 2019, the Company recognized the present value of its lease payments and a corresponding lease liability of </span><span style="font-family:inherit;font-size:10pt;"><span>$91.7 million</span></span><span style="font-family:inherit;font-size:10pt;">. In addition, the Company reclassified </span><span style="font-family:inherit;font-size:10pt;"><span>$45.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> of prepaid ground leases and below-market lease intangibles from the Other assets line item, </span><span style="font-family:inherit;font-size:10pt;"><span>$1.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> of above-market lease intangibles from the Other liabilities line and </span><span style="font-family:inherit;font-size:10pt;"><span>$8.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> of straight-line rent from the Accounts payable and accrued liabilities line item to the Operating lease right-of-use assets line item on the Condensed Consolidated Balance Sheets.</span></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For lessors, the new standard requires a lessor to classify leases as either sales-type, direct-financing or operating. A lease will be treated as a sale if it is considered to transfer control of the underlying asset to the lessee. A lease will be classified as direct-financing if risks and rewards are conveyed without the transfer of control. Otherwise, the lease is treated as an operating lease. Lessor accounting remains largely unchanged with some exceptions including the concept of separating lease and nonlease components. Nonlease components, such as common area maintenance, are generally accounted for under Topic 606 and separated from the lease payments. However, the Company elected the lessor practical expedient allowing the Company to not separate these components when certain conditions are met. The combined component is accounted for under Topic 842. Lease related receivables, which include accounts receivable and accrued straight-line rent receivables, are reduced for revenue reserves and are recognized as a reduction to rental income. The adoption of Topic 842, where the Company is the lessor, did not have a material impact on the Company's Condensed Consolidated Financial Statements for the three months ended </span><span style="font-family:inherit;font-size:10pt;">March 31, 2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The new standard was effective for the Company on January 1, 2019. Topic 842 provides two transition alternatives. The Company elected to choose the prospective optional transition method available to apply the guidance in Accounting Standards Codification Topic 840 in the comparative periods presented in the year Topic 842 is adopted. Topic 842 includes extensive quantitative and qualitative disclosures as compared to Topic 840, Leases, for both lessees and lessors. See Note 3 for additional disclosures. </span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:8pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:8pt;font-style:italic;font-weight:bold;">Accounting Standards Update No. 2016-13 and No. 2018-19</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2016, the FASB issued ASU 2016-13, "Measurement of Credit Losses on Financial Instruments." This update is intended to improve financial reporting by requiring timelier recognition of credit losses on loans and other financial instruments that are not accounted for at fair value through net income, including loans held for investment, held-to-maturity debt securities, trade and other receivables, net investment in leases and other such commitments. This update requires that financial statement assets measured at an amortized cost and certain other financial instruments be presented at the net amount expected to be collected, through an allowance for credit losses that is deducted from the amortized cost basis. ASU 2018-19 also clarifies that receivables arising from operating leases are not within the scope of this topic. Instead, impairment of these receivables should be accounted for in accordance with Topic 842, Leases. This standard is effective for annual and interim periods beginning after December 15, 2019 with early adoption permitted. The Company is in the initial stages of evaluating the impact from the adoption of this new standard on the Condensed Consolidated Financial Statements and related notes.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:8pt;font-style:italic;font-weight:bold;">Accounting Standards Update No. 2017-04</span></div>In January 2017, the FASB issued ASU 2017-04, "Simplifying the Test for Goodwill Impairment." This update eliminates Step 2 of the goodwill impairment test. As such, an entity will perform its annual, or interim, goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An entity should recognize a goodwill impairment charge for the amount by which the reporting unit's carrying amount exceeds its fair value. This standard is effective for the Company for annual and interim periods beginning after December 15, 2019. The Company does not expect a material impact on the Condensed Consolidated Financial Statements and related notes from the adoption of this standard. 4000000000.0 201 26 15000000.0 11300000 Basis of Presentation<div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. They do not include all of the information and footnotes required by GAAP for complete financial statements. However, except as disclosed herein, management believes there has been no material change in the information disclosed in the Notes to the Consolidated Financial Statements included in the Annual Report on Form 10-K for the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">. All material intercompany transactions and balances have been eliminated in consolidation.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span style="font-family:inherit;font-size:10pt;">This interim financial information should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">. Management believes that all adjustments of a normal, recurring nature considered necessary for a fair presentation have been included. In addition, the interim financial information does not necessarily represent or indicate what the operating results will be for the year ending </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span> for many reasons including, but not limited to, acquisitions, dispositions, capital financing transactions, changes in interest rates and the effects of other trends, risks and uncertainties. Use of Estimates in the Condensed Consolidated Financial StatementsPreparation of the Condensed Consolidated Financial Statements in accordance with GAAP requires management to make estimates and assumptions that affect amounts reported in the Condensed Consolidated Financial Statements and accompanying notes. Actual results may differ from those estimates. Revenue from Contracts with Customers (Topic 606)<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company recognizes certain revenue under the core principle of Topic 606. This requires an entity to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Lease revenue is not within the scope of Topic 606. To achieve the core principle, the Company applies the five step model specified in the guidance. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenue that is accounted for under Topic 606 is segregated on the Company’s Condensed Consolidated Statements of Income in the Other operating line item. This line item includes parking income, rental lease guaranty income, management fee income and other miscellaneous income. Below is a detail of the amounts by category:</span></div><div style="line-height:120%;padding-bottom:4px;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:73.6328125%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:62%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Three Months Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Type of Revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Parking income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,734</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,626</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Rental lease guaranty</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>128</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>175</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Management fee income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>69</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>68</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Miscellaneous</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>30</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>26</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,961</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,895</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div>The Company’s three major types of revenue that are accounted for under Topic 606 that are listed above are all accounted for as the performance obligation is satisfied. The performance obligations that are identified for each of these items are satisfied over time and the Company recognizes revenue monthly based on this principle. Below is a detail of the amounts by category:<div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:73.6328125%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:62%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Three Months Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Type of Revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Parking income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,734</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,626</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Rental lease guaranty</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>128</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>175</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Management fee income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>69</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>68</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Miscellaneous</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>30</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>26</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,961</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,895</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 1734000 1626000 128000 175000 69000 68000 30000 26000 1961000 1895000 New Accounting Pronouncements<div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:8pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:8pt;font-style:italic;font-weight:bold;">Accounting Standards Update No. 2016-02, No. 2018-01 and No. 2018-11</span></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2016, the Financial Accounting Standards Board ("FASB") issued ASU 2016-02, "Leases." In January 2018, FASB issued ASU 2018-01, "Leases - Land Easement Practical Expedient for Transition to Topic 842," in July 2018, FASB issued ASU 2018-10, "Codification Improvements to Topic 842, Leases" and ASU 2018-11, "Leases - Targeted Improvements," and in December 2018, FASB issued ASU 2018-20, “Narrow-Scope Improvements for Lessors.” These accounting standard updates are collectively referred to as "Topic 842." </span></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Topic 842 provides several practical expedients that the Company elected. These are (a) the package of practical expedients offered that allows an entity not to reassess upon adoption (i) whether an expired or existing contract contains a lease, (ii) lease classification related to expired or existing lease arrangements, and (iii) whether costs incurred on expired or existing leases qualify as initial direct costs, (b) the lessor practical expedient not to separate certain non-lease components, such as common area maintenance, from the lease component if (i) the timing and pattern of transfer are the same for the non-lease component and associated lease component, and (ii) the lease component would be classified as an operating lease if accounted for separately and (c) the lessee practical expedient not to separate certain non-lease components from the associated lease component.</span></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For lessees, the new standard establishes a right-of-use ("ROU") model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with the classification affecting the pattern of expense recognition in the income statement. Ground leases executed or assumed prior to the adoption of Topic 842 will continue to be accounted for as operating leases and will not result in a materially different ground lease expense. However, each ground lease executed after the adoption of Topic 842 will be evaluated to determine if it is an operating or finance lease. If the lease is to be accounted for as a finance lease, ground lease expense would be accounted for using the effective interest method instead of the straight-line method over the term of the lease, which would result in higher ground lease expense in the earlier years of a ground lease when compared to the straight-line method. The Company's lease population is primarily ground leases, but also includes management office leases in third party buildings and certain copier and postage machine leases. The Company utilized a third party to assist in determining the discount rate for its ground leases. The terms of the ground leases generally range from </span><span style="font-family:inherit;font-size:10pt;"><span>40</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>99</span></span><span style="font-family:inherit;font-size:10pt;"> years with a weighted average remaining lease term remaining of </span><span style="font-family:inherit;font-size:10pt;"><span>54.9 years</span></span><span style="font-family:inherit;font-size:10pt;">, excluding renewal options. The Company's discount rates, which approximates the Company's incremental borrowing rate, ranged from </span><span style="font-family:inherit;font-size:10pt;"><span>3.4%</span></span><span style="font-family:inherit;font-size:10pt;"> for leases expiring in 2019 to </span><span style="font-family:inherit;font-size:10pt;"><span>6.2%</span></span><span style="font-family:inherit;font-size:10pt;"> for leases expiring in 2115. The Company utilized a third party to assist in determining the discount rates. The discount rates consider the general economic environment and factor in various financing and asset specific adjustments so that the discount rate is appropriate for the intended use of the underlying lease. As of January 1, 2019, the Company recognized the present value of its lease payments and a corresponding lease liability of </span><span style="font-family:inherit;font-size:10pt;"><span>$91.7 million</span></span><span style="font-family:inherit;font-size:10pt;">. In addition, the Company reclassified </span><span style="font-family:inherit;font-size:10pt;"><span>$45.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> of prepaid ground leases and below-market lease intangibles from the Other assets line item, </span><span style="font-family:inherit;font-size:10pt;"><span>$1.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> of above-market lease intangibles from the Other liabilities line and </span><span style="font-family:inherit;font-size:10pt;"><span>$8.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> of straight-line rent from the Accounts payable and accrued liabilities line item to the Operating lease right-of-use assets line item on the Condensed Consolidated Balance Sheets.</span></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For lessors, the new standard requires a lessor to classify leases as either sales-type, direct-financing or operating. A lease will be treated as a sale if it is considered to transfer control of the underlying asset to the lessee. A lease will be classified as direct-financing if risks and rewards are conveyed without the transfer of control. Otherwise, the lease is treated as an operating lease. Lessor accounting remains largely unchanged with some exceptions including the concept of separating lease and nonlease components. Nonlease components, such as common area maintenance, are generally accounted for under Topic 606 and separated from the lease payments. However, the Company elected the lessor practical expedient allowing the Company to not separate these components when certain conditions are met. The combined component is accounted for under Topic 842. Lease related receivables, which include accounts receivable and accrued straight-line rent receivables, are reduced for revenue reserves and are recognized as a reduction to rental income. The adoption of Topic 842, where the Company is the lessor, did not have a material impact on the Company's Condensed Consolidated Financial Statements for the three months ended </span><span style="font-family:inherit;font-size:10pt;">March 31, 2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The new standard was effective for the Company on January 1, 2019. Topic 842 provides two transition alternatives. The Company elected to choose the prospective optional transition method available to apply the guidance in Accounting Standards Codification Topic 840 in the comparative periods presented in the year Topic 842 is adopted. Topic 842 includes extensive quantitative and qualitative disclosures as compared to Topic 840, Leases, for both lessees and lessors. See Note 3 for additional disclosures. </span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:8pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:8pt;font-style:italic;font-weight:bold;">Accounting Standards Update No. 2016-13 and No. 2018-19</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2016, the FASB issued ASU 2016-13, "Measurement of Credit Losses on Financial Instruments." This update is intended to improve financial reporting by requiring timelier recognition of credit losses on loans and other financial instruments that are not accounted for at fair value through net income, including loans held for investment, held-to-maturity debt securities, trade and other receivables, net investment in leases and other such commitments. This update requires that financial statement assets measured at an amortized cost and certain other financial instruments be presented at the net amount expected to be collected, through an allowance for credit losses that is deducted from the amortized cost basis. ASU 2018-19 also clarifies that receivables arising from operating leases are not within the scope of this topic. Instead, impairment of these receivables should be accounted for in accordance with Topic 842, Leases. This standard is effective for annual and interim periods beginning after December 15, 2019 with early adoption permitted. The Company is in the initial stages of evaluating the impact from the adoption of this new standard on the Condensed Consolidated Financial Statements and related notes.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:8pt;font-style:italic;font-weight:bold;">Accounting Standards Update No. 2017-04</span></div>In January 2017, the FASB issued ASU 2017-04, "Simplifying the Test for Goodwill Impairment." This update eliminates Step 2 of the goodwill impairment test. As such, an entity will perform its annual, or interim, goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An entity should recognize a goodwill impairment charge for the amount by which the reporting unit's carrying amount exceeds its fair value. This standard is effective for the Company for annual and interim periods beginning after December 15, 2019. The Company does not expect a material impact on the Condensed Consolidated Financial Statements and related notes from the adoption of this standard. P40Y P99Y P54Y10M24D 0.034 0.062 91700000 45000000.0 1900000 8400000 Real Estate Investments<div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:9pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:9pt;font-weight:bold;">2019 Acquisitions</span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table details the Company's acquisitions for the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">March 31, 2019</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="23"/></tr><tr><td style="width:26%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-style:italic;text-decoration:underline;">(Dollars in millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Type </span><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Date<br/>Acquired</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Purchase Price</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Cash<br/>Consideration</span><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(2)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Real<br/>Estate</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Other </span><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(3) </sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Square<br/>Footage<br/></span><span style="font-family:Arial;font-size:7pt;font-style:italic;">(Unaudited)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Washington, D.C. </span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(4)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">MOB</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3/28/19</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>46.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>45.9</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>50.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(4.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>158,338</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Indianapolis, IN </span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(5)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">MOB</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3/28/19</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>47.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>44.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>43.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>143,499</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>93.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>90.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>93.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(3.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>301,837</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">______</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">MOB = medical office building</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;">(2)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Cash consideration excludes prorations of revenue and expense due to/from seller at the time of the acquisition.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;">(3)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Includes other assets acquired, liabilities assumed, and intangibles recognized at acquisition.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;">(4)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Includes </span><span style="font-family:inherit;font-size:9pt;"><span>two</span></span><span style="font-family:inherit;font-size:9pt;"> properties. The Company assumed two ground leases in connection with this acquisition that are classified as financing leases. The present value of future lease payments totaling </span><span style="font-family:inherit;font-size:9pt;"><span>$14.4 million</span></span><span style="font-family:inherit;font-size:9pt;"> was recorded on the Company's Condensed Consolidated Balance Sheets. In addition, the right-of-use assets were partially offset by </span><span style="font-family:inherit;font-size:9pt;"><span>$5.2 million</span></span><span style="font-family:inherit;font-size:9pt;"> of above-market lease intangibles included in Other.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;">(5)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">The Company assumed a prepaid ground lease totaling </span><span style="font-family:inherit;font-size:9pt;"><span>$0.8 million</span></span><span style="font-family:inherit;font-size:9pt;"> and recorded a below-market lease intangible totaling </span><span style="font-family:inherit;font-size:9pt;"><span>$0.9 million</span></span><span style="font-family:inherit;font-size:9pt;"> in connection with this acquisition that is classified as an operating lease that are included in Other.</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:24px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:9pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:9pt;font-weight:bold;">Subsequent Acquisition</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On April 2, 2019, the Company acquired a </span><span style="font-family:inherit;font-size:10pt;"><span>47,963</span></span><span style="font-family:inherit;font-size:10pt;"> square foot medical office building in Atlanta, Georgia for a purchase price of </span><span style="font-family:inherit;font-size:10pt;"><span>$28.0 million</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:9pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:9pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:9pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:9pt;font-weight:bold;">Subsequent Disposition</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On April 9, 2019, the Company disposed of </span><span style="font-family:inherit;font-size:10pt;"><span>three</span></span><span style="font-family:inherit;font-size:10pt;"> off-campus medical office buildings and </span><span style="font-family:inherit;font-size:10pt;"><span>one</span></span><span style="font-family:inherit;font-size:10pt;"> on-campus medical office building to a single purchaser. The buildings are located in Tucson, Arizona and total </span><span style="font-family:inherit;font-size:10pt;"><span>67,345</span></span><span style="font-family:inherit;font-size:10pt;"> square feet. The sales price was approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$13.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> and as of March 31, 2019, the Company's net investment in the buildings was </span><span style="font-family:inherit;font-size:10pt;"><span>$6.9 million</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;padding-left:24px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:9pt;font-weight:bold;">Assets Held for Sale</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In March 2019, the Company reclassified an inpatient rehabilitation facility to held for sale upon notification that a ground lessor is exercising a purchase option. The purchase price is determined by an appraisal process that is currently underway. The Company expects the purchase price to be greater than the current net investment of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$1.3 million</span></span><span style="font-family:inherit;font-size:10pt;">. As of March 31, 2019 and </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">, the Company had </span><span style="font-family:inherit;font-size:10pt;"><span>two</span></span><span style="font-family:inherit;font-size:10pt;"> properties and </span><span style="font-family:inherit;font-size:10pt;"><span>one</span></span><span style="font-family:inherit;font-size:10pt;"> property, respectively, classified as held for sale.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The table below reflects the assets and liabilities of the properties classified as held for sale as of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">:</span></div><span style="font-family:inherit;font-size:10pt;"> </span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:75%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-style:italic;">(Dollars in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">March 31, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">December 31, <br/>2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Balance Sheet data:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Land</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,125</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,125</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Buildings, improvements and lease intangibles</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>39,586</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>18,231</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>40,711</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>19,356</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Accumulated depreciation</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(30,706</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(10,657</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Real estate assets held for sale, net</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>10,005</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>8,699</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Operating lease right-of-use assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>168</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other assets, net</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>395</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>573</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Assets held for sale, net</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>10,568</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>9,272</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Accounts payable and accrued liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>251</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>450</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Operating lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>168</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>214</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>137</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Liabilities of properties held for sale</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>633</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>587</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> The following table details the Company's acquisitions for the <span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">March 31, 2019</span><span style="font-family:inherit;font-size:10pt;">:</span><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="23"/></tr><tr><td style="width:26%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-style:italic;text-decoration:underline;">(Dollars in millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Type </span><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Date<br/>Acquired</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Purchase Price</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Cash<br/>Consideration</span><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(2)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Real<br/>Estate</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Other </span><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(3) </sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Square<br/>Footage<br/></span><span style="font-family:Arial;font-size:7pt;font-style:italic;">(Unaudited)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Washington, D.C. </span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(4)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">MOB</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3/28/19</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>46.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>45.9</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>50.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(4.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>158,338</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Indianapolis, IN </span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(5)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">MOB</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3/28/19</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>47.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>44.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>43.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>143,499</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>93.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>90.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>93.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(3.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>301,837</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">______</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">MOB = medical office building</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;">(2)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Cash consideration excludes prorations of revenue and expense due to/from seller at the time of the acquisition.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;">(3)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Includes other assets acquired, liabilities assumed, and intangibles recognized at acquisition.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;">(4)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Includes </span><span style="font-family:inherit;font-size:9pt;"><span>two</span></span><span style="font-family:inherit;font-size:9pt;"> properties. The Company assumed two ground leases in connection with this acquisition that are classified as financing leases. The present value of future lease payments totaling </span><span style="font-family:inherit;font-size:9pt;"><span>$14.4 million</span></span><span style="font-family:inherit;font-size:9pt;"> was recorded on the Company's Condensed Consolidated Balance Sheets. In addition, the right-of-use assets were partially offset by </span><span style="font-family:inherit;font-size:9pt;"><span>$5.2 million</span></span><span style="font-family:inherit;font-size:9pt;"> of above-market lease intangibles included in Other.</span></div></td></tr></table><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;">(5)</span></div><span style="font-family:inherit;font-size:9pt;">The Company assumed a prepaid ground lease totaling </span><span style="font-family:inherit;font-size:9pt;"><span>$0.8 million</span></span><span style="font-family:inherit;font-size:9pt;"> and recorded a below-market lease intangible totaling </span><span style="font-family:inherit;font-size:9pt;"><span>$0.9 million</span></span> in connection with this acquisition that is classified as an operating lease that are included in Other. 2019-03-28 46000000.0 45900000 50200000 -4300000 158338 2019-03-28 47000000.0 44800000 43700000 1100000 143499 93000000.0 90700000 93900000 -3200000 301837 2 14400000 5200000 800000 900000 47963 28000000.0 3 1 67345 13000000.0 6900000 1300000 2 1 The table below reflects the assets and liabilities of the properties classified as held for sale as of <span style="font-family:inherit;font-size:10pt;">March 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">:</span><span style="font-family:inherit;font-size:10pt;"> </span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:75%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-style:italic;">(Dollars in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">March 31, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">December 31, <br/>2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Balance Sheet data:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Land</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,125</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,125</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Buildings, improvements and lease intangibles</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>39,586</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>18,231</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>40,711</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>19,356</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Accumulated depreciation</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(30,706</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(10,657</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Real estate assets held for sale, net</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>10,005</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>8,699</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Operating lease right-of-use assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>168</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other assets, net</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>395</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>573</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Assets held for sale, net</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>10,568</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>9,272</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Accounts payable and accrued liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>251</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>450</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Operating lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>168</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>214</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>137</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Liabilities of properties held for sale</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>633</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>587</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 1125000 1125000 39586000 18231000 40711000 19356000 30706000 10657000 10005000 8699000 168000 0 395000 573000 10568000 9272000 251000 450000 168000 0 214000 137000 633000 587000 Leases<div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:9pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:9pt;font-weight:bold;">Lessor Accounting Under ASC 842</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company’s properties generally are leased pursuant to non-cancelable, fixed-term operating leases with expiration dates through 2036. Some leases provide for fixed rent renewal terms in addition to market rent renewal terms. Some leases provide the lessee, during the term of the lease, with an option or right of first refusal to purchase the leased property. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company's leases typically have escalators that are either based on a stated percentage or an index such as CPI (consumer price index). In addition, most of the Company's leases include nonlease components such as reimbursement of operating expenses as additional rent or include the reimbursement of expected operating expenses as part of the lease payment. The Company elected the practical expedient and adopted an accounting policy to combine lease and nonlease components. Rent escalators based on indices and reimbursements of operating expenses that are not included in the lease rate are considered variable lease payments. Variable payments are recognized in the periods when the information is known. As of March 31, 2019, the Company had </span><span style="font-family:inherit;font-size:10pt;">one</span><span style="font-family:inherit;font-size:10pt;"> ground lease that is associated with a property under construction where rent has not yet commenced. Lease income for the Company's operating leases recognized for the three months ended March 31, 2019 was </span><span style="font-family:inherit;font-size:10pt;"><span>$110.7 million</span></span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Future lease payments under the non-cancelable operating leases, excluding any reimbursements, as of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> are as follows (in thousands): </span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:38.0859375%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:62%;"/><td style="width:1%;"/><td style="width:36%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>250,619</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2020</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>294,900</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>250,050</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>213,822</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>175,215</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2024 and thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>502,647</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,687,253</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:9pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:9pt;font-weight:bold;">Lessor Accounting Under ASC 840</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company’s properties are generally leased pursuant to non-cancelable, fixed-term operating leases with expiration dates through </span><span style="font-family:inherit;font-size:10pt;">2036</span><span style="font-family:inherit;font-size:10pt;">. Some leases and financial arrangements provide for fixed rent renewal terms in addition to market rent renewal terms. Some leases provide the lessee, during the term of the lease and for a short period thereafter, with an option or a right of first refusal to purchase the leased property. The Company’s portfolio of single-tenant net leases generally requires the lessee to pay minimum rent and all taxes (including property tax), insurance, maintenance and other operating costs associated with the leased property.</span></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Future minimum lease payments under the non-cancelable operating leases, excluding any reimbursements, as of December 31, 2018 are as follows (in thousands): </span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:38.0859375%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:62%;"/><td style="width:1%;"/><td style="width:36%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>326,441</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2020</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>279,211</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>235,660</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>201,072</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>163,978</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2024 and thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>476,673</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,683,035</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:9pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:9pt;font-weight:bold;">Lessee Accounting Under ASC 842</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company was obligated, as the lessee, under operating lease agreements consisting primarily of the Company’s ground leases. As of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company had </span><span style="font-family:inherit;font-size:10pt;"><span>109</span></span><span style="font-family:inherit;font-size:10pt;"> properties, excluding </span><span style="font-family:inherit;font-size:10pt;">one</span><span style="font-family:inherit;font-size:10pt;"> property classified as held for sale, totaling </span><span style="font-family:inherit;font-size:10pt;"><span>9.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> square feet that were held under ground leases with a remaining weighted average term of </span><span style="font-family:inherit;font-size:10pt;"><span>54.9 years</span></span><span style="font-family:inherit;font-size:10pt;">, excluding renewal options. Including renewal options, the remaining weighted average term would be </span><span style="font-family:inherit;font-size:10pt;"><span>70.7</span></span><span style="font-family:inherit;font-size:10pt;"> years. Some lease renewal terms are based on fixed rent renewal terms in addition to market rent renewal terms. These ground leases typically have initial terms of </span><span style="font-family:inherit;font-size:10pt;"><span>40</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>99</span></span><span style="font-family:inherit;font-size:10pt;"> years with expiration dates through 2117. Any increases related to the Company’s ground leases are generally either stated or based on the Consumer Price Index. The Company had </span><span style="font-family:inherit;font-size:10pt;"><span>46</span></span><span style="font-family:inherit;font-size:10pt;"> prepaid ground leases as of March 31, 2019. The amortization of the prepaid rent, included in the operating lease right-of-use asset represented approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$0.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> of the Company’s rental expense for the three months ended </span><span style="font-family:inherit;font-size:10pt;">March 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">March 31, 2018</span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company’s future lease payments (primarily for its </span><span style="font-family:inherit;font-size:10pt;"><span>63</span></span><span style="font-family:inherit;font-size:10pt;"> non-prepaid ground leases) as of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> were as follows (in thousands):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:9pt;"> </span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:54.1015625%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:58%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Operating</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Financing</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,948</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>626</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2020</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4,849</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>611</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4,879</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>619</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4,909</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>628</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4,947</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>637</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2024 and thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>314,406</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>74,766</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total undiscounted lease payments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>336,938</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>77,887</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Discount</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(245,894</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(63,593</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Lease Liability</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>91,044</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>14,294</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides a detail of the Company's total lease expense for the three months ended </span><span style="font-family:inherit;font-size:10pt;">March 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> (in thousands):</span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:82.8125%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:70%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Operating</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">FInancing</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Lease expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Operating lease expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,116</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Variable lease expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>740</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total lease expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,856</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other information</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Operating cash flows outflows related to operating leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,771</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Right-of-use assets obtained in exchange for new lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>14,294</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Weighted-average remaining lease term (excluding renewal options)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>54.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>70.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Weighted-average discount rate </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:9pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:9pt;font-weight:bold;">Lessee Accounting Under ASC 840</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of December 31, 2018, the Company was obligated under operating lease agreements consisting primarily of the Company’s ground leases. At December 31, 2018, the Company had </span><span style="font-family:inherit;font-size:10pt;"><span>107</span></span><span style="font-family:inherit;font-size:10pt;"> properties totaling </span><span style="font-family:inherit;font-size:10pt;"><span>8.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> square feet that were held under ground leases with a remaining weighted average term of </span><span style="font-family:inherit;font-size:10pt;"><span>53.9</span></span><span style="font-family:inherit;font-size:10pt;"> years, excluding renewal options. These ground leases typically have initial terms of </span><span style="font-family:inherit;font-size:10pt;"><span>50</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>75</span></span><span style="font-family:inherit;font-size:10pt;"> years with one or more renewal options extending the terms to </span><span style="font-family:inherit;font-size:10pt;"><span>75</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>100</span></span><span style="font-family:inherit;font-size:10pt;"> years, with expiration dates through 2117. Any rental increases related to the Company’s ground leases are generally either stated or based on the Consumer Price Index. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span style="font-family:inherit;font-size:10pt;">The Company’s future minimum lease payments (primarily for its </span><span style="font-family:inherit;font-size:10pt;"><span>60</span></span><span style="font-family:inherit;font-size:10pt;"> non-prepaid ground leases) as of December 31, 2018 were as follows (in thousands): </span><span style="font-family:inherit;font-size:9pt;"> </span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:90%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5,288</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2020</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5,260</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5,238</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5,207</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5,224</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2024 and thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>323,533</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>349,750</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 110700000 Future lease payments under the non-cancelable operating leases, excluding any reimbursements, as of <span style="font-family:inherit;font-size:10pt;">March 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> are as follows (in thousands): </span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:38.0859375%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:62%;"/><td style="width:1%;"/><td style="width:36%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>250,619</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2020</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>294,900</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>250,050</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>213,822</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>175,215</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2024 and thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>502,647</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,687,253</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 250619000 294900000 250050000 213822000 175215000 502647000 1687253000 Future minimum lease payments under the non-cancelable operating leases, excluding any reimbursements, as of December 31, 2018 are as follows (in thousands): <div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:38.0859375%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:62%;"/><td style="width:1%;"/><td style="width:36%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>326,441</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2020</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>279,211</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>235,660</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>201,072</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>163,978</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2024 and thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>476,673</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,683,035</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 326441000 279211000 235660000 201072000 163978000 476673000 1683035000 109 9100000 P54Y10M24D P70Y8M12D P40Y P99Y 46 100000 The Company’s future lease payments (primarily for its <span style="font-family:inherit;font-size:10pt;"><span>63</span></span><span style="font-family:inherit;font-size:10pt;"> non-prepaid ground leases) as of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> were as follows (in thousands):</span><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:9pt;"> </span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:54.1015625%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:58%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Operating</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Financing</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,948</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>626</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2020</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4,849</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>611</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4,879</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>619</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4,909</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>628</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4,947</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>637</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2024 and thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>314,406</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>74,766</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total undiscounted lease payments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>336,938</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>77,887</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Discount</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(245,894</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(63,593</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Lease Liability</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>91,044</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>14,294</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> The Company’s future lease payments (primarily for its <span style="font-family:inherit;font-size:10pt;"><span>63</span></span><span style="font-family:inherit;font-size:10pt;"> non-prepaid ground leases) as of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> were as follows (in thousands):</span><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:9pt;"> </span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:54.1015625%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:58%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Operating</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Financing</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,948</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>626</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2020</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4,849</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>611</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4,879</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>619</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4,909</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>628</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4,947</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>637</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2024 and thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>314,406</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>74,766</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total undiscounted lease payments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>336,938</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>77,887</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Discount</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(245,894</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(63,593</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Lease Liability</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>91,044</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>14,294</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 63 2948000 626000 4849000 611000 4879000 619000 4909000 628000 4947000 637000 314406000 74766000 336938000 77887000 245894000 63593000 91044000 14294000 The following table provides a detail of the Company's total lease expense for the three months ended <span style="font-family:inherit;font-size:10pt;">March 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> (in thousands):</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:82.8125%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:70%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Operating</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">FInancing</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Lease expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Operating lease expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,116</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Variable lease expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>740</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total lease expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,856</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other information</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Operating cash flows outflows related to operating leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,771</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Right-of-use assets obtained in exchange for new lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>14,294</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Weighted-average remaining lease term (excluding renewal options)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>54.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>70.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Weighted-average discount rate </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td></tr></table></div> 1116000 740000 1856000 2771000 0 14294000 P54Y P70Y7M6D 0.055 0.059 107 8800000 P53Y10M24D P50Y P75Y P75Y P100Y The Company’s future minimum lease payments (primarily for its <span style="font-family:inherit;font-size:10pt;"><span>60</span></span><span style="font-family:inherit;font-size:10pt;"> non-prepaid ground leases) as of December 31, 2018 were as follows (in thousands): </span><span style="font-family:inherit;font-size:9pt;"> </span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:90%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5,288</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2020</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5,260</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5,238</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5,207</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5,224</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2024 and thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>323,533</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>349,750</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 60 5288000 5260000 5238000 5207000 5224000 323533000 349750000 Notes and Bonds Payable<div style="line-height:120%;padding-top:4px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The table below details the Company’s notes and bonds payable.</span><span style="font-family:inherit;font-size:9pt;"> </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.8046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:38%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:19%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"> </span></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Maturity</span></div><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Dates</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Balance as of</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Effective Interest Rate as of </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-style:italic;text-decoration:underline;">(Dollars in thousands)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">March 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">December 31, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">March 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Unsecured Credit Facility</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">7/20</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>260,000</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>262,000</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3.49</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Unsecured Term Loan Facility, net of issuance costs </span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">12/22</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>149,234</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>149,183</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3.53</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Senior Notes due 2023, net of discount and issuance costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">4/23</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>248,223</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>248,117</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3.95</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Senior Notes due 2025, net of discount and issuance costs </span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(2)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">5/25</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>248,338</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>248,278</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4.08</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Senior Notes due 2028, net of discount and issuance costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">1/28</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>295,309</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>295,198</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3.84</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Mortgage notes payable, net of discounts and issuance costs and including premiums</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">7/19-5/40</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>142,006</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>143,208</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4.79</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,343,110</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,345,984</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">______</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">The effective interest rate includes the impact of interest rate swaps on </span><span style="font-family:inherit;font-size:8pt;"><span>$25.0 million</span></span><span style="font-family:inherit;font-size:8pt;"> and </span><span style="font-family:inherit;font-size:8pt;"><span>$50.0 million</span></span><span style="font-family:inherit;font-size:8pt;"> of the outstanding balance at a rate of </span><span style="font-family:inherit;font-size:8pt;"><span>2.18%</span></span><span style="font-family:inherit;font-size:8pt;"> and </span><span style="font-family:inherit;font-size:8pt;"><span>2.46%</span></span><span style="font-family:inherit;font-size:8pt;">, respectively (plus the applicable margin rate, currently 110 basis points).</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;">(2)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">The effective interest rate includes the impact of the </span><span style="font-family:inherit;font-size:8pt;"><span>$1.7 million</span></span><span style="font-family:inherit;font-size:8pt;"> settlement of a forward-starting interest rate swap that is included in Accumulated other comprehensive income (loss) on the Company's Condensed Consolidated Balance Sheets. </span></div></td></tr></table><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:9pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:9pt;font-weight:bold;">Subsequent Mortgage Note Payable Payoff</span></div><span style="font-family:inherit;font-size:10pt;">On April 10, 2019, the Company repaid in full a mortgage note payable bearing interest at a rate of </span><span style="font-family:inherit;font-size:10pt;"><span>5.00%</span></span><span style="font-family:inherit;font-size:10pt;"> per annum with an outstanding principal of </span><span style="font-family:inherit;font-size:10pt;"><span>$8.9 million</span></span><span style="font-family:inherit;font-size:10pt;">. The mortgage note encumbered a </span><span style="font-family:inherit;font-size:10pt;"><span>52,813</span></span> square foot property in Washington. The table below details the Company’s notes and bonds payable.<span style="font-family:inherit;font-size:9pt;"> </span><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.8046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:38%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:19%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"> </span></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Maturity</span></div><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Dates</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Balance as of</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Effective Interest Rate as of </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-style:italic;text-decoration:underline;">(Dollars in thousands)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">March 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">December 31, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">March 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Unsecured Credit Facility</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">7/20</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>260,000</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>262,000</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3.49</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Unsecured Term Loan Facility, net of issuance costs </span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">12/22</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>149,234</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>149,183</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3.53</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Senior Notes due 2023, net of discount and issuance costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">4/23</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>248,223</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>248,117</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3.95</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Senior Notes due 2025, net of discount and issuance costs </span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(2)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">5/25</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>248,338</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>248,278</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4.08</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Senior Notes due 2028, net of discount and issuance costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">1/28</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>295,309</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>295,198</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3.84</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Mortgage notes payable, net of discounts and issuance costs and including premiums</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">7/19-5/40</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>142,006</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>143,208</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4.79</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,343,110</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,345,984</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">______</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">The effective interest rate includes the impact of interest rate swaps on </span><span style="font-family:inherit;font-size:8pt;"><span>$25.0 million</span></span><span style="font-family:inherit;font-size:8pt;"> and </span><span style="font-family:inherit;font-size:8pt;"><span>$50.0 million</span></span><span style="font-family:inherit;font-size:8pt;"> of the outstanding balance at a rate of </span><span style="font-family:inherit;font-size:8pt;"><span>2.18%</span></span><span style="font-family:inherit;font-size:8pt;"> and </span><span style="font-family:inherit;font-size:8pt;"><span>2.46%</span></span><span style="font-family:inherit;font-size:8pt;">, respectively (plus the applicable margin rate, currently 110 basis points).</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;">(2)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">The effective interest rate includes the impact of the </span><span style="font-family:inherit;font-size:8pt;"><span>$1.7 million</span></span><span style="font-family:inherit;font-size:8pt;"> settlement of a forward-starting interest rate swap that is included in Accumulated other comprehensive income (loss) on the Company's Condensed Consolidated Balance Sheets. </span></div></td></tr></table><br/> 260000000 262000000 0.0349 149234000 149183000 0.0353 248223000 248117000 0.0395 248338000 248278000 0.0408 295309000 295198000 0.0384 142006000 143208000 0.0479 1343110000 1345984000 25000000.0 50000000.0 0.0218 0.0246 1700000 0.0500 8900000 52813 Derivative Financial Instruments<div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:9pt;font-weight:bold;">Risk Management Objective of Using Derivatives</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company is exposed to certain risks arising from both its business operations and economic conditions. The Company principally manages its exposures to a wide variety of business and operational risks through management of its core business activities. The Company manages economic risks, including interest rate, liquidity, and credit risk, primarily by managing the amount, sources, and duration of its assets and liabilities and the use of derivative financial instruments. Specifically, the Company enters into derivative financial instruments to manage exposures that arise from business activities that result in the</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">receipt or payment of future known and uncertain cash amounts, the value of which are determined by interest rates. The Company’s derivative financial instruments are used to manage differences in the amount, timing, and duration of the Company’s known or expected cash receipts and its known or expected cash payments principally related to the Company’s borrowings.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:9pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:9pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:9pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:9pt;font-weight:bold;">Cash Flow Hedges of Interest Rate Risk</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company’s objectives in using interest rate derivatives are to add stability to interest expense and to manage its exposure to interest rate movements. To accomplish this objective, the Company primarily uses interest rate swaps as part of its interest rate risk management strategy. Interest rate swaps designated as cash flow hedges involve the receipt of variable amounts from a counterparty in exchange for the Company making fixed-rate payments over the life of the agreements without exchange of the underlying notional amount. Such derivatives were used to hedge the variable cash flows associated with existing variable-rate debt.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For derivatives designated and that qualify as cash flow hedges of interest rate risk, the gain or loss on the derivative is recorded in Accumulated Other Comprehensive Income (Loss) and subsequently reclassified into interest expense in the same period(s) during which the hedged transaction affects earnings. Amounts reported in Accumulated other comprehensive income (loss) related to derivatives will be reclassified to interest expense as interest payments are made on the Company’s variable-rate debt. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> As of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company had </span><span style="font-family:inherit;font-size:10pt;"><span>four</span></span><span style="font-family:inherit;font-size:10pt;"> outstanding interest rate derivatives that were designated as cash flow hedges of interest rate risk:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:65%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Derivative Instrument</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Number of Instruments</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Notional Amount</span></div><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">(in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest rate swaps</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$75.0</span></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:9pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:9pt;font-weight:bold;">Tabular Disclosure of Fair Values of Derivative Instruments on the Balance Sheet</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The table below presents the fair value of the Company's derivative financial instruments, as well as their classification on the Condensed Consolidated Balance Sheet as of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:59%;"/><td style="width:20%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Balance at March 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-style:italic;">(Dollars in thousands)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Balance Sheet Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Fair Value</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Derivatives designated as hedging instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Interest rate swaps</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>589</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total derivatives designated as hedging instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>589</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:9pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:9pt;font-weight:bold;">Tabular Disclosure of the Effect of Cash Flow Hedge Accounting on Accumulated Other Comprehensive Income (Loss)</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The table below presents the effect of cash flow hedge accounting on Accumulated Other Comprehensive Income (Loss) ("OCI") during the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">March 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and 2018 related to the Company's outstanding interest rate swaps.</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:27%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:23%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Amount of Loss Recognized in OCI on Derivative</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Amount of Loss Reclassified from OCI into Income</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-style:italic;">(Dollars in thousands)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Interest rate products</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>724</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Interest expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(27</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>105</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Settled interest rate swaps</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Interest expense</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>42</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>42</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>724</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total interest expense</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>15</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>147</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:9pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:9pt;font-weight:bold;">Credit-risk-related Contingent Features</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company's agreements with each of its derivative counterparties contain a cross-default provision under which the Company could be declared in default of its derivative obligations if repayment of the underlying indebtedness is accelerated by the lender due to the Company's default on the indebtedness.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company estimates that </span><span style="font-family:inherit;font-size:10pt;"><span>$13 thousand</span></span><span style="font-family:inherit;font-size:10pt;"> related to active interest rate swaps will be reclassified from OCI as a decrease to interest expense over the next 12 months, and that </span><span style="font-family:inherit;font-size:10pt;"><span>$0.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> related to settled interest rate swaps will be amortized from OCI as an increase to interest expense over the next 12 months.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:9pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:9pt;font-weight:bold;">Subsequent Activity</span></div><span style="font-family:inherit;font-size:10pt;">On April 12, 2019, the Company entered into </span><span style="font-family:inherit;font-size:10pt;"><span>two</span></span><span style="font-family:inherit;font-size:10pt;"> interest rate swaps totaling </span><span style="font-family:inherit;font-size:10pt;"><span>$50.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> to hedge the 1-month LIBOR portion of the cost of borrowing under the Company's variable rate debt to a fixed interest rate of </span><span style="font-family:inherit;font-size:10pt;"><span>2.334%</span></span>. These derivatives were used to hedge variable cash flows associated with variable-rate debt. As of <span style="font-family:inherit;font-size:10pt;">March 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company had </span><span style="font-family:inherit;font-size:10pt;"><span>four</span></span><span style="font-family:inherit;font-size:10pt;"> outstanding interest rate derivatives that were designated as cash flow hedges of interest rate risk:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:65%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Derivative Instrument</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Number of Instruments</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Notional Amount</span></div><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">(in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest rate swaps</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$75.0</span></span></div></td></tr></table></div> 4 4 75000000.0 The table below presents the fair value of the Company's derivative financial instruments, as well as their classification on the Condensed Consolidated Balance Sheet as of <span style="font-family:inherit;font-size:10pt;">March 31, 2019</span><span style="font-family:inherit;font-size:10pt;">.</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:59%;"/><td style="width:20%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Balance at March 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-style:italic;">(Dollars in thousands)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Balance Sheet Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Fair Value</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Derivatives designated as hedging instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Interest rate swaps</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>589</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total derivatives designated as hedging instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>589</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 589000 589000 The table below presents the effect of cash flow hedge accounting on Accumulated Other Comprehensive Income (Loss) ("OCI") during the <span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">March 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and 2018 related to the Company's outstanding interest rate swaps.</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:27%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:23%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Amount of Loss Recognized in OCI on Derivative</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Amount of Loss Reclassified from OCI into Income</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-style:italic;">(Dollars in thousands)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Interest rate products</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>724</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Interest expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(27</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>105</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Settled interest rate swaps</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Interest expense</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>42</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>42</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>724</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total interest expense</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>15</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>147</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><br/> 724000 -27000 105000 0 42000 42000 724000 15000 147000 13000 -200000 2 50000000.0 0.02334 Commitments and Contingencies<div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:9pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:9pt;font-weight:bold;">Legal Proceedings</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company is, from time to time, involved in litigation arising in the ordinary course of business. The Company is not aware of any pending or threatened litigation that, if resolved against the Company, would have a material adverse effect on the Company’s consolidated financial position, results of operations or cash flows.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:9pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:9pt;font-weight:bold;">Redevelopment Activity</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company is redeveloping a medical office building in Charlotte, North Carolina, which includes a </span><span style="font-family:inherit;font-size:10pt;"><span>38,000</span></span><span style="font-family:inherit;font-size:10pt;"> square foot vertical expansion. As of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company had funded approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$9.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> on the redevelopment of this property. The project is expected to be completed in the second quarter of 2019.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:9pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:9pt;font-weight:bold;">Development Activity</span></div><span style="font-family:inherit;font-size:10pt;">The Company began the development of a </span><span style="font-family:inherit;font-size:10pt;"><span>151,000</span></span><span style="font-family:inherit;font-size:10pt;"> square foot medical office building in Seattle, Washington during 2017. As of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company had funded approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$30.9 million</span></span> on the development. The Company expects the project to be completed in the fourth quarter of 2019. 38000 9700000 151000 30900000 Stockholders' Equity<div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:9pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:9pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:9pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:9pt;font-weight:bold;">Common Stock    </span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides a reconciliation of the beginning and ending shares of common stock outstanding for the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">March 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:69%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">March 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Balance, beginning of period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>125,279,455</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>125,131,593</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Issuance of common stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,889,411</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>26,203</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Nonvested share-based awards, net of withheld shares</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>45,225</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>121,659</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Balance, end of period</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>129,214,091</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>125,279,455</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:9pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:9pt;font-weight:bold;">Equity Offering</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On March 19, 2019, the Company issued </span><span style="font-family:inherit;font-size:10pt;"><span>3,737,500</span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock, par value </span><span style="font-family:inherit;font-size:10pt;"><span>$0.01</span></span><span style="font-family:inherit;font-size:10pt;"> per share, at </span><span style="font-family:inherit;font-size:10pt;"><span>$31.40</span></span><span style="font-family:inherit;font-size:10pt;"> per share in an underwritten public offering pursuant to the Company's existing effective registration statement. The net proceeds of the offering, after underwriting discounts and offering expenses, were approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$115.8 million</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:9pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:9pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:9pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:9pt;font-weight:bold;">At-The-Market Equity Offering Program</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company sold </span><span style="font-family:inherit;font-size:10pt;"><span>135,265</span></span><span style="font-family:inherit;font-size:10pt;"> shares under the Company's at-the-market equity offering program during the three months ended March 31, 2019. The sales generated </span><span style="font-family:inherit;font-size:10pt;"><span>$4.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> in net proceeds at prices to the public ranging from </span><span style="font-family:inherit;font-size:10pt;"><span>$32.01</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>$32.86</span></span><span style="font-family:inherit;font-size:10pt;"> (weighted average of </span><span style="font-family:inherit;font-size:10pt;"><span>$32.36</span></span><span style="font-family:inherit;font-size:10pt;">). The Company had </span><span style="font-family:inherit;font-size:10pt;"><span>5,733,432</span></span><span style="font-family:inherit;font-size:10pt;"> authorized shares remaining available to be sold under the current sales agreements as of </span><span style="font-family:inherit;font-size:10pt;">April 26, 2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:9pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:9pt;font-weight:bold;">Common Stock Dividends</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">March 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company declared and paid common stock dividends totaling </span><span style="font-family:inherit;font-size:10pt;"><span>$0.30</span></span><span style="font-family:inherit;font-size:10pt;"> per share. On </span><span style="font-family:inherit;font-size:10pt;">April 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company declared a quarterly common stock dividend in the amount of </span><span style="font-family:inherit;font-size:10pt;"><span>$0.30</span></span><span style="font-family:inherit;font-size:10pt;"> per share payable on </span><span style="font-family:inherit;font-size:10pt;">May 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> to stockholders of record on</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span><span style="font-family:inherit;font-size:10pt;">May 15, 2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:9pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:9pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:9pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:9pt;font-weight:bold;">Earnings Per Common Share</span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company uses the two-class method of computing net earnings per common shares. The Company's nonvested share-based awards are considered participating securities pursuant to the two-class method. The following table sets forth the computation of basic and diluted earnings per common share for the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">March 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Three Months Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-style:italic;">(Dollars in thousands, except per share data)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Weighted average Common Shares outstanding</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Weighted average Common Shares outstanding</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>125,908,335</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>125,167,128</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Nonvested shares</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(1,778,700</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(1,909,777</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Weighted average Common Shares outstanding—Basic</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>124,129,635</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>123,257,351</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Weighted average Common Shares outstanding—Basic</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>124,129,635</span></span></div></td><td style="vertical-align:bottom;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>123,257,351</span></span></div></td><td style="vertical-align:bottom;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Dilutive effect of employee stock purchase plan</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>102,132</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>90,330</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Weighted average Common Shares outstanding—Diluted</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>124,231,767</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>123,347,681</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Net Income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4,891</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>9,180</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Dividends paid on nonvested share-based awards</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(536</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(579</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Net income applicable to common stockholders</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4,355</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>8,601</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Basic earnings per common share - Net income </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.04</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.07</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Diluted earnings per common share - Net income </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.04</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.07</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:9pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:9pt;font-weight:bold;">Incentive Plans</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A summary of the activity under the Company's share-based incentive plans for the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">March 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> is included in the table below.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:71%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Three Months Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Share-based awards, beginning of period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,769,863</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,907,645</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>64,771</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>76,762</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Vested</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(50,507</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(54,065</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Share-based awards, end of period</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,784,127</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,930,342</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">March 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, the Company withheld </span><span style="font-family:inherit;font-size:10pt;"><span>19,546</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>21,196</span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock, respectively, from participants to pay estimated withholding taxes related to shares that vested. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition to the share-based incentive plans, the Company maintains the 2000 Employee Stock Purchase Plan (the "Purchase Plan"). A summary of the activity under the Purchase Plan for the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">March 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> is included in the table below.</span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:71%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Three Months Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Outstanding and exercisable, beginning of period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>328,533</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>318,100</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>235,572</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>203,836</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Exercised</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(14,630</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(8,835</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Forfeited</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(16,625</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(10,580</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Expired</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(142,074</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(135,790</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Outstanding and exercisable, end of period</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>390,776</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>366,731</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> The following table provides a reconciliation of the beginning and ending shares of common stock outstanding for the <span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">March 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:69%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">March 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Balance, beginning of period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>125,279,455</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>125,131,593</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Issuance of common stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,889,411</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>26,203</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Nonvested share-based awards, net of withheld shares</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>45,225</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>121,659</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Balance, end of period</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>129,214,091</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>125,279,455</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 125279455 125131593 3889411 26203 45225 121659 129214091 125279455 3737500 0.01 31.40 115800000 135265 4300000 32.01 32.86 32.36 5733432 0.30 0.30 The following table sets forth the computation of basic and diluted earnings per common share for the <span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">March 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">.</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Three Months Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-style:italic;">(Dollars in thousands, except per share data)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Weighted average Common Shares outstanding</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Weighted average Common Shares outstanding</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>125,908,335</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>125,167,128</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Nonvested shares</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(1,778,700</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(1,909,777</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Weighted average Common Shares outstanding—Basic</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>124,129,635</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>123,257,351</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Weighted average Common Shares outstanding—Basic</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>124,129,635</span></span></div></td><td style="vertical-align:bottom;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>123,257,351</span></span></div></td><td style="vertical-align:bottom;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Dilutive effect of employee stock purchase plan</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>102,132</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>90,330</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Weighted average Common Shares outstanding—Diluted</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>124,231,767</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>123,347,681</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Net Income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4,891</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>9,180</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Dividends paid on nonvested share-based awards</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(536</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(579</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Net income applicable to common stockholders</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4,355</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>8,601</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Basic earnings per common share - Net income </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.04</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.07</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Diluted earnings per common share - Net income </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.04</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.07</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 125908335 125167128 1778700 1909777 124129635 123257351 124129635 123257351 102132 90330 124231767 123347681 4891000 9180000 536000 579000 4355000 8601000 0.04 0.07 0.04 0.07 A summary of the activity under the Company's share-based incentive plans for the <span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">March 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> is included in the table below.</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:71%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Three Months Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Share-based awards, beginning of period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,769,863</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,907,645</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>64,771</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>76,762</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Vested</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(50,507</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(54,065</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Share-based awards, end of period</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,784,127</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,930,342</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 1769863 1907645 64771 76762 50507 54065 1784127 1930342 19546 21196 A summary of the activity under the Purchase Plan for the <span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">March 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> is included in the table below.</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:71%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Three Months Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Outstanding and exercisable, beginning of period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>328,533</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>318,100</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>235,572</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>203,836</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Exercised</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(14,630</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(8,835</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Forfeited</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(16,625</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(10,580</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Expired</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(142,074</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(135,790</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Outstanding and exercisable, end of period</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>390,776</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>366,731</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 328533 318100 235572 203836 14630 8835 16625 10580 142074 135790 390776 366731 Fair Value of Financial Instruments<div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following methods and assumptions were used to estimate the fair value of each class of financial instrument for which it is practical to estimate that value.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Cash and cash equivalents - </span><span style="font-family:inherit;font-size:10pt;">The carrying amount approximates fair value due to the short term maturity of these investments. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Borrowings under the unsecured credit facility due 2020 and unsecured term loan facility due 2022 - </span><span style="font-family:inherit;font-size:10pt;">The carrying amount approximates fair value because the borrowings are based on variable market interest rates.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Senior Notes and Mortgage Notes payable - </span><span style="font-family:inherit;font-size:10pt;">The fair value of notes and bonds payable is estimated using cash flow analyses, based on the Company’s current interest rates for similar types of borrowing arrangements.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Interest rate swap agreements - </span><span style="font-family:inherit;font-size:10pt;">Interest rate swap agreements are recorded in other liabilities on the Company's Consolidated Balance Sheets at fair value. Fair value is estimated by utilizing pricing models that consider forward yield curves and discount rates.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The table below details the fair values and carrying values for notes and bonds payable at </span><span style="font-family:inherit;font-size:10pt;">March 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:53%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">March 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-style:italic;">(Dollars in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Carrying Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Carrying Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Notes and bonds payable </span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,343.1</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,329.8</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,346.0</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,326.5</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">______</span></div><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;">(1)</span></div>Level 2 – model-derived valuations in which significant inputs and significant value drivers are observable in active markets. The table below details the fair values and carrying values for notes and bonds payable at <span style="font-family:inherit;font-size:10pt;">March 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">.</span><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:53%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">March 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-style:italic;">(Dollars in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Carrying Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Carrying Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Notes and bonds payable </span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,343.1</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,329.8</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,346.0</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,326.5</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">______</span></div><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;">(1)</span></div>Level 2 – model-derived valuations in which significant inputs and significant value drivers are observable in active markets. 1343100000 1329800000 1346000000.0 1326500000 XML 11 R1.htm IDEA: XBRL DOCUMENT v3.19.1
Document and Entity Information - shares
3 Months Ended
Mar. 31, 2019
Apr. 26, 2019
Document and Entity Information [Abstract]    
Entity Registrant Name HEALTHCARE REALTY TRUST INCORPORATED  
Entity Central Index Key 0000899749  
Current Fiscal Year End Date --12-31  
Entity Filer Category Large Accelerated Filer  
Document Type 10-Q  
Document Period End Date Mar. 31, 2019  
Document Fiscal Year Focus 2019  
Document Fiscal Period Focus Q1  
Amendment Flag false  
Entity Common Stock, Shares Outstanding   129,214,135
Entity Emerging Growth Company false  
Entity Small Business false  
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.19.1
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Mar. 31, 2019
Dec. 31, 2018
Real estate properties:    
Land $ 230,206 $ 230,206
Buildings, improvements and lease intangibles 3,757,260 3,675,415
Personal property 10,739 10,696
Construction in progress 40,326 33,107
Land held for development 24,647 24,647
Real estate properties, Total 4,063,178 3,974,071
Less accumulated depreciation and amortization (1,035,800) (1,015,174)
Total real estate properties, net 3,027,378 2,958,897
Cash and cash equivalents 11,313 8,381
Assets held for sale, net 10,568 9,272
Operating lease right-of-use assets 128,141  
Financing lease right-of-use assets 9,259  
Other assets, net 175,864 214,697
Total assets 3,362,523 3,191,247
Liabilities:    
Notes and bonds payable 1,343,110 1,345,984
Accounts payable and accrued liabilities 61,519 80,411
Liabilities of properties held for sale 633 587
Operating lease liabilities 91,044  
Financing lease liabilities 14,294  
Other liabilities 46,144 47,623
Total liabilities 1,556,744 1,474,605
Commitments and contingencies
Stockholders' equity:    
Preferred stock, $.01 par value per share; 50,000 shares authorized; none issued and outstanding 0 0
Common stock, $.01 par value per share; 300,000 shares authorized; 129,214 and 125,279 shares issued and outstanding at March 31, 2019 and December 31, 2018, respectively 1,292 1,253
Additional paid-in capital 3,302,814 3,180,284
Accumulated other comprehensive loss (1,611) (902)
Cumulative net income attributable to common stockholders 1,093,010 1,088,119
Cumulative dividends (2,589,726) (2,552,112)
Total stockholders' equity 1,805,779 1,716,642
Total liabilities and stockholders' equity $ 3,362,523 $ 3,191,247
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.19.1
Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares
Mar. 31, 2019
Dec. 31, 2018
Statement of Financial Position [Abstract]    
Preferred stock, par value (dollars per share) $ 0.01 $ 0.01
Preferred stock, authorized shares 50,000,000 50,000,000
Preferred stock, issued shares 0 0
Preferred stock, outstanding shares 0 0
Common stock, par value (dollars per share) $ 0.01 $ 0.01
Common stock, authorized shares 300,000,000 300,000,000
Common stock, issued shares 129,214,000 125,279,000
Common stock, outstanding shares 129,214,000 125,279,000
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.19.1
Condensed Consolidated Statements of Income (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2019
Mar. 31, 2018
REVENUES    
Rental income $ 110,696 $ 110,229
Other operating 1,961 1,895
Revenues 112,657 112,124
EXPENSES    
Property operating 42,725 41,818
General and administrative 8,510 9,101
Acquisition and pursuit costs 305 277
Depreciation and amortization 42,662 39,573
Total Expenses 94,202 90,769
OTHER INCOME (EXPENSE)    
Gain on sales of real estate assets 15  
Interest expense (13,588) (12,668)
Interest and other income, net 9 493
Total other income (expense) (13,564) (12,175)
NET INCOME $ 4,891 $ 9,180
Basic earnings per common share (in dollars per share) $ 0.04 $ 0.07
Diluted earnings per common share (in dollars per share) $ 0.04 $ 0.07
Weighted average common shares outstanding - basic (in shares) 124,129,635 123,257,351
Weighted average common shares outstanding - diluted (in shares) 124,231,767 123,347,681
Dividends declared, per common share, during the period (in dollars per share) $ 0.30 $ 0.30
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.19.1
Condensed Consolidated Statements of Comprehensive Income (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2019
Mar. 31, 2018
Statement of Comprehensive Income [Abstract]    
NET INCOME $ 4,891 $ 9,180
Interest rate swaps:    
Reclassification adjustments for losses included in net income (interest expense) 15 147
(Losses) gains arising during the period on interest rate swaps (724) 513
Total other comprehensive income (loss) (709) 660
COMPREHENSIVE INCOME $ 4,182 $ 9,840
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.19.1
Condensed Consolidated Statement of Equity (Unaudited) Statement - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-in Capital
Accumulated Other Comprehensive Income (Loss)
Cumulative Net Income
Cumulative Dividends
Beginning balance at Dec. 31, 2017 $ 1,789,883 $ 1,251 $ 3,173,429 $ (1,299) $ 1,018,348 $ (2,401,846)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Issuance of common stock, net of issuance costs 239   239      
Common stock redemptions (680)   (680)      
Share-based compensation 2,822 1 2,821      
Net income 9,180       9,180  
Reclassification adjustments for losses included in net income (interest expense) 147     147    
Gains (losses) arising during the period on interest rate swaps 513     513    
Dividends to common stockholders ($0.30 per share) (37,556)         (37,556)
Ending balance at Mar. 31, 2018 1,764,548 1,252 3,175,809 (639) 1,027,528 (2,439,402)
Beginning balance at Dec. 31, 2018 1,716,642 1,253 3,180,284 (902) 1,088,119 (2,552,112)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Issuance of common stock, net of issuance costs 120,500 38 120,462      
Common stock redemptions (570)   (570)      
Share-based compensation 2,639 1 2,638      
Net income 4,891       4,891  
Reclassification adjustments for losses included in net income (interest expense) 15     15    
Gains (losses) arising during the period on interest rate swaps (724)     (724)    
Dividends to common stockholders ($0.30 per share) (37,614)         (37,614)
Ending balance at Mar. 31, 2019 $ 1,805,779 $ 1,292 $ 3,302,814 $ (1,611) $ 1,093,010 $ (2,589,726)
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.19.1
Condensed Consolidated Statement of Equity (Unaudited) (Parenthetical)
3 Months Ended
Mar. 31, 2019
$ / shares
Statement of Stockholders' Equity [Abstract]  
Dividend per share to common Stockholders (in dollars per share) $ 0.30
XML 18 R8.htm IDEA: XBRL DOCUMENT v3.19.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2019
Mar. 31, 2018
OPERATING ACTIVITIES    
Net income $ 4,891 $ 9,180
Adjustments to reconcile net income to net cash provided by operating activities:    
Depreciation and amortization 42,662 39,573
Other amortization 727 584
Share-based compensation 2,639 2,822
Amortization of straight-line rent receivable (lessor) (668) (1,722)
Amortization of straight-line rent on operating leases (lessee) 390 384
Gain on sales of real estate assets (15)  
Equity from unconsolidated joint ventures loss 10 10
Distributions from unconsolidated joint ventures 88 37
Changes in operating assets and liabilities:    
Other assets, including right-of-use-assets (4,971) (4,193)
Accounts payable and accrued liabilities (10,276) (6,949)
Other liabilities (673) 1,094
Net cash provided by operating activities 34,804 40,820
INVESTING ACTIVITIES    
Acquisitions of real estate (91,787) (1,756)
Development of real estate (5,712) (7,573)
Additional long-lived assets (11,741) (16,764)
Proceeds from notes receivable repayments 0 5
Net cash used in investing activities (109,240) (26,088)
FINANCING ACTIVITIES    
Net (repayments) borrowings on unsecured credit facility (2,000) 24,000
Repayments on notes and bonds payable (1,193) (1,154)
Dividends paid (37,614) (37,556)
Net proceeds from issuance of common stock 120,617 236
Common stock redemptions (2,442) (2,633)
Debt issuance and assumption costs   (44)
Net cash provided by (used in) financing activities 77,368 (17,151)
Increase (decrease) in cash and cash equivalents 2,932 (2,419)
Cash and cash equivalents at beginning of period 8,381 6,215
Cash and cash equivalents at end of period 11,313 3,796
Supplemental Cash Flow Information:    
Interest paid 11,071 3,899
Invoices accrued for construction, tenant improvements and other capitalized costs 13,509 8,592
Capitalized interest $ 307 $ 186
XML 19 R9.htm IDEA: XBRL DOCUMENT v3.19.1
Summary of Significant Accounting Policies
3 Months Ended
Mar. 31, 2019
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies Business Overview
Healthcare Realty Trust Incorporated (the "Company") is a real estate investment trust ("REIT") that owns, leases, manages, acquires, finances, develops and redevelops income-producing real estate properties associated primarily with the delivery of outpatient healthcare services throughout the United States. As of March 31, 2019, the Company had gross investments of approximately $4.0 billion in 201 real estate properties located in 26 states totaling approximately 15.0 million square feet. The Company provided leasing and property management services to approximately 11.3 million square feet nationwide.

Basis of Presentation
The Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. They do not include all of the information and footnotes required by GAAP for complete financial statements. However, except as disclosed herein, management believes there has been no material change in the information disclosed in the Notes to the Consolidated Financial Statements included in the Annual Report on Form 10-K for the year ended December 31, 2018. All material intercompany transactions and balances have been eliminated in consolidation.

This interim financial information should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2018. Management believes that all adjustments of a normal, recurring nature considered necessary for a fair presentation have been included. In addition, the interim financial information does not necessarily represent or indicate what the operating results will be for the year ending December 31, 2019 for many reasons including, but not limited to, acquisitions, dispositions, capital financing transactions, changes in interest rates and the effects of other trends, risks and uncertainties.

Use of Estimates in the Condensed Consolidated Financial Statements
Preparation of the Condensed Consolidated Financial Statements in accordance with GAAP requires management to make estimates and assumptions that affect amounts reported in the Condensed Consolidated Financial Statements and accompanying notes. Actual results may differ from those estimates.
Revenue from Contracts with Customers (Topic 606)
The Company recognizes certain revenue under the core principle of Topic 606. This requires an entity to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Lease revenue is not within the scope of Topic 606. To achieve the core principle, the Company applies the five step model specified in the guidance.

Revenue that is accounted for under Topic 606 is segregated on the Company’s Condensed Consolidated Statements of Income in the Other operating line item. This line item includes parking income, rental lease guaranty income, management fee income and other miscellaneous income. Below is a detail of the amounts by category:
(in thousands)
 
Three Months Ended March 31,
Type of Revenue
 
2019
 
2018
Parking income
 
$
1,734

 
$
1,626

Rental lease guaranty
 
128

 
175

Management fee income
 
69

 
68

Miscellaneous
 
30

 
26

 
 
$
1,961

 
$
1,895



The Company’s three major types of revenue that are accounted for under Topic 606 that are listed above are all accounted for as the performance obligation is satisfied. The performance obligations that are identified for each of these items are satisfied over time and the Company recognizes revenue monthly based on this principle.

New Accounting Pronouncements
Accounting Standards Update No. 2016-02, No. 2018-01 and No. 2018-11
In February 2016, the Financial Accounting Standards Board ("FASB") issued ASU 2016-02, "Leases." In January 2018, FASB issued ASU 2018-01, "Leases - Land Easement Practical Expedient for Transition to Topic 842," in July 2018, FASB issued ASU 2018-10, "Codification Improvements to Topic 842, Leases" and ASU 2018-11, "Leases - Targeted Improvements," and in December 2018, FASB issued ASU 2018-20, “Narrow-Scope Improvements for Lessors.” These accounting standard updates are collectively referred to as "Topic 842."
Topic 842 provides several practical expedients that the Company elected. These are (a) the package of practical expedients offered that allows an entity not to reassess upon adoption (i) whether an expired or existing contract contains a lease, (ii) lease classification related to expired or existing lease arrangements, and (iii) whether costs incurred on expired or existing leases qualify as initial direct costs, (b) the lessor practical expedient not to separate certain non-lease components, such as common area maintenance, from the lease component if (i) the timing and pattern of transfer are the same for the non-lease component and associated lease component, and (ii) the lease component would be classified as an operating lease if accounted for separately and (c) the lessee practical expedient not to separate certain non-lease components from the associated lease component.
For lessees, the new standard establishes a right-of-use ("ROU") model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with the classification affecting the pattern of expense recognition in the income statement. Ground leases executed or assumed prior to the adoption of Topic 842 will continue to be accounted for as operating leases and will not result in a materially different ground lease expense. However, each ground lease executed after the adoption of Topic 842 will be evaluated to determine if it is an operating or finance lease. If the lease is to be accounted for as a finance lease, ground lease expense would be accounted for using the effective interest method instead of the straight-line method over the term of the lease, which would result in higher ground lease expense in the earlier years of a ground lease when compared to the straight-line method. The Company's lease population is primarily ground leases, but also includes management office leases in third party buildings and certain copier and postage machine leases. The Company utilized a third party to assist in determining the discount rate for its ground leases. The terms of the ground leases generally range from 40 to 99 years with a weighted average remaining lease term remaining of 54.9 years, excluding renewal options. The Company's discount rates, which approximates the Company's incremental borrowing rate, ranged from 3.4% for leases expiring in 2019 to 6.2% for leases expiring in 2115. The Company utilized a third party to assist in determining the discount rates. The discount rates consider the general economic environment and factor in various financing and asset specific adjustments so that the discount rate is appropriate for the intended use of the underlying lease. As of January 1, 2019, the Company recognized the present value of its lease payments and a corresponding lease liability of $91.7 million. In addition, the Company reclassified $45.0 million of prepaid ground leases and below-market lease intangibles from the Other assets line item, $1.9 million of above-market lease intangibles from the Other liabilities line and $8.4 million of straight-line rent from the Accounts payable and accrued liabilities line item to the Operating lease right-of-use assets line item on the Condensed Consolidated Balance Sheets.
For lessors, the new standard requires a lessor to classify leases as either sales-type, direct-financing or operating. A lease will be treated as a sale if it is considered to transfer control of the underlying asset to the lessee. A lease will be classified as direct-financing if risks and rewards are conveyed without the transfer of control. Otherwise, the lease is treated as an operating lease. Lessor accounting remains largely unchanged with some exceptions including the concept of separating lease and nonlease components. Nonlease components, such as common area maintenance, are generally accounted for under Topic 606 and separated from the lease payments. However, the Company elected the lessor practical expedient allowing the Company to not separate these components when certain conditions are met. The combined component is accounted for under Topic 842. Lease related receivables, which include accounts receivable and accrued straight-line rent receivables, are reduced for revenue reserves and are recognized as a reduction to rental income. The adoption of Topic 842, where the Company is the lessor, did not have a material impact on the Company's Condensed Consolidated Financial Statements for the three months ended March 31, 2019.
The new standard was effective for the Company on January 1, 2019. Topic 842 provides two transition alternatives. The Company elected to choose the prospective optional transition method available to apply the guidance in Accounting Standards Codification Topic 840 in the comparative periods presented in the year Topic 842 is adopted. Topic 842 includes extensive quantitative and qualitative disclosures as compared to Topic 840, Leases, for both lessees and lessors. See Note 3 for additional disclosures.
Accounting Standards Update No. 2016-13 and No. 2018-19
In June 2016, the FASB issued ASU 2016-13, "Measurement of Credit Losses on Financial Instruments." This update is intended to improve financial reporting by requiring timelier recognition of credit losses on loans and other financial instruments that are not accounted for at fair value through net income, including loans held for investment, held-to-maturity debt securities, trade and other receivables, net investment in leases and other such commitments. This update requires that financial statement assets measured at an amortized cost and certain other financial instruments be presented at the net amount expected to be collected, through an allowance for credit losses that is deducted from the amortized cost basis. ASU 2018-19 also clarifies that receivables arising from operating leases are not within the scope of this topic. Instead, impairment of these receivables should be accounted for in accordance with Topic 842, Leases. This standard is effective for annual and interim periods beginning after December 15, 2019 with early adoption permitted. The Company is in the initial stages of evaluating the impact from the adoption of this new standard on the Condensed Consolidated Financial Statements and related notes.

Accounting Standards Update No. 2017-04
In January 2017, the FASB issued ASU 2017-04, "Simplifying the Test for Goodwill Impairment." This update eliminates Step 2 of the goodwill impairment test. As such, an entity will perform its annual, or interim, goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An entity should recognize a goodwill impairment charge for the amount by which the reporting unit's carrying amount exceeds its fair value. This standard is effective for the Company for annual and interim periods beginning after December 15, 2019. The Company does not expect a material impact on the Condensed Consolidated Financial Statements and related notes from the adoption of this standard.
XML 20 R10.htm IDEA: XBRL DOCUMENT v3.19.1
Real Estate Investments
3 Months Ended
Mar. 31, 2019
Business Combinations [Abstract]  
Real Estate Investments Real Estate Investments
2019 Acquisitions
The following table details the Company's acquisitions for the three months ended March 31, 2019:
(Dollars in millions)
Type (1)
 
Date
Acquired
 
Purchase Price

 
Cash
Consideration
(2)

 
Real
Estate

 
Other (3)

 
Square
Footage
(Unaudited)

Washington, D.C. (4)
MOB
 
3/28/19
 
$
46.0

 
$
45.9

 
$
50.2

 
$
(4.3
)
 
158,338

Indianapolis, IN (5)
MOB
 
3/28/19
 
47.0

 
44.8

 
43.7

 
1.1

 
143,499

 
 
 
 
 
$
93.0

 
$
90.7

 
$
93.9

 
$
(3.2
)
 
301,837

______
(1)
MOB = medical office building
(2)
Cash consideration excludes prorations of revenue and expense due to/from seller at the time of the acquisition.
(3)
Includes other assets acquired, liabilities assumed, and intangibles recognized at acquisition.
(4)
Includes two properties. The Company assumed two ground leases in connection with this acquisition that are classified as financing leases. The present value of future lease payments totaling $14.4 million was recorded on the Company's Condensed Consolidated Balance Sheets. In addition, the right-of-use assets were partially offset by $5.2 million of above-market lease intangibles included in Other.
(5)
The Company assumed a prepaid ground lease totaling $0.8 million and recorded a below-market lease intangible totaling $0.9 million in connection with this acquisition that is classified as an operating lease that are included in Other.

Subsequent Acquisition
On April 2, 2019, the Company acquired a 47,963 square foot medical office building in Atlanta, Georgia for a purchase price of $28.0 million.

Subsequent Disposition
On April 9, 2019, the Company disposed of three off-campus medical office buildings and one on-campus medical office building to a single purchaser. The buildings are located in Tucson, Arizona and total 67,345 square feet. The sales price was approximately $13.0 million and as of March 31, 2019, the Company's net investment in the buildings was $6.9 million.




Assets Held for Sale
In March 2019, the Company reclassified an inpatient rehabilitation facility to held for sale upon notification that a ground lessor is exercising a purchase option. The purchase price is determined by an appraisal process that is currently underway. The Company expects the purchase price to be greater than the current net investment of approximately $1.3 million. As of March 31, 2019 and December 31, 2018, the Company had two properties and one property, respectively, classified as held for sale.

The table below reflects the assets and liabilities of the properties classified as held for sale as of March 31, 2019 and December 31, 2018:
(Dollars in thousands)
March 31,
2019
 
December 31,
2018
Balance Sheet data:
 
 
 
Land
$
1,125

 
$
1,125

Buildings, improvements and lease intangibles
39,586

 
18,231

 
40,711

 
19,356

Accumulated depreciation
(30,706
)
 
(10,657
)
Real estate assets held for sale, net
10,005

 
8,699

Operating lease right-of-use assets
168

 

Other assets, net
395

 
573

Assets held for sale, net
$
10,568

 
$
9,272

 
 
 
 
Accounts payable and accrued liabilities
$
251

 
$
450

Operating lease liabilities
168

 

Other liabilities
214

 
137

Liabilities of properties held for sale
$
633

 
$
587

XML 21 R11.htm IDEA: XBRL DOCUMENT v3.19.1
Leases
3 Months Ended
Mar. 31, 2019
Leases [Abstract]  
Leases Leases
Lessor Accounting Under ASC 842
The Company’s properties generally are leased pursuant to non-cancelable, fixed-term operating leases with expiration dates through 2036. Some leases provide for fixed rent renewal terms in addition to market rent renewal terms. Some leases provide the lessee, during the term of the lease, with an option or right of first refusal to purchase the leased property.

The Company's leases typically have escalators that are either based on a stated percentage or an index such as CPI (consumer price index). In addition, most of the Company's leases include nonlease components such as reimbursement of operating expenses as additional rent or include the reimbursement of expected operating expenses as part of the lease payment. The Company elected the practical expedient and adopted an accounting policy to combine lease and nonlease components. Rent escalators based on indices and reimbursements of operating expenses that are not included in the lease rate are considered variable lease payments. Variable payments are recognized in the periods when the information is known. As of March 31, 2019, the Company had one ground lease that is associated with a property under construction where rent has not yet commenced. Lease income for the Company's operating leases recognized for the three months ended March 31, 2019 was $110.7 million.

Future lease payments under the non-cancelable operating leases, excluding any reimbursements, as of March 31, 2019 are as follows (in thousands):
2019
$
250,619

2020
294,900

2021
250,050

2022
213,822

2023
175,215

2024 and thereafter
502,647

 
$
1,687,253



Lessor Accounting Under ASC 840
The Company’s properties are generally leased pursuant to non-cancelable, fixed-term operating leases with expiration dates through 2036. Some leases and financial arrangements provide for fixed rent renewal terms in addition to market rent renewal terms. Some leases provide the lessee, during the term of the lease and for a short period thereafter, with an option or a right of first refusal to purchase the leased property. The Company’s portfolio of single-tenant net leases generally requires the lessee to pay minimum rent and all taxes (including property tax), insurance, maintenance and other operating costs associated with the leased property.
Future minimum lease payments under the non-cancelable operating leases, excluding any reimbursements, as of December 31, 2018 are as follows (in thousands):
2019
$
326,441

2020
279,211

2021
235,660

2022
201,072

2023
163,978

2024 and thereafter
476,673

 
$
1,683,035



Lessee Accounting Under ASC 842
As of March 31, 2019, the Company was obligated, as the lessee, under operating lease agreements consisting primarily of the Company’s ground leases. As of March 31, 2019, the Company had 109 properties, excluding one property classified as held for sale, totaling 9.1 million square feet that were held under ground leases with a remaining weighted average term of 54.9 years, excluding renewal options. Including renewal options, the remaining weighted average term would be 70.7 years. Some lease renewal terms are based on fixed rent renewal terms in addition to market rent renewal terms. These ground leases typically have initial terms of 40 to 99 years with expiration dates through 2117. Any increases related to the Company’s ground leases are generally either stated or based on the Consumer Price Index. The Company had 46 prepaid ground leases as of March 31, 2019. The amortization of the prepaid rent, included in the operating lease right-of-use asset represented approximately $0.1 million of the Company’s rental expense for the three months ended March 31, 2019 and March 31, 2018.

The Company’s future lease payments (primarily for its 63 non-prepaid ground leases) as of March 31, 2019 were as follows (in thousands):

 
 
Operating

 
Financing

2019
$
2,948

 
$
626

2020
4,849

 
611

2021
4,879

 
619

2022
4,909

 
628

2023
4,947

 
637

2024 and thereafter
314,406

 
74,766

Total undiscounted lease payments
336,938

 
77,887

Discount
(245,894
)
 
(63,593
)
Lease Liability
$
91,044

 
$
14,294



The following table provides a detail of the Company's total lease expense for the three months ended March 31, 2019 (in thousands):
 
 
Operating
 
FInancing
Lease expense
 
 
 
 
Operating lease expense
 
$
1,116

 
$

Variable lease expense
 
740

 

Total lease expense
 
$
1,856

 
$

 
 
 
 
 
Other information
 
 
 
 
Operating cash flows outflows related to operating leases
 
$
2,771

 
$

Right-of-use assets obtained in exchange for new lease liabilities
 
$

 
$
14,294

Weighted-average remaining lease term (excluding renewal options)
 
54.0

 
70.6

Weighted-average discount rate
 
5.5
%
 
5.9
%


Lessee Accounting Under ASC 840

As of December 31, 2018, the Company was obligated under operating lease agreements consisting primarily of the Company’s ground leases. At December 31, 2018, the Company had 107 properties totaling 8.8 million square feet that were held under ground leases with a remaining weighted average term of 53.9 years, excluding renewal options. These ground leases typically have initial terms of 50 to 75 years with one or more renewal options extending the terms to 75 to 100 years, with expiration dates through 2117. Any rental increases related to the Company’s ground leases are generally either stated or based on the Consumer Price Index.

The Company’s future minimum lease payments (primarily for its 60 non-prepaid ground leases) as of December 31, 2018 were as follows (in thousands):  
2019
$
5,288

2020
5,260

2021
5,238

2022
5,207

2023
5,224

2024 and thereafter
323,533

 
$
349,750

XML 22 R12.htm IDEA: XBRL DOCUMENT v3.19.1
Notes and Bonds Payable
3 Months Ended
Mar. 31, 2019
Debt Disclosure [Abstract]  
Notes and Bonds Payable Notes and Bonds Payable
The table below details the Company’s notes and bonds payable. 
 
Maturity
Dates
 
Balance as of
 
Effective Interest Rate as of

(Dollars in thousands)
March 31, 2019

 
December 31, 2018

March 31, 2019

Unsecured Credit Facility
7/20
 
$
260,000

 
$
262,000

 
3.49
%
Unsecured Term Loan Facility, net of issuance costs (1)
12/22
 
149,234

 
149,183

 
3.53
%
Senior Notes due 2023, net of discount and issuance costs
4/23
 
248,223

 
248,117

 
3.95
%
Senior Notes due 2025, net of discount and issuance costs (2)
5/25
 
248,338

 
248,278

 
4.08
%
Senior Notes due 2028, net of discount and issuance costs
1/28
 
295,309

 
295,198

 
3.84
%
Mortgage notes payable, net of discounts and issuance costs and including premiums
7/19-5/40
 
142,006

 
143,208

 
4.79
%
 
 
 
$
1,343,110

 
$
1,345,984

 
 

______
(1)
The effective interest rate includes the impact of interest rate swaps on $25.0 million and $50.0 million of the outstanding balance at a rate of 2.18% and 2.46%, respectively (plus the applicable margin rate, currently 110 basis points).
(2)
The effective interest rate includes the impact of the $1.7 million settlement of a forward-starting interest rate swap that is included in Accumulated other comprehensive income (loss) on the Company's Condensed Consolidated Balance Sheets.

Subsequent Mortgage Note Payable Payoff
On April 10, 2019, the Company repaid in full a mortgage note payable bearing interest at a rate of 5.00% per annum with an outstanding principal of $8.9 million. The mortgage note encumbered a 52,813 square foot property in Washington.
XML 23 R13.htm IDEA: XBRL DOCUMENT v3.19.1
Derivative Financial Instruments
3 Months Ended
Mar. 31, 2019
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Derivative Financial Instruments Derivative Financial Instruments
Risk Management Objective of Using Derivatives
The Company is exposed to certain risks arising from both its business operations and economic conditions. The Company principally manages its exposures to a wide variety of business and operational risks through management of its core business activities. The Company manages economic risks, including interest rate, liquidity, and credit risk, primarily by managing the amount, sources, and duration of its assets and liabilities and the use of derivative financial instruments. Specifically, the Company enters into derivative financial instruments to manage exposures that arise from business activities that result in the
receipt or payment of future known and uncertain cash amounts, the value of which are determined by interest rates. The Company’s derivative financial instruments are used to manage differences in the amount, timing, and duration of the Company’s known or expected cash receipts and its known or expected cash payments principally related to the Company’s borrowings.

Cash Flow Hedges of Interest Rate Risk
The Company’s objectives in using interest rate derivatives are to add stability to interest expense and to manage its exposure to interest rate movements. To accomplish this objective, the Company primarily uses interest rate swaps as part of its interest rate risk management strategy. Interest rate swaps designated as cash flow hedges involve the receipt of variable amounts from a counterparty in exchange for the Company making fixed-rate payments over the life of the agreements without exchange of the underlying notional amount. Such derivatives were used to hedge the variable cash flows associated with existing variable-rate debt.

For derivatives designated and that qualify as cash flow hedges of interest rate risk, the gain or loss on the derivative is recorded in Accumulated Other Comprehensive Income (Loss) and subsequently reclassified into interest expense in the same period(s) during which the hedged transaction affects earnings. Amounts reported in Accumulated other comprehensive income (loss) related to derivatives will be reclassified to interest expense as interest payments are made on the Company’s variable-rate debt.

As of March 31, 2019, the Company had four outstanding interest rate derivatives that were designated as cash flow hedges of interest rate risk:
Derivative Instrument
 
Number of Instruments

 
Notional Amount
(in millions)
Interest rate swaps
 
4

 
$75.0


Tabular Disclosure of Fair Values of Derivative Instruments on the Balance Sheet
The table below presents the fair value of the Company's derivative financial instruments, as well as their classification on the Condensed Consolidated Balance Sheet as of March 31, 2019.
 
Balance at March 31, 2019
(Dollars in thousands)
Balance Sheet Location
 
Fair Value

Derivatives designated as hedging instruments
 
 
 
Interest rate swaps
Other liabilities
 
$
589

Total derivatives designated as hedging instruments
 
 
$
589



Tabular Disclosure of the Effect of Cash Flow Hedge Accounting on Accumulated Other Comprehensive Income (Loss)
The table below presents the effect of cash flow hedge accounting on Accumulated Other Comprehensive Income (Loss) ("OCI") during the three months ended March 31, 2019 and 2018 related to the Company's outstanding interest rate swaps.
 
Amount of Loss Recognized in OCI on Derivative
 
Amount of Loss Reclassified from OCI into Income
(Dollars in thousands)
2019

2019

 
2018

Interest rate products
$
724

Interest expense
$
(27
)
 
$
105

Settled interest rate swaps

Interest expense
42

 
42

 
$
724

Total interest expense
$
15

 
$
147


Credit-risk-related Contingent Features
The Company's agreements with each of its derivative counterparties contain a cross-default provision under which the Company could be declared in default of its derivative obligations if repayment of the underlying indebtedness is accelerated by the lender due to the Company's default on the indebtedness.

The Company estimates that $13 thousand related to active interest rate swaps will be reclassified from OCI as a decrease to interest expense over the next 12 months, and that $0.2 million related to settled interest rate swaps will be amortized from OCI as an increase to interest expense over the next 12 months.

Subsequent Activity
On April 12, 2019, the Company entered into two interest rate swaps totaling $50.0 million to hedge the 1-month LIBOR portion of the cost of borrowing under the Company's variable rate debt to a fixed interest rate of 2.334%. These derivatives were used to hedge variable cash flows associated with variable-rate debt.
XML 24 R14.htm IDEA: XBRL DOCUMENT v3.19.1
Commitments and Contingencies
3 Months Ended
Mar. 31, 2019
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies Commitments and Contingencies
Legal Proceedings
The Company is, from time to time, involved in litigation arising in the ordinary course of business. The Company is not aware of any pending or threatened litigation that, if resolved against the Company, would have a material adverse effect on the Company’s consolidated financial position, results of operations or cash flows.

Redevelopment Activity
The Company is redeveloping a medical office building in Charlotte, North Carolina, which includes a 38,000 square foot vertical expansion. As of March 31, 2019, the Company had funded approximately $9.7 million on the redevelopment of this property. The project is expected to be completed in the second quarter of 2019.

Development Activity
The Company began the development of a 151,000 square foot medical office building in Seattle, Washington during 2017. As of March 31, 2019, the Company had funded approximately $30.9 million on the development. The Company expects the project to be completed in the fourth quarter of 2019.
XML 25 R15.htm IDEA: XBRL DOCUMENT v3.19.1
Stockholders' Equity
3 Months Ended
Mar. 31, 2019
Equity [Abstract]  
Stockholders' Equity Stockholders' Equity

Common Stock    
The following table provides a reconciliation of the beginning and ending shares of common stock outstanding for the three months ended March 31, 2019 and the year ended December 31, 2018:
 
March 31, 2019
 
December 31, 2018
Balance, beginning of period
125,279,455

 
125,131,593

Issuance of common stock
3,889,411

 
26,203

Nonvested share-based awards, net of withheld shares
45,225

 
121,659

Balance, end of period
129,214,091

 
125,279,455



Equity Offering
On March 19, 2019, the Company issued 3,737,500 shares of common stock, par value $0.01 per share, at $31.40 per share in an underwritten public offering pursuant to the Company's existing effective registration statement. The net proceeds of the offering, after underwriting discounts and offering expenses, were approximately $115.8 million.

At-The-Market Equity Offering Program
The Company sold 135,265 shares under the Company's at-the-market equity offering program during the three months ended March 31, 2019. The sales generated $4.3 million in net proceeds at prices to the public ranging from $32.01 to $32.86 (weighted average of $32.36). The Company had 5,733,432 authorized shares remaining available to be sold under the current sales agreements as of April 26, 2019.

Common Stock Dividends
During the three months ended March 31, 2019, the Company declared and paid common stock dividends totaling $0.30 per share. On April 30, 2019, the Company declared a quarterly common stock dividend in the amount of $0.30 per share payable on May 30, 2019 to stockholders of record on May 15, 2019.

Earnings Per Common Share
The Company uses the two-class method of computing net earnings per common shares. The Company's nonvested share-based awards are considered participating securities pursuant to the two-class method. The following table sets forth the computation of basic and diluted earnings per common share for the three months ended March 31, 2019 and 2018.
 
Three Months Ended March 31,
(Dollars in thousands, except per share data)
2019
 
2018
Weighted average Common Shares outstanding
 
 
 
Weighted average Common Shares outstanding
125,908,335

 
125,167,128

Nonvested shares
(1,778,700
)
 
(1,909,777
)
Weighted average Common Shares outstanding—Basic
124,129,635

 
123,257,351

Weighted average Common Shares outstanding—Basic
124,129,635

 
123,257,351

Dilutive effect of employee stock purchase plan
102,132

 
90,330

Weighted average Common Shares outstanding—Diluted
124,231,767

 
123,347,681

Net Income
$
4,891

 
$
9,180

Dividends paid on nonvested share-based awards
(536
)
 
(579
)
Net income applicable to common stockholders
$
4,355

 
$
8,601

Basic earnings per common share - Net income
$
0.04

 
$
0.07

Diluted earnings per common share - Net income
$
0.04

 
$
0.07



Incentive Plans
A summary of the activity under the Company's share-based incentive plans for the three months ended March 31, 2019 and 2018 is included in the table below.
 
Three Months Ended March 31,
 
2019
 
2018
Share-based awards, beginning of period
1,769,863

 
1,907,645

Granted
64,771

 
76,762

Vested
(50,507
)
 
(54,065
)
Share-based awards, end of period
1,784,127

 
1,930,342



During the three months ended March 31, 2019 and 2018, the Company withheld 19,546 and 21,196 shares of common stock, respectively, from participants to pay estimated withholding taxes related to shares that vested.

In addition to the share-based incentive plans, the Company maintains the 2000 Employee Stock Purchase Plan (the "Purchase Plan"). A summary of the activity under the Purchase Plan for the three months ended March 31, 2019 and 2018 is included in the table below.
 
Three Months Ended March 31,
 
2019
 
2018
Outstanding and exercisable, beginning of period
328,533

 
318,100

Granted
235,572

 
203,836

Exercised
(14,630
)
 
(8,835
)
Forfeited
(16,625
)
 
(10,580
)
Expired
(142,074
)
 
(135,790
)
Outstanding and exercisable, end of period
390,776

 
366,731

XML 26 R16.htm IDEA: XBRL DOCUMENT v3.19.1
Fair Value of Financial Instruments
3 Months Ended
Mar. 31, 2019
Fair Value Disclosures [Abstract]  
Fair Value of Financial Instruments Fair Value of Financial Instruments
The following methods and assumptions were used to estimate the fair value of each class of financial instrument for which it is practical to estimate that value.

Cash and cash equivalents - The carrying amount approximates fair value due to the short term maturity of these investments.

Borrowings under the unsecured credit facility due 2020 and unsecured term loan facility due 2022 - The carrying amount approximates fair value because the borrowings are based on variable market interest rates.

Senior Notes and Mortgage Notes payable - The fair value of notes and bonds payable is estimated using cash flow analyses, based on the Company’s current interest rates for similar types of borrowing arrangements.

Interest rate swap agreements - Interest rate swap agreements are recorded in other liabilities on the Company's Consolidated Balance Sheets at fair value. Fair value is estimated by utilizing pricing models that consider forward yield curves and discount rates.

The table below details the fair values and carrying values for notes and bonds payable at March 31, 2019 and December 31, 2018.
 
March 31, 2019
 
December 31, 2018
(Dollars in millions)
Carrying Value
 
Fair Value
 
Carrying Value
 
Fair Value
Notes and bonds payable (1)
$
1,343.1

 
$
1,329.8

 
$
1,346.0

 
$
1,326.5


______
(1)
Level 2 – model-derived valuations in which significant inputs and significant value drivers are observable in active markets.
XML 27 R17.htm IDEA: XBRL DOCUMENT v3.19.1
Summary of Significant Accounting Policies (Policies)
3 Months Ended
Mar. 31, 2019
Accounting Policies [Abstract]  
Business Overview Business OverviewHealthcare Realty Trust Incorporated (the "Company") is a real estate investment trust ("REIT") that owns, leases, manages, acquires, finances, develops and redevelops income-producing real estate properties associated primarily with the delivery of outpatient healthcare services throughout the United States. As of March 31, 2019, the Company had gross investments of approximately $4.0 billion in 201 real estate properties located in 26 states totaling approximately 15.0 million square feet. The Company provided leasing and property management services to approximately 11.3 million square feet nationwide.
Basis of Presentation Basis of Presentation
The Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. They do not include all of the information and footnotes required by GAAP for complete financial statements. However, except as disclosed herein, management believes there has been no material change in the information disclosed in the Notes to the Consolidated Financial Statements included in the Annual Report on Form 10-K for the year ended December 31, 2018. All material intercompany transactions and balances have been eliminated in consolidation.

This interim financial information should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2018. Management believes that all adjustments of a normal, recurring nature considered necessary for a fair presentation have been included. In addition, the interim financial information does not necessarily represent or indicate what the operating results will be for the year ending December 31, 2019 for many reasons including, but not limited to, acquisitions, dispositions, capital financing transactions, changes in interest rates and the effects of other trends, risks and uncertainties.
Use of Estimates in the Condensed Consolidated Financial Statements Use of Estimates in the Condensed Consolidated Financial StatementsPreparation of the Condensed Consolidated Financial Statements in accordance with GAAP requires management to make estimates and assumptions that affect amounts reported in the Condensed Consolidated Financial Statements and accompanying notes. Actual results may differ from those estimates.
Revenue from Contracts with Customers (Topic 606) Revenue from Contracts with Customers (Topic 606)
The Company recognizes certain revenue under the core principle of Topic 606. This requires an entity to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Lease revenue is not within the scope of Topic 606. To achieve the core principle, the Company applies the five step model specified in the guidance.

Revenue that is accounted for under Topic 606 is segregated on the Company’s Condensed Consolidated Statements of Income in the Other operating line item. This line item includes parking income, rental lease guaranty income, management fee income and other miscellaneous income. Below is a detail of the amounts by category:
(in thousands)
 
Three Months Ended March 31,
Type of Revenue
 
2019
 
2018
Parking income
 
$
1,734

 
$
1,626

Rental lease guaranty
 
128

 
175

Management fee income
 
69

 
68

Miscellaneous
 
30

 
26

 
 
$
1,961

 
$
1,895



The Company’s three major types of revenue that are accounted for under Topic 606 that are listed above are all accounted for as the performance obligation is satisfied. The performance obligations that are identified for each of these items are satisfied over time and the Company recognizes revenue monthly based on this principle.
New Accounting Pronouncements New Accounting Pronouncements
Accounting Standards Update No. 2016-02, No. 2018-01 and No. 2018-11
In February 2016, the Financial Accounting Standards Board ("FASB") issued ASU 2016-02, "Leases." In January 2018, FASB issued ASU 2018-01, "Leases - Land Easement Practical Expedient for Transition to Topic 842," in July 2018, FASB issued ASU 2018-10, "Codification Improvements to Topic 842, Leases" and ASU 2018-11, "Leases - Targeted Improvements," and in December 2018, FASB issued ASU 2018-20, “Narrow-Scope Improvements for Lessors.” These accounting standard updates are collectively referred to as "Topic 842."
Topic 842 provides several practical expedients that the Company elected. These are (a) the package of practical expedients offered that allows an entity not to reassess upon adoption (i) whether an expired or existing contract contains a lease, (ii) lease classification related to expired or existing lease arrangements, and (iii) whether costs incurred on expired or existing leases qualify as initial direct costs, (b) the lessor practical expedient not to separate certain non-lease components, such as common area maintenance, from the lease component if (i) the timing and pattern of transfer are the same for the non-lease component and associated lease component, and (ii) the lease component would be classified as an operating lease if accounted for separately and (c) the lessee practical expedient not to separate certain non-lease components from the associated lease component.
For lessees, the new standard establishes a right-of-use ("ROU") model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with the classification affecting the pattern of expense recognition in the income statement. Ground leases executed or assumed prior to the adoption of Topic 842 will continue to be accounted for as operating leases and will not result in a materially different ground lease expense. However, each ground lease executed after the adoption of Topic 842 will be evaluated to determine if it is an operating or finance lease. If the lease is to be accounted for as a finance lease, ground lease expense would be accounted for using the effective interest method instead of the straight-line method over the term of the lease, which would result in higher ground lease expense in the earlier years of a ground lease when compared to the straight-line method. The Company's lease population is primarily ground leases, but also includes management office leases in third party buildings and certain copier and postage machine leases. The Company utilized a third party to assist in determining the discount rate for its ground leases. The terms of the ground leases generally range from 40 to 99 years with a weighted average remaining lease term remaining of 54.9 years, excluding renewal options. The Company's discount rates, which approximates the Company's incremental borrowing rate, ranged from 3.4% for leases expiring in 2019 to 6.2% for leases expiring in 2115. The Company utilized a third party to assist in determining the discount rates. The discount rates consider the general economic environment and factor in various financing and asset specific adjustments so that the discount rate is appropriate for the intended use of the underlying lease. As of January 1, 2019, the Company recognized the present value of its lease payments and a corresponding lease liability of $91.7 million. In addition, the Company reclassified $45.0 million of prepaid ground leases and below-market lease intangibles from the Other assets line item, $1.9 million of above-market lease intangibles from the Other liabilities line and $8.4 million of straight-line rent from the Accounts payable and accrued liabilities line item to the Operating lease right-of-use assets line item on the Condensed Consolidated Balance Sheets.
For lessors, the new standard requires a lessor to classify leases as either sales-type, direct-financing or operating. A lease will be treated as a sale if it is considered to transfer control of the underlying asset to the lessee. A lease will be classified as direct-financing if risks and rewards are conveyed without the transfer of control. Otherwise, the lease is treated as an operating lease. Lessor accounting remains largely unchanged with some exceptions including the concept of separating lease and nonlease components. Nonlease components, such as common area maintenance, are generally accounted for under Topic 606 and separated from the lease payments. However, the Company elected the lessor practical expedient allowing the Company to not separate these components when certain conditions are met. The combined component is accounted for under Topic 842. Lease related receivables, which include accounts receivable and accrued straight-line rent receivables, are reduced for revenue reserves and are recognized as a reduction to rental income. The adoption of Topic 842, where the Company is the lessor, did not have a material impact on the Company's Condensed Consolidated Financial Statements for the three months ended March 31, 2019.
The new standard was effective for the Company on January 1, 2019. Topic 842 provides two transition alternatives. The Company elected to choose the prospective optional transition method available to apply the guidance in Accounting Standards Codification Topic 840 in the comparative periods presented in the year Topic 842 is adopted. Topic 842 includes extensive quantitative and qualitative disclosures as compared to Topic 840, Leases, for both lessees and lessors. See Note 3 for additional disclosures.
Accounting Standards Update No. 2016-13 and No. 2018-19
In June 2016, the FASB issued ASU 2016-13, "Measurement of Credit Losses on Financial Instruments." This update is intended to improve financial reporting by requiring timelier recognition of credit losses on loans and other financial instruments that are not accounted for at fair value through net income, including loans held for investment, held-to-maturity debt securities, trade and other receivables, net investment in leases and other such commitments. This update requires that financial statement assets measured at an amortized cost and certain other financial instruments be presented at the net amount expected to be collected, through an allowance for credit losses that is deducted from the amortized cost basis. ASU 2018-19 also clarifies that receivables arising from operating leases are not within the scope of this topic. Instead, impairment of these receivables should be accounted for in accordance with Topic 842, Leases. This standard is effective for annual and interim periods beginning after December 15, 2019 with early adoption permitted. The Company is in the initial stages of evaluating the impact from the adoption of this new standard on the Condensed Consolidated Financial Statements and related notes.

Accounting Standards Update No. 2017-04
In January 2017, the FASB issued ASU 2017-04, "Simplifying the Test for Goodwill Impairment." This update eliminates Step 2 of the goodwill impairment test. As such, an entity will perform its annual, or interim, goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An entity should recognize a goodwill impairment charge for the amount by which the reporting unit's carrying amount exceeds its fair value. This standard is effective for the Company for annual and interim periods beginning after December 15, 2019. The Company does not expect a material impact on the Condensed Consolidated Financial Statements and related notes from the adoption of this standard.
XML 28 R18.htm IDEA: XBRL DOCUMENT v3.19.1
Summary of Significant Accounting Policies (Tables)
3 Months Ended
Mar. 31, 2019
Accounting Policies [Abstract]  
Disaggregation of revenue Below is a detail of the amounts by category:
(in thousands)
 
Three Months Ended March 31,
Type of Revenue
 
2019
 
2018
Parking income
 
$
1,734

 
$
1,626

Rental lease guaranty
 
128

 
175

Management fee income
 
69

 
68

Miscellaneous
 
30

 
26

 
 
$
1,961

 
$
1,895

XML 29 R19.htm IDEA: XBRL DOCUMENT v3.19.1
Real Estate Investments (Tables)
3 Months Ended
Mar. 31, 2019
Business Combinations [Abstract]  
Summary of acquisitions The following table details the Company's acquisitions for the three months ended March 31, 2019:
(Dollars in millions)
Type (1)
 
Date
Acquired
 
Purchase Price

 
Cash
Consideration
(2)

 
Real
Estate

 
Other (3)

 
Square
Footage
(Unaudited)

Washington, D.C. (4)
MOB
 
3/28/19
 
$
46.0

 
$
45.9

 
$
50.2

 
$
(4.3
)
 
158,338

Indianapolis, IN (5)
MOB
 
3/28/19
 
47.0

 
44.8

 
43.7

 
1.1

 
143,499

 
 
 
 
 
$
93.0

 
$
90.7

 
$
93.9

 
$
(3.2
)
 
301,837

______
(1)
MOB = medical office building
(2)
Cash consideration excludes prorations of revenue and expense due to/from seller at the time of the acquisition.
(3)
Includes other assets acquired, liabilities assumed, and intangibles recognized at acquisition.
(4)
Includes two properties. The Company assumed two ground leases in connection with this acquisition that are classified as financing leases. The present value of future lease payments totaling $14.4 million was recorded on the Company's Condensed Consolidated Balance Sheets. In addition, the right-of-use assets were partially offset by $5.2 million of above-market lease intangibles included in Other.
(5)
The Company assumed a prepaid ground lease totaling $0.8 million and recorded a below-market lease intangible totaling $0.9 million in connection with this acquisition that is classified as an operating lease that are included in Other.
Assets held for sale The table below reflects the assets and liabilities of the properties classified as held for sale as of March 31, 2019 and December 31, 2018:
(Dollars in thousands)
March 31,
2019
 
December 31,
2018
Balance Sheet data:
 
 
 
Land
$
1,125

 
$
1,125

Buildings, improvements and lease intangibles
39,586

 
18,231

 
40,711

 
19,356

Accumulated depreciation
(30,706
)
 
(10,657
)
Real estate assets held for sale, net
10,005

 
8,699

Operating lease right-of-use assets
168

 

Other assets, net
395

 
573

Assets held for sale, net
$
10,568

 
$
9,272

 
 
 
 
Accounts payable and accrued liabilities
$
251

 
$
450

Operating lease liabilities
168

 

Other liabilities
214

 
137

Liabilities of properties held for sale
$
633

 
$
587

XML 30 R20.htm IDEA: XBRL DOCUMENT v3.19.1
Leases (Tables)
3 Months Ended
Mar. 31, 2019
Leases [Abstract]  
Future Minimum Lease Payments Receivable Future lease payments under the non-cancelable operating leases, excluding any reimbursements, as of March 31, 2019 are as follows (in thousands):
2019
$
250,619

2020
294,900

2021
250,050

2022
213,822

2023
175,215

2024 and thereafter
502,647

 
$
1,687,253

Future Minimum Lease Payments Receivable under ASC 840 Future minimum lease payments under the non-cancelable operating leases, excluding any reimbursements, as of December 31, 2018 are as follows (in thousands):
2019
$
326,441

2020
279,211

2021
235,660

2022
201,072

2023
163,978

2024 and thereafter
476,673

 
$
1,683,035

Future Minimum Operating Lease Payments The Company’s future lease payments (primarily for its 63 non-prepaid ground leases) as of March 31, 2019 were as follows (in thousands):

 
 
Operating

 
Financing

2019
$
2,948

 
$
626

2020
4,849

 
611

2021
4,879

 
619

2022
4,909

 
628

2023
4,947

 
637

2024 and thereafter
314,406

 
74,766

Total undiscounted lease payments
336,938

 
77,887

Discount
(245,894
)
 
(63,593
)
Lease Liability
$
91,044

 
$
14,294

Future Minimum Financing Lease Payments The Company’s future lease payments (primarily for its 63 non-prepaid ground leases) as of March 31, 2019 were as follows (in thousands):

 
 
Operating

 
Financing

2019
$
2,948

 
$
626

2020
4,849

 
611

2021
4,879

 
619

2022
4,909

 
628

2023
4,947

 
637

2024 and thereafter
314,406

 
74,766

Total undiscounted lease payments
336,938

 
77,887

Discount
(245,894
)
 
(63,593
)
Lease Liability
$
91,044

 
$
14,294

Lease Cost The following table provides a detail of the Company's total lease expense for the three months ended March 31, 2019 (in thousands):
 
 
Operating
 
FInancing
Lease expense
 
 
 
 
Operating lease expense
 
$
1,116

 
$

Variable lease expense
 
740

 

Total lease expense
 
$
1,856

 
$

 
 
 
 
 
Other information
 
 
 
 
Operating cash flows outflows related to operating leases
 
$
2,771

 
$

Right-of-use assets obtained in exchange for new lease liabilities
 
$

 
$
14,294

Weighted-average remaining lease term (excluding renewal options)
 
54.0

 
70.6

Weighted-average discount rate
 
5.5
%
 
5.9
%
Future Minimum Lease Payments under ASC 840 The Company’s future minimum lease payments (primarily for its 60 non-prepaid ground leases) as of December 31, 2018 were as follows (in thousands):  
2019
$
5,288

2020
5,260

2021
5,238

2022
5,207

2023
5,224

2024 and thereafter
323,533

 
$
349,750

XML 31 R21.htm IDEA: XBRL DOCUMENT v3.19.1
Notes and Bonds Payable (Tables)
3 Months Ended
Mar. 31, 2019
Debt Disclosure [Abstract]  
Schedule of Debt The table below details the Company’s notes and bonds payable. 
 
Maturity
Dates
 
Balance as of
 
Effective Interest Rate as of

(Dollars in thousands)
March 31, 2019

 
December 31, 2018

March 31, 2019

Unsecured Credit Facility
7/20
 
$
260,000

 
$
262,000

 
3.49
%
Unsecured Term Loan Facility, net of issuance costs (1)
12/22
 
149,234

 
149,183

 
3.53
%
Senior Notes due 2023, net of discount and issuance costs
4/23
 
248,223

 
248,117

 
3.95
%
Senior Notes due 2025, net of discount and issuance costs (2)
5/25
 
248,338

 
248,278

 
4.08
%
Senior Notes due 2028, net of discount and issuance costs
1/28
 
295,309

 
295,198

 
3.84
%
Mortgage notes payable, net of discounts and issuance costs and including premiums
7/19-5/40
 
142,006

 
143,208

 
4.79
%
 
 
 
$
1,343,110

 
$
1,345,984

 
 

______
(1)
The effective interest rate includes the impact of interest rate swaps on $25.0 million and $50.0 million of the outstanding balance at a rate of 2.18% and 2.46%, respectively (plus the applicable margin rate, currently 110 basis points).
(2)
The effective interest rate includes the impact of the $1.7 million settlement of a forward-starting interest rate swap that is included in Accumulated other comprehensive income (loss) on the Company's Condensed Consolidated Balance Sheets.

XML 32 R22.htm IDEA: XBRL DOCUMENT v3.19.1
Derivative Financial Instruments (Tables)
3 Months Ended
Mar. 31, 2019
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) As of March 31, 2019, the Company had four outstanding interest rate derivatives that were designated as cash flow hedges of interest rate risk:
Derivative Instrument
 
Number of Instruments

 
Notional Amount
(in millions)
Interest rate swaps
 
4

 
$75.0
Schedule of Derivative Instruments in Statement of Financial Position, Fair Value The table below presents the fair value of the Company's derivative financial instruments, as well as their classification on the Condensed Consolidated Balance Sheet as of March 31, 2019.
 
Balance at March 31, 2019
(Dollars in thousands)
Balance Sheet Location
 
Fair Value

Derivatives designated as hedging instruments
 
 
 
Interest rate swaps
Other liabilities
 
$
589

Total derivatives designated as hedging instruments
 
 
$
589

Schedule of Derivative Instruments, Effect on Other Comprehensive Income (Loss) The table below presents the effect of cash flow hedge accounting on Accumulated Other Comprehensive Income (Loss) ("OCI") during the three months ended March 31, 2019 and 2018 related to the Company's outstanding interest rate swaps.
 
Amount of Loss Recognized in OCI on Derivative
 
Amount of Loss Reclassified from OCI into Income
(Dollars in thousands)
2019

2019

 
2018

Interest rate products
$
724

Interest expense
$
(27
)
 
$
105

Settled interest rate swaps

Interest expense
42

 
42

 
$
724

Total interest expense
$
15

 
$
147


XML 33 R23.htm IDEA: XBRL DOCUMENT v3.19.1
Stockholders' Equity (Tables)
3 Months Ended
Mar. 31, 2019
Equity [Abstract]  
Reconciliation of beginning and ending common stock outstanding The following table provides a reconciliation of the beginning and ending shares of common stock outstanding for the three months ended March 31, 2019 and the year ended December 31, 2018:
 
March 31, 2019
 
December 31, 2018
Balance, beginning of period
125,279,455

 
125,131,593

Issuance of common stock
3,889,411

 
26,203

Nonvested share-based awards, net of withheld shares
45,225

 
121,659

Balance, end of period
129,214,091

 
125,279,455

Earnings (loss) per share The following table sets forth the computation of basic and diluted earnings per common share for the three months ended March 31, 2019 and 2018.
 
Three Months Ended March 31,
(Dollars in thousands, except per share data)
2019
 
2018
Weighted average Common Shares outstanding
 
 
 
Weighted average Common Shares outstanding
125,908,335

 
125,167,128

Nonvested shares
(1,778,700
)
 
(1,909,777
)
Weighted average Common Shares outstanding—Basic
124,129,635

 
123,257,351

Weighted average Common Shares outstanding—Basic
124,129,635

 
123,257,351

Dilutive effect of employee stock purchase plan
102,132

 
90,330

Weighted average Common Shares outstanding—Diluted
124,231,767

 
123,347,681

Net Income
$
4,891

 
$
9,180

Dividends paid on nonvested share-based awards
(536
)
 
(579
)
Net income applicable to common stockholders
$
4,355

 
$
8,601

Basic earnings per common share - Net income
$
0.04

 
$
0.07

Diluted earnings per common share - Net income
$
0.04

 
$
0.07

Summary of the activity under the Incentive Plan A summary of the activity under the Company's share-based incentive plans for the three months ended March 31, 2019 and 2018 is included in the table below.
 
Three Months Ended March 31,
 
2019
 
2018
Share-based awards, beginning of period
1,769,863

 
1,907,645

Granted
64,771

 
76,762

Vested
(50,507
)
 
(54,065
)
Share-based awards, end of period
1,784,127

 
1,930,342

Summary of employee stock purchase plan activity A summary of the activity under the Purchase Plan for the three months ended March 31, 2019 and 2018 is included in the table below.
 
Three Months Ended March 31,
 
2019
 
2018
Outstanding and exercisable, beginning of period
328,533

 
318,100

Granted
235,572

 
203,836

Exercised
(14,630
)
 
(8,835
)
Forfeited
(16,625
)
 
(10,580
)
Expired
(142,074
)
 
(135,790
)
Outstanding and exercisable, end of period
390,776

 
366,731

XML 34 R24.htm IDEA: XBRL DOCUMENT v3.19.1
Fair Value of Financial Instruments (Tables)
3 Months Ended
Mar. 31, 2019
Fair Value Disclosures [Abstract]  
Fair value and carrying values for notes and bonds payable, mortgage notes receivable, and notes receivable The table below details the fair values and carrying values for notes and bonds payable at March 31, 2019 and December 31, 2018.
 
March 31, 2019
 
December 31, 2018
(Dollars in millions)
Carrying Value
 
Fair Value
 
Carrying Value
 
Fair Value
Notes and bonds payable (1)
$
1,343.1

 
$
1,329.8

 
$
1,346.0

 
$
1,326.5


______
(1)
Level 2 – model-derived valuations in which significant inputs and significant value drivers are observable in active markets.
XML 35 R25.htm IDEA: XBRL DOCUMENT v3.19.1
Summary of Significant Accounting Policies (Details)
ft² in Millions, $ in Billions
Mar. 31, 2019
USD ($)
ft²
state
property
Business Overview:  
Gross investment amount, total | $ $ 4.0
Number of real estate properties | property 201
Number of states that the Company owns real estate in, whole units | state 26
Square footage of owned real estate properties 15.0
Approximate square feet for which Nationwide property management services provided by company 11.3
XML 36 R26.htm IDEA: XBRL DOCUMENT v3.19.1
Summary of Significant Accounting Policies - Revenue Recognition (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2019
Mar. 31, 2018
Disaggregation of Revenue [Line Items]    
Other operating $ 1,961 $ 1,895
Parking Income    
Disaggregation of Revenue [Line Items]    
Other operating 1,734 1,626
Rental Lease Guaranty    
Disaggregation of Revenue [Line Items]    
Other operating 128 175
Management Fee Income    
Disaggregation of Revenue [Line Items]    
Other operating 69 68
Miscellaneous    
Disaggregation of Revenue [Line Items]    
Other operating $ 30 $ 26
XML 37 R27.htm IDEA: XBRL DOCUMENT v3.19.1
Summary of Significant Accounting Policies - Impact of Adoption of New Accounting Standard (Details) - USD ($)
$ in Thousands
Jan. 01, 2019
Mar. 31, 2019
Dec. 31, 2018
New Accounting Pronouncements or Change in Accounting Principle [Line Items]      
Weighted-average remaining lease term - operating leases   54 years  
Operating lease right-of-use assets   $ 128,141  
Operating lease liabilities   $ 91,044  
Minimum      
New Accounting Pronouncements or Change in Accounting Principle [Line Items]      
Ground lease, initial term     50 years
Maximum      
New Accounting Pronouncements or Change in Accounting Principle [Line Items]      
Ground lease, initial term     75 years
Weighted Average Remaining Term      
New Accounting Pronouncements or Change in Accounting Principle [Line Items]      
Ground lease, initial term     53 years 10 months 24 days
Accounting Standards Update 2016-02 | Minimum      
New Accounting Pronouncements or Change in Accounting Principle [Line Items]      
Ground lease, initial term   40 years  
Ground lease, discount rate (percent)     3.40%
Operating lease liabilities     $ 91,700
Accounting Standards Update 2016-02 | Maximum      
New Accounting Pronouncements or Change in Accounting Principle [Line Items]      
Ground lease, initial term   99 years  
Ground lease, discount rate (percent)     6.20%
Accounting Standards Update 2016-02 | Weighted Average Remaining Term      
New Accounting Pronouncements or Change in Accounting Principle [Line Items]      
Ground lease, initial term   54 years 10 months 24 days  
Other Assets      
New Accounting Pronouncements or Change in Accounting Principle [Line Items]      
Transfers to operating lease, right-of-use assets $ 45,000    
Other liabilities      
New Accounting Pronouncements or Change in Accounting Principle [Line Items]      
Transfers to operating lease, right-of-use assets 1,900    
Accounts Payable and Accrued Liabilities      
New Accounting Pronouncements or Change in Accounting Principle [Line Items]      
Transfers to operating lease, right-of-use assets $ 8,400    
XML 38 R28.htm IDEA: XBRL DOCUMENT v3.19.1
Real Estate Investments - Acquisitions and dispositions (Details)
$ in Thousands
3 Months Ended
Apr. 02, 2019
USD ($)
ft²
Mar. 28, 2019
USD ($)
ft²
May 21, 2018
USD ($)
May 03, 2018
USD ($)
property
Mar. 31, 2019
USD ($)
ft²
Apr. 09, 2019
USD ($)
ft²
Building
Business Acquisition [Line Items]            
Financing lease liabilities         $ 14,294  
Real Estate Acquisition            
Business Acquisition [Line Items]            
Purchase price         93,000  
Cash consideration         90,700  
Real Estate         93,900  
Other         $ (3,200)  
Square footage | ft²         301,837  
Medical Office Building | Washington, D.C. (4) | Real Estate Acquisition            
Business Acquisition [Line Items]            
Number of properties acquired | property       2    
Date Acquired       Mar. 28, 2019    
Purchase price       $ 46,000    
Cash consideration   $ 45,900        
Real Estate   50,200        
Other   $ (4,300)        
Square footage | ft²   158,338        
Financing lease liabilities         $ 14,400  
Above-market lease intangibles         5,200  
Medical Office Building | Indianapolis, IN (5) | Real Estate Acquisition            
Business Acquisition [Line Items]            
Date Acquired     Mar. 28, 2019      
Purchase price     $ 47,000      
Cash consideration   $ 44,800        
Real Estate   43,700        
Other   $ 1,100        
Square footage | ft²   143,499        
Prepaid ground leases   $ 800        
Below-market lease intangible   $ 900        
Medical Office Building | Tucson, Arizona | Real Estate Dispositions            
Business Acquisition [Line Items]            
Net Real Estate Investment         $ 6,900  
Subsequent Event | Medical Office Building | Atlanta, Georgia | Real Estate Acquisition            
Business Acquisition [Line Items]            
Purchase price $ 28,000          
Square footage | ft² 47,963          
Subsequent Event | Medical Office Building | Tucson, Arizona | Real Estate Dispositions            
Business Acquisition [Line Items]            
Square footage | ft²           67,345
Number of Off-campus Buildings | Building           3
Number of On-campus Buildings | Building           1
Sales price           $ 13,000
XML 39 R29.htm IDEA: XBRL DOCUMENT v3.19.1
Real Estate Investments - Assets Held for Sale (Details)
$ in Millions
Mar. 31, 2019
USD ($)
property
Dec. 31, 2018
property
Business Combinations [Abstract]    
Net investment in property held for sale | $ $ 1.3  
Number of properties held for sale | property 2 1
XML 40 R30.htm IDEA: XBRL DOCUMENT v3.19.1
Real Estate Investments - Discontinued Operations and Assets Held for Sale - Balance Sheet (Details) - USD ($)
$ in Thousands
Mar. 31, 2019
Dec. 31, 2018
Balance Sheet data (as of the period ended):    
Land $ 230,206 $ 230,206
Investment Building and Building Improvements 3,757,260 3,675,415
Real estate properties, Total 4,063,178 3,974,071
Accumulated depreciation (1,035,800) (1,015,174)
Total real estate properties, net 3,027,378 2,958,897
Liabilities of properties held for sale 633 587
Inpatient Rehabilitation Facility | Disposal Group, Held-for-sale, Not Discontinued Operations    
Balance Sheet data (as of the period ended):    
Land 1,125 1,125
Investment Building and Building Improvements 39,586 18,231
Real estate properties, Total 40,711 19,356
Accumulated depreciation (30,706) (10,657)
Total real estate properties, net 10,005 8,699
Operating lease right-of-use assets 168 0
Other assets, net 395 573
Assets held for sale, net 10,568 9,272
Accounts payable and accrued liabilities 251 450
Operating lease liabilities 168 0
Other liabilities 214 137
Liabilities of properties held for sale $ 633 $ 587
XML 41 R31.htm IDEA: XBRL DOCUMENT v3.19.1
Leases - Lease Income (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2019
Mar. 31, 2018
Leases [Abstract]    
Rental income $ 110,696 $ 110,229
XML 42 R32.htm IDEA: XBRL DOCUMENT v3.19.1
Leases - Lessor Accounting (Details)
$ in Thousands
Mar. 31, 2019
USD ($)
Future Lease Payments Receivable [Abstract]  
2019 $ 250,619
2020 294,900
2021 250,050
2022 213,822
2023 175,215
2024 and thereafter 502,647
Total $ 1,687,253
XML 43 R33.htm IDEA: XBRL DOCUMENT v3.19.1
Leases - Future Lease Payments Receivable under ASC 840 (Details)
$ in Thousands
Dec. 31, 2018
USD ($)
Leases [Abstract]  
2019 $ 326,441
2020 279,211
2021 235,660
2022 201,072
2023 163,978
2024 and thereafter 476,673
Total $ 1,683,035
XML 44 R34.htm IDEA: XBRL DOCUMENT v3.19.1
Leases - Ground Leases (Details)
ft² in Millions
3 Months Ended 12 Months Ended
Mar. 31, 2019
USD ($)
ft²
property
Lease
Mar. 31, 2018
USD ($)
Dec. 31, 2018
ft²
property
Lease
Dec. 31, 2017
USD ($)
Dec. 31, 2016
USD ($)
Lessee, Lease, Description [Line Items]          
Number of properties subject to ground leases | property 109   107    
Square feet subject to ground leases | ft² 9.1   8.8    
Number of prepaid ground leases 46        
Amortization of prepaid rent | $ $ 100,000 $ 100,000   $ 500,000 $ 500
Number of non-prepaid ground leases 63   60    
Weighted Average Remaining Term          
Lessee, Lease, Description [Line Items]          
Ground lease, initial term     53 years 10 months 24 days    
Minimum          
Lessee, Lease, Description [Line Items]          
Ground lease, initial term     50 years    
Term of lease, including renewals     75 years    
Maximum          
Lessee, Lease, Description [Line Items]          
Ground lease, initial term     75 years    
Term of lease, including renewals     100 years    
Accounting Standards Update 2016-02 | Weighted Average Remaining Term          
Lessee, Lease, Description [Line Items]          
Ground lease, initial term 54 years 10 months 24 days        
Term of lease, including renewals 70 years 8 months 12 days        
Accounting Standards Update 2016-02 | Minimum          
Lessee, Lease, Description [Line Items]          
Ground lease, initial term 40 years        
Accounting Standards Update 2016-02 | Maximum          
Lessee, Lease, Description [Line Items]          
Ground lease, initial term 99 years        
XML 45 R35.htm IDEA: XBRL DOCUMENT v3.19.1
Leases - Future Minimum Lease Payments (Details)
$ in Thousands
Mar. 31, 2019
USD ($)
Operating  
2019 $ 2,948
2020 4,849
2021 4,879
2022 4,909
2023 4,947
2024 and thereafter 314,406
Total undiscounted lease payments 336,938
Discount (245,894)
Lease Liability 91,044
Financing  
2019 626
2020 611
2021 619
2022 628
2023 637
2024 and thereafter 74,766
Total undiscounted lease payments 77,887
Discount (63,593)
Lease Liability $ 14,294
XML 46 R36.htm IDEA: XBRL DOCUMENT v3.19.1
Leases - Lease Cost (Details)
$ in Thousands
3 Months Ended
Mar. 31, 2019
USD ($)
Lease expense  
Operating lease expense $ 1,116
Variable lease expense 740
Total lease expense 1,856
Other information  
Operating cash flows outflows related to operating leases 2,771
Right-of-use assets obtained in exchange for new operating lease liabilities 0
Right-of-use assets obtained in exchange for new finance lease liabilities $ 14,294
Weighted-average remaining lease term - operating leases 54 years
Weighted-average remaining lease term - finance leases 70 years 7 months 6 days
Weighted-average discount rate - operating leases (percent) 5.50%
Weighted-average discount rate - finance leases (percent) 5.90%
XML 47 R37.htm IDEA: XBRL DOCUMENT v3.19.1
Leases - Future Minimum Lease Payments under ASC 840 (Details)
$ in Thousands
Dec. 31, 2018
USD ($)
Leases [Abstract]  
2019 $ 5,288
2020 5,260
2021 5,238
2022 5,207
2023 5,224
2024 and thereafter 323,533
Total $ 349,750
XML 48 R38.htm IDEA: XBRL DOCUMENT v3.19.1
Notes and Bonds Payable (Details)
$ in Thousands
3 Months Ended
Apr. 10, 2019
USD ($)
ft²
Mar. 31, 2019
USD ($)
ft²
Dec. 31, 2018
USD ($)
Debt Instrument [Line Items]      
Notes and bonds payable   $ 1,343,110 $ 1,345,984
Area of Real Estate Property | ft²   15,000,000.0  
Line of Credit | Unsecured Credit Facility      
Debt Instrument [Line Items]      
Notes and bonds payable   $ 260,000 262,000
Effective interest rate (percent)   3.49%  
Medium-term Notes | Unsecured Term Loan Facility, net of issuance costs (1)      
Debt Instrument [Line Items]      
Notes and bonds payable   $ 149,234 149,183
Effective interest rate (percent)   3.53%  
Notional amount   $ 50,000  
Derivative, fixed interest rate (percent)   2.46%  
Basis spread on variable rate (percent)   1.10%  
Senior Notes | Senior Notes due 2023, net of discount and issuance costs      
Debt Instrument [Line Items]      
Notes and bonds payable   $ 248,223 248,117
Effective interest rate (percent)   3.95%  
Senior Notes | Senior Notes due 2025, net of discount and issuance costs (2)      
Debt Instrument [Line Items]      
Notes and bonds payable   $ 248,338 248,278
Effective interest rate (percent)   4.08%  
Senior Notes | Senior Notes due 2028, net of discount and issuance costs      
Debt Instrument [Line Items]      
Notes and bonds payable   $ 295,309 295,198
Effective interest rate (percent)   3.84%  
Mortgages | Mortgage notes payable, net of discounts and issuance costs and including premiums      
Debt Instrument [Line Items]      
Notes and bonds payable   $ 142,006 $ 143,208
Effective interest rate (percent)   4.79%  
Interest Rate Swap | Medium-term Notes | Unsecured Term Loan Facility, net of issuance costs (1)      
Debt Instrument [Line Items]      
Notional amount   $ 25,000  
Derivative, fixed interest rate (percent)   2.18%  
Interest Rate Swap | Senior Notes | Senior Notes due 2025, net of discount and issuance costs (2)      
Debt Instrument [Line Items]      
Loss on forward starting interest rate swap agreement recognized in OCI   $ 1,700  
Subsequent Event | Mortgages | Mortgage notes payable, net of discounts and issuance costs and including premiums      
Debt Instrument [Line Items]      
Effective interest rate (percent) 5.00%    
Extinguishment of Debt, Amount $ 8,900    
Area of Real Estate Property | ft² 52,813    
XML 49 R39.htm IDEA: XBRL DOCUMENT v3.19.1
Derivative Financial Instruments - Derivative Instruments Designated as Cash Flow Hedges (Details) - Cash Flow Hedging - Designated as Hedging Instrument - Interest Rate Swap
$ in Millions
Mar. 31, 2019
USD ($)
swap_agreement
Derivative [Line Items]  
Number of instruments | swap_agreement 4
Notional amount | $ $ 75.0
XML 50 R40.htm IDEA: XBRL DOCUMENT v3.19.1
Derivative Financial Instruments - Fair Value of Derivative Instruments on the Balance Sheet (Details) - Designated as Hedging Instrument - Interest Rate Swap
$ in Thousands
Mar. 31, 2019
USD ($)
Derivative [Line Items]  
Liability derivatives $ 589
Other liabilities  
Derivative [Line Items]  
Liability derivatives $ 589
XML 51 R41.htm IDEA: XBRL DOCUMENT v3.19.1
Derivative Financial Instruments - Effect of Cash Flow Hedging on AOCI (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2019
Mar. 31, 2018
Derivative [Line Items]    
Amount of Loss Recognized in OCI on Derivative $ 724  
Amount of Loss Reclassified from OCI into Income (15) $ (147)
Interest Rate Products    
Derivative [Line Items]    
Amount of Loss Recognized in OCI on Derivative 724  
Settled Interest Rate Swaps    
Derivative [Line Items]    
Amount of Loss Recognized in OCI on Derivative 0  
Interest Expense    
Derivative [Line Items]    
Amount of Loss Reclassified from OCI into Income 15 147
Interest Expense | Interest Rate Products    
Derivative [Line Items]    
Amount of Loss Reclassified from OCI into Income (27) 105
Interest Expense | Settled Interest Rate Swaps    
Derivative [Line Items]    
Amount of Loss Reclassified from OCI into Income $ 42 $ 42
XML 52 R42.htm IDEA: XBRL DOCUMENT v3.19.1
Derivative Financial Instruments - Additional Information (Details)
$ in Thousands
Apr. 12, 2019
USD ($)
derivative
Mar. 31, 2019
USD ($)
Active Interest Rate Swap    
Derivative Instruments, Gain (Loss) [Line Items]    
Interest rate cash flow hedge gain (loss) to be reclassified to interest expense during the next 12 months   $ 13
Settled Interest Rate Swap    
Derivative Instruments, Gain (Loss) [Line Items]    
Interest rate cash flow hedge gain (loss) to be reclassified to interest expense during the next 12 months   $ (200)
Cash Flow Hedging | Subsequent Event | Interest Rate Products    
Derivative Instruments, Gain (Loss) [Line Items]    
Number of instruments | derivative 2  
Notional amount $ 50,000  
Derivative, fixed interest rate (percent) 2.334%  
XML 53 R43.htm IDEA: XBRL DOCUMENT v3.19.1
Commitments and Contingencies - Construction Activity (Details)
$ in Millions
Mar. 31, 2019
USD ($)
ft²
Other Commitments [Line Items]  
Approximate Square Feet 15,000,000.0
Medical Office Building Expansion | NORTH CAROLINA  
Other Commitments [Line Items]  
Approximate Square Feet 38,000
Medical Office Building | NORTH CAROLINA  
Other Commitments [Line Items]  
Total amount funded | $ $ 9.7
Medical Office Building | COLORADO  
Other Commitments [Line Items]  
Approximate Square Feet 151,000
Total amount funded | $ $ 30.9
XML 54 R44.htm IDEA: XBRL DOCUMENT v3.19.1
Stockholders' Equity - Reconciliation of beginning and ending common stock outstanding (Details) - shares
3 Months Ended
Mar. 31, 2019
Mar. 31, 2018
Reconciliation of the beginning and ending common stock outstanding    
Balance, beginning of period 125,279,000  
Balance, end of period 129,214,000  
Common Stock    
Reconciliation of the beginning and ending common stock outstanding    
Balance, beginning of period 125,279,455 125,131,593
Issuance of common stock 3,889,411 26,203
Nonvested share-based awards, net of withheld shares 45,225 121,659
Balance, end of period 129,214,091 125,279,455
XML 55 R45.htm IDEA: XBRL DOCUMENT v3.19.1
Stockholders' Equity (Stock Transactions - Narrative) (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended
Apr. 30, 2019
Mar. 19, 2019
Mar. 31, 2019
Mar. 31, 2018
Apr. 26, 2019
Dec. 31, 2018
Class of Stock [Line Items]            
Common stock, par value (dollars per share)     $ 0.01     $ 0.01
Proceeds from Issuance of Common Stock     $ 120,617 $ 236    
Dividends declared per common share, during the period (in dollars per share)     $ 0.30 $ 0.30    
At The Market Equity Offering Program            
Class of Stock [Line Items]            
Issuance of common stock (shares)     135,265      
Proceeds from Issuance of Common Stock     $ 4,300      
Subsequent Event            
Class of Stock [Line Items]            
Dividends declared per common share, during the period (in dollars per share) $ 0.30          
Subsequent Event | At The Market Equity Offering Program            
Class of Stock [Line Items]            
Number of authorized shares remaining under offering program (shares)         5,733,432  
Equity Offering            
Class of Stock [Line Items]            
Issuance of common stock (shares)   3,737,500        
Common stock, par value (dollars per share)   $ 0.01        
Shares Issued, Price Per Share   $ 31.40        
Proceeds from Issuance of Common Stock   $ 115,800        
Minimum | At The Market Equity Offering Program            
Class of Stock [Line Items]            
Shares Issued During Period, Price Per Share     $ 32.01      
Maximum | At The Market Equity Offering Program            
Class of Stock [Line Items]            
Shares Issued During Period, Price Per Share     32.86      
Weighted Average | At The Market Equity Offering Program            
Class of Stock [Line Items]            
Shares Issued During Period, Price Per Share     $ 32.36      
XML 56 R46.htm IDEA: XBRL DOCUMENT v3.19.1
Stockholders' Equity - Computation of basic and diluted earnings (loss) per common share (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended
Mar. 31, 2019
Mar. 31, 2018
Weighted average Common Shares outstanding    
Weighted average Common Shares outstanding 125,908,335 125,167,128
Nonvested shares (1,778,700) (1,909,777)
Weighted average Common Shares—Basic 124,129,635 123,257,351
Dilutive effect of employee stock purchase plan 102,132 90,330
Weighted average Common Shares outstanding—Diluted 124,231,767 123,347,681
Net Income $ 4,891 $ 9,180
Dividends paid on nonvested share-based awards (536) (579)
Net income applicable to common stockholders $ 4,355 $ 8,601
Basic earnings per common share (in dollars per share) $ 0.04 $ 0.07
Diluted earnings per common share (in dollars per share) $ 0.04 $ 0.07
XML 57 R47.htm IDEA: XBRL DOCUMENT v3.19.1
Stockholders' Equity - Summary of activity under stock-based incentive plans (Details) - Stock Incentive Plan - shares
3 Months Ended
Mar. 31, 2019
Mar. 31, 2018
Summary of the activity under the incentive plans    
Share-based awards, beginning of period 1,769,863 1,907,645
Granted (shares) 64,771 76,762
Vested (shares) (50,507) (54,065)
Share-based awards, end of period 1,784,127 1,930,342
Restricted Stock    
Summary of the activity under the incentive plans    
Shares withheld to pay estimated withholding taxes 19,546 21,196
XML 58 R48.htm IDEA: XBRL DOCUMENT v3.19.1
Stockholders' Equity - Summary of activity under Employee Stock Purchase Plan (Details) - Employee Stock Purchase Plan - shares
3 Months Ended
Mar. 31, 2019
Mar. 31, 2018
Summary of the Employee Stock Purchase Plan activity    
Outstanding and exercisable, beginning of period (shares) 328,533 318,100
Granted (shares) 235,572 203,836
Exercised (shares) (14,630) (8,835)
Forfeited (shares) (16,625) (10,580)
Expired (shares) (142,074) (135,790)
Outstanding and exercisable, end of period (shares) 390,776 366,731
XML 59 R49.htm IDEA: XBRL DOCUMENT v3.19.1
Fair Value of Financial Instruments (Details) - USD ($)
$ in Millions
Mar. 31, 2019
Dec. 31, 2018
Carrying Value    
Derivative [Line Items]    
Notes and bonds payable $ 1,343.1 $ 1,346.0
Fair Value    
Derivative [Line Items]    
Notes and bonds payable $ 1,329.8 $ 1,326.5
EXCEL 60 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( "&'H4X?(\\#P !," + 7W)E;',O+G)E;'.MDD^+ MPD ,Q;]*F?L:5\'#8CUYZ6U9_ )Q)OU#.Y,A$[%^>X>];+=44/ 87O+>CT?V M/S2@=AQ2V\54C'X(J32M:OP"2+8ECVG%D4)6:A:/FD=I(*+ML2'8K-<[D*F' M.>RGGD7E2B.5^S3%":4A+,*P).B0\5?UX^8 TBTH_0(:+L A#&^NQT:E8(C M-R."?S]PN -02P,$% @ (8>A3B?HAPZ" L0 ! !D;V-0&UL38Y-"\(P$$3_2NG=;BGH06) L$?!D_>0;FP@R8;-"OGYIH(? MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/ M-(X'P"J8%EQV^3O8:W7..7AKQ%/25V^9"CGIYFHQ*/B76_..7+8\#?NW_+"" MWTG] E!+ P04 " AAZ%.\T@I^>X K @ $0 &1O8U!R;W!S+V-O M&ULS9+!2@,Q$(9?17+?G:2E"X9M+HHG!<&"XBTDTS:XR89D9+=O;W9M MMX@^@,?,_/GF&YC61&GZA,^ICYC(8;X9?1>R-''+CD11 F1S1*]S71*A-/=] M\IK*,QT@:O.A#P@KSAOP2-IJTC !J[@0F6JMD2:AICZ=\=8L^/B9NAEF#6"' M'@-E$+4 IJ:)\31V+5P!$XPP^?Q=0+L0Y^J?V+D#[)P\>F%IQ<5OQ3<7%3C1RTTC.WR?7 M'WY78=];MW?_V/@BJ%KX=1?J"U!+ P04 " AAZ%.F5R<(Q & "<)P M$P 'AL+W1H96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03 M621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS M[BYBZ(:(E/)X8-DOV]:[MR_>X%#BVR]*+41B1%G\@MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C( MWXV(]ZMOFCU7H5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU M+,76>)7 \:V@S&L%&KQMUAVC2/'K^!?F<-0HACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=* MY \FIS_I,C0'HYI9";V$5FJ?JH,@H%\;D>/N5Z> HWEL:\4*Z">P'_ MT=HWPJOX@L Y?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=R MSTS0LS0[=R M2^JVE+ZU)CA*]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZ MG=PZ.)Z8D;D*TU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCR MHB'NH8:8S\-#AWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)2 M56 Q6\8#*Y"B?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYE ML<%5'<]56_*POFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=[=7G MFYRN>B)V^I=WP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5 M' 86%S+D4.Z2D 83 >LX=SFWJXPD6L_UC6'ODR MWSEPVSK> U[F$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\ MU*M:I60K$3]+!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHS MU8NL.8T*;T'50.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\! M4$L#!!0 ( "&'H4[&\9\F80( '4( 8 >&PO=V]R:W-H965T&UL?5;;CILP$/T5Q NY>)4E8RIX:^I6[L)2J>XYBF11LH;*)]ZQ5I]< MN6BHTDMQBV0G&+U84E-'.(Y744.K-LPSNW<2><;OJJY:=A*!O#<-%;\/K.;] M+D3A^\9+=2N5V8CRK*,W]HVI[]U)Z%4T6;E4#6MEQ=M L.LNW*/G(TH-P2)^ M5*R7LWE@0CES_FH6GR^[,#8>L9H5RIB@>GBP(ZMK8TG[\6LT&DZ:ACB?OUO_ M:(/7P9RI9$=>_ZPNJMR%FS"XL"N]U^J%]Y_8&% :!F/T7]B#U1IN/-$:!:^E M?0;%72K>C%:T*PU]&\:JM6,_G"1DI,$$/!+P1"#K_Q+(2" 3 24V^,$S&^H' MJFB>"=X'8LA61\U+@9Z)OLS";-J[LV(="$B+3M M20!# @?LT?&_ DD(K-P]PKX%-^T09B'O M""Y?1'P+3N:/(R:UF'9\N[88)8BD"V)PL2._EG'BA@1@ED*"*Q[Y!8W=-PW" MN"K1["/>,'&S_4X&!;^WMMG.=J>>NL>V"?R%#PWY*Q6WJI7!F2O=2NP'_\JY M8MJ5^$F[4NI_@&E1LZLRT[6>BZ$1#@O%N[')1].?1OX'4$L#!!0 ( "&' MH4Y:%R?00 0 !,4 8 >&PO=V]R:W-H965T&ULA9C; M;N,V$(9?Q?!]5ISA20H< [6*H@5:(-BB[;42,[&QDN5*2KQ]^U*R8M@SP^R- M=? _Y#\4]7'$U:GMOO6[$(;%]Z8^] _+W3 <[[.L?]Z%INJ_M,=PB/^\M%U3 M#?&R>\WZ8Q>J[134U!DJY;*FVA^6Z]5T[[%;K]JWH=X?PF.WZ-^:INK^VX2Z M/3TL8?EQX^O^=3>,-[+UZEB]AC_#\-?QL8M7V:65[;X)AW[?'A9=>'E8_@3W MI39CP*3X>Q]._=7Y8DSEJ6V_C1>_;1^6:G04ZO \C$U4\? >RE#78TO1Q[]S MH\M+GV/@]?E'Z[],R<=DGJH^E&W]SWX[[!Z6^7*Q#2_56SU\;4^_ACDANUS, MV?\>WD,=Y:.3V,=S6_?3[^+YK1_:9FXE6FFJ[^?C_C =3W/['V%R ,X!> D M\VF G@,T"/=] MC6Z5O8_MS)+-68+7DEM%*2C\19+%_B\F4#2!4[R^CL_E>"W&ZRG>7,<7)(FS MQ$V2PUFB%2J2:_E#V8T;([HQS(U6Q,U98J^ZT=YZ=$17"CKGK0$K^[&B'\O] M /%C63^@O"9C6$HJ5R3&QHE>'/=")M/&L5Z,TG12EERE=?0L>_&B%\^]:.+% MLU[0...)EQ^I;KSDHI><>S'$2RZ,B]/@<^*&ZW3AC?(@^RE$/P7W8XF?@O5S M!TK;7-%)+ K!@C>R(U RJ13WQ%"E>/(*O6:#) BQL'E>))X:).@)W).GGH"_ M-J!!4T=*R CTF[,A8!LYERI3-K+FQ@SF8 M5.(R&CC#7(1B7G($R4($3U5"B M@@1+AQ;9'!2$4 "F6 8R6,&S]=SH1 LR#H'ST% > @<=:*,!*']DH2WR%']D M) )GHJ%,!,XZ%TE'%U)!EBL#B3F/,@^1\]!0'B+'G*.+7"F(;)ZJWV0.(N<@ M724WR %7@#*)AX")2I$3SE#"H4 X@T6J(YE=R-EE*+N0L\LXH!.UE&3>8>*- M0)EPR EG*>&0$PZL=9X[$H3&&Z<2=27*-$1.0TMI*&GHY\/GFELG,@71,>+8 MU/C*S$)>#5I*'.2%'F7-IY);'S+YD)//4LJ@ #0LV*A*JN2HR,Q#SCS+&,-A MIF/1%==P:D@00AZ5B3=3R]S3G'N6LD9SI-V! S(Y2TE6J,34TS+Z-$>?I432 M0@FH"JW84B4*\QP@4:9HF9*:4]*R#V).R3NTL0!FGUJRTB) :J027^D+H3W.6W#9 M91]P_3]02P,$% @ (8>A3B_PN,$Y @ M < !@ !X;"]W;W)K9$68V%7+(SXBT#?-2FFJ# \Q)4XZIQBUSO[5B1TXL@50,[YO!+76/V M=P.$=FO7=S\V7JIS*=0&*O(6G^$GB%_MCLD5&J,LABD2I\7L_5HT>N_Y-D@XVNR$8#,%H\*.[AG PA(8!]62ZU,]8 MX")GM'-8_V^U6!T*?Q7*CWE0F_K;Z7>R6BYWKT42Y.BJX@R232\))A)#L;4H MTE&"9/X1(K!"!-H?3B%"NS^T^D/MCZ;^R"BBEZ1:TFB)M_!\HXX'HAN2R$H2 MS4EB@Z27Q),DL=?_#)HGA#=$L94HGA,E!E$\2V2BW%/<,"16AF3.D!H,R4.& M>XH;AM3*D,X9E@9#^LP9>2"Z(5E:299SDLP@6<.469FR&5-J M9-IDLTQ^D 5^-&>R*>,@S?[+)/N ]6[RYE2^>3EY3V-9I78N-+D^53_[@=FY M:KBSIT+>Q/J^/%$J0(;U%C)@*5OHN"!P$FJ:RCGK^TB_$+0=>B0:&W7Q#U!+ M P04 " AAZ%.R/7[V78# !:#@ & 'AL+W=OSNM6+3ME!)]$IT MW+Y]J4-<96;4;2XBD?Z'\P\I?2)7-]M^Z<[&N.!K737=.CP[=WF,HFY_-G71 M/=B+:?PO1]O6A?/-]A1UE]84AR&HKB(1QUE4%V43;E9#WW.[6=FKJ\K&/+=! M=ZWKHOVV-96]K4,(WSH^EZ>SZSNBS>I2G,Q?QOU]>6Y]*[J/]T/,Q64 MAL%4_4?S:BHO[YWX''M;=0'OV<07(:M(.$HP8XJ3LFY2Z@:EV8Z2=)Y&9X"\ M,"*E4]Y)QCK)J),<.A1VC @4+7C3K11,O*D9>-,FB4D"B'15IB!?>3HAY ,34"V "Q"2/C/&T M,"(Q>U[>>UF $5 OA$; +%*68:8P,JG3):X BZXG$-2/Q'X$78-$Q,0/(XOS M;($,P(,.*.G4PCL$/.J LDYAUDV:=V_K C> 1QA0ABG,,*!\^@UDJA2>.$[G M%WSA?0,>94!9IC#+@%)*8S-4DNBE9XK'&.34B<).%@*"DL\"=M)\S_F>-4OFN/I*2@]-::GH%CTGV$0.I.8YZQ4"L_0=,D73U%! M*:HQ107%H_HMF.O#;M M:3B\=,'>7AO7;WYGO?<#TI/H=_2H?^L/3N,QY\RJ8+7JSSYX5A M5W^TUAGO,7[P\W7V![U[HS)'U]_F_KX=3SMCP]G+=)*+[L?)S7=02P,$% M @ (8>A3BC]]9U! @ Q@8 !@ !X;"]W;W)KY?[+2)(&ZJJE5HIVJKMLY-, EJ#J>V$[=_7-H2EMM,7 M; _GS)QCFZ$<"7UE#0!WWCKR(#].+-F= .<;&D%X\- M%-!)D3KLA;Z?>AUJ>[5 [K =^ _ACT5*V_)H?">>L^!YNZD'@%^-G"R%9S1SHY$/(J M%U].6]>7@@##D2DKB>W[-_4MZ%EP-B4!/\JSWQ M9NOFKG.",[IB_D+&SS#[25QG-O\5;H %7"H1-8X$,_5TCE?&23=G$5(Z]#:- M;:_&<&)Y$N%T%9A%QKT\-\"M8G( M(GN%R.HA4OQH[2&U\V,K/U;\>,7/"VT/)DBJ(+V"Q'D1:#Y,4!'DOEU)8E62 MF$XR.S^U\E/#29%K3B9(LA(9: =>6R#Q QF9549FRM W-#-J?,C"6!-B@I+@ MP:Q+ M\5:??P?THCHE9NKPWQ"]M#US#H2+ MYJ1:R)D0#D*C_R0VJA$_E66!X&PO=V]R:W-H965T&ULE9C;;N)($(9?!?F>L:O/C@!I(9!=:5>*9K0[UPYT AH;L[839M]^VX<0 MNKH"S$VPG:^J_ZYNUV][ZQFD_*UR7=[^UB-ZM>B MR*K_YC8OC],(HO<+7WZS/CD?M5)[*\D=[\L=F&B6M(IO;==.FR-S/FUW8/&\S M.1W_#DFCTYAMX/GQ>_95-WDWF:>LMHLR_[[;--MI9*+1QCYGKWGSM3S^;H<) MR6@TS/Y/^V9SA[=*W!CK,J^[OZ/U:]V4Q9#%22FRG_WO;M_]'H?\[V%T !L" MV"D V,4 /@3PCP!^,4 , >(4P/3% #D$R%. 4!<#U!"@/D:X/ <]!.B/@'X! M^^IVRW6?-=EL4I7'4=7ON$/6;FRXTVY#K-N+W?IW_W,K5KNK;S-(V"1^:Q,- MS+QGF,=PGUE0C/"9>XJ1/K.D&.4S*XK1/O- ,>;$Q*XFI\(PLC"L2R"\!"DJ M3,^HCMGWC#:I,;@X!,,/)/*.)KV_67&$R))(9(0@N\'&0PR M5B9!2JY GA1%2E&$%+2SYBJH%R+ ME0;W]24!CA7N-2MJT(1IR7"/I=(QP5-QYK1^S6A+ L*3 &_M ?)K!DH)W!4H MD$F.:Q92W-V/S AF8E.R\&_LUHYT)?L&:@/8F MN,6<('0>8(E,$ESUD.,&UYS,)=1G,Z>=#&ZQ,B!L2FKL9= (&V-+C%TR#T*V%2P-O^"N7+H6T-;O U($PK>,*^R/A* M:&.#6YP-0ML::Q9TC2N4_Z!.NQN[Q=T8Z5H*K^?#='N \!G= M)%)KO-\ID*78W0B*<]>H\127!#@&A3O:BAHU27D""2X9D8])DVJ&'PGBL[?2 M]E/'7UGULMO7HZ>R<2^XW6OHA3DL4V".[ 0 U , !@ !X;"]W M;W)KV$ *[Y0VRSIW]BQPBE\,#[SM7#"0,N]9"S_!_>K/QFMD8:FY!&6Y5LA 4^#;]'C:!WP$ M_.8PVI6,0B47K9^"\JTNX R$"D4_CS\R)EY#!<2V_L'^- MM?M:+LS"G1:/O'9=@3]C5$/#!N$>]'@/,O$Q*BUL/%$U M6*?ES.)3D>QYNKF*]SB]'-+9;=N!S@YT<:"Q.60*%#/_PAPK]RR, M.#U2WYLJ&&,KXIM/WGKKM4QIDI-K()HQIPE#UY@%03S[$H)NA3C1C^[T/P39 M9HY9),C>$-!M@OTFP3X2[-\09.^*G#"'B%$1D^RR=T'(JJL23!OWR:)*#RKN M\LJZK.PMC5-YA4_[_H.9EBN++MKYV<8)-%H[\*DD.[]$G?]BBR*@<4$\>-E, MBS8I3O?S'R++1R[_ 5!+ P04 " AAZ%.Q?>]U)H$ H%@ & 'AL M+W=O*S83&RM9KJ3$V[9^9P;V)).1R>$FKW[8OR^[4NG(W-JJK)451LJS+ MPW&^7HW/'MOUJGGMJ\/1/;:S[K6NR_:_C:N:\_W8VR.]3NV!V:XZQUS_?S!W-7<#XT&!5_']RYN[F>#:D\-;WW?T\&ARYRFW[(43I?]Y7K]'_S(F[Y-Y*CM7 M--4_AUV_OY]G\]G./9>O5?^U.?_FIH3B^6S*_@_WYBHO'YSX/K9-U8U_9]O7 MKF_J*8JW4I<_+K^'X_A[GN*_-\,-:&I UP:^[U\UX*D!_VQ@Q^0OSL94/Y=] MN5ZUS7G67D;K5 Z3PMRQ?YG;X>'X[L;_^6P[__1M;$NMB0:DX?.RBT(F7< \,D>&S/'Y*(<0 + ]@Q@+T-8.1;N&B247,< M-3;+C7ZC\!,B(0;) J-D0FPR.BI&TLO!F0=6.L& M\NC!D,Z9(]D/J7Z,2OF7FH]6,+@, RM&6F'532;G M!P&K""$6BL!@^')A-& MEXE!-G*53:(/ VCS5((4RDP>H(_!*#2:A59-*(VYA8DH3:0AH$MRFP<,81X: M#42K5IN&W2))6=K1*A/EH?6&H6@ %5EM_IIX;+/(2C]:9J.,0LL!H]'D8 X& M%C=AH!$ &HNQW)!FU2(W:2:W':0S:1S8C@E3C335#,M-D #6XM2H0@G(TN"> M3)A_A/@G=R#2;%L8DUJY3J$N29/ 3"3,04(U EI64^\RBP MT@F#D$!E:.5608"$YG8/F Q!61R:@9B%!%AH)0M)0V[!:2(_%0JLBX/@P#0D M4"FJ[8MT%6@H2HQ"F=81!_PP1BL#M$I";1@@DZR<:P64)1SZZL-D94!6*_=M M!LBT@;G!&)@,@&DEP5F#,$U9%>U YK<4$P?6,P<^> $OK40X:QA2SFHDM,H/ MF G4-8RQR0B;DM^L:9AQ)C<4H$HH5.$S)B:#0C26%&==8?IO0OE56 9IWEH MY6#\\9,#+6 *<-0=]/1?);VH@ MR^(\\.W!&)8,8!E+?D^BV^,9CB0I@+XQ=\7ET/)GF,L9ZI]E^W(X=K.GIN^;>CRC>VZ:WGF/T2?_ MKO:NW%UO*O?<#Y>IOVXO9Y>7F[XY3>>RR^OA\/I_4$L#!!0 ( "&'H4YX M'>":M $ -(# 8 >&PO=V]R:W-H965T&UL?5-A;]L@ M$/TKB!]0$L=IJ\BVU+2J.FF3HE;;/A/[;*,"YP*.NW]?P*[G;=:^ '?<>_?N M.+(!S:MM 1QY5U+;G+;.=0?&;-F"XO8*.]#^ID:CN/.F:9CM#/ J@I1DR69S MS107FA99])U,D6'OI-!P,L3V2G'SZP@2AYQNZ:?C632M"PY69!UOX 7<]^YD MO,5FEDHHT%:@)@;JG-YM#\ 'P(&NSB34,D9\3487ZJ<;H(@D%"ZP,#] M=H%[D#(0>1EO$R>=4P;@\OS)_AAK][6(*I MGCTE4_%?X0+2AP)TL:5E+UUJ"86+T7Q]W$7.N[#>)/N)M@Z()D R0RX MC7G8F"@J?^".%YG!@9BQ]QT/3[P])+XW97#&5L0[+]YZ[Z78[O<9NP2B*>8X MQB3+F#F">?8Y1;*6XIC\ T_6X;M5A;L(W_VA\'J=(%TE2"-!^M\2UV)N_DK" M%CU58)HX39:4V.LXR0OO/+!W27R3W^'CM'_CIA':DC,Z_[*Q_S6B R]E<^5' MJ/4?;#8DU"X<;_S9C&,V&@Z[Z0>Q^1L7'U!+ P04 " AAZ%.V$ *[Y0VRSIWW=L"*4)ZHOM&<\YF!XTWC;&*>S1MRUQO@=<1I"1+D^2.*2XT M+?/H.]LR-X.70L/9$CWO$T@S%G1'7QR/HNU\<+ R[WD+W\!_[\\6+;:P MU$*!=L)H8J$IZ/WN>-J'^!CP0\#H5F<2*KD8\Q2,SW5!DR ()%0^,'#)*JL%YHV86E*+X\[0+'?=QNLFR&;8-2&= N@ .,0^; M$D7E'[CG96[-2.S4^YZ')]X=4^Q-%9RQ%?$.Q3OT7LO=[2%GUT TQYRFF'0= MLT0P9%]2I%LI3ND;>+H-SS859A&>_:/P_3;!?I-@'PGV_RUQ(^8N>96$K7JJ MP+9QFARIS*#C)*^\R\#>I_%-_H9/T_Z5VU9H1R[&X\O&_C?&>$ IR0V.4(A3EQDTF6S 0 MT@, !D !X;"]W;W)K&UL?5/;;MP@$/T5Q >$ M-;M-5RO;4C95U4BMM$K5YIFUQS8*%P?P.OW[ B:.D[IY 6:8<^;,,.2C-H^V M W#H60IE"]PYUQ\(L54'DMDKW8/R-XTVDCEOFI;8W@"K(T@*0C>;:R(95[C, MH^]DREP/3G %)X/L("4S?XX@]%C@#+\X[GG;N> @9=ZS%GZ"^]6?C+?(S%)S M"&X"_$QX#>'T2[.*%1RUOHQ&'=U@3=!$ BH7&!@?KO +0@1 MB+R,I\2)YY0!N#R_L'^-M?M:SLS"K18/O'9=@?<8U="P0;A[/7Z#5,\GC%+Q MW^$"PH<')3Y'I86-*ZH&Z[1,+%Z*9,_3SE7F"L[8BGCGQ5OOO939=9:32R!*,<<4="W%D?X#I^OP[:K";81OWRC\#\%NE6 7"78?EK@6LWV7A"QZ*L&T<9HL MJO2@XB0OO// WM#X)J_AT[3_8*;ERJ*S=OYE8_\;K1UX*9LK/T*=_V"S(:!Q MX?C9G\TT9I/A=)]^$)F_&PO=V]R:W-H965T[^OI3L>MYF[$42*9[#0XI*!V-?70/@R;N2 MVF6T\;X[,.:*!I1P5Z8#C3>5L4IX-&W-7&=!E!&D)..;S9XIT6J:I]%WLGEJ M>B];#2=+7*^4L+^.(,V0T2W]=#RW=>.#@^5I)VIX ?^].UFTV,Q2M@JT:XTF M%JJ,WFT/QR3$QX ?+0QN<2:ADK,QK\'X4F9T$P2!A,('!H';!>Y!RD"$,MXF M3CJG#,#E^9/],=:.M9R%@WLC?[:E;S)Z2TD)E>BE?S;#$TSU7%,R%?\5+B Q M/"C!'(61+JZDZ)TW:F)!*4J\CWNKXSZ,-_QF@JT#^ 3@,^ VYF%CHJC\07B1 MI]8,Q(Z][T1XXNV!8V^*X(RMB'A3D0:^,FU 0 T@, !D !X M;"]W;W)K&UL?5/;CM,P$/T5RQ^P;MW2+542:;L( M@012M0AX=I-)8JTOP7::Y>\9.]D0(.+%]HSGG#DS'F>#=<^^!0CD12OC<]J& MT)T8\V4+6O@[VX'!F]HZ+0*:KF&^SKO8WP*^"9A\(LSB95-B9*RM^)((K,V8&X ML?>=B$^\/7'L31F=J17I#L5[]-Z*[>$^8[=(-,6"_7]+7(MY^U<2MNBI!M>D:?*DM+U)D[SP MS@/[P-.;_ X?I_VS<(TTGEQMP)=-_:^M#8!2-GS&\=L M-(+MIA_$YF]<_ )02P,$% @ (8>A3N="8BJR 0 T@, !D !X;"]W M;W)K&UL?5-AC]0@$/TKA!]P=-D][[)IF]R>,9IH MLCFC?F;;:4L.F IT>_Y[@?9JU>H78(9Y;]X,0SZB?78=@"OI(&S)6[0 M6M@?)U X%G1'7QU/LNU\=+ R[T4+G\%_Z<\V6&QAJ:4&XR0:8J$IZ,/N>#K$ M^!3P5<+H5F<2*[D@/D?C0UW0+ H"!96/#")L5W@$I2)1D/%]YJ1+R@A 1U3=9^ZZ@]Y34T(A!^2<%RJ65 M5(/SJ&>6($6+EVF7)NWC='/+9]@V@,\ O@#N4QXV)4K*WPHORMSB2.S4^U[$ M)]X=>>A-%9VI%>DNB'?!>RUW=UG.KI%HCCE-,7P=LT2PP+ZDX%LI3OPO.-^& M[S<5[A-\_YO"?^0_;!(<$L'AOR5NQ?RIDJUZJL&V:9HA3MS*?#RT 0 T@, !D !X;"]W;W)K&UL?5/;;MP@$/T5Q >$->M$ MT:W.)%1R-N8E&%^KG.Z"(%!0^L @<+O R@5B%#&Z\Q)EY0!N#Y_L'^.M6,M M9^'@P:AG6?DVIW>45%"+0?E',WZ!N9YK2N;BO\$%%(8')9BC-,K%E92#\T;/ M+"A%B[=IEUWA"=.#AQ[ M4P9G;$6\0_$.O93_P/DV?+^I>5=!O:>QS?Y'3Y- M^W=A&]DY7S;VOS;& TK97>$(M?C!%D-![PT.*2GICGUT-X,FKDMJEM/:^/3+F\AJ4<#>F!8TW MI;%*>#1MQ5QK0101I"3CJ]6.*=%HFB71=[998CHO&PUG2URGE+!_3B!-G](U M?7,\-E7M@X-E22LJ^ G^5WNV:+&)I6@4:-<832R4*;U='T_;$!\#?C?0N]F9 MA$HNQCP'XUN1TE40!!)R'Q@$;E>X RD#$H7B'WFNVWN\2=@U$8\QIB.'SF"F"(?N4@B^E./%_X'P9OEE4N(GPS0>% M^V6"[2+!-A)L_UOB4LSA4Q(VZZD"6\5I-S[ 0[FX1\52V ]MXXZU7NMUH/9T)4V0*GZD$,T)N36DA. MM3%E0]0@@58NB#,2!D%,..UZO\B<[RJ+3(R:=3UEN/ES HEC M05/ZZG@2;>>"@Y5YSUOX#NY'?S;>8@M++11H*U 3 TU![]/C:1_B8\!/ :-= MG4FHY(+X'(PO=4&3( @D5"XP<+]=X0&D#$1>QN^9DRXI W!]?F7_%&OWM5RX MA0>4OT3MNH+>45)#PP?IGG#\#',]!TKFXK_"%:0/#TI\C@JEC2NI!NM0S2Q> MBN(OTRYTW,?IYI#-L&U -@.R!7 7\[ I453^R!TOQZ>.#UFOC=5 M<,96Q#LOWGKOM4P_)CF[!J(YYC3%9.N8)8)Y]B5%MI7BE+V#9]OPW:;"783O MUMD/M]L$^TV"?238_U=B^J;$K9BW*MFJIPI,&Z?)D@H''2=YY5T&]CX^(OL7 M/DW[-VY:H2VYH/,O&_O?(#KP4I(;/T*=_V"+(:%QX?C!G\TT9I/AL)]_$%N^ M&PO=V]R:W-H965T M&,"* M+\0V2_KWM0VA9.,7[!F?.6?&XR$?E7XU'8!%[X)+4^#.VGY/B*DZ$-1? ==9FKP7(FX:B1&82@^N\!N!H+ MO,4?CF?6=M8[2)GWM(5?8'_W1^TLLK#43( T3$FDH2GP_79_R#P^ /XP&,UJ MCWPE)Z5>O?&]+O#&)P0<*NL9J%O.\ "<>R*7QMO,B1=)'[C>?[ _A=I=+2=J MX$'Q%U;;KL"W&-70T(';9S5^@[F>#*.Y^!]P!N[@/A.G42ENPA=5@[%*S"PN M%4'?IY7)L([329K.8?& 9 Y(EH#;H$,FH9#Y([6TS+4:D9[NOJ>^Q=M]XNZF M\LYP%>',)6^<]UQN[]*#06+^] M<7L]O>7)L*J?QY0L_XKR'U!+ P04 " AAZ%.6<6N ?H! #+!0 &0 M 'AL+W=OC8GKI*3E*]N\?6:_$M-%B1\U]KO&(3$*B1&# M< '!-'2H) $,=@N()AFAT-2%)(B M!LMO&].D"PB=/28!ZNK;B":E[!K?PF:[4Z=ZC/QC_"_B+U!+ P04 M" AAZ%.YOI3AK8! #2 P &0 'AL+W=ODW+//K.ILQQ=++7<#;$CDH)\^<$$J>"IO35\=2WG0L.5N:# M:.$[N!_#V7B+K2QUKT#;'C4QT!3T(3V>#B$^!OSL8;*;,PF57!"?@_&E+F@2 M!(&$R@4&X;>]UW*?Y)LL6 MV#Z +P"^ NYC'C8GBLH_"B?*W.!$S-S[080G3H_<]Z8*SMB*>.?%6^^]ECQ- M?4W!]U*<^']PO@_/=A5F$9YML]_=[A,<=@D.D>#P M3XGINQ+W8MZK9)N>*C!MG"9+*AQUG.2-=QW8!Q[?Y"U\GO9OPK2]MN2"SK]L M['^#Z,!+26[\"'7^@ZV&A,:%XP=_-O.8S8;#8?E!;/W&Y5]02P,$% @ M(8>A3O/-6RS. 0 G 0 !D !X;"]W;W)K&UL M;51M;]L@$/XKB!]08I*X661;:CI-G;1)4:>UGXE]?E'!N(#C[M\/L.-Z'E\" M=WY>[@A',DCUIFL @SX$;W6*:V.Z(R$ZKT$P?2<[:.V74BK!C U5172G@!6> M)#BAFTU,!&M:G"4^=U99(GO#FQ;."NE>"*;^G(#+(<41OB6>FZHV+D&RI&,5 M_ +SNSLK&Y%9I6@$M+J1+5)0IO@A.IYBA_> EP8&O=@CU\E%RC<7?"]2O'$% M 8?<. 5FERL\ N=.R);Q/FGBV=(1E_N;^C??N^WEPC0\2O[:%*9.\0&C DK6 M<_,LAR>8^MEC-#7_ Z[ +=Q58CURR;7_17FOC123BBU%L(]Q;5J_#I/^C18F MT(E 5P0R&OG*OS+#LD3) :GQ[#OF_N+H2.W9Y"[IC\)_L\5KF[UF--HFY.J$ M)LQIQ- %)IH1Q*K/%C1D<:+_T6F8O@U6N/7T[=(]/H0%=D&!G1?8_=/B;M5B M"+,/F^R#)ON 0+PR"6'NPR9QT"0."!Q6)B',EY4)6=P. :KR _6WZQ,^SNU/IJJFU>@BC;VC_B:54AJPI6SN;,.U?2KF@$-IW/;>[M4X M,&-@9#>]!61^D+*_4$L#!!0 ( "&'H4XZ?0)GWP$ $% 9 >&PO M=V]R:W-H965TMUL,9 M8U6VP*EZ$ /TYJ06DE-M3-E@-4B@E0OB#),P3#"G71\4F?-=99&)4;.NAZM$ M:N2P2MK M[?Z-_:.KW=1RHPJ>!/O95;K-@U. *JCIR/2SF#[!4L\Q0$OQ7^ .S,!M)D:C M%$RY+RI'I05?6$PJG+[.:]>[=9I/DG@)\P>0)8"L 2>G@VXJW)E)7AGOO2 DS/#=$BV8RXPA&TRT(K!A7R6(3^)" M_@LG_O"#-\.#"S]LU=/83Q!["6)'$/]38K0KT8=Y)\NC5^3H(3CL1'R8=RI) MO"*)A^"X$_%A$K](ZA5)/03I3L2'.>U$\.8)&PO=V]R:W-H M965T?$X'8U]= ^#)NU:MRVCC?7=@S!4-:.'N M3 Z:%;&F>QMC)YJGIO9(MG"QQO=;"_CV" M,D-&-_0:>))UXT. Y6DG:O@-_D]WLNBQ6:64&EHG34LL5!E]V!R.NX"/@&<) M@UO8)'1R-N8U.#_*C":A(%!0^* @\+C (R@5A+",MTF3SBD#<6E?U;_%WK&7 MLW#P:-2++'V3T<^4E%")7ODG,WR'J9]/E$S-_X0+*(2'2C!'892+7U+TSAL] MJ6 I6KR/IVSC.4SZ5]HZ@4\$?D-@8Z)8^5?A19Y:,Q [SKX3X8HW!XZS*4(P MCB+^P^(=1B\YYU]2=@E"$^8X8O@"LYD1#-7G%'PMQ9'_1^?K].UJA=M(WRZS M[_?K KM5@5T4V"WS;Y.;%MJY="I5G2!A/J /D?[8V;U3O"KA4$M MYH'MY"S$FUU\K0XHM 4!@U);!VJ&&SP!8];(E/%G\D0STB8NYW?W%]>[Z>5, M%3P)]KNM='- .Q144-,KTZ]B^ )3/PD*IN:_P0V8D=M*#*,43+EG4%Z5%GQR M,:5P^CZ.;>?&8?*_I_D3R)1 YH38;0X>0:[R9ZIID4LQ!'+<^Y[:3QSMB=F; MT@;=5KAWIGAEHK>"Q"3'-VLT:8ZCACQHXEF#C?\,(5X(<0;Q@\'6;Q![#6)G ML'TP2%95CIK4:3JG^0]BZT5L/8ATA1@UR0)!PL@/2;R0Q /)5I#D(R3U,U(O M(_4P=BM&^H$1)7Y&YF5D'L:G%6/4[):,:+,^-GAQ3NTU\)W*2]NIX"RT.?+N M8-9":#"&X<;4VYB;9UXPJ+6=9F8NQ_]O7&C13U<+GN^WXA]02P,$% @ M(8>A3A= L*MQ @ G@@ !D !X;"]W;W)K&UL ME5;MCILP$'P5Q ,KD_ MP3:SL[,3EB6Y,OXB$:FV_.2( MAE-R,$%5Z6#7#9V*%+6=)N9LQ].$G659U'3'+7&N*L+_;FC)KBL;V;>#Y^*4 M2WW@I$E#3O0'E3^;'5<[IVR M9^Q%;[X>5K:K%=&29E)3$'6YT"TM2\VD=/SI2.T^IPX8K.[:M SV2PDAA4$@->S#P7 M"Y!@\;@7R(7;PWW?C0YS5RF.1VY H&CFR4 SK8H /_P9"K 5UPA_P!&XUY#W M@"/>I-AP,38$P,0S2N"F1=.NQ?Z #?L#]AL('_ @G[P7/'?LQQ4RZ MQ1F\U2O*3V8 "BMCYUKJ]^?@M!^R:ZRGPNA\HX>OF19O-.WD_D[XJ:B%M6=2 MS1PS&8Z,2:HDND_*K5Q]+/2;DAZE7D9JS=N)V6XD:[JO :?_)$G_ 5!+ P04 M " AAZ%.@K+"BPL# !@#@ &0 'AL+W=O5CZ53'+!/EGP>9 MJO/")>Y[QU.R/^BZPUO."[&7/Z3^63R6IN7U+-LDDWF5J-PIY6[A?B+W:Q;4 M 0WB.9'GZN+=J:6\*/5:-[YN%ZY?5R13N=$UA3"/DUS)-*V93!V_.U*WSUD' M7KZ_LW]NQ!LQ+Z*2*Y7^2K;ZL'!CU]G*G3BF^DF=O\A.4. ZG?IO\B13 Z\K M,3DV*JV:7V=SK+3*.A932B;>VF>2-\]SQ_\>A@-H%T#[ ,(_#&!= .L#:/1A M .\"^"C :Z4T8[,66BSGI3H[93N]A:C_1>2>F]'?U)W-8#??S/!4IO>TI#R< M>Z>:J,,\M!@ZP$1#S I@AH@U0/PC\4R1?:445DJ;>#:H(L8$#!*PAH /"&8C M&0 3^#@)ATGXA("-<[20L('D#830F'""TP0P33!),YF18))F1GS.<9809@G! M:%C*C"!!=/V[ M@J"9)0]V"P%6"/WQJ"*0Q=4$&X9,'3->?M8=9KC^1+YE,:785]0'M5(+!?85 M)==/'[7L/,@RX^E#H-"R#%'L*PIVG\GT09!EM:+8?!3X*K2L(A3[B@8WC"KV M%46[RV14 2BTK%84FX\"7X6VDP?V%8UO4(LM0\$F$\9#M0]TZAD>^#;/,.P9 M-O4,MRPC#%N&W6 9ABW#D!O&R_;.TS:T*KK[G-=?*I=_ 5!+ P04 " AAZ%.L1%4=>L# &% M&0 'AL+W=ONQ!GJ M%M@&-LDZ+= "P19MGQ6;CHW5Q964>/OO*\F,UR(/L\J++UE4[=+?=]WQ)@C:S5Z5>?NI/JJJ_V57-V7>];?-<] >&Y5OQZ"R M""@,XZ#,#Y6_6HS/'IO5HG[IBD.E'ANO?2G+O/GO5A7U:>D+_^W!U\/SOAL> M!*O%,7]6?ZKNK^-CT]\%ERS;0ZFJ]E!77J-V2_^SN'F0<@@8%7\?U*F]NO:& M4I[J^MMP\]MVZ8=#BU2A-MV0(N^_7M6=*HHA4]^.?W52_^(Y!%Y?OV5?C\7W MQ3SEK;JKBW\.VVZ_]%/?VZI=_E)T7^O3KTH7%/F>KOYW]:J*7CZTI/?8U$4[ M?GJ;E[:K2YVE;TJ9?S]_'ZKQ^Z3SOX7A -(!= D@^6X ZP">&R!U@/P1\'Z3 M(AT0_0A(WPV(=4 \MTF)#D@N 4QC!Y[?[MA=]WF7KQ9-??*:\X@[YL/ %C=) M/R VP\.Q_\??^AYK^Z>O*TK"1? Z)-*:V[.&)AHQU=PA#4TU]TC#4\T7I)%3 MS1IIHJGF 6GBBR;HW\GEQ1!\,30FX$F"!"=@F(#'!/(J@4R-0LZ2>)14HT1( MRB1VD=!%6BZ4I#A!!!-$\^N,88(8M" S"CUKHJM",P[#$-LDT":Q;5)CH*X3 MVR9,7#8IM$F!C3'6URFH)G/99- F S8&+NO,&AV_,+EL1(CQ#H$1FSR%5D$< MBI0=PT X9A(!K!QC66#FQ >@$Y@Z86-':61.,FP53 X73)T V*6QZ8)$KFHP MG"+Z.5Q?M.AZH,C829? % N L+:< MA-U/SFXBQTI+P"ASI,#4$\^?. @C33.0OHV29 M9#$[G#"##!C,(IQ"8K9D./_-2HR-1.N@4>^#M-?!.&'I:BP&1R)P8M.)[,VZ MPP6S)<$..4M,%WN'+!PNCO^E"+_4=+'Q$^!_87!UF#&ZJZK MR_'T8E?7G>I3AI_Z)N]5OKW<%&K7#9=)?]V<3Z;.-UU]U*=NP>7H;_4_4$L# M!!0 ( "&'H4[-A!*HQ0$ #0$ 9 >&PO=V]R:W-H965TA.\USENC1GVA.BJ!<'T1@[0VY5&*L&, M#=6)Z$$!JSU)<$*CZ L1K.MQD?G<0169/!O>]7!02)^%8.K/'7 YYCC&[XG' M[M0:ER!%-K 3_ +S>S@H&Y%9I>X$]+J3/5+0Y/@VWI=;A_> IPY&O9@CU\E1 MRA<7?*]S'#E#P*$R3H'9X0(E<.Z$K(W721//)1UQ.7]7_^9[M[TN M-FV.OV)40\/.W#S*\0&F?G883REHFF;DXH0FS%W T 4FB:+/F'(-$\\88CW,1NBJ$>H% MDH5 O$O7!9)5@<0+;#\YH%>=!$SJ,7THLDG6BVQ7BVQ7BB1710)FMRAR9:/\ M%W&]561Q?NX]_63JU/4:':6Q5\$?6".E :L6;:Q0:Y_P''!HC)O>V+D*%SD$ M1@[3&R7SCZ+X"U!+ P04 " AAZ%.0[,Y>#X# #*#0 &0 'AL+W=O MNV6RC=M_H?-T'567$&4NB*B_J<#'KGSTT MBYDYV+*H]4,3M(>JRIM_][HTIWD(X>N#QV*[L]V#:#';YUO]4]M?^X?&M:)S MEG51Z;HM3!TT>C,//\'=DO,NH%?\+O2IO;@/NE*>C'GN&M_6\Y!U1+K4*]NE MR-WEJ)>Z++M,CN/OF#0\]]D%7MZ_9O_2%^^*>N>'A>"Q;/HV"4:-?>#AE]H^+5B22C461(Y@#,%)REX'R^N*"2=0) ) M1)\@O@3(O"H&2=)+ZD$B&&>)5\J[LBN:F*2)$8WP^[D?-/*B'Z&DX@GS> A= MHF0,$\,C22")@?Q)EJB?F"4"5.KQ8)W(5,P4T#P)R9,0 Z0\H 1U= -,R)3Y M(T0*08**:21%(BF,Y$^9PJ4SK@0:(JSCF4S3;&)+I"1/BGABGR=%_21">"Q8 M(],)CHSDR(BI2ND$P&B+81_?W3#A4O#^_AXUEZ4"<.D[U3NJ:QK:K8!_8'^/ MHNN-(E/?;@@9I%Q,[":@W0^P_:']/6JN-[@"\'FP##(A)^P/:/\#R@#]_0W8 MV6Z<"ADRI0.6R(E5#+0# F&!:,JPMP%C#"TA+$N3+)O H0T0" =$"QH;&R2^ MUQ B-D%"^QY@XXO!)R&<+T/#@D52B0D6VO, FYY(?1;L:, D'AXDV%1;%-FK<7#"&:(J&]F&,OCOVER['+ M+6)#K\F"1%^3T87A^KN*^='WFR+N@V>C'7G M\_X4O3'&:I>0W;JR=N[#ZMPH]<9VM\K=-\/7Q="P9C]^.47GS[?%?U!+ P04 M " AAZ%."3%E[> ! !G! &0 'AL+W=O\3EG9NP9LE&J9]T"F.B%,Z%SU!K3'S'690N :T\B3-,XCC%G'8"%9GW7521R<&P3L!%17K@G*H_)V!RS-$&O3J>NJ8U MSH&+K*<-? ?SH[\H:^%9I>HX"-U)$2FH<_2X.9ZW#N\!/SL8]6(?N4JN4CX[ MXTN5H]@E! Q*XQ2H76YP!L:?:.L$,A'(3+"Q_T=()D+R1O"WB4-FOM2/U- B4W*,5'BLGKJ>V!P3 M>YFE<_J[\V>V6FV]MR*)#QF^.:$)AX-J?"OKJ)2#,.XF%MYY6AZ)>]\[_\E.46CZ-YDP@M^H:CJAHZLTMGO\ M&]=2&K!9Q@^VKUL[];/!H#9NN[=[%7H_&$;VTUCC^=]2_ 502P,$% @ M(8>A3K, E]0- @ S04 !D !X;"]W;W)K&UL M=93;CILP$(9?!?$ BS&80T20FJVJ5FJE:*NVUPZ9!+0&4]L)V[>O;5A$P'N# M3__\WXRQ70QODWJ^5ZG=!(*L:6BJ?> ^=7KEPT5*EA^(:R%X M/=N@E@48H21H:=/Y96'GCJ(L^$VQIH.C\.2M;:GX=P#&A[T?^N\3+\VU5F8B M*(N>7N$GJ%_]4>A1,+NBOXW< @%WW/5'+B_-4, MOIWW/C() 8-*&0>JFSL\ V/&2*?Q=_+T9Z0)7/;?W;_8VG4M)RKAF;,_S5G5 M>S_SO3-XGM3\=_A#DS+32::47$F[=>K;E+Q=G+1J;3T;6R; MSK;#N$+P%.8.P%, G@/P6,L(LIE_IHJ6A>"#)\:][ZGYQ>$.Z[VIS*3="KNF MDY=Z]EY&(2J"NS&:-(=1@Q\TX:P)M/\,P4X(M@;1@P%V&T1.@\@:Q N#,%LE M.4H2*^FL!!.4A+D;$SLQ\083A=&*,VK(DI/'.4)N#G%RB(,3KSADRR$(D0\X MB9.3.#ADQ4FVG##*\ >_)W5R4@KFY$Y.OCUN:'T.\LUY"Y,LQ21:@8+%330/W0\JKDTGO1-7^E+;JW?A7('V M1$\Z[5J_K?. P469;JK[8GQAQH'B_?1X!O,+7OX'4$L#!!0 ( "&'H4Y/ M*8Q8"P( ,T% 9 >&PO=V]R:W-H965T"HFY::7C^S[NQJ#L4"NU[?OH"NL^Z$I M"!A4RBA0/=SA&1@S0KJ,/Y.F/R--XG+^4/]B>]>]G*B$9\Y^-V=5[_W,]\YP MH3>F7OCP%:9^$M^;FO\.=V ZW%2B&15GTGZ]ZB85;R<574I+W\>QZ>PX3/J/ M-'<"FA+0G(#&7D:0K?PS5;0L!!\\,>Y]3\TOCG9([TUEG'8K[)HN7FKOO<11 M5@1W(S3%',88]%],/L<$6G^&("<$60&\$(@(<@M@IP"V O%28%WD&$)L2#<6 MB4@<1VY,[,3$&PR.\(HSQB0+#DIS%'W 29RA?.%6C-\$F77>NW M=3887)29IGHNQA=F-!3OI\A3MFSC^)" P MQPX !D !X;"]W;W)K&ULE5?M;MHP%'V5* ] MXIL/0@5(#2W:I$VJ.FW[G8*!J$G,$@/=V\_Y: K.<0?\(+%S[KWG7OO?2>LNSHIK9.RGW=XY3K78\3ZJ1V/-"/=F(,D^D&I9;I]J7/%DW1GGF MD.N&3IZDA3V?-G-/Y7PJ#C)+"_Y46M4ASY/R;\PS<9K9S'Z?>$ZW.UE/.//I M/MGR'US^W#^5:N3T7M9ISHLJ%855\LW,OF=W2YK4!@WB5\I/U=F]5:?R(L1K M/?BZGMENS8AG?"5K%XFZ'/F"9UGM2?'XTSFU^YBUX?G]N_=ED[Q*YB6I^$)D MO].UW,WLR+;6?),<,ODL3E]XEU!@6UWVW_B19PI>,U$Q5B*KFG]K=:BDR#LO MBDJ>O+77M&BNI_;)^-T,&U!G0+V!-_[4P.L,O-Z V*<&?F?@?T3XG%+0&037 M1@@[@U S<-IB-=5_2&0RGY;B9)7M!MHG]3YE=Z%:WU4]V2QG\TPM0*5FCW./ MW*ESK!UUF+C%T!F&72(>A@B//C".8M#3($0C)N" +H,L$,;3B"",?XEY1)C@ M$K-$F! GY,&Z>HT#[\+!&#OPH0._<>!?.(BTA6DQ08,IVH5Q)UI%$,9 )(!$ M D!$"Q*WF.@LR&2D[Y$A)AI%[OG/L&-"2"L\[TFY38O*>A%2G02:[_6-$)(K[NY([8B=.E7V@XQO9'T[5O=E>[1J M!U+LNV.CTY]=Y_\ 4$L#!!0 ( "&'H4Y^3I3&J ( (P* 9 >&PO M=V]R:W-H965T=C3_BS4VJU^XLA [>ZJKIMN%9 MZ_8^BKK]6=2\NY.M:,R3HU0UUZ:I3E'7*L$/=E!=122.653SL@EW&]OWI'8; M>=%5V8@G%727NN;J[X.HY&T;0OC>\5R>SKKOB':;EI_$#Z%_MD_*M*(IRZ&L M1=.5L@F4.&[#CW#_0.P &_&K%+=N=A_T4WF1\K5O?#ULP[BO2%1BK_L4W%RN MXE%459_)U/%G3!I.S'[@_/X]^V<[>3.9%]Z)1UG]+@_ZO WS,#B(([]4^EG> MOHAQ0FD8C+/_)JZB,N%])8:QEU5G?X/]I=.R'K.84FK^-ES+QEYOPQ-&QV'X M #(.(-. 87&B 60K_\0UWVV4O 5J6/R6]^\8[HE9FWW?:9?"/C/%=Z;WNDL2 MMHFN?:(QYF&((?,8@"DF,ODG"$$AQ"9(_H-D>(($39#8!'26 /)%D4,(LR&- M#2$%S7$(12'4@220+"A#3#JCT)P6."5%*2E"H0M*BE R#X6A%(90T@6%N90B M]E RE)(AE.7FR1 *];S\'*7D""5;4'*'8E:5Q@SG%"BG<#G)+9 M9Q#CSL4(J5A*%SNH#X2F>4$]+(_?X+)HO&2!PRH@ICX2+CD@EE//9P)PS6&% MYV/,O%9&/.\9<-%AC>G@JLY\7SW 58I#9'$GMP.$JIA4D9WYFZ MS^9H.#4J<=3];6;NU7 ^&AI:MN/9+YH.H+M_4$L#!!0 ( "&'H4ZP]]B) M4@( +4' 9 >&PO=V]R:W-H965T:]K)OX>H>+=WB7NN^&EO!7*&+PL;=D-?H#Z MV9Z$/GDCRZ6LH9$E;QP!U[U[(+LC"8V#1?PJH9.3O6-2.7/^:@Y?+WO7-Q%! M!;DR%$PO#WB&JC),.HX_ ZD[:AK'Z?Z=_;--7B=S9A*>>?6[O*AB[VYT!6" (TQL 2!!]B#'""$"4(+4'X M@2"<)=EC8HMI^B0)B7&5"%6)$)5HIM)CHHE*$OJX2(R*Q(A(/!.)%R)D$ZVD MDJ J"5+Q!"?8H 0;),S-+,S-(DR:)"L?QA95V2(JVYG*=J&R4F_BXPWB+T4B M?]XA_O+K">DV7%%::46R4**+=#!0M)81VH\'0I&,R%P' ]$5';QM28!0!',= M#+16-[R["=+>T;SQ4-"\)[S)JUF#N-EY(9V*C@JLPVT7O1#Y+^H'@[#$EOG-39 M/U!+ P04 " AAZ%.!RT+00$" #"!0 &0 'AL+W=OLZ)O_L@8NQ M\B/_?>*EO3;:3@1U.; K? ?]8SA(,PH6EW/;0:]:T7L2+I7_(=KM"ZMW@I\M MC&K5]VPE1R%>[>#+N?)#FQ!P.&GKP$QSAV?@W!J9-'[/GOZ"M('K_KO[)U>[ MJ>7(%#P+_JL]ZZ;R<]\[PX7=N'X1XV>8ZTE\;R[^*]R!&[G-Q#!.@BOW]4XW MI44WNYA4.O8VM6WOVG%:R?(Y# \@VUYY1Z'-37;W[2*$!F,9 M/IFL&_.@+@,.%VV[F>G+Z5F9!EH,\XL9+,]V_1=02P,$% @ (8>A3J8A MAC'! P SQ( !D !X;"]W;W)K&ULE9CM;M,P M%(9O)!7737=,MP9L[^)HFZ]4W71O=%[U?2?;'5;%Z:_;)^B M;M^J8C,.JJN(QW$:U479A*O%>.^A72WTLZG*1CVT0?=M?PP7'S;+,!XJ4I5:FR%$T1]>U)VJJB%27\?/.6AXS#D,/#U_ MC?YNG'P_F<>B4W>Z^EYNS&X9RC#8J&WQ7)G/^O!>S1-*PF">_4?UHJI>/E32 MYUCKJAO_!^OGSNAZCM*74A>_IF/9C,?#'/]U&![ YP'\.("+?PZ@>0!=.D#, M \3? 9-;TU1&;^X+4ZP6K3X$[?3U[HMA%;$;T;N_'FZ.9H^?]?9T_=V7%25R M$;T,@6;-[:3A9YK\7'/G:GB6G&ON01SV-T[4UWDLEL-B^1B 3@.D,0Y , "- M <1) "&LB4R2=)0THX21(,9B:S)0E^12X'H$K$G91"?K,\<1GG*O'Q)6(X$?9)6#-)ZO M-X=)=>0AG_S=^UIRM9I%S$C;!S%V,(F>2/!5AC!F_P'PH M2CUY,.W,Q9W2S,[C@ISXX6*88X9 EG8F)/+L?PQ3S #&66SG02+FR8-A9RD( MX=DN&,:=95>L7,PH28]%6&B.2+:]A^) M,L^VRS'/'*":>38?CE'ER17^8PJY2Z'K?^KZGR<4Y[;_J>M_GK#I<*1I7G5SPL8@K)I=!]7(Q!YQQ^=MF/BTA'//9,BC#4 MY/9RUW\DRCQ]AC#Y!)JO])GG>=2F*_S'%!)JF';_GD5G "3>_DT85D*/QW;_ M1B+IZ:N$B2;05Z6GKQ)&D*[HJX3I(D"7=%:1VUA9YK45,TB@$WI_(&$&Q14/ MP )#(RZ YA:)I*=I" R-0-"D=AZW7\K<9ZO : G4!9F=B)P-/^&2V<\ATB?2J;+GC4QNAZ?#.PU=JH/F3\I@^V4\7F>%&IK1E.L_Z\G5ZQ3!=& M[^?71]'Q'=;J#U!+ P04 " AAZ%.GGX^.JP! "\ P &0 'AL+W=O MT?]^U(8A&O&#O>G9F=HVS7ILWVP X\J%D:W/:.-?M&+-E M XK;.]U!BR>U-HH[#,V)V-JMT\] M/@#^">CM;$]\)T>MWWSPL\IIY V!A-)Y!H[+!9Y 2D^$-MY'3CI)^L+Y_LK^ M$GK'7H[R>H46IIPY>4 M9^NT&EG0BN(?PRK:L/8C_[5LN2 >"^*I(%F'7@:AX/R9.UYD1O?$#+/ON+_B MU2[&V90^&481SM"\Q>RE2+:;C%T\T8C9#YCX&V8[81CR3R+QHD@<"))O! _+ M!,DB01((TCG!0W3C#]?_V; MFY-H+3EJAW<8)EUK[0#IHCLTV^!3F@()M?/;#>[-\$,-@=/=^%;8]&"++U!+ M P04 " AAZ%.O%OYD[@! ! ! &0 'AL+W=OFS?; CCT(86R!6Z=Z[:$V*H%R>R-[D#YE48; MR9P/S9'8S@"K8Y$4A*Y6&9&,*USF,;X/L24IF?N] Z+[ ";XD M7OFQ=2%!RKQC1_@.[D>W-SXB$TO-)2C+M4(&F@)_3;:[+. CX">'WL[F*#@Y M:/T6@F]U@5=!$ BH7&!@?CC#/0@1B+R,]Y$33RU#X7Q^87^,WKV7 [-PK\4O M7KNVP+<8U="PDW"ONG^"T<\&H]'\,YQ!>'A0XGM46MCX1=7).BU'%B]%LH]A MY"J._F6'O.Q:..-E2OS=52,:MB&M> MO/79T9R< ]&(V0T8.L;T$B0S@EN[Y8)TD6"-!*L_U*9 M_J-RP&01HR)F\UF3]6*3]7]-UI_4;Q;K-]>[S!8)LBM<9E>X)+/##V_KA9DC M5Q8=M//W*)YVH[4#S[>Z\:I;_YRG0$#CPO2+GYOA4@^!T]WX7LGTTRC_ %!+ M P04 " AAZ%.PE;@?9H" #0"0 &0 'AL+W=O.,;XR\BHU1:KV51B;6=25FO'$>D&2V)>&0UK=23 M$^,ED6K)SXZH.25'$U06#G;=T"E)7ME);/;V/(G9119Y1??<$I>R)/S?EA;L MMK:1?=]XRL^9U!M.$M?D3']1^5SON5HY'9F5*_ M$$F2F+.;Q9M_JR;ZI4 K3S4SU9NF=^:9JE:HW6OB+?W8N6JB%K-M,+B'01W" M4>R=!(8DMG@4CM\+[,:(R(,5/+ (S\1[_2(62YC !PE\0^"_ZT(PZ$*#"0VF M:I+$/BP2@"(!(!(.1!I,T!-Y0(-$=L$HD0?D1W F(9A)"&0R01"!!-'\AB] M@L6,AB]&O9AL^!(460(B"Y@ N; [W/F%H@F#H1FEMJ!^K>Z$"NBQ#<* RE2B ML(G0)UR$8!LAR$?#5[P%]6L=O>(09NH51[#;T-ANOCO55-@F*/Q$1V"CH&A. M1Z*QZW$T;,D8A-Q@(AG8=&CL.M^=^)0CV%)H.;\E&/84=F>TI 7U/W+^Z-3X M$-.DXO3.P9+RLQD9A)6R2R7UB=/;[<:2#=;GZ&!_J\:59KAXHVEFG9^$G_-* M6 S!C-0K*ZG9^<;HA+_@-0 M2P,$% @ (8>A3H$[4FP9 @ D@8 !D !X;"]W;W)K&ULC55=C]HP$/PK4=Y[CF.2 J1[CA5K=1*Z*JVSP86$IT3I[8A MUW]?VPD1'TO%"_8ZLS,[QE[GG53ON@0PP4_-]9=[J*S>\R)7L M M7_6RUWAX+.F=W,C5OT>^>_6;?:KAZ+213GY.B(!LQ+CXDO,.P2L[S%,$I' M#+$UC(7$:"&Q)YAZ31OC)CI : M9M='NPTSOAOLI#1@":,GNS6E?2#&0,#.N&EFYZKODGU@9#N\ M &1\AHI_4$L#!!0 ( "&'H4Z&I2 D%0( )@& 9 >&PO=V]R:W-H M965TAY4QW1,A>E]! MP_5"=M#:F:-4#3>VJTY$=PKXP0:^CUK!TX*SLIWUSGVV$=1BXC$+ WCH+;SP6>00C'9//X,Y*&DZ8+ MG+<_V+]X\];,CFMXEN)W?3#5.ER&P0&._"S,B^R_PF@H#8/1_7>X@+!PEXG5 MV$NA_3O8G[61SX+DBB"^R7+ I![3>@Q-(__@2@FJE"!*"4Z0H@3IXUXS ME"![P&OVG]=X>==HCLKDB,R=15VB!,O'C:Y0@A62079C=,"L9D97BVQU]>"2 M-,)_]P@1S>]0W-DQ]''C%-\/E#VPQB/H^H>F=U>9XCN'8EOGMLHC:%[F.%K< M5I;,SA1W9O_@ZE2W.MA)8X\G?X@ V2ZC,I_4$L#!!0 ( "&'H4[)K:DV7@( ($' 9 >&PO=V]R M:W-H965TU M?7;()J #3&TG7/^^MB$.O(@>0SEM5UF+KYE(V&\\3 M60X5%4^L@5I].3->4:FV_.*)A@,]&:>J] A"*Z^B1>VFB;$=>)JPJRR+&@[< M$=>JHOSO#DK6;EWLW@TOQ267VN"E24,O\ /DS^; UA4CHR]ZLW7T]9%.B(H(9.:@JK7#?90EII)Q?&G)W4' M3>TX7M_9/YOD53)'*F#/RM_%2>9;-W*=$YSIM90OK/T"?4*AZ_39?X,;E JN M(U$:&2N%>3K954A6]2PJE(J^=>^B-N^VY[^[V1U([T &!Z7]/P>_=_#?'0*3 M?!>92?43E31-.&L=WIU60_6EP!M?%3/31E,[\TUE*Y3UE@8X2KR;)NHQNPY# M1A@\(#S%/D@0F\2.S-S)1X']'+'V[0J^-0G?^/L?DHCM!(&5(# $P9B H$D5 M.DQH,'57!1*2=8P0LDN%5JG0(H4G4J%%*B8X6)1:6:56,RF, CO!VDJP?KRN MD94@>J"NT4)=@S"<7!,K$OLXC!=N2VP-*K8$-;F1NW@FY4=1'.#)2>WG.+(B M:"$9+FE\;1*5NCT MC+O O%'CJH!?3(\73L:NM=0M8F0=YL@ST8UO8M_I^6(:XCM--YR^4WXI:N$< MF51MU32_,V,25*3H2<68JWDX;$HX2[U>LWHF2EZH?W:B MRIE4PVKOU67%V;8QRC,/?#_ROW 04NHZ)_CL_\4S!M2=J MCHW(ZN;7V1QK*7+#HES)V5O[3(OF>3;\[V:X 1@#N!B0X$,#:@SH5(/ & 13 M#4)C$$XUB(Q!--4@-@;QP,!KL]N4ZXY)MEY6XNQ4;<>53#EH'$"R]DR8RF-L6 SU,V,(F/8A#V/( /&( M3!-?()[*QB4E@*8$&GO:"\5"0%$"VA $'8)H/DA%"XD;2-% _)E/!H%\ NIY M$J">!"-/ ABZTF*BSBP$_(C$@]*,84 CW)<0]25$?%D,? F1B ?EO?\8TW,D M0AV)QHY0'R>(48)X>H/,48(YXL&@^'Q83R+T9U5=FP MI(/X^!KB(_& A<*R#)'I.26X; E\WF"W!C2I>PBN;C*6=T!M%+@L27!%M+B: M""(G&@S7RG#41&%,J;TXN& (IAA+(Q)<,N0*S1!<-&2":A(RE@V-:1Q:.QH7 M#ADK9[B$)P8S;7D&7#F *6>P;28&U)V(DEE@F0C7%Y#/EX+$@'I; 0GGMMR! M9?M$=$AM&S N,:#3NP5PB0&R]='AVF= OK[L!SRW[..!"!$2(@:U'<'W!XHHS%BX=BDEG=,Q"I .ST;G%ZYR6 M]17L!ZOV:5$[+T*J@W=S/-X)(;FB]&>JW =UZ[L,,KZ3^C56[U5[]6D'4I3F M6N==[I;K_U!+ P04 " AAZ%.E@9"D,(" "="0 &0 'AL+W=O!-O\[^YWA^7SXB+5LSX*8:*7IF[U,CX:T]TF MB=X>1Q$:]_LI6JXL5-U2'2G!-]YHZ9."$)YTO"JC5<+OW:O5@MY,G75 MBGL5Z5/38.@.O^%&)BQZ-(Y?*DY3/;O)EMXR1(Q*UV!KG@MO'66Q$73M/ MEN/7X#2^QG2&X_&K]T\^>9O,$]=B(^N?U8E4_[4Z[C8%OJ6VF%NWZ&OGW]ELM5T]K](4 M+Y*S3%3HA*$*@&H(-2ZU^2C M4&E1!D?!9BHJ<3%3'XS@$P?LYA.X2;- M@OX7'*CZ!UPR:FJ-4 ??_W6TE:?6N/8Q6KW>,>Z(:XK!^MK=/7RS?'/37UR^ M<76H6AT]26-;KF^,>RF-L,SHQNZSH[TK72>UV!LW9':L^@M#/S&R&RY#R?5& MMOH#4$L#!!0 ( "&'H4X)"X['5P( "L' 9 >&PO=V]R:W-H965T M@, MIK83KO^^MB%<0C957["]S,[.&+S.>B%?5<68]MX:WJJU7VG=K8) E15KJ'H2 M'6O-FX.0#=5F*8^!ZB2C>Y?4\"!"" <-K5L_SUQL*_-,G#2O6[:5GCHU#95_ M"L9%O_9#_Q)XJ8^5MH$@SSIZ9-^9_M%MI5D%$\N^;EBK:M%ZDAW6_G.XVH3( M)CC$SYKUZFKN62L[(5[MXLM^[2.KB'%6:DM!S7!F&\:Y93(Z?H^D_E33)E[/ M+^R?G'EC9D<5VPC^J][K:NTO?&_/#O3$]8OH/[/14.I[H_NO[,RX@5LEID8I MN')/KSPI+9J1Q4AIZ-LPUJT;^Y'_D@8G1&-"-"68VO]*B,>$^#TA<>8'9<[J M1ZIIGDG1>W+X6AVU/T6XBLUFEC;H]LZ],VZ5B9[S)$59<+9$(Z88,-$5)IP0 M@6&?2D10B2*Z2X]N"VSN$22&*\2@B=CEQSE<()X2$,SGW*(()CF Q&!2# 3') M3 R^*_,A12DB,S40+$'XP=X04 X!Y*0S.03X6(LDC.9Z -PR1G'R8'\6H* % M( C#!$N08/G__Z]IF> Q1H &,C_'"'";)GBV)P L"L/EW%%PU6(:)H^N&RNO M%*=6V\-\%9TZ_G-D6]0L7MB;P+6N=YKA&OE&Y;%NE;<3VC1 UZ8.0FAF5*(G MHZ\R-]>TX.R@[928N1S:][#0HANOIF"Z'_._4$L#!!0 ( "&'H4[_0'O> M70( #0' 9 >&PO=V]R:W-H965T>)8T5;(AY83SOUY,QX2Z3:\HLG>D[)R22UC1?Z M?NRUI.[<(C>Q/2]R=I5-W=$]=\2U;0G_6]*LW<.^!I_I221WPBKPG%_J3 MRN=^S]7.FUE.=4L[4;/.X?2\=1^#S2[3> /X5=-!+-:.=G)@[$5OOIVVKJ\% MT88>I68@ZG:C.]HTFDC)^#-QNG-)G;A/+ZLG^IL(-D@U\ZB# MIG?FF7(K5/161#C-O9LFFC#EB D7F&!&>(I]+A%")!=I:"<%)!COZL4:D[H)Y&E!\(AG&0?",I 01D@ MR"I49NN/-/.3)+;T + X3I#]]WN+8=-2?C%S63A'=NVD_JT7T7GT/X9Z6%GQ M4AT)XP1_HQG/DQ^$7^I.. &PO M=V]R:W-H965T0/B,,]B0"IFZIJI5:* MMFK[[, AH+4QM9VP_?O:AB!"O6U?L'T\,\P9C+.!BQ?9 "COE=%.YJA1JC]@ M+,L&&)$;WD.G=VHN&%%Z*2Y8]@)(94F,XF"[33 C;8>*S-9.HLCX5=&V@Y/P MY)4Q(GX] >5#CGQT+SRWET:9 BZRGES@*ZAO_4GH%9Y5JI9!)UO>>0+J'+WS M#\?4X"W@>PN#7,P]T\F9\Q>S^%3E:&L, 852&06BAQL<@5(CI&W\G#31_$I# M7,[OZA]L[[J7,Y%PY/1'6ZDF1SOD55"3*U7/?/@(4S\Q\J;F/\,-J(8;)_H= M):?2/KWR*A5GDXJVPLCK.+:='8=Q)[W3W(1@(@0SP8_^2@@G0K@BX-&9;?4] M4:3(!!\\,7ZLGI@SX1]"'69IBC8[NZ>[E;IZ*Z(DSO#-"$V8IQ$3+##!(^+H M0*0S!&L#LXO Z2*P_.C!1>(6")T"H14(%P+A;N\6B)P"T9\.HE4,(V1O(9V% M^&$4;OQ5%B,L>82]T4SL]!([TG@CSL0ID/Q_&JE3(/UW&JDCC6"_V:W2<,*2 M3;QR@Q?GU=P?7XBXM)WTSESIHV\/:,VY BVYW>A\&GUES0L*M3+35,_%^... M"\7[Z4["\\58_ 902P,$% @ (8>A3M3)U_AG1 MB4! !0 !X;"]S M:&%R9613=')I;F=S+GAM;.U]^7/;1I;PS[-_19=6V4A5(,W[<&92)4MRHAE; MTDIR=K>VOMJ"2$C"A"08 +2LJ?SQWSOZ1#= TDYF9VN#47YZLR+5_$Q8K'3+.5:(GB*&>>S*N_ MOH_SMNAW(]'K=*?5'T_6\&-O%/YQVWK^^^2^*/-X5OZ_ZIORX9OD,<4G8(C+ M>)E4G_KQ_.3=W8^G)S?GX@;__"]Q=_/A]DY<7)Y>W5Q?W9SJL]UX+_)=#H>>+LZW>0Y;NIM6LQ@A/]*XAP!)\[BTEMAJ]7M MM?K=FD6\31=)+D[AO<1KY\LD?X2?Q0]Y]EP^ MX3#K>.4=F7SZ=ADO%N+-IDA72>%MYS0#G%L5<)[P5Y$MTCD=[IMX$:]F":P) M+GPACCZLXLT\A5^.X=Y^N#T31X?'XE"D*W'WE&T*6*XW\EDRTS=U4OWQ)@$P M)[#/,A'K'.A-7J9)\=K'NI5' =YLT@4"IXA$NH1W/R8(^X*N]2*)BP16!?![ M3.\7/G&!DRVR%(' ]%"\*! -]'X+>"PXXM4:J0/B)A]%GCX^ ME:WLH;6!#S&-4GWE;;H"5-OKE:OR"4@5_Q9PRAIO"[6\2SYTP&@=)'D'Y.#[T5U M2"*%3]EB#O?T6\+(\L4[I>L\>4B [)-^93EZ=^2^7=BE:V 4A0%'ADN/JLGNY),;YVLWZF=K=N;1KWN M@&;J]H91;SQ5CX77(.)2 ,^;/6EAAYX HIHL[V%*15@CN._%.@%Z!13(HV8G MCS' <#3UYL@T#S=./*3 DGYTP-A8!_-B*MP2Y7=[ MQRAR/25E"L(",L1#\:I&F+U%,DRR =QW>3E1P,B*=(O0Z2&Y0;FC>;98Q'EA M<.]XZ]L&&6M6ZKTA\7+'IVW4#;_BWJ*]=N.^NG4K[N.-^W ?W64300S1QTQT M_8(OPN<(3;9ZXPM-YS^=7WXXO_5%C!5B/-^_,)G/% OQW_V8K#;^1L__\_K\ M\M:?ZUK*3?4C_I"L$E1FB"?.E^F*E":\W#[-@5LH+P(^O=[D!5Q+H!B%S[;/ M]I>$SC^M\:Q\SG?WX_D-Z67OS\61W*F'=#^ >BL0-X CT[':@E58M+A8E0D@ M32D2GKGV=R+V=#!\: U"C/V8.)(#>XN]/+^3&_+$Y;A(9P+4H17*S'3)%$5& M#!='L,OM-_ L76P0T;]TG/](4+I#=O<1D 0T2GN,PKF +7%/2\>!^>%<\$=4%'?;^TZTX]3ANE] 21S.$QRU MGO=H/$5-7Q3/\=H7E6\00D61/@ 3Y#LY_^NFD-(@2K(H,:!XLYHM-G/8)RS6 MDA( 9.Y=\<\6V'2R>P#D)',Y)FM]W/=.@SF@;$1KDOVLI_YUNE_^8980Q M\5T02$9^NX0CO@@R(NNALSHA[TWRF*Z0P,#=9YD+Q&#;D##V4766DZ9S!(_1 M7\<(0E>/D,#_[QNXH^)MEC_'^=Q'>I 3:$HXK9DC%B#:PI>I>B#(GVQ) EC% M/%FN$?+^O43:T +2ELP)#P&^019VJ>]*B#$5C*YX/;[T8ABB%Q;6 2\[[7ZG M@;"=,XFUCJQ1C-EZR-X;S1/X-M'/NX\5N;[1\KRCQ!]&PUJZJX["P-HZDUOG M3'Y#CH.VG[>+[/GSS'Q7U^\FPI-@ &ZXS^FL'5%2"; MEQL494+J]QD*UJAI(YG981 /.Y[BU2-Q:!O(;.DC8VJ#HQXKLB19BY7)Y>GS2#!@8_,O,?B M/LOS[)FD>$#6#="'V08U>6"?L$_Q$,_PU#WCR(T> E];[68I-KCUDZ2PIM M]$:!?V:Y3B)1)BOTE'HN&BF!LQ1*1IRP.&4]H(08?U?+99R_$*--'U>DBL"4 MTCJ/H+P&4A@P1G\?>*2!+2O?F;@"-?-CFCR+'X%8E$\S9-#HWP$:?I<#AR/) M-U]G[" ]0E'L0#KG#@!5 ".$8%O.!&@DEX_.K@YO[B#1\LG.-'L>06TE5E( M));Q"C1<^"-&$I?C7XRS^)?T/S&$4?B4'YFWMN (YAM"[K!S""]/AK856/4Z M3P&HZ>)%/*?E$XF3\P0I'@,:=.HU( RN^4PP:UWV2H"\32'C.H("+F^5SHIYTSK&Y$8 !,,@:K5Z/;,N#!P+L!/\)Q%'P:JTP@,N0X_HQ$,05;>[UF:/DCNR@!0'QK MMIV^;7[!-TY6JPT\ 2\P-J:(Y1&2:, *FXV# (PEK%-BDI%6X1T\Q[38@C,%T)8%C(RB5*S&^"O( MO?2KQB9Y5?_M7R>][OB[XC?8]OO@B0*91D2S;5](J^!P8<$+=,Z!;$5Z.>P9 MI"S:,5QNQ+D5S%(4R,!P"3$(7FDNUO95-V!3Q]@&%@.SL3P:26QI@M<\@W7B MO5"S(67/$SF-H#LZ1Q,>T '<#8YHA'%X:K. /3T#I4*85V&%SU2!-:6GEH@0 M*",A+FC](!*@KM!R$ T0"(\>M,?Y*"@B6?V5@6R9M3L,!LV3H8 M 7&MR<-#,N-S8=FCS%$@A;-)BY_Y,4 ?(-TQ#) BF_I0D/QY#M+WDH:2=VJ-!&@-UXI I::.@P?68\.4\@5?YCA 6XLXXCF.9(N0>LPP4&8SBL!C_ M3&\$#W4E#X#/)$\>%H2@R>T)Z%X"G*[N!B+-(F='! M?847BC)9BV4&\J/ & 40T V^/6Y20FZ#!021M%"BB-0J^"CU@O"!(GG,DT<. M55@%R?T^;EJYGHJ?5)!%!TC44J*)_JQH,:JT^<_XJ/+AY:Q?<>3-(\ATH(V\ MZ%^M&PN2GHZ6T"H1H- L60##3+*-DMQ!!DQ042/589X CFNA1MUCD%QF,F;S M-9D%2V6IP]N2PTQV.*TE?&.$)@M3#'XBW<3LKIU]B4/1C<;] ?T[ A'Z)KC- M;F\BNN.AS2>M;8ZF8C01[YTM]CLHD..HTU&7_IU,A_8-U\=9TCZ6\5\1N6'9 MTK1CH0W*S\UXHQ];I 6Y#.]!+>7WD($[[\:%,J,3(R5[Q/TB?>2;B1@(?Q6( MS:P8A!\LS)QH RD9_7'\!&Z4/,>"D:J@Q_2P M8&6TTE@I1AJJ<@L,0#!K;. M3@6Z$K!&?4G;XA)45EOES;-5ACR/KX+URRVZ2^,1M4 TJV@?X Q_CE=J@DDD\*W*.[@T_8YH"8K2/(;-HG+#;B5#)GQM'Z(5M\G &9 )<'+!*HT=P MEGR'@=:(B/8P$;\"R]'25L.2>K DO#N]SG>7,=KZ6K=$V)V%X<;?D96[:-/# MW>\0EXO$5@4+>51B0^C 6#K+%@L5<"9T'!"JN(4XT)N%$]-_*XT92?='"@Y9 MZZ-(U%'(ZV+C>H+SR$M6\&4]BH_Y;L:SG]'C3^PW,%:&8@9($;P M-KS.Q+'B(<\3]J_"S*$Q^1TX,&3D?.QTZC"@M2"REB%9W1#8L_#ZI./A%Q#' MTH<7/)D4%':\B'-X=B9C;&"Q]PQ.]G>$0*E@5; \FVA9:Y6M6G*;<%S9BA=< M;("TP732> M'%@M,%"%SX S (R7!1%3>%>D# 9Z$*]01I5DE+D&J9QE:B5SD M%T-Q)5X:E22P'"4'*]-6Y6<-W>/@>IZ5HJE.D6S^B! 5_PZNW.4?"E9H-\$I M9@;(2?+%0#8@K-];&Q5<.6'!M'@%3$#?9S23 :,JGA(R2MHAUT<'-UTLY1,QF%PN%J*RX)_FR(!<+ M">\ Z6Z/F9N278TFZAY*DM+=D 91O GZC")C%*@&K)!"I'WF!M%D1(IBM2H5 M@)5M$F>T/:B-.1@;E7D "_D$"G_)EY$T,+:H(HZRQ483&2UE(WVD77'X-&L: M]U5Q!C;IN179?@9O(O:PTD4ZAC;/+)3^A2CV:"U4;=&V9J%,4GE&[B5^**4V MU;!Z5$@PH%-1.)!6X3A):'X $8=$6/OJ9.:X:+JVN'BP[F%:U($A=M^+@ALS MM[8 QX)[A8B5Q)G(/^E)-U1=J1G,>!!:SHBL>2X=8MSS%7?UO(U]?96EE- M63R4=GY[CH(M-/&BR(R>8VDNP%93!7EI%TESI-)H^;Y7F3GLI)(D#$2/E!@I M/ 9,!YGV$C7*E1K&-:YORI2]/K$S-HD7!7 WG%3AECI+-)*24DVTDPS/0":= M??$D3&'D<3F_6Z;NG!5I)+*##DX\G*Z&'>8)LCC#$ @IS)(EL@0K#*QWH@['K4[M4_T^T.?^-CDYMWO],V$3XP&5F,X2/9$J-: M5Q]3T&5T5N<#,%:R:(J/@-JH8UINW95TV2M3Q,RQVA:9$3]==$+"A1"'"Z.P M2YE=2:/>L+40OR.=<_&B$4%YO)3>(@VDKM5$*W2LYRG++ ?'8]A9J2^P\K\S MGP7VB[D?&9MA/:[[( ZGW?98>YD"IF-K"8:='@YL)QC)UPGZ@"OWA>S[:)QH M 1GY&<#JY=X9.<6.%C&&E$@<=N%66#.13K[S>':&!PV*2SJWHL^&RT14?!Z"VTF MD93\6^9*V&(2H*KB,I*;ER"ZEU+FI7$,([><& @0)9>34I0M K>!+YX$'HN0 M_H2N2.>M%F8W%OL\>28+ NNCJX_)2\*^1.5YMNVS M0.:OBOQM<>E_N8.RA>!Q?+@-!C)*DI+ZQ[RJIBG28PF, 45]FRI)>K@"@WJW M9+^M5GW8*&:I.RSV:&EB-9?A7;BYI?+-P_/W<.'FMD+99$I&"X6VA[-:;L*T M-*O5SF1%*:Q0+IM8-$83%GP.<%LV,[D29;F3B9"2HN>)S0QB#A>9RUQDTKBL M/!_>=E @Q]4G4D=64$X+ZW"0%LP)ZN1AC"U_+CP]*RMF]6]K#>I![Y#BD-)J MR];GI&)])BF#]^#0MV>D75HT5T.I762K*B]MAZQ,Y;.D2C*W:(&:'86>5X1- MC;= 0Y\R])HP"\Y42J64S&"#UGA2!X@_QNE"93FB[^/%<6R@&!*T>CK&0K7Z MCE("6+[G.'D.YBJ43&"<)^1_-1M'3$=$(%.9^5;)[\FG4D;Q_[*)T0#&HR/. MD8&H5*F7%&I \:9,5+2BH5>I3)@1''[9["AF60#@,X)!!;9;+G;VI%*3^(GDTT;ETF9!*9YL2D"/Q(A9Z M$8LL7MGQ<;8S7R_*^!/PZE84XY+C!UALE&%85GRU':3+D^F4-L!M!9O M:*N! !PE72WY5.>X<7:J8F"VC"9T],\F@-XGUMV2TC_N0?IHV=_*9WZO#=^8 M%:8 C%,C4Z,+3\%#SLDJE^:_ YH+: MD,?F<#)(D)(FK5=*/)&VDL-QJS,(EA@Y MY\#'"Q,U61O&>DJRDO11UH>]U@S+0'<"[1'$#YD6[H@GLK>Z:J"P0WWV$!1> MBZ,SF>T"YR?5.W1PHP_[J'M,)8/$]09>0HGN.D.S]FE;' V.Q?NK-Z+_JC=Y!0LX%(,1:,7PS["-GX:= M=@_^.1JT^^(84'$2]?L3K-^4QJMX#0]THTE_+/Z'_J,MX[A_ CHX)R%; M&N:4"8[V30!PHTK8](2Q"WF6QU::!,NCB)/**#DG2_0KN@!%LL#B4))"DE]: MA2&8 VT3="^4U)'92K\,6@8ZX]1E8 MYI"Z^UO1M,;BLS#&PYD!!SX3ZNG== MF=_Q&==TP6K$*G%B!E,'.0VK=;72![>^BIS2L]D\;"C8KV*VT4''A]V!9:5 MD9>=*5Y 2[WD7;4:>+:=D$GB&;4"-,RQ;P!P!M5RD%@.AX!ENQMB[*!2NE=M MPO00]..@^<@"10N 6QN,(ZFH[Z._:9":PTRYR&ELDAF(ET@2!QAB6U9O%RO2GJ M5BEE/!#*L]661TE?$BB\P#&J+>1\E:SA\ *9V/V[S:Q W#[)T[^!(L%Q,933 M/1I'_<'0#]?GP@T,&;QCE0R";M\"%%N'_>R$J'(;?0&W=!:-\QR.+'Q$$S#= MO1^5N'V+IC2XKCQ1T!YLX25BM$JXR),GIIU,RU6B%H+3J1_%X0P@4Q@UDS'9 MW$$RT:3DK\QG+$=:V,22CJ1M+HJ1,"L]>Q0VCQ(P #9."ZZJAE'&YH9Q=4*R MD $/>HY?*OJW"FCT)V*1^Y$L<](;3.JQK'=8.0@_0<1.L*C)/ D65 KDH[A< M1N.YROAP2S!%%;+BG(ST0I& 1-3-C0 -)U\J5FLMH6&*(!K7;-45JZS 0?.V M\Y+#= 0PHO@UAUAA\%ZW-]3_[E6C3_2GT7 R$MU)U.MWQ: 3C;L@%TVC_G D M3NJ*X1WUX;G."&2CHVXG&@W'0@IZ3H660,DZT<4J74,QB48@=NUBR>^.)A1/ MU>U])[S2<[#ZH1B.^^J>!R8\Q"F', A(=5%OW-O=\7 H>L,N29T=;Z7V<_X* M[5^Q\%@7A,<=R\_!?*-^'X7YW^")@GVO'E\]*X2%"B<969ESVX[%E.C13&8?DDNO@/AH0_(H2U_!@6DBD-F3LLTF>N,&!Z=Q.CJ M*-HF%!X.I6OGL)3X7V-X?@K'@W'Q+#+I$H>ULO,P7_5%UH6XUU$4]9XC#->V MCU ?&27^),H086VSJ(&68WZL)I9)\DFDU\US0E\\4;FJ*^DG]8-Q;+LN$#FT M,@61(XB--R;!":2,GU?9\RK,XWUFCIS;5454VH$)II-Q'CJEDQU'=GZS]+ 0 MQF!&'T+D!3/,LR7L9(9VIW>2SU' 6,61\6T@FLO:]^Z&$9(WN]V.X^=_&]0^ M34Z,2R:]E=@!*BR0VK@1U0@8.4D>; 4J*HD(K_D9Y&; JBG-H-<1O>D@FG8Z M^*%+OW2&]*$'#*L?3?#?3J^/2051KSO$#P,5#0]2(1D#AYU>-!J,.35A,HYZ MP_X6)M/9QF1Y47EVUHM_W"OL* MP6ZWN-\;18-!5][B,5:V[AVIDZ%;G-FMGK9I.Q%Q@HV;7>#!06(O9'AC][D;;OV4,GN M3,"B%^"H*,"N88P7JYJ?I&URRTPZ>'>,C(WFLPE6A>;A5K50\QM0QCOR?;D@ MJDC$RGNDXTE#@:+U=+_;'0.2K%XX7E-R?YT;LA7!*CQ*A7JQ_)WE=AX8EP@@ M69N=(M1BPI5%$14'H[HPOP JR]"32BTL&;Q(8^3D3*Z*B-7+YNO:)C,=4<(U MZ'0L!*^YAC) 1GDP=A>CD" Y7TU$F.N$#?M'AD"HX.-1GVAT$*C'81&*+FD# M]34& %/E74N^-B;,&V&CR!# MC?KC('7N=P?1H#,2XT$T'HVX;P&2$1DDJW-/-#3Z_5$T[4_$>!Q-)F,T.W,T M[5%O,(PFTP&:;( ;#*?H.F,I^9T.6ST44^ : \HV'40@(@:=BSK2IYH5:^1K MM@V[ 8:(AZY"ZP>$J0 M'=H#L:7'5H;,(JA$U /A4;8I^0^+QGB2*N+0>-RU1K\)6,*R>PRI2/R4RB^$>BO_6:+.-&1'#M0 M7;]6H/A]!8ARVUI8?AC;FHL6!2:62^WW$P7Z2A38EM"P-S,=$C,=#VUF2HZE M'.YLGE0GX?BVN:VM%'( ^/\N:)ARF;MR91-G^;_.G*N,IT8Q"#&@SG8&Y"L MVWB0Y#>@D4\FS&G@SY'4X>'/_H0Y#/S9&3-W@3^!J00Y2P^X %F:^X-I-!YV MZMNQO*$B@]Q)7!4U*$$_^K1 M7_WV .FC>?,.[_>[##1W]7)- 60*0NGV7L%I=^'X>OT!_=N=]&'081\&O4U6 MF/G(0)]3B0DX<36:)M84_.$./7@%B-,;3 !U^%^XFS#J=%@SZG"G43$F9OBJ M-Z01,5Z'9@"E%#C*I&;DR4XC=U^A+#4=1GV0J_#?[G0"ZYT,8-3W("8_(N5D MQ)'HX@U;A,;EN!AC@4B6Z0:(V_A5=]H:O@*^U1W@,8XHBJC7P9V,\3A15NC# M5]UN1_X]C*:P&BM\"%$^D /)*4\ZOL8$PN'Y^\6DD9 =]H853_KAL..F$)'T M;U7CMRHYQSP:/-1K=R??T/N]]F#TC7#]JD#C%AOI)L4Z,S.ZKD#T'K'N#V6X M&6\S[IM"*L4:2^ 6QVTZ_,_8,WXZM-.H0 XJ%]H;0($8F(K2@KUQ + /)6UB MMA6B;0UWG*KTGQT69(5_:#RDN&Q%^>#?[.'!Q(-@.8M03 (Q$5CVPP:KI2 ? M-DBMW9CWP&<=$#CG"UC2^8:J56.XY])8""W$D$5+*&8$<[GL0 H\/7?>9 4P MO$\XH&;8BR;=OL\;\O0CQ[<' [T;GK>>(JS\,9E3U[T372!V-Z:S;0D@:1<_ MVW5SKN[_JK(/'L2'@HNLJ3&*:D K"#04JX,>(54&B_.D[ !A"M5'N>!>18%* MR575ZM-)E2;#IEKU4A[-0M6X+&A FI^2!BBL!TM7DLLGX21$/1]91M6,/?]FDIPF6 M*@)(UI.C$JMI(6,S]0)=9#>W<<,^?U_ZL!SN:5E]!.^T4XT7VU ECR]M SAK M*&#]Z>-*I8%J\PFHRG.N+_DQ6WQ,W-OP8'S;JAP;W2K,S4;36,Y)\'Y]/IM^ M4:DU=B+2@+MG'S6+C:D'FY)9+J7Y6?L>6SPKF19)JLZD0=O3]QD"HUK>Z2L M'FXPI 0CBS"D5C1U1<[:VMB&DV"US+2H1&,2W?4N@DJOP6I$[ @]@I&D_]34 M<*2-S>WRI;("3:&[:K7%2: ZYWZ2HD53G'.62=;.?H+7VKI&3ES&$O.^:NHM MAC!@1R?8 W!41P2L)TW&?K7EL@:1Y[4(RG;BDD1(IJ>&D5RJF\,G0H80DW<2 M(B #<3A&1>@NOH?#RFW9$,9^B\EY/R$/E):7H)@IP>O&65:-$])#(NMLFJ0_ MSP2^C5N23_0Y08&>!H.1*B62]JA<$/9IM(T9Q.MG6F/T<$=]E\FE& ZPK"+ M"4]21+=%@M!9^3&2&.TXE7;W.KH5'E^^&3QU!!Y;?BCUU.7AMC4ZVY=0-2)% MHJ>L7 T[D&SO*8\.KDXO#HZ=R)"=/&MDJ@K+.M\6#7>?SDK11-P-KD/<./%A ML"3CTQ[V!^=$X:XYZ&)&, MH;]#<4LV@WE0A%$>$F^(00__Q^,S7GJT&D:GF.O!6!K\6DCH6@K4IZH? M)C$W$G+C/2O2A"Y,BL*413TL:2;EHCPDY(.8@YT:6O/D(49E@;QR14I-9="U M8'B?(O@SY=A7_16Y+!"_[L]KUU+%\A^)I7Q4)!V,(;V'39,RPY4?DD7"M2SN M7V3D!ZV*\]H\4BG7H (,S6B5P$U=9)NXT6&WKW'&1O$X9&+B P]R8HV8,?LT M9:.9$(/68N$J^52:"GF1D:L..U8VE[6HH@$-U:I,7K*SI)7VANRSIDJ6%&F8 M+Y:M*9@C13JN$K8P]2*T7)/\Y9@:'1FVVZ)5B'<7;ZYN*%[,4N]F,KS85,DR MP54&+;08K.4:-G)PE(F[,+)@]ON#;[:U23]M:)/>_/!N]J;F(=XEC]@-DKLN M4RBK\B.YA&5V.)4RRFE#ID&R^ M(99>"<296M;P3-F'YFXW-5F!V@[@A$^HYDN3I5M7@1NNZ$"A JUY5)PD+UDT MY["CLVUPO0?D5@JALYX8.&77 TT#T&\! TMTTYC4<"7X8!;^%X*P;Z6L^@TD M_9Z1-8T#ZVE L/'DJ=5(K1F#I&,:L8 YJ,[4[I7&C+ZH%JRW7[16+A MDXW=6%YO]XQ*+2(*]54#QC.,,&YU,!S2WUUX#<.1ZEK BGXTF<#C&$XUBGJ= M/I;CPMS#1/:5E_U<8RI*IEU[*%)1I(6$T !=X3AC-QH-IV:)3NLV^!D#:@=1 M9]IU%BH/\0JMF;B=*Y5"V@WF\,I:./UHW!]'0T3\X#%%:$"3"B3(#9VN:2<: MH_R4VTR,EZX',Z'&\33 MDG1=W;LG+L6B^P,J-Z*<)9+U0/1*<%C7F:H7I#)8(AG?4,D4[0ZM@!D,OFG! MY*WW'"%:!3MPSL<\7CID!Y@&G%L?0R&&"LXA<2(N6_"%RFA/>&0#-CGR/OJ5 MG>G,02>(DX<#*_E5]MW6<(Q+3KO23:3D\6&J@787'?9[B OP!/XU&8DC+Q ( M'73P6W\DCOUXTB&@73\:]'LBWH!\G)-$*2%C@HN<"EK " B.5N\6F>O+V[-T M%38UR#S[D38U./3-=)X\VT=?K23"*S6%2Y&GPK.XW@N"OSN9]L-F2!I>S(PH^]O=@ZGB!U7OED_J6CIM<2YMD>*: MS0$$41K=/N--(3WE(*"W2(_1E9&)OJPW=!\1\91QD]:I-D:84,T^7#40U6I2 M&>FBZ$?A/@6Z0)5'?*H+; [@R/&#F3L:(E()]F+TDB+Z2I5+# &O6='@@0/3'M $PZ^Z_F3*(4KJ<' MYST>C6D]_<$X&DVZ AO77JA./(-H,NU2'GEWTA%N=UUNR]MPA8Z&?9^T,T-DVB$3 &!F']+6C9PQ\*$"P&_,]8G&V]0@TO R" M ^#I7"^PB-V)*$P36"*.2BT(\5\;)JD>:4TC?<:]K43TE*Y)=LNM-O?T-B!! M!J560(UI-!GUL6-2!Y!C,!0_8/,E>&\TH.CM\0B>Z8F?& 6.AAV0_,9TY"!/ M@FQR')RL(G]&XPG>C#%. RRD/^CMQT(U?"K1TTH:!DEU..!ZLR )=Z>C6M'4 MK:M!@HFF^S+" ?/WE$V._9*(LDS8/[FANW(6,I'Q)7%2SG5!_7HD<3=$:7]4 M!AB_[:%R>:X(!B/X); MU.]ZO=:- PK]>;L$D]D^*ZNX:KW:OL,<%?&%A1J_Y:/CUU<7). Q)(L_RT>4 ME^N["0G=I*&IY,X1JEZ!.W0L"Z#)8!6*KJHV*F]QL>8XS[DN.(NR3D<#:WV6 MJ9[SC"GY0-UAX)Q;%6OM>5W53%" MA7MDGFF ZUXUO) QJY0/1@V3)'_1?2MD>+!X29'U M ;Q4M>]0\XNZ% 2S)-E:1:&>_(XRL&J.V?>[AVM!M;?;U,(U.$_58IAN622L M_I?+FL5B8+J,76]S2\A^;]J>R.^X B=^-VH/K5AVS_AI^.EM^KBB< :R&)L. MB%A$!9'C2/WE#:*KI5Y]Q/ZIR?/6!\2/2;PHGV:(DEB)"FW3^:9@Z3U?9VR; M82E 8B,U/21KJRE<954U*^GUHX.;\XN[@V/&K.P9Y1"5YB_#7R-561#=-]P= M"3LILPU<57C1'UFR;K$/F[.VS/1V*0P3\&5B\73M D!V$(P8S*#5J")U3P8( MI@LN!_FJW@Q.[_B=+>F/Z&NV27V@Z!NF!MX;NQ>,5+<8Z7$#9W$;\L\=*-T!MCRM=4A?*>'Y"IW MKTQLVHY3]IATTU>K/-LUB52KT<+M-I&L+:>.<^IDOUN"W#6+ ;^QM37@-Y>3 M;NIFCB#5")B:NG/; M5G]Y2M:,"SZ-568SMCJ^ZZ'ECTQLM2U^>^MQ5T\XX=K<-Q212 7S M)9S_XK6##SIKX((#8$V'"3S@F>K]8?5R9W; [-C&P01;Q:_4934N6EFA4I;F MK\<94[@\QZYN/,9?-RNG0JPOVGSYMM\'3Y3;D3J]I\@_N<(%+U#G1:&*C*<4 MLF,;/5<)5M=$UL;%=T@N6-M7W8!-'6.@-' SO.99PNYY-5M*8;"JQC'=472; MEMB03E:$-EG0RD.NXDFJL.)D%A=8TRH9^\#! ^S68R<) M[$Y5 R24"(@N3&11 (JK_SFQHHVJ^ATC$ELHXT#0\+ZKDQ4H^1+(T'$N25]N MJ#0>'^LR5BTE565\;)JBE]GV:\AS87%Z^%0VS97!9J=P 4 . 7GR2'++5+%OG1LD!+3>3T](>CU:/)@F,:;JE.PC+!J@TN!Z38J[A5;\%%7#Y M)9DW'C/4UJE'K)$"9GHC[%V5&J5,Q+$*Q+K%W.%-$V(GUZ4KZI)#C;[DD*]J M"@*>F[<8TQ*)-R0#=4)-)&P88;S;$Q*X #PK!;#1TBQ=1P]H5RO*9"U;S=MNY1KVOU-7:RPE83":B(7*>A1G6MN1S6E:"(<+)!R_5PB*Q5\4%U M>)-H8CJ^Z8@<(!@_+ H!\J:WSNJ08H- L M 15LE6!O0]4'Z@WIBZE?#$71!1!5D%P_9OG+ZTI&?[/AC]HKD/3$X#>&P&MG M7Z25C?L#KN %\O1-<)OH)NJ.AS9CM+8YFHK11+QWMMCOH'2.HTY'K ].ID,O MJ;^IN_U>#^_6CPC;TNMF1*!AN,V)NLAOWR;WN>I4KQH4::H;G.1-AE:"HP/L M8T1:H=O)".>4/>+;!]3^2+;!:F@#WW'ZRE.=YO-8%C*]UC:\ER MY72N/\ [\.?-HG%"S!T^<+I;.1WGG0%E9QCN:V]&<)9\A]WU\%+:PT0',BO> MB!$-2^K!DJB[?>>[RQCM3ZU;(F#.PG#C[V3G*GJX^YWJ.&^.2K=ZX4Y%RB%- M'8$X01TH=9++AED@LA^81G,'H29E!>H$5#,]T+Y>]R*M%(Q5!56H@4G,;<77 M\>QG&9 1'(L"3)*YECTIETLS,MEY'&-["[1F4.UXW>SFR.H\'X=;S<\D4U9A MX85J 1YQ;W59D=9-++'<,K7MZQT[H6[6;BV(:R0 ^=@0V+/P^F19%BO93!6< MX1:3/ PL]MYT::_I7[A/E_8=NC-6>BSJ=S'(]4AVI><451E_HCN4:]$BEFW^ M*/E,R=J!Y2CYL:9=O(;N<7 ]NA[?UHX9L'*7-RM8H4$ IY@9("?ATL?[ -EJ MSU2[-]-1-4E"'571-G2/R:@<]VA7O3HZN+GZ -28Y1,ICCG]5[F(J RFB04\ M+@O9$;S]IKRR7X0T.A>4XD2ZW&+AE&#B(D:+#-!?-C^P@NK?J0=#?5-EP2'5 M(]WN\1H9;;=R'5F14"Y>"]%4@+_=OT[;'(AM6R%[/SAUD'3[>&K;SMU@0"KD MCK5T9/7-Y&<4LKY1<6%>#WB_W1D9AN!-Q!Z3NVXBP!UBNVE1!X;8?2\*=Y=_ M#C=N8YE)/> 'F5)Y@C$KEL6HR+;9S MP[Z)7 &,#"3.X]P3UNI06;>\8(5[L<[6RAQ(#DUEW':J9$7B?E-R&SXMSSME M*BAHW/24LON>NUUQ3//:=4J,=(XY!50C?XF:DRKB7DF3^.*>ZKH86*6\W-U3 M8JJMD:;EW%RK:#(KC$AD0Q5.8[\\7+",NI1I729E 6 ]4N6>.>;((C/BIXM.J6RB!!=& M89>R)Y+F*"N#H5O'JJ9&+AJNFWJ5>:WKJRWB(ZPQ-=VC M UME/*]9/57AFEA-YF#(0)-J/<# MMX$OG@0>BY#^A*Y(YZT6D^"XQ!,Y=IT Z8_)BPR$4^Y6VPXIU]5FO'E."VF? M,Y*&M55/O&^KY@J67LRT',<1. M:5PWVE]=0Y-+_\L=E"VW+&>S 9&J@$C]8UY5TTS_$BTP!A3U;:IDK.//K7=+ M=DAJU8>CFRQUA\4>+4VH0EU^F+/J&Y8;=-LGV+K)5 ME9>V0U8F3*"V6M?'"]3LN+9%341! M&_^+8\"756Q\JZ=C+-1-YI42P/(]EP)0/8!,>7CY$#D6K:;WA>J;9(-#R^]4 M*IAJ6_R"22+42O$C(S 9B.1GJTF])"I:T="K5";,B(Z&ZNM)(X-L<\<&17&; MR)*+?5;;3+\I:Y:=>C]C0_N*M7E*MN#-*K$MS;XA%-^,Q,'[A)JFJZ18623V MG>Y"'PPX1>NEU:%=^ML)A[$4 !M2+5\R>R%Q'_>JZPK1N729D$IGFQ*0(SD- MT^$[[DYOG!XUQ>WL7E05Q=B.X5.Q1[)A)/M9#!/BR71/#1-=%-&7K3)KZ7!3 M2O\WF481WH.Y[9YQZ)S?*=22%OEYXEDSDZW?=@!M-:S!'?F1)4JZ6O*I"(YH3DPB],2 !VV MU2SBUP8?*-%#QQUL)8?C5F?P):&?=W2:7L3!65K$C^P]EGN4(HH7;/=/[G>E M;JOG'%EY885EU@'6.ANK&[?GH;U[\M,S _78OW5Z>N\C:KVN"60FJ&,$,M9O MMU)NJ#0_I31@#6G:-6O=V.[^EL-!CSZL8N H@,#'5L6(2)RU3[EE_?NK-Z+_ MJC=Y1?7S92CS )M3'(HAUNLYA,?:V!&E.^3BY!<@W<.!8;]'8"<7E]1BW1YF M,(9!!H/V1 SZ[;'HMKM4!GPPQ3&G?9IAB@V4Z!-^>=2'B8[A=.$\^V.[&CB. M^Z?:>ABX;P* &W_"QKN$"GWH6BCZNLAT&S;K!9DBL>0X5F=.:3 M/M V0?="R6V9;3917=0CM\PN^Q@B13JUK<16),K*' -K#K?-LTLME0,#GW&- M/SLWG"?]W-'KC4)O&V8]JU>XYY#)..\.+#O/=2QDU*$,(TK' M(XT:< 8-&T#S#H=6^:GMIBP[WI3N59LP/03].&B @V)N-E YPQ1 M6YDEU.$Y1+V^]O?^VM_[_W1_[UH6+MM3OI==:-AH=*U(THV6D6O>^^?L2/NY M0)3PD2VJ:D;YI^\4N@6ZYE:Y< [1[6J(Z-=F?W_O9G];#M. HODP^=?3K"AW M42Z^-A/\VDQPGV:"^]'S1B+>0'6^=GJCA. Z6\+L*9EO.%L#V[]5?A>?EHO7 MQ3J>)7\Z6$O/TH$GFW_M\O:UR]O7+F]?N[S]G^_RMG?'L5W(JM=QZ*)F7UL[ M!^Q$G/]9^X4T<[9@EQ L3ZR=@$Z=H&M=J=H4V]AFH?K:3N0?KYW(_D@1Z3XC MJ[TO9#-*?&TF\L_63&2G8N)U+.3&*QP>+!I>5RI\3X7]:YGR?[ RY5ZE>E7E M4XHXNESM+@?]M2KOUZJ\7ZOR_L-7Y6T(]&"OOE?/U"WCZ_E9OQ;U_3L4]6TX MM<:;I0[C2V;K?3!R*9ZN%^NTU'^5H?\^]2 M'_.,P7PL'LI_^]?N>/(=;NZ]W%P$T\''-_)C=1X 6%O#Z\/MF3@Z/%;#4!"' MJHZXM;3FZ^H3/U2*09J6WJ3<_"H./0^#-MO45(3\5=0MQ[RJZD16JW-@4\D3#,J6<$#1J+\F] 2/8IKLE_MLI16P>9+$I:?01QI MKD2I:U?>OPA9 ^P+D*:E U=OK%A_@THM(9&!T>=.2<_;(W'5N/_]#I.++LID M67@UM%6(+$MGOGI*$;+LI/M!1LCZB*M!]#9):D9R(F:_"%H7V@Y]8D565RH5 MJ2CHSX#CG^-56W1J:NTU%T0"3#K5E2:=QU2YM*:CV,T_V_(/ M@'RD >*@/:"1#F_'N;R!.S4#QY]" X^'X<>U=G$B]WFC]WD7FK4O\]^['27U M] :@*+[X-[PA"E[6A0+24@.&0T6\/.I[G>\?EA8&I M2@E4OQ^U>Y\[T[[G,-CU'-B>R1& GF BTVN+0"A$%(HWK-F;<7I322P9+6C% M].T:?]^"EZW >%EL7#6QM'EZ,]DX60/[[O2"[#O(ZM&-NM.S+]CX@V0F^6CH M$9"H[4?JF'.3D!'>T33XK IIK95%+* V$CW[6*QW/#:EE2K,+_!ZN'K1]@W3 M!+%UBZCQJZ@]'ID$<,5) HN>+U"B0V_BATW;*0HN\2X#.5OD+[.]+CP7!W> M_-H>>[[SR8B['SSJ]#D3G!;**ZI>Z^TKO-K,#S.TNJ(&L.TUS1?L M6^,EC-J:QMF2FGYW4*D1>;JO6+MQ(\T8]K#8^O9X6U,.' D^Y:-A<12XJ[A>$7:OB M&=Y?K/:S)<11;+(YV!A#YJQC3W\UBS=(3-%OZH-=H#(@, 1S)OQ)5%.&F^2) MQ0CE_)8!8[_*FP%01:EP'1&06@"D%J0D @8K(6*%N7[<2;[@PQ MY]K70$RO02H0*E>DT414':3;1.H]IOC'<8=50+ M.BP,(7/ ,>FJF.7I>JLH&:25Q>:>^JB7U4S$>K)Y:QF'&EZODPCM9>P@R9QP M/K\VVJB7\C(;Z!>V9X."))?MF-U3+YBX:M/Q]QW9*@C:-O*MUSAFP_@*- MU04:!>_/EOP*WPA8;XL:MH>^A6CK^.XVFD:?^J/O>/L_C_G6)C_L8ZCI=G8R M@6"RA!W-VL1^3K"(&EG=C=1]K03]>G9!(YKR0K_6)RQ4WSROB=INLDI.O;-" M)7&S;!'V,FA__=S,!W^^8=^;3X?^L@_*A[B*)L3>;)^\R+W:S5%\O*]T8+Q[ ML:9>1G;GR.:QNNVNC]1.)L2OGY_(X4-I.ORW.Y',FW"GMP]_= M9.#CG'1NXTR_?2J(O]^QC_9NQM$M9B2PP>1WN@N4R+'3(G[/HZ>PW&RE^VPV M)6CHMJ%V21 .^]W%]O1W/>)AN^-?V/-/N+5-6CRIT'\DYY&,4JXG/#51'JVZ M!(,S)TK=2P2Q=7KW1]Q1J_*Z^MYB.E935X,G>YNP\$S_1Y]IP^YW4['L(/Q? M1?/@%9(?TFIV@+X;B5-S%C)GHMY8]070KI?C=8JVE;SP&3L\U\&:/IY@R@!& MS^]O(=HOAG_[V\TA_-A0I&J MB]0/?WKU[NKFY.S*PZ%0LDY+?&%:CD.E.97 ]\WLG(JS:_)/4W9,[;-.,*QW MMVM29WP&OW_BS$XG<43?DUGCYP4E+^]WOVHTN@7V'C'QG=]IC'7B!0;4+5$4,] M$$'KDMH=U(?/6IBAS/&F?,IR$G(D)AAK'5N=,C76FL>J77QE;F_M//P%%9". M9/G+:YC@-I2VI0QAG[E!9S)QQH=^30>^?6J.*_OV5S??Z6W&PN;X,ZB:N>1NV2PQ4:=]Z^35T& U^4\V"C$Y=S.O:IGY]A2NRE3!B[T]_ZGZFLJKJ:-=*@FJ MCBYO2X3RA1:02-,9=_X-\"J)49K3PQFNXQ?=\)J;G.!I<=+JIQVE@*;S/%<7 M@0_,39FR#[3QP1T/MG&,NDROO;.G:CF1R9:J><)*F:H=0Z9-U?R^1^)4[2)V MR9BJLV+4Z3-N\D_]E.:75T51?O__ 5!+ P04 " AAZ%.I#1'44L" !: M"P #0 'AL+W-T>6QE)(8:6W#!X* (T: MSD05X4+K\JWG54D!G%3GL@1A(IE4G&C35;E7E0I(6MDDSKR9[R\]3JC <2AJ M?LMUA1)9"QWAB\&%7/Z-3"'"CZ>OO]127[]"KCUY ,(Z?Q M(8UPL+S WJ^+GOO/ZYK81'KQC'0WW"CUF9/$Y>\Q_0!I(GQIA;UN5>,PDV)< MW#EV#E.9<$ ;PB)\0QA=*VJS,L(IVSKWS#H2R:1"VNRJ(0NLIWIRX<#U[(9W M.IP*J=K:KH+[77?#)X&^9P$I8P/@##M'')9$:U#BUG3:P:WSNQ#J[-6V-(2Y M(MM@ML!C0MN8(FNI4E!#F0#WKCADD%D<1?/"MEJ6G@UJ+;DQ4DIR*4C+T&=T MAI%-@+$'^S5\SO:TFPRY,79+?(PL16^:67?FN&M^B[RKYK1W90_3127=2/V^ M-M,1;=\>';A7D-&F[3?9 Ʃ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end XML 61 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 62 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 63 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.1 html 137 254 1 false 53 0 false 11 false false R1.htm 0001000 - Document - Document and Entity Information Sheet http://healthcarerealty.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 1001000 - Statement - Condensed Consolidated Balance Sheets (Unaudited) Sheet http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited Condensed Consolidated Balance Sheets (Unaudited) Statements 2 false false R3.htm 1001501 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 1002000 - Statement - Condensed Consolidated Statements of Income (Unaudited) Sheet http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited Condensed Consolidated Statements of Income (Unaudited) Statements 4 false false R5.htm 1003000 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited) Sheet http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited Condensed Consolidated Statements of Comprehensive Income (Unaudited) Statements 5 false false R6.htm 1004000 - Statement - Condensed Consolidated Statement of Equity (Unaudited) Statement Sheet http://healthcarerealty.com/role/CondensedConsolidatedStatementOfEquityUnauditedStatement Condensed Consolidated Statement of Equity (Unaudited) Statement Statements 6 false false R7.htm 1004001 - Statement - Condensed Consolidated Statement of Equity (Unaudited) (Parenthetical) Sheet http://healthcarerealty.com/role/CondensedConsolidatedStatementOfEquityUnauditedParenthetical Condensed Consolidated Statement of Equity (Unaudited) (Parenthetical) Statements 7 false false R8.htm 1005000 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 8 false false R9.htm 2101100 - Disclosure - Summary of Significant Accounting Policies Sheet http://healthcarerealty.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 9 false false R10.htm 2102100 - Disclosure - Real Estate Investments Sheet http://healthcarerealty.com/role/RealEstateInvestments Real Estate Investments Notes 10 false false R11.htm 2103100 - Disclosure - Leases Sheet http://healthcarerealty.com/role/Leases Leases Notes 11 false false R12.htm 2104100 - Disclosure - Notes and Bonds Payable Notes http://healthcarerealty.com/role/NotesAndBondsPayable Notes and Bonds Payable Notes 12 false false R13.htm 2105100 - Disclosure - Derivative Financial Instruments Sheet http://healthcarerealty.com/role/DerivativeFinancialInstruments Derivative Financial Instruments Notes 13 false false R14.htm 2106100 - Disclosure - Commitments and Contingencies Sheet http://healthcarerealty.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 14 false false R15.htm 2108100 - Disclosure - Stockholders' Equity Sheet http://healthcarerealty.com/role/StockholdersEquity Stockholders' Equity Notes 15 false false R16.htm 2109100 - Disclosure - Fair Value of Financial Instruments Sheet http://healthcarerealty.com/role/FairValueOfFinancialInstruments Fair Value of Financial Instruments Notes 16 false false R17.htm 2201201 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://healthcarerealty.com/role/SummaryOfSignificantAccountingPolicies 17 false false R18.htm 2301302 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://healthcarerealty.com/role/SummaryOfSignificantAccountingPolicies 18 false false R19.htm 2302301 - Disclosure - Real Estate Investments (Tables) Sheet http://healthcarerealty.com/role/RealEstateInvestmentsTables Real Estate Investments (Tables) Tables http://healthcarerealty.com/role/RealEstateInvestments 19 false false R20.htm 2303301 - Disclosure - Leases (Tables) Sheet http://healthcarerealty.com/role/LeasesTables Leases (Tables) Tables http://healthcarerealty.com/role/Leases 20 false false R21.htm 2304301 - Disclosure - Notes and Bonds Payable (Tables) Notes http://healthcarerealty.com/role/NotesAndBondsPayableTables Notes and Bonds Payable (Tables) Tables http://healthcarerealty.com/role/NotesAndBondsPayable 21 false false R22.htm 2305301 - Disclosure - Derivative Financial Instruments (Tables) Sheet http://healthcarerealty.com/role/DerivativeFinancialInstrumentsTables Derivative Financial Instruments (Tables) Tables http://healthcarerealty.com/role/DerivativeFinancialInstruments 22 false false R23.htm 2308301 - Disclosure - Stockholders' Equity (Tables) Sheet http://healthcarerealty.com/role/StockholdersEquityTables Stockholders' Equity (Tables) Tables http://healthcarerealty.com/role/StockholdersEquity 23 false false R24.htm 2309301 - Disclosure - Fair Value of Financial Instruments (Tables) Sheet http://healthcarerealty.com/role/FairValueOfFinancialInstrumentsTables Fair Value of Financial Instruments (Tables) Tables http://healthcarerealty.com/role/FairValueOfFinancialInstruments 24 false false R25.htm 2401403 - Disclosure - Summary of Significant Accounting Policies (Details) Sheet http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesDetails Summary of Significant Accounting Policies (Details) Details http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesTables 25 false false R26.htm 2401404 - Disclosure - Summary of Significant Accounting Policies - Revenue Recognition (Details) Sheet http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails Summary of Significant Accounting Policies - Revenue Recognition (Details) Details 26 false false R27.htm 2401405 - Disclosure - Summary of Significant Accounting Policies - Impact of Adoption of New Accounting Standard (Details) Sheet http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfNewAccountingStandardDetails Summary of Significant Accounting Policies - Impact of Adoption of New Accounting Standard (Details) Details 27 false false R28.htm 2402402 - Disclosure - Real Estate Investments - Acquisitions and dispositions (Details) Sheet http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsAndDispositionsDetails Real Estate Investments - Acquisitions and dispositions (Details) Details 28 false false R29.htm 2402404 - Disclosure - Real Estate Investments - Assets Held for Sale (Details) Sheet http://healthcarerealty.com/role/RealEstateInvestmentsAssetsHeldForSaleDetails Real Estate Investments - Assets Held for Sale (Details) Details 29 false false R30.htm 2402405 - Disclosure - Real Estate Investments - Discontinued Operations and Assets Held for Sale - Balance Sheet (Details) Sheet http://healthcarerealty.com/role/RealEstateInvestmentsDiscontinuedOperationsAndAssetsHeldForSaleBalanceSheetDetails Real Estate Investments - Discontinued Operations and Assets Held for Sale - Balance Sheet (Details) Details 30 false false R31.htm 2403402 - Disclosure - Leases - Lease Income (Details) Sheet http://healthcarerealty.com/role/LeasesLeaseIncomeDetails Leases - Lease Income (Details) Details 31 false false R32.htm 2403403 - Disclosure - Leases - Lessor Accounting (Details) Sheet http://healthcarerealty.com/role/LeasesLessorAccountingDetails Leases - Lessor Accounting (Details) Details 32 false false R33.htm 2403404 - Disclosure - Leases - Future Lease Payments Receivable under ASC 840 (Details) Sheet http://healthcarerealty.com/role/LeasesFutureLeasePaymentsReceivableUnderAsc840Details Leases - Future Lease Payments Receivable under ASC 840 (Details) Details 33 false false R34.htm 2403405 - Disclosure - Leases - Ground Leases (Details) Sheet http://healthcarerealty.com/role/LeasesGroundLeasesDetails Leases - Ground Leases (Details) Details 34 false false R35.htm 2403406 - Disclosure - Leases - Future Minimum Lease Payments (Details) Sheet http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails Leases - Future Minimum Lease Payments (Details) Details 35 false false R36.htm 2403407 - Disclosure - Leases - Lease Cost (Details) Sheet http://healthcarerealty.com/role/LeasesLeaseCostDetails Leases - Lease Cost (Details) Details 36 false false R37.htm 2403408 - Disclosure - Leases - Future Minimum Lease Payments under ASC 840 (Details) Sheet http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsUnderAsc840Details Leases - Future Minimum Lease Payments under ASC 840 (Details) Details 37 false false R38.htm 2404402 - Disclosure - Notes and Bonds Payable (Details) Notes http://healthcarerealty.com/role/NotesAndBondsPayableDetails Notes and Bonds Payable (Details) Details http://healthcarerealty.com/role/NotesAndBondsPayableTables 38 false false R39.htm 2405402 - Disclosure - Derivative Financial Instruments - Derivative Instruments Designated as Cash Flow Hedges (Details) Sheet http://healthcarerealty.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsDesignatedAsCashFlowHedgesDetails Derivative Financial Instruments - Derivative Instruments Designated as Cash Flow Hedges (Details) Details 39 false false R40.htm 2405403 - Disclosure - Derivative Financial Instruments - Fair Value of Derivative Instruments on the Balance Sheet (Details) Sheet http://healthcarerealty.com/role/DerivativeFinancialInstrumentsFairValueOfDerivativeInstrumentsOnBalanceSheetDetails Derivative Financial Instruments - Fair Value of Derivative Instruments on the Balance Sheet (Details) Details 40 false false R41.htm 2405404 - Disclosure - Derivative Financial Instruments - Effect of Cash Flow Hedging on AOCI (Details) Sheet http://healthcarerealty.com/role/DerivativeFinancialInstrumentsEffectOfCashFlowHedgingOnAociDetails Derivative Financial Instruments - Effect of Cash Flow Hedging on AOCI (Details) Details 41 false false R42.htm 2405405 - Disclosure - Derivative Financial Instruments - Additional Information (Details) Sheet http://healthcarerealty.com/role/DerivativeFinancialInstrumentsAdditionalInformationDetails Derivative Financial Instruments - Additional Information (Details) Details 42 false false R43.htm 2406401 - Disclosure - Commitments and Contingencies - Construction Activity (Details) Sheet http://healthcarerealty.com/role/CommitmentsAndContingenciesConstructionActivityDetails Commitments and Contingencies - Construction Activity (Details) Details 43 false false R44.htm 2408402 - Disclosure - Stockholders' Equity - Reconciliation of beginning and ending common stock outstanding (Details) Sheet http://healthcarerealty.com/role/StockholdersEquityReconciliationOfBeginningAndEndingCommonStockOutstandingDetails Stockholders' Equity - Reconciliation of beginning and ending common stock outstanding (Details) Details 44 false false R45.htm 2408403 - Disclosure - Stockholders' Equity (Stock Transactions - Narrative) (Details) Sheet http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails Stockholders' Equity (Stock Transactions - Narrative) (Details) Details http://healthcarerealty.com/role/StockholdersEquityTables 45 false false R46.htm 2408406 - Disclosure - Stockholders' Equity - Computation of basic and diluted earnings (loss) per common share (Details) Sheet http://healthcarerealty.com/role/StockholdersEquityComputationOfBasicAndDilutedEarningsLossPerCommonShareDetails Stockholders' Equity - Computation of basic and diluted earnings (loss) per common share (Details) Details 46 false false R47.htm 2408407 - Disclosure - Stockholders' Equity - Summary of activity under stock-based incentive plans (Details) Sheet http://healthcarerealty.com/role/StockholdersEquitySummaryOfActivityUnderStockBasedIncentivePlansDetails Stockholders' Equity - Summary of activity under stock-based incentive plans (Details) Details 47 false false R48.htm 2408408 - Disclosure - Stockholders' Equity - Summary of activity under Employee Stock Purchase Plan (Details) Sheet http://healthcarerealty.com/role/StockholdersEquitySummaryOfActivityUnderEmployeeStockPurchasePlanDetails Stockholders' Equity - Summary of activity under Employee Stock Purchase Plan (Details) Details 48 false false R49.htm 2409402 - Disclosure - Fair Value of Financial Instruments (Details) Sheet http://healthcarerealty.com/role/FairValueOfFinancialInstrumentsDetails Fair Value of Financial Instruments (Details) Details http://healthcarerealty.com/role/FairValueOfFinancialInstrumentsTables 49 false false All Reports Book All Reports hr-2019331xsinglesourc.htm hr-20190331.xsd hr-20190331_cal.xml hr-20190331_def.xml hr-20190331_lab.xml hr-20190331_pre.xml hr-2019331xex311.htm hr-2019331xex312.htm hr-2019331xex32.htm http://fasb.org/us-gaap/2018-01-31 http://xbrl.sec.gov/invest/2013-01-31 http://xbrl.sec.gov/stpr/2018-01-31 http://xbrl.sec.gov/dei/2018-01-31 http://fasb.org/srt/2018-01-31 true true JSON 66 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "hr-2019331xsinglesourc.htm": { "axisCustom": 2, "axisStandard": 20, "contextCount": 137, "dts": { "calculationLink": { "local": [ "hr-20190331_cal.xml" ] }, "definitionLink": { "local": [ "hr-20190331_def.xml" ], "remote": [ "http://xbrl.fasb.org/srt/2018/elts/srt-eedm1-def-2018-01-31.xml", "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-eedm-def-2018-01-31.xml" ] }, "inline": { "local": [ "hr-2019331xsinglesourc.htm" ] }, "labelLink": { "local": [ "hr-20190331_lab.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-doc-2018-01-31.xml", "http://xbrl.sec.gov/invest/2013/invest-doc-2013-01-31.xml", "https://xbrl.sec.gov/dei/2018/dei-doc-2018-01-31.xml" ] }, "presentationLink": { "local": [ "hr-20190331_pre.xml" ] }, "referenceLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-ref-2018-01-31.xml", "http://xbrl.sec.gov/invest/2013/invest-ref-2013-01-31.xml", "https://xbrl.sec.gov/dei/2018/dei-ref-2018-01-31.xml" ] }, "schema": { "local": [ "hr-20190331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd", "http://xbrl.fasb.org/srt/2018/elts/srt-roles-2018-01-31.xsd", "http://xbrl.fasb.org/srt/2018/elts/srt-types-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2018/elts/us-parts-codification-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2018/elts/us-roles-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2018/elts/us-types-2018-01-31.xsd", "http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd", "http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd", "http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd", "https://xbrl.sec.gov/exch/2018/exch-2018-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" ] } }, "elementCount": 418, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2018-01-31": 18, "http://healthcarerealty.com/20190331": 3, "http://xbrl.sec.gov/dei/2018-01-31": 9, "total": 30 }, "keyCustom": 37, "keyStandard": 217, "memberCustom": 22, "memberStandard": 31, "nsprefix": "hr", "nsuri": "http://healthcarerealty.com/20190331", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hr-2019331xsinglesourc.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001000 - Document - Document and Entity Information", "role": "http://healthcarerealty.com/role/DocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hr-2019331xsinglesourc.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hr-2019331xsinglesourc.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "hr:AcquisitionsAndDispositionsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2102100 - Disclosure - Real Estate Investments", "role": "http://healthcarerealty.com/role/RealEstateInvestments", "shortName": "Real Estate Investments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hr-2019331xsinglesourc.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "hr:AcquisitionsAndDispositionsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hr-2019331xsinglesourc.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "hr:OperatingandFinanceLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2103100 - Disclosure - Leases", "role": "http://healthcarerealty.com/role/Leases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hr-2019331xsinglesourc.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "hr:OperatingandFinanceLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hr-2019331xsinglesourc.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2104100 - Disclosure - Notes and Bonds Payable", "role": "http://healthcarerealty.com/role/NotesAndBondsPayable", "shortName": "Notes and Bonds Payable", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hr-2019331xsinglesourc.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hr-2019331xsinglesourc.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2105100 - Disclosure - Derivative Financial Instruments", "role": "http://healthcarerealty.com/role/DerivativeFinancialInstruments", "shortName": "Derivative Financial Instruments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hr-2019331xsinglesourc.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hr-2019331xsinglesourc.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2106100 - Disclosure - Commitments and Contingencies", "role": "http://healthcarerealty.com/role/CommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hr-2019331xsinglesourc.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hr-2019331xsinglesourc.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2108100 - Disclosure - Stockholders' Equity", "role": "http://healthcarerealty.com/role/StockholdersEquity", "shortName": "Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hr-2019331xsinglesourc.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hr-2019331xsinglesourc.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2109100 - Disclosure - Fair Value of Financial Instruments", "role": "http://healthcarerealty.com/role/FairValueOfFinancialInstruments", "shortName": "Fair Value of Financial Instruments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hr-2019331xsinglesourc.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hr-2019331xsinglesourc.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "hr:NatureOfOperationsPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2201201 - Disclosure - Summary of Significant Accounting Policies (Policies)", "role": "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hr-2019331xsinglesourc.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "hr:NatureOfOperationsPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "hr-2019331xsinglesourc.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2301302 - Disclosure - Summary of Significant Accounting Policies (Tables)", "role": "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesTables", "shortName": "Summary of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "hr-2019331xsinglesourc.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hr-2019331xsinglesourc.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2302301 - Disclosure - Real Estate Investments (Tables)", "role": "http://healthcarerealty.com/role/RealEstateInvestmentsTables", "shortName": "Real Estate Investments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hr-2019331xsinglesourc.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "hr-2019331xsinglesourc.htm", "contextRef": "FI2019Q1", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Land", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001000 - Statement - Condensed Consolidated Balance Sheets (Unaudited)", "role": "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "shortName": "Condensed Consolidated Balance Sheets (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "hr-2019331xsinglesourc.htm", "contextRef": "FI2019Q1", "decimals": "-3", "lang": null, "name": "hr:PersonalProperty", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hr-2019331xsinglesourc.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2303301 - Disclosure - Leases (Tables)", "role": "http://healthcarerealty.com/role/LeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hr-2019331xsinglesourc.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hr-2019331xsinglesourc.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2304301 - Disclosure - Notes and Bonds Payable (Tables)", "role": "http://healthcarerealty.com/role/NotesAndBondsPayableTables", "shortName": "Notes and Bonds Payable (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hr-2019331xsinglesourc.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hr-2019331xsinglesourc.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2305301 - Disclosure - Derivative Financial Instruments (Tables)", "role": "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsTables", "shortName": "Derivative Financial Instruments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hr-2019331xsinglesourc.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hr-2019331xsinglesourc.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "hr:ReconciliationOfBeginningAndEndingCommonStockOutstandingTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2308301 - Disclosure - Stockholders' Equity (Tables)", "role": "http://healthcarerealty.com/role/StockholdersEquityTables", "shortName": "Stockholders' Equity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hr-2019331xsinglesourc.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "hr:ReconciliationOfBeginningAndEndingCommonStockOutstandingTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hr-2019331xsinglesourc.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueByBalanceSheetGroupingTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2309301 - Disclosure - Fair Value of Financial Instruments (Tables)", "role": "http://healthcarerealty.com/role/FairValueOfFinancialInstrumentsTables", "shortName": "Fair Value of Financial Instruments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hr-2019331xsinglesourc.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueByBalanceSheetGroupingTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "span", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "hr-2019331xsinglesourc.htm", "contextRef": "FI2019Q1", "decimals": "-8", "first": true, "lang": null, "name": "hr:InvestmentInRealEstatePropertiesAndMortgageNotes", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2401403 - Disclosure - Summary of Significant Accounting Policies (Details)", "role": "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesDetails", "shortName": "Summary of Significant Accounting Policies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "hr-2019331xsinglesourc.htm", "contextRef": "FI2019Q1", "decimals": "-8", "first": true, "lang": null, "name": "hr:InvestmentInRealEstatePropertiesAndMortgageNotes", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "hr-2019331xsinglesourc.htm", "contextRef": "FD2019Q1YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2401404 - Disclosure - Summary of Significant Accounting Policies - Revenue Recognition (Details)", "role": "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails", "shortName": "Summary of Significant Accounting Policies - Revenue Recognition (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "hr-2019331xsinglesourc.htm", "contextRef": "FD2019Q1QTD_srt_ProductOrServiceAxis_hr_ParkingIncomeMember", "decimals": "-3", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "hr-2019331xsinglesourc.htm", "contextRef": "FI2019Q1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2401405 - Disclosure - Summary of Significant Accounting Policies - Impact of Adoption of New Accounting Standard (Details)", "role": "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfNewAccountingStandardDetails", "shortName": "Summary of Significant Accounting Policies - Impact of Adoption of New Accounting Standard (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "hr-2019331xsinglesourc.htm", "contextRef": "FI2018Q4_srt_RangeAxis_srt_MinimumMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member", "decimals": "3", "lang": null, "name": "us-gaap:LesseeOperatingLeaseDiscountRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "hr-2019331xsinglesourc.htm", "contextRef": "FI2019Q1", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FinanceLeaseLiability", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402402 - Disclosure - Real Estate Investments - Acquisitions and dispositions (Details)", "role": "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsAndDispositionsDetails", "shortName": "Real Estate Investments - Acquisitions and dispositions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "hr-2019331xsinglesourc.htm", "contextRef": "FD2019Q1YTD_hr_RealEstateAcquisitionsAndMortgageNoteFinancingAxis_hr_RealEstateAcquisitionsMember", "decimals": "-5", "lang": null, "name": "us-gaap:BusinessCombinationConsiderationTransferred1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hr-2019331xsinglesourc.htm", "contextRef": "FI2019Q1", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:RealEstateHeldforsale", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402404 - Disclosure - Real Estate Investments - Assets Held for Sale (Details)", "role": "http://healthcarerealty.com/role/RealEstateInvestmentsAssetsHeldForSaleDetails", "shortName": "Real Estate Investments - Assets Held for Sale (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hr-2019331xsinglesourc.htm", "contextRef": "FI2019Q1", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:RealEstateHeldforsale", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R3": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "1001501 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "role": "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R30": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "hr-2019331xsinglesourc.htm", "contextRef": "FI2019Q1", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Land", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402405 - Disclosure - Real Estate Investments - Discontinued Operations and Assets Held for Sale - Balance Sheet (Details)", "role": "http://healthcarerealty.com/role/RealEstateInvestmentsDiscontinuedOperationsAndAssetsHeldForSaleBalanceSheetDetails", "shortName": "Real Estate Investments - Discontinued Operations and Assets Held for Sale - Balance Sheet (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "hr-2019331xsinglesourc.htm", "contextRef": "FI2019Q1_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_hr_InpatientRehabMember", "decimals": "-3", "lang": null, "name": "us-gaap:Land", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "hr-2019331xsinglesourc.htm", "contextRef": "FD2019Q1YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasesIncomeStatementLeaseRevenue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403402 - Disclosure - Leases - Lease Income (Details)", "role": "http://healthcarerealty.com/role/LeasesLeaseIncomeDetails", "shortName": "Leases - Lease Income (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R32": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "hr-2019331xsinglesourc.htm", "contextRef": "FI2019Q1", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403403 - Disclosure - Leases - Lessor Accounting (Details)", "role": "http://healthcarerealty.com/role/LeasesLessorAccountingDetails", "shortName": "Leases - Lessor Accounting (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "hr-2019331xsinglesourc.htm", "contextRef": "FI2019Q1", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "hr-2019331xsinglesourc.htm", "contextRef": "FI2018Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403404 - Disclosure - Leases - Future Lease Payments Receivable under ASC 840 (Details)", "role": "http://healthcarerealty.com/role/LeasesFutureLeasePaymentsReceivableUnderAsc840Details", "shortName": "Leases - Future Lease Payments Receivable under ASC 840 (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "hr-2019331xsinglesourc.htm", "contextRef": "FI2018Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hr-2019331xsinglesourc.htm", "contextRef": "FI2019Q1", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfPropertiesSubjectToGroundLeases", "reportCount": 1, "unique": true, "unitRef": "property", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403405 - Disclosure - Leases - Ground Leases (Details)", "role": "http://healthcarerealty.com/role/LeasesGroundLeasesDetails", "shortName": "Leases - Ground Leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hr-2019331xsinglesourc.htm", "contextRef": "FI2019Q1", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfPropertiesSubjectToGroundLeases", "reportCount": 1, "unique": true, "unitRef": "property", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "hr-2019331xsinglesourc.htm", "contextRef": "FI2019Q1", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403406 - Disclosure - Leases - Future Minimum Lease Payments (Details)", "role": "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails", "shortName": "Leases - Future Minimum Lease Payments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "hr-2019331xsinglesourc.htm", "contextRef": "FI2019Q1", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "hr-2019331xsinglesourc.htm", "contextRef": "FD2019Q1YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403407 - Disclosure - Leases - Lease Cost (Details)", "role": "http://healthcarerealty.com/role/LeasesLeaseCostDetails", "shortName": "Leases - Lease Cost (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "hr-2019331xsinglesourc.htm", "contextRef": "FD2019Q1YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "hr-2019331xsinglesourc.htm", "contextRef": "FI2018Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403408 - Disclosure - Leases - Future Minimum Lease Payments under ASC 840 (Details)", "role": "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsUnderAsc840Details", "shortName": "Leases - Future Minimum Lease Payments under ASC 840 (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "hr-2019331xsinglesourc.htm", "contextRef": "FI2018Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "hr-2019331xsinglesourc.htm", "contextRef": "FI2019Q1", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LongTermDebt", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2404402 - Disclosure - Notes and Bonds Payable (Details)", "role": "http://healthcarerealty.com/role/NotesAndBondsPayableDetails", "shortName": "Notes and Bonds Payable (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "hr-2019331xsinglesourc.htm", "contextRef": "FI2019Q1_us-gaap_DebtInstrumentAxis_hr_UnsecuredCreditFacilityDue2020Member_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember", "decimals": "-3", "lang": null, "name": "us-gaap:LongTermDebt", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "span", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "hr-2019331xsinglesourc.htm", "contextRef": "FI2019Q1_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfInterestRateDerivativesHeld", "reportCount": 1, "unique": true, "unitRef": "swap_agreement", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2405402 - Disclosure - Derivative Financial Instruments - Derivative Instruments Designated as Cash Flow Hedges (Details)", "role": "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsDesignatedAsCashFlowHedgesDetails", "shortName": "Derivative Financial Instruments - Derivative Instruments Designated as Cash Flow Hedges (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "hr-2019331xsinglesourc.htm", "contextRef": "FI2019Q1_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfInterestRateDerivativesHeld", "reportCount": 1, "unique": true, "unitRef": "swap_agreement", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "hr-2019331xsinglesourc.htm", "contextRef": "FD2019Q1YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasesIncomeStatementLeaseRevenue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002000 - Statement - Condensed Consolidated Statements of Income (Unaudited)", "role": "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited", "shortName": "Condensed Consolidated Statements of Income (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "hr-2019331xsinglesourc.htm", "contextRef": "FD2019Q1YTD", "decimals": "-3", "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "hr-2019331xsinglesourc.htm", "contextRef": "FI2019Q1_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DerivativeFairValueOfDerivativeLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2405403 - Disclosure - Derivative Financial Instruments - Fair Value of Derivative Instruments on the Balance Sheet (Details)", "role": "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsFairValueOfDerivativeInstrumentsOnBalanceSheetDetails", "shortName": "Derivative Financial Instruments - Fair Value of Derivative Instruments on the Balance Sheet (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "hr-2019331xsinglesourc.htm", "contextRef": "FI2019Q1_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DerivativeFairValueOfDerivativeLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "hr-2019331xsinglesourc.htm", "contextRef": "FD2019Q1YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2405404 - Disclosure - Derivative Financial Instruments - Effect of Cash Flow Hedging on AOCI (Details)", "role": "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsEffectOfCashFlowHedgingOnAociDetails", "shortName": "Derivative Financial Instruments - Effect of Cash Flow Hedging on AOCI (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "hr-2019331xsinglesourc.htm", "contextRef": "FD2019Q1YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hr-2019331xsinglesourc.htm", "contextRef": "FI2019Q1_us-gaap_DerivativeInstrumentRiskAxis_hr_ActiveInterestRateSwapsMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2405405 - Disclosure - Derivative Financial Instruments - Additional Information (Details)", "role": "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsAdditionalInformationDetails", "shortName": "Derivative Financial Instruments - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hr-2019331xsinglesourc.htm", "contextRef": "FI2019Q1_us-gaap_DerivativeInstrumentRiskAxis_hr_ActiveInterestRateSwapsMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "span", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "hr-2019331xsinglesourc.htm", "contextRef": "FI2019Q1", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AreaOfRealEstateProperty", "reportCount": 1, "unitRef": "sqft", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406401 - Disclosure - Commitments and Contingencies - Construction Activity (Details)", "role": "http://healthcarerealty.com/role/CommitmentsAndContingenciesConstructionActivityDetails", "shortName": "Commitments and Contingencies - Construction Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hr-2019331xsinglesourc.htm", "contextRef": "FI2019Q1_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis_hr_MedicalOfficeBuildingExpansionMember_srt_StatementGeographicalAxis_stpr_NC", "decimals": "0", "lang": null, "name": "us-gaap:AreaOfRealEstateProperty", "reportCount": 1, "unique": true, "unitRef": "sqft", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "hr-2019331xsinglesourc.htm", "contextRef": "FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408402 - Disclosure - Stockholders' Equity - Reconciliation of beginning and ending common stock outstanding (Details)", "role": "http://healthcarerealty.com/role/StockholdersEquityReconciliationOfBeginningAndEndingCommonStockOutstandingDetails", "shortName": "Stockholders' Equity - Reconciliation of beginning and ending common stock outstanding (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "hr-2019331xsinglesourc.htm", "contextRef": "FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "hr-2019331xsinglesourc.htm", "contextRef": "FD2019Q1YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProceedsFromIssuanceOfCommonStock", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408403 - Disclosure - Stockholders' Equity (Stock Transactions - Narrative) (Details)", "role": "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails", "shortName": "Stockholders' Equity (Stock Transactions - Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hr-2019331xsinglesourc.htm", "contextRef": "FD2019Q1YTD_hr_StockIssuanceProgramAxis_hr_AtTheMarketEquityOfferingProgramMember", "decimals": "INF", "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "hr-2019331xsinglesourc.htm", "contextRef": "FD2019Q1YTD", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:WeightedAverageNumberOfSharesIssuedBasic", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408406 - Disclosure - Stockholders' Equity - Computation of basic and diluted earnings (loss) per common share (Details)", "role": "http://healthcarerealty.com/role/StockholdersEquityComputationOfBasicAndDilutedEarningsLossPerCommonShareDetails", "shortName": "Stockholders' Equity - Computation of basic and diluted earnings (loss) per common share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "hr-2019331xsinglesourc.htm", "contextRef": "FD2019Q1YTD", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:WeightedAverageNumberOfSharesIssuedBasic", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "hr-2019331xsinglesourc.htm", "contextRef": "FI2018Q4_us-gaap_PlanNameAxis_hr_StockIncentivePlanMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408407 - Disclosure - Stockholders' Equity - Summary of activity under stock-based incentive plans (Details)", "role": "http://healthcarerealty.com/role/StockholdersEquitySummaryOfActivityUnderStockBasedIncentivePlansDetails", "shortName": "Stockholders' Equity - Summary of activity under stock-based incentive plans (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "hr-2019331xsinglesourc.htm", "contextRef": "FI2018Q4_us-gaap_PlanNameAxis_hr_StockIncentivePlanMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "hr-2019331xsinglesourc.htm", "contextRef": "FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408408 - Disclosure - Stockholders' Equity - Summary of activity under Employee Stock Purchase Plan (Details)", "role": "http://healthcarerealty.com/role/StockholdersEquitySummaryOfActivityUnderEmployeeStockPurchasePlanDetails", "shortName": "Stockholders' Equity - Summary of activity under Employee Stock Purchase Plan (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "hr-2019331xsinglesourc.htm", "contextRef": "FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "hr-2019331xsinglesourc.htm", "contextRef": "FI2019Q1_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409402 - Disclosure - Fair Value of Financial Instruments (Details)", "role": "http://healthcarerealty.com/role/FairValueOfFinancialInstrumentsDetails", "shortName": "Fair Value of Financial Instruments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "hr-2019331xsinglesourc.htm", "contextRef": "FI2019Q1_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "hr-2019331xsinglesourc.htm", "contextRef": "FD2019Q1YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003000 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited)", "role": "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited", "shortName": "Condensed Consolidated Statements of Comprehensive Income (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "hr-2019331xsinglesourc.htm", "contextRef": "FD2019Q1YTD", "decimals": "-3", "lang": null, "name": "us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "hr-2019331xsinglesourc.htm", "contextRef": "FI2017Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004000 - Statement - Condensed Consolidated Statement of Equity (Unaudited) Statement", "role": "http://healthcarerealty.com/role/CondensedConsolidatedStatementOfEquityUnauditedStatement", "shortName": "Condensed Consolidated Statement of Equity (Unaudited) Statement", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "hr-2019331xsinglesourc.htm", "contextRef": "FI2017Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "1004001 - Statement - Condensed Consolidated Statement of Equity (Unaudited) (Parenthetical)", "role": "http://healthcarerealty.com/role/CondensedConsolidatedStatementOfEquityUnauditedParenthetical", "shortName": "Condensed Consolidated Statement of Equity (Unaudited) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R8": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "hr-2019331xsinglesourc.htm", "contextRef": "FD2019Q1YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005000 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)", "role": "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "hr-2019331xsinglesourc.htm", "contextRef": "FD2019Q1YTD", "decimals": "-3", "lang": null, "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "hr:NatureOfOperationsPolicyTextBlock", "span", "div", "body", "html" ], "baseRef": "hr-2019331xsinglesourc.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101100 - Disclosure - Summary of Significant Accounting Policies", "role": "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "hr:NatureOfOperationsPolicyTextBlock", "span", "div", "body", "html" ], "baseRef": "hr-2019331xsinglesourc.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 53, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "If the value is true, then the document is an amendment to previously-filed/accepted document.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/DocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/DocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/DocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/DocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/DocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r282" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/DocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/DocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r282" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r282" ], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated), (5) Smaller Reporting Accelerated Filer or (6) Smaller Reporting Company and Large Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/DocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r282" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r282" ], "lang": { "en-US": { "role": { "documentation": "Indicates that the company is a smaller reporting company with both a public float and revenues of less than $75 million.", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "hr_AcquisitionsAndDispositionsTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Acquisitions and dispositions.", "label": "Acquisitions and Dispositions [Text Block]", "verboseLabel": "Real Estate Investments" } } }, "localname": "AcquisitionsAndDispositionsTextBlock", "nsuri": "http://healthcarerealty.com/20190331", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestments" ], "xbrltype": "textBlockItemType" }, "hr_ActiveInterestRateSwapsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Active Interest Rate Swaps [Member]", "label": "Active Interest Rate Swaps [Member]", "terseLabel": "Active Interest Rate Swap" } } }, "localname": "ActiveInterestRateSwapsMember", "nsuri": "http://healthcarerealty.com/20190331", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "hr_AmortizationofPrepaidRent": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amortization of Prepaid Rent", "label": "Amortization of Prepaid Rent", "terseLabel": "Amortization of prepaid rent" } } }, "localname": "AmortizationofPrepaidRent", "nsuri": "http://healthcarerealty.com/20190331", "presentation": [ "http://healthcarerealty.com/role/LeasesGroundLeasesDetails" ], "xbrltype": "monetaryItemType" }, "hr_ApproximateSquareFeetProvidedByCompany": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Approximate square feet for which Nationwide property management services provided by company", "label": "Approximate Square Feet Provided by Company", "verboseLabel": "Approximate square feet for which Nationwide property management services provided by company" } } }, "localname": "ApproximateSquareFeetProvidedByCompany", "nsuri": "http://healthcarerealty.com/20190331", "presentation": [ "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "areaItemType" }, "hr_AssetsAndLiabilitiesRelatedToHeldForSaleAndDiscontinuedOperationsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Assets and liabilities related to held for sale and discontinued operations.", "label": "Assets and Liabilities Related to Held for Sale and Discontinued Operations [Abstract]", "verboseLabel": "Asset Dispositions and Potential Dispositions" } } }, "localname": "AssetsAndLiabilitiesRelatedToHeldForSaleAndDiscontinuedOperationsAbstract", "nsuri": "http://healthcarerealty.com/20190331", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsDiscontinuedOperationsAndAssetsHeldForSaleBalanceSheetDetails" ], "xbrltype": "stringItemType" }, "hr_AssetsHeldForSaleAndDiscontinuedOperationsNet": { "auth_ref": [], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Assets held for sale and discontinued operations, net.", "label": "Assets Held-for-sale and Discontinued Operations Net", "verboseLabel": "Assets held for sale, net" } } }, "localname": "AssetsHeldForSaleAndDiscontinuedOperationsNet", "nsuri": "http://healthcarerealty.com/20190331", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "hr_AtTheMarketEquityOfferingProgramMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "At The Market Equity Offering Program [Member]", "label": "At The Market Equity Offering Program [Member]", "terseLabel": "At The Market Equity Offering Program" } } }, "localname": "AtTheMarketEquityOfferingProgramMember", "nsuri": "http://healthcarerealty.com/20190331", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "hr_BusinessAcquisitionPurchasePriceAllocationSquareFootage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Business Acquisition Purchase Price Allocation Square Footage.", "label": "Business Acquisition Purchase Price Allocation Square Footage", "verboseLabel": "Square footage" } } }, "localname": "BusinessAcquisitionPurchasePriceAllocationSquareFootage", "nsuri": "http://healthcarerealty.com/20190331", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsAndDispositionsDetails" ], "xbrltype": "areaItemType" }, "hr_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRealProperty": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Real Property", "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Real Property", "terseLabel": "Real Estate" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRealProperty", "nsuri": "http://healthcarerealty.com/20190331", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsAndDispositionsDetails" ], "xbrltype": "monetaryItemType" }, "hr_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedIntangibleAssetsFairValueAdjustmentsandOther": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Fair Value Adjustments and Other", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Fair Value Adjustments and Other", "terseLabel": "Other" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedIntangibleAssetsFairValueAdjustmentsandOther", "nsuri": "http://healthcarerealty.com/20190331", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsAndDispositionsDetails" ], "xbrltype": "monetaryItemType" }, "hr_BusinessOverviewAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Business Overview [Abstract]", "label": "Business Overview [Abstract]", "terseLabel": "Business Overview:" } } }, "localname": "BusinessOverviewAbstract", "nsuri": "http://healthcarerealty.com/20190331", "presentation": [ "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "hr_ConstructionActivityTotalAmountFunded": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Construction Activity, Total Amount Funded", "label": "Construction Activity, Total Amount Funded", "terseLabel": "Total amount funded" } } }, "localname": "ConstructionActivityTotalAmountFunded", "nsuri": "http://healthcarerealty.com/20190331", "presentation": [ "http://healthcarerealty.com/role/CommitmentsAndContingenciesConstructionActivityDetails" ], "xbrltype": "monetaryItemType" }, "hr_CumulativeDividendsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cumulative Dividends [Member].", "label": "Cumulative Dividends [Member]", "terseLabel": "Cumulative Dividends" } } }, "localname": "CumulativeDividendsMember", "nsuri": "http://healthcarerealty.com/20190331", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementOfEquityUnauditedStatement" ], "xbrltype": "domainItemType" }, "hr_CumulativeNetIncomeAttributableToCommonStockholders": { "auth_ref": [], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Cumulative net income attributable to common stockholders.", "label": "Cumulative Net Income Attributable to Common Stockholders", "verboseLabel": "Cumulative net income attributable to common stockholders" } } }, "localname": "CumulativeNetIncomeAttributableToCommonStockholders", "nsuri": "http://healthcarerealty.com/20190331", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "hr_CumulativeNetIncomeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cumulative Net Income [Member].", "label": "Cumulative Net Income [Member]", "terseLabel": "Cumulative Net Income" } } }, "localname": "CumulativeNetIncomeMember", "nsuri": "http://healthcarerealty.com/20190331", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementOfEquityUnauditedStatement" ], "xbrltype": "domainItemType" }, "hr_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilities": { "auth_ref": [], "calculation": { "http://healthcarerealty.com/role/RealEstateInvestmentsDiscontinuedOperationsAndAssetsHeldForSaleBalanceSheetDetails": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Disposal Group, Including Discontinued Operation, Operating Lease Liabilities", "label": "Disposal Group, Including Discontinued Operation, Operating Lease Liabilities", "terseLabel": "Operating lease liabilities" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilities", "nsuri": "http://healthcarerealty.com/20190331", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsDiscontinuedOperationsAndAssetsHeldForSaleBalanceSheetDetails" ], "xbrltype": "monetaryItemType" }, "hr_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightofUseAssets": { "auth_ref": [], "calculation": { "http://healthcarerealty.com/role/RealEstateInvestmentsDiscontinuedOperationsAndAssetsHeldForSaleBalanceSheetDetails": { "order": 3.0, "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Disposal Group, Including Discontinued Operation, Operating Lease, Right-of-Use Assets", "label": "Disposal Group, Including Discontinued Operation, Operating Lease, Right-of-Use Assets", "terseLabel": "Operating lease right-of-use assets" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightofUseAssets", "nsuri": "http://healthcarerealty.com/20190331", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsDiscontinuedOperationsAndAssetsHeldForSaleBalanceSheetDetails" ], "xbrltype": "monetaryItemType" }, "hr_DispositionSalesPrice": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Disposition Sales Price", "label": "Disposition Sales Price", "terseLabel": "Sales price" } } }, "localname": "DispositionSalesPrice", "nsuri": "http://healthcarerealty.com/20190331", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsAndDispositionsDetails" ], "xbrltype": "monetaryItemType" }, "hr_DocumentAndEntityInformationAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Document and Entity Information.", "label": "Document and Entity Information [Abstract]" } } }, "localname": "DocumentAndEntityInformationAbstract", "nsuri": "http://healthcarerealty.com/20190331", "xbrltype": "stringItemType" }, "hr_EquityOfferingMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Equity Offering [Member]", "label": "Equity Offering [Member]", "terseLabel": "Equity Offering" } } }, "localname": "EquityOfferingMember", "nsuri": "http://healthcarerealty.com/20190331", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "hr_FutureMinimumLeasePaymentsReceivableunderASC840TableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Future Minimum Lease Payments Receivable under ASC 840 [Table Text Block]", "label": "Future Minimum Lease Payments Receivable under ASC 840 [Table Text Block]", "terseLabel": "Future Minimum Lease Payments Receivable under ASC 840" } } }, "localname": "FutureMinimumLeasePaymentsReceivableunderASC840TableTextBlock", "nsuri": "http://healthcarerealty.com/20190331", "presentation": [ "http://healthcarerealty.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "hr_GainsLossesonSalesofInvestmentRealEstateIncludingDiscontinuedOperation": { "auth_ref": [], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Gains (Losses) on Sales of Investment Real Estate, Including Discontinued Operation", "label": "Gains (Losses) on Sales of Investment Real Estate, Including Discontinued Operation", "negatedLabel": "Gain on sales of real estate assets" } } }, "localname": "GainsLossesonSalesofInvestmentRealEstateIncludingDiscontinuedOperation", "nsuri": "http://healthcarerealty.com/20190331", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "hr_IncrementalCommonSharesAttributableToDilutiveEffectOfEmployeeStockPurchasePlan": { "auth_ref": [], "calculation": { "http://healthcarerealty.com/role/StockholdersEquityComputationOfBasicAndDilutedEarningsLossPerCommonShareDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Incremental common shares attributable to dilutive effect of employee stock purchase plan.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Employee Stock Purchase Plan", "verboseLabel": "Dilutive effect of employee stock purchase plan" } } }, "localname": "IncrementalCommonSharesAttributableToDilutiveEffectOfEmployeeStockPurchasePlan", "nsuri": "http://healthcarerealty.com/20190331", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityComputationOfBasicAndDilutedEarningsLossPerCommonShareDetails" ], "xbrltype": "sharesItemType" }, "hr_InpatientRehabMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Inpatient rehab.", "label": "Inpatient Rehab [Member]", "terseLabel": "Inpatient Rehabilitation Facility" } } }, "localname": "InpatientRehabMember", "nsuri": "http://healthcarerealty.com/20190331", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsDiscontinuedOperationsAndAssetsHeldForSaleBalanceSheetDetails" ], "xbrltype": "domainItemType" }, "hr_InvestmentInRealEstatePropertiesAndMortgageNotes": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Investment in real estate properties and mortgage notes.", "label": "Investment in Real Estate Properties and Mortgage Notes", "terseLabel": "Gross investment amount, total" } } }, "localname": "InvestmentInRealEstatePropertiesAndMortgageNotes", "nsuri": "http://healthcarerealty.com/20190331", "presentation": [ "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "hr_LesseeOperatingLeaseTermofContractIncludingRenewals": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Lessee, Operating Lease, Term of Contract, Including Renewals", "label": "Lessee, Operating Lease, Term of Contract, Including Renewals", "terseLabel": "Term of lease, including renewals" } } }, "localname": "LesseeOperatingLeaseTermofContractIncludingRenewals", "nsuri": "http://healthcarerealty.com/20190331", "presentation": [ "http://healthcarerealty.com/role/LeasesGroundLeasesDetails" ], "xbrltype": "durationItemType" }, "hr_ManagementFeeIncomeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Management Fee Income [Member]", "label": "Management Fee Income [Member]", "terseLabel": "Management Fee Income" } } }, "localname": "ManagementFeeIncomeMember", "nsuri": "http://healthcarerealty.com/20190331", "presentation": [ "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "hr_MedicalOfficeBuildingExpansionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Medical Office Building Expansion [Member]", "label": "Medical Office Building Expansion [Member]", "terseLabel": "Medical Office Building Expansion" } } }, "localname": "MedicalOfficeBuildingExpansionMember", "nsuri": "http://healthcarerealty.com/20190331", "presentation": [ "http://healthcarerealty.com/role/CommitmentsAndContingenciesConstructionActivityDetails" ], "xbrltype": "domainItemType" }, "hr_MedicalOfficeBuildingMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Medical Office Building [Member]", "label": "Medical Office Building [Member]", "terseLabel": "Medical Office Building" } } }, "localname": "MedicalOfficeBuildingMember", "nsuri": "http://healthcarerealty.com/20190331", "presentation": [ "http://healthcarerealty.com/role/CommitmentsAndContingenciesConstructionActivityDetails", "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsAndDispositionsDetails" ], "xbrltype": "domainItemType" }, "hr_MiscellaneousMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Miscellaneous [Member]", "label": "Miscellaneous [Member]", "terseLabel": "Miscellaneous" } } }, "localname": "MiscellaneousMember", "nsuri": "http://healthcarerealty.com/20190331", "presentation": [ "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "hr_MortgageNotesPayableNetMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Mortgage Notes Payable, Net [Member]", "label": "Mortgage Notes Payable, Net [Member]", "terseLabel": "Mortgage notes payable, net of discounts and issuance costs and including premiums" } } }, "localname": "MortgageNotesPayableNetMember", "nsuri": "http://healthcarerealty.com/20190331", "presentation": [ "http://healthcarerealty.com/role/NotesAndBondsPayableDetails" ], "xbrltype": "domainItemType" }, "hr_NatureOfOperationsPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Nature Of Operations Policy.", "label": "Nature of Operations [Policy Text Block]", "terseLabel": "Business Overview" } } }, "localname": "NatureOfOperationsPolicyTextBlock", "nsuri": "http://healthcarerealty.com/20190331", "presentation": [ "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "hr_NetIncomeLossfromContinuingOperationsAvailabletoCommonStockholdersBasic": { "auth_ref": [], "calculation": { "http://healthcarerealty.com/role/StockholdersEquityComputationOfBasicAndDilutedEarningsLossPerCommonShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Net Income (Loss) from Continuing Operations Available to Common Stockholders, Basic", "label": "Net Income (Loss) from Continuing Operations Available to Common Stockholders, Basic", "totalLabel": "Net income applicable to common stockholders" } } }, "localname": "NetIncomeLossfromContinuingOperationsAvailabletoCommonStockholdersBasic", "nsuri": "http://healthcarerealty.com/20190331", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityComputationOfBasicAndDilutedEarningsLossPerCommonShareDetails" ], "xbrltype": "monetaryItemType" }, "hr_NumberOfPropertiesHeldForSale": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of properties held for sale.", "label": "Number of Properties Held for Sale", "terseLabel": "Number of properties held for sale" } } }, "localname": "NumberOfPropertiesHeldForSale", "nsuri": "http://healthcarerealty.com/20190331", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAssetsHeldForSaleDetails" ], "xbrltype": "integerItemType" }, "hr_NumberOfRealEstateInvestments": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of real estate investments.", "label": "Number of Real Estate Investments", "terseLabel": "Number of real estate properties" } } }, "localname": "NumberOfRealEstateInvestments", "nsuri": "http://healthcarerealty.com/20190331", "presentation": [ "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "integerItemType" }, "hr_NumberofAuthorizedSharesRemainingUnderOfferingProgram": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of Authorized Shares Remaining Under Offering Program", "label": "Number of Authorized Shares Remaining Under Offering Program", "terseLabel": "Number of authorized shares remaining under offering program (shares)" } } }, "localname": "NumberofAuthorizedSharesRemainingUnderOfferingProgram", "nsuri": "http://healthcarerealty.com/20190331", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "xbrltype": "sharesItemType" }, "hr_NumberofGroundLeasesExcludingPrepaidLeases": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of Ground Leases, Excluding Prepaid Leases", "label": "Number of Ground Leases, Excluding Prepaid Leases", "terseLabel": "Number of non-prepaid ground leases" } } }, "localname": "NumberofGroundLeasesExcludingPrepaidLeases", "nsuri": "http://healthcarerealty.com/20190331", "presentation": [ "http://healthcarerealty.com/role/LeasesGroundLeasesDetails" ], "xbrltype": "integerItemType" }, "hr_NumberofGroundLeasesPrepaid": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of Ground Leases Prepaid", "label": "Number of Ground Leases Prepaid", "terseLabel": "Number of prepaid ground leases" } } }, "localname": "NumberofGroundLeasesPrepaid", "nsuri": "http://healthcarerealty.com/20190331", "presentation": [ "http://healthcarerealty.com/role/LeasesGroundLeasesDetails" ], "xbrltype": "integerItemType" }, "hr_NumberofOffcampusBuildings": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of Off-campus Buildings", "label": "Number of Off-campus Buildings", "terseLabel": "Number of Off-campus Buildings" } } }, "localname": "NumberofOffcampusBuildings", "nsuri": "http://healthcarerealty.com/20190331", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsAndDispositionsDetails" ], "xbrltype": "integerItemType" }, "hr_NumberofOncampusBuildings": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of On-campus Buildings", "label": "Number of On-campus Buildings", "terseLabel": "Number of On-campus Buildings" } } }, "localname": "NumberofOncampusBuildings", "nsuri": "http://healthcarerealty.com/20190331", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsAndDispositionsDetails" ], "xbrltype": "integerItemType" }, "hr_NumberofPropertiesAcquired": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of Properties Acquired", "label": "Number of Properties Acquired", "terseLabel": "Number of properties acquired" } } }, "localname": "NumberofPropertiesAcquired", "nsuri": "http://healthcarerealty.com/20190331", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsAndDispositionsDetails" ], "xbrltype": "integerItemType" }, "hr_OperatingandFinanceLeasesTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Operating and Finance Leases [Text Block]", "label": "Operating and Finance Leases [Text Block]", "terseLabel": "Leases" } } }, "localname": "OperatingandFinanceLeasesTextBlock", "nsuri": "http://healthcarerealty.com/20190331", "presentation": [ "http://healthcarerealty.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "hr_ParkingIncomeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Parking Income [Member]", "label": "Parking Income [Member]", "terseLabel": "Parking Income" } } }, "localname": "ParkingIncomeMember", "nsuri": "http://healthcarerealty.com/20190331", "presentation": [ "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "hr_PersonalProperty": { "auth_ref": [], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_RealEstateInvestmentPropertyAtCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Personal property.", "label": "Personal Property", "terseLabel": "Personal property" } } }, "localname": "PersonalProperty", "nsuri": "http://healthcarerealty.com/20190331", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "hr_RealEstateAcquisitionsAndMortgageNoteFinancingAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Real Estate Acquisitions and Mortgage Note Financing.", "label": "Real Estate Acquisitions and Mortgage Note Financing [Axis]", "terseLabel": "Real Estate Acquisitions and Mortgage Note Financing [Axis]" } } }, "localname": "RealEstateAcquisitionsAndMortgageNoteFinancingAxis", "nsuri": "http://healthcarerealty.com/20190331", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsAndDispositionsDetails" ], "xbrltype": "stringItemType" }, "hr_RealEstateAcquisitionsAndMortgageNoteFinancingDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Real Estate Acquisitions and Mortgage Note Financing.", "label": "Real Estate Acquisitions and Mortgage Note Financing [Domain]", "terseLabel": "Real Estate Acquisitions and Mortgage Note Financing [Domain]" } } }, "localname": "RealEstateAcquisitionsAndMortgageNoteFinancingDomain", "nsuri": "http://healthcarerealty.com/20190331", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsAndDispositionsDetails" ], "xbrltype": "domainItemType" }, "hr_RealEstateAcquisitionsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Real estate acquisitions.", "label": "Real Estate Acquisitions [Member]", "terseLabel": "Real Estate Acquisition" } } }, "localname": "RealEstateAcquisitionsMember", "nsuri": "http://healthcarerealty.com/20190331", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsAndDispositionsDetails" ], "xbrltype": "domainItemType" }, "hr_RealEstateDispositionsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Real Estate Dispositions [Member]", "label": "Real Estate Dispositions [Member]", "terseLabel": "Real Estate Dispositions" } } }, "localname": "RealEstateDispositionsMember", "nsuri": "http://healthcarerealty.com/20190331", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsAndDispositionsDetails" ], "xbrltype": "domainItemType" }, "hr_RealEstateInvestmentNetDisposedOfDuringPeriod": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Real estate investment net disposed of during the Period.", "label": "Real Estate Investment Net Disposed of During Period", "verboseLabel": "Net Real Estate Investment" } } }, "localname": "RealEstateInvestmentNetDisposedOfDuringPeriod", "nsuri": "http://healthcarerealty.com/20190331", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsAndDispositionsDetails" ], "xbrltype": "monetaryItemType" }, "hr_RealEstateInvestmentsPropertyOwnedInNumberOfStates": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Real estate investments property owned in number of states.", "label": "Real Estate Investments Property Owned in Number of States", "verboseLabel": "Number of states that the Company owns real estate in, whole units" } } }, "localname": "RealEstateInvestmentsPropertyOwnedInNumberOfStates", "nsuri": "http://healthcarerealty.com/20190331", "presentation": [ "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "integerItemType" }, "hr_ReconciliationOfBeginningAndEndingCommonStockOutstandingRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Reconciliation of the beginning and ending common stock outstanding.", "label": "Reconciliation of Beginning and Ending Common Stock Outstanding [Roll Forward]", "verboseLabel": "Reconciliation of the beginning and ending common stock outstanding" } } }, "localname": "ReconciliationOfBeginningAndEndingCommonStockOutstandingRollForward", "nsuri": "http://healthcarerealty.com/20190331", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityReconciliationOfBeginningAndEndingCommonStockOutstandingDetails" ], "xbrltype": "stringItemType" }, "hr_ReconciliationOfBeginningAndEndingCommonStockOutstandingTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Reconciliation of beginning and ending common stock outstanding.", "label": "Reconciliation of Beginning and Ending Common Stock Outstanding [Table Text Block]", "terseLabel": "Reconciliation of beginning and ending common stock outstanding" } } }, "localname": "ReconciliationOfBeginningAndEndingCommonStockOutstandingTableTextBlock", "nsuri": "http://healthcarerealty.com/20190331", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "hr_RentalLeaseGuarantyMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Rental Lease Guaranty [Member]", "label": "Rental Lease Guaranty [Member]", "terseLabel": "Rental Lease Guaranty" } } }, "localname": "RentalLeaseGuarantyMember", "nsuri": "http://healthcarerealty.com/20190331", "presentation": [ "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "hr_SeniorNotesdue2023Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Senior Notes due 2023 [Member]", "label": "Senior Notes due 2023 [Member]", "terseLabel": "Senior Notes due 2023, net of discount and issuance costs" } } }, "localname": "SeniorNotesdue2023Member", "nsuri": "http://healthcarerealty.com/20190331", "presentation": [ "http://healthcarerealty.com/role/NotesAndBondsPayableDetails" ], "xbrltype": "domainItemType" }, "hr_SeniorNotesdue2025Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Senior Notes due 2025 [Member]", "label": "Senior Notes due 2025 [Member]", "terseLabel": "Senior Notes due 2025, net of discount and issuance costs (2)" } } }, "localname": "SeniorNotesdue2025Member", "nsuri": "http://healthcarerealty.com/20190331", "presentation": [ "http://healthcarerealty.com/role/NotesAndBondsPayableDetails" ], "xbrltype": "domainItemType" }, "hr_SeniorNotesdue2028Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Senior Notes due 2028 [Member]", "label": "Senior Notes due 2028 [Member]", "terseLabel": "Senior Notes due 2028, net of discount and issuance costs" } } }, "localname": "SeniorNotesdue2028Member", "nsuri": "http://healthcarerealty.com/20190331", "presentation": [ "http://healthcarerealty.com/role/NotesAndBondsPayableDetails" ], "xbrltype": "domainItemType" }, "hr_SettledInterestRateSwapMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Settled Interest Rate Swap [Member]", "label": "Settled Interest Rate Swap [Member]", "terseLabel": "Settled Interest Rate Swap" } } }, "localname": "SettledInterestRateSwapMember", "nsuri": "http://healthcarerealty.com/20190331", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "hr_SharesIssuedDuringPeriodPricePerShare": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Shares Issued During Period, Price Per Share", "label": "Shares Issued During Period, Price Per Share", "terseLabel": "Shares Issued During Period, Price Per Share" } } }, "localname": "SharesIssuedDuringPeriodPricePerShare", "nsuri": "http://healthcarerealty.com/20190331", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "xbrltype": "perShareItemType" }, "hr_SquareFeetSubjecttoGroundLeases": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Square Feet Subject to Ground Leases", "label": "Square Feet Subject to Ground Leases", "terseLabel": "Square feet subject to ground leases" } } }, "localname": "SquareFeetSubjecttoGroundLeases", "nsuri": "http://healthcarerealty.com/20190331", "presentation": [ "http://healthcarerealty.com/role/LeasesGroundLeasesDetails" ], "xbrltype": "areaItemType" }, "hr_StockIncentivePlanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock Incentive Plan [Member]", "label": "Stock Incentive Plan [Member]", "terseLabel": "Stock Incentive Plan" } } }, "localname": "StockIncentivePlanMember", "nsuri": "http://healthcarerealty.com/20190331", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquitySummaryOfActivityUnderStockBasedIncentivePlansDetails" ], "xbrltype": "domainItemType" }, "hr_StockIssuanceProgramAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock Issuance Program [Axis]", "label": "Stock Issuance Program [Axis]", "terseLabel": "Stock Issuance Program [Axis]" } } }, "localname": "StockIssuanceProgramAxis", "nsuri": "http://healthcarerealty.com/20190331", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "xbrltype": "stringItemType" }, "hr_StockIssuanceProgramDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Domain] for Stock Issuance Program [Axis]", "label": "Stock Issuance Program [Domain]", "terseLabel": "Stock Issuance Program [Domain]" } } }, "localname": "StockIssuanceProgramDomain", "nsuri": "http://healthcarerealty.com/20190331", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "hr_StraightLineRentReceivable": { "auth_ref": [], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Straight-line rent receivable.", "label": "Straight-line Rent Receivable", "negatedLabel": "Amortization of straight-line rent receivable (lessor)" } } }, "localname": "StraightLineRentReceivable", "nsuri": "http://healthcarerealty.com/20190331", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "hr_StraightlineRentLiability": { "auth_ref": [], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Straight-line rent liability.", "label": "Straight-line Rent Liability", "terseLabel": "Amortization of straight-line rent on operating leases (lessee)" } } }, "localname": "StraightlineRentLiability", "nsuri": "http://healthcarerealty.com/20190331", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "hr_TermLoandue2022Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Term Loan due 2022 [Member]", "label": "Term Loan due 2022 [Member]", "terseLabel": "Unsecured Term Loan Facility, net of issuance costs (1)" } } }, "localname": "TermLoandue2022Member", "nsuri": "http://healthcarerealty.com/20190331", "presentation": [ "http://healthcarerealty.com/role/NotesAndBondsPayableDetails" ], "xbrltype": "domainItemType" }, "hr_TransferstoOperatingLeaseRightofuseAssets": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Transfers to Operating Lease, Right-of-use Assets", "label": "Transfers to Operating Lease, Right-of-use Assets", "terseLabel": "Transfers to operating lease, right-of-use assets" } } }, "localname": "TransferstoOperatingLeaseRightofuseAssets", "nsuri": "http://healthcarerealty.com/20190331", "presentation": [ "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfNewAccountingStandardDetails" ], "xbrltype": "monetaryItemType" }, "hr_UnsecuredCreditFacilityDue2020Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Unsecured Credit Facility Due 2020 [Member]", "label": "Unsecured Credit Facility Due 2020 [Member]", "terseLabel": "Unsecured Credit Facility" } } }, "localname": "UnsecuredCreditFacilityDue2020Member", "nsuri": "http://healthcarerealty.com/20190331", "presentation": [ "http://healthcarerealty.com/role/NotesAndBondsPayableDetails" ], "xbrltype": "domainItemType" }, "invest_DerivativeNotionalAmount": { "auth_ref": [ "r284" ], "lang": { "en-US": { "role": { "documentation": "Aggregate notional amount specified by the derivative(s). Expressed as an absolute value.", "label": "Derivative, Notional Amount", "terseLabel": "Notional amount" } } }, "localname": "DerivativeNotionalAmount", "nsuri": "http://xbrl.sec.gov/invest/2013-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsAdditionalInformationDetails", "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsDesignatedAsCashFlowHedgesDetails", "http://healthcarerealty.com/role/NotesAndBondsPayableDetails" ], "xbrltype": "monetaryItemType" }, "srt_MaximumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesGroundLeasesDetails", "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails", "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfNewAccountingStandardDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesGroundLeasesDetails", "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails", "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfNewAccountingStandardDetails" ], "xbrltype": "domainItemType" }, "srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis": { "auth_ref": [ "r280", "r281" ], "lang": { "en-US": { "role": { "label": "Real Estate, Type of Property [Axis]", "terseLabel": "Real Estate, Type of Property [Axis]" } } }, "localname": "MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CommitmentsAndContingenciesConstructionActivityDetails", "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsAndDispositionsDetails" ], "xbrltype": "stringItemType" }, "srt_MortgageLoansOnRealEstateNamePropertyTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Real Estate [Domain]", "terseLabel": "Real Estate [Domain]" } } }, "localname": "MortgageLoansOnRealEstateNamePropertyTypeDomain", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CommitmentsAndContingenciesConstructionActivityDetails", "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsAndDispositionsDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r117", "r148", "r149", "r279" ], "lang": { "en-US": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Range [Axis]", "terseLabel": "Range [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesGroundLeasesDetails", "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails", "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfNewAccountingStandardDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Range [Domain]", "terseLabel": "Range [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesGroundLeasesDetails", "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails", "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfNewAccountingStandardDetails" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Geographical [Domain]", "terseLabel": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CommitmentsAndContingenciesConstructionActivityDetails", "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsAndDispositionsDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r118", "r148", "r150", "r280", "r281" ], "lang": { "en-US": { "role": { "label": "Geographical [Axis]", "terseLabel": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CommitmentsAndContingenciesConstructionActivityDetails", "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsAndDispositionsDetails" ], "xbrltype": "stringItemType" }, "srt_WeightedAverageMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Weighted Average [Member]", "terseLabel": "Weighted Average", "verboseLabel": "Weighted Average Remaining Term" } } }, "localname": "WeightedAverageMember", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesGroundLeasesDetails", "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails", "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfNewAccountingStandardDetails" ], "xbrltype": "domainItemType" }, "stpr_AZ": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "ARIZONA", "terseLabel": "Tucson, Arizona" } } }, "localname": "AZ", "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsAndDispositionsDetails" ], "xbrltype": "domainItemType" }, "stpr_CO": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "COLORADO", "terseLabel": "COLORADO" } } }, "localname": "CO", "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CommitmentsAndContingenciesConstructionActivityDetails" ], "xbrltype": "domainItemType" }, "stpr_DC": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "DISTRICT OF COLUMBIA", "terseLabel": "Washington, D.C. (4)" } } }, "localname": "DC", "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsAndDispositionsDetails" ], "xbrltype": "domainItemType" }, "stpr_GA": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "GEORGIA", "terseLabel": "Atlanta, Georgia" } } }, "localname": "GA", "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsAndDispositionsDetails" ], "xbrltype": "domainItemType" }, "stpr_IN": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "INDIANA", "terseLabel": "Indianapolis, IN (5)" } } }, "localname": "IN", "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsAndDispositionsDetails" ], "xbrltype": "domainItemType" }, "stpr_NC": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "NORTH CAROLINA", "terseLabel": "NORTH CAROLINA" } } }, "localname": "NC", "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CommitmentsAndContingenciesConstructionActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountingStandardsUpdate201602Member": { "auth_ref": [ "r228" ], "lang": { "en-US": { "role": { "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).", "label": "Accounting Standards Update 2016-02 [Member]", "terseLabel": "Accounting Standards Update 2016-02" } } }, "localname": "AccountingStandardsUpdate201602Member", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesGroundLeasesDetails", "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfNewAccountingStandardDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent": { "auth_ref": [ "r254", "r274" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date, including liabilities incurred and payable to vendors for goods and services received, taxes, interest, rent and utilities, compensation costs, payroll taxes and fringe benefits (other than pension and postretirement obligations), contractual rights and obligations, and statutory obligations.", "label": "Accounts Payable and Accrued Liabilities", "verboseLabel": "Accounts payable and accrued liabilities" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing accounts payable and accrued liabilities.", "label": "Accounts Payable and Accrued Liabilities [Member]", "terseLabel": "Accounts Payable and Accrued Liabilities" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfNewAccountingStandardDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax": { "auth_ref": [ "r39", "r42" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after tax, of accumulated other comprehensive (income) loss for defined benefit plan, that has not been recognized in net periodic benefit cost (credit).", "label": "Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax", "negatedLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r40", "r42", "r45", "r179" ], "lang": { "en-US": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Income (Loss)" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementOfEquityUnauditedStatement" ], "xbrltype": "domainItemType" }, "us-gaap_AcquisitionCosts": { "auth_ref": [ "r247", "r248" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": { "order": 4.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The capitalized costs incurred during the period (excluded from amortization) to purchase, lease or otherwise acquire an unproved property, including costs of lease bonuses and options to purchase or lease properties, the portion of costs applicable to minerals when land including mineral rights is purchased in fee, brokers' fees, recording fees, legal costs, and other costs incurred in acquiring properties.", "label": "Acquisition Costs, Period Cost", "terseLabel": "Acquisition and pursuit costs" } } }, "localname": "AcquisitionCosts", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r22" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid in Capital, Common Stock", "verboseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementOfEquityUnauditedStatement" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "auth_ref": [ "r89" ], "lang": { "en-US": { "role": { "documentation": "Information by new accounting pronouncement.", "label": "Adjustments for New Accounting Pronouncements [Axis]", "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]" } } }, "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesGroundLeasesDetails", "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfNewAccountingStandardDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r153", "r155", "r167", "r168" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) from recognition of equity-based compensation.", "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition", "terseLabel": "Share-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementOfEquityUnauditedStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "verboseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AreaOfRealEstateProperty": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area of a real estate property.", "label": "Area of Real Estate Property", "netLabel": "Approximate Square Feet", "terseLabel": "Area of Real Estate Property", "verboseLabel": "Square footage of owned real estate properties" } } }, "localname": "AreaOfRealEstateProperty", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CommitmentsAndContingenciesConstructionActivityDetails", "http://healthcarerealty.com/role/NotesAndBondsPayableDetails", "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "areaItemType" }, "us-gaap_Assets": { "auth_ref": [ "r115", "r250", "r265" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets [Abstract]", "verboseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation": { "auth_ref": [ "r0", "r1", "r8", "r10", "r124" ], "calculation": { "http://healthcarerealty.com/role/RealEstateInvestmentsDiscontinuedOperationsAndAssetsHeldForSaleBalanceSheetDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Assets", "totalLabel": "Assets held for sale, net" } } }, "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperation", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsDiscontinuedOperationsAndAssetsHeldForSaleBalanceSheetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r156", "r166" ], "lang": { "en-US": { "role": { "documentation": "Information by award type pertaining to equity-based compensation.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquitySummaryOfActivityUnderEmployeeStockPurchasePlanDetails", "http://healthcarerealty.com/role/StockholdersEquitySummaryOfActivityUnderStockBasedIncentivePlansDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsFairValueOfDerivativeInstrumentsOnBalanceSheetDetails", "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfNewAccountingStandardDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r188", "r193" ], "lang": { "en-US": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsFairValueOfDerivativeInstrumentsOnBalanceSheetDetails", "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfNewAccountingStandardDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BelowMarketLeaseNet": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after amortization of leases acquired as part of a real property acquisition at below market lease rate with a finite life.", "label": "Below Market Lease, Net", "terseLabel": "Below-market lease intangible" } } }, "localname": "BelowMarketLeaseNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsAndDispositionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1": { "auth_ref": [ "r169", "r170", "r171" ], "lang": { "en-US": { "role": { "documentation": "Date when the acquirer obtains control of the acquiree, in CCYY-MM-DD format.", "label": "Business Acquisition, Effective Date of Acquisition", "terseLabel": "Date Acquired" } } }, "localname": "BusinessAcquisitionEffectiveDateOfAcquisition1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsAndDispositionsDetails" ], "xbrltype": "dateItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition [Line Items]", "terseLabel": "Business Acquisition [Line Items]" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsAndDispositionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "auth_ref": [ "r174", "r175", "r176" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.", "label": "Business Combination, Consideration Transferred", "verboseLabel": "Purchase price" } } }, "localname": "BusinessCombinationConsiderationTransferred1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsAndDispositionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Business Combinations [Abstract]" } } }, "localname": "BusinessCombinationsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "auth_ref": [ "r80", "r81", "r82" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.", "label": "Capital Expenditures Incurred but Not yet Paid", "verboseLabel": "Invoices accrued for construction, tenant improvements and other capitalized costs" } } }, "localname": "CapitalExpendituresIncurredButNotYetPaid", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CarryingReportedAmountFairValueDisclosureMember": { "auth_ref": [ "r216", "r217" ], "lang": { "en-US": { "role": { "documentation": "Measured as reported on the statement of financial position (balance sheet).", "label": "Reported Value Measurement [Member]", "terseLabel": "Carrying Value" } } }, "localname": "CarryingReportedAmountFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/FairValueOfFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r14", "r26", "r78" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "verboseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r73", "r78", "r83" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash and cash equivalents at end of period", "periodStartLabel": "Cash and cash equivalents at beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "auth_ref": [ "r73", "r218" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect", "totalLabel": "Increase (decrease) in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowHedgingMember": { "auth_ref": [ "r184" ], "lang": { "en-US": { "role": { "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.", "label": "Cash Flow Hedging [Member]", "terseLabel": "Cash Flow Hedging" } } }, "localname": "CashFlowHedgingMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsAdditionalInformationDetails", "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsDesignatedAsCashFlowHedgesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]", "terseLabel": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityReconciliationOfBeginningAndEndingCommonStockOutstandingDetails", "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r32", "r128", "r256", "r269" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "verboseLabel": "Commitments and contingencies" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r127", "r129" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "verboseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockDividendsPerShareCashPaid": { "auth_ref": [ "r144" ], "lang": { "en-US": { "role": { "documentation": "Aggregate dividends paid during the period for each share of common stock outstanding.", "label": "Common Stock, Dividends, Per Share, Cash Paid", "verboseLabel": "Dividend per share to common Stockholders (in dollars per share)" } } }, "localname": "CommonStockDividendsPerShareCashPaid", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementOfEquityUnauditedParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockDividendsPerShareDeclared": { "auth_ref": [ "r144" ], "lang": { "en-US": { "role": { "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.", "label": "Common Stock, Dividends, Per Share, Declared", "terseLabel": "Dividends declared per common share, during the period (in dollars per share)", "verboseLabel": "Dividends declared, per common share, during the period (in dollars per share)" } } }, "localname": "CommonStockDividendsPerShareDeclared", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited", "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementOfEquityUnauditedStatement", "http://healthcarerealty.com/role/StockholdersEquityReconciliationOfBeginningAndEndingCommonStockOutstandingDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r21" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r21" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "verboseLabel": "Common stock, authorized shares" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r21" ], "lang": { "en-US": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "verboseLabel": "Common stock, issued shares" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r21", "r137" ], "lang": { "en-US": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "periodEndLabel": "Balance, end of period", "periodStartLabel": "Balance, beginning of period", "verboseLabel": "Common stock, outstanding shares" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://healthcarerealty.com/role/StockholdersEquityReconciliationOfBeginningAndEndingCommonStockOutstandingDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r21" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "verboseLabel": "Common stock, $.01 par value per share; 300,000 shares authorized; 129,214 and 125,279 shares issued and outstanding at March 31, 2019 and December 31, 2018, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r48", "r50", "r51" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "COMPREHENSIVE INCOME" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractualObligationFiscalYearMaturityScheduleTableTextBlock": { "auth_ref": [ "r283" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the aggregate amount of payments due on known contractual obligations for the five years following the date of the latest balance sheet and the combined aggregate amount of maturities of known contractual obligations.", "label": "Contractual Obligation, Fiscal Year Maturity Schedule [Table Text Block]", "terseLabel": "Future Minimum Lease Payments under ASC 840" } } }, "localname": "ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_CumulativeDividends": { "auth_ref": [], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cumulative cash dividends distributed to shareholders.", "label": "Cumulative Dividends", "negatedLabel": "Cumulative dividends" } } }, "localname": "CumulativeDividends", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r133" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "verboseLabel": "Notes and Bonds Payable" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/NotesAndBondsPayable" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r17", "r18", "r19", "r251", "r252", "r263" ], "lang": { "en-US": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/NotesAndBondsPayableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "Debt Instrument, Basis Spread on Variable Rate", "terseLabel": "Basis spread on variable rate (percent)" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/NotesAndBondsPayableDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentFairValue": { "auth_ref": [ "r215" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.", "label": "Debt Instrument, Fair Value Disclosure", "verboseLabel": "Notes and bonds payable" } } }, "localname": "DebtInstrumentFairValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/FairValueOfFinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "auth_ref": [ "r30", "r132", "r221" ], "lang": { "en-US": { "role": { "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.", "label": "Debt Instrument, Interest Rate, Effective Percentage", "terseLabel": "Effective interest rate (percent)" } } }, "localname": "DebtInstrumentInterestRateEffectivePercentage", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/NotesAndBondsPayableDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/NotesAndBondsPayableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r31" ], "lang": { "en-US": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/NotesAndBondsPayableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r31", "r85", "r138", "r141", "r142", "r143", "r220", "r221", "r223", "r262" ], "lang": { "en-US": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/NotesAndBondsPayableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r76", "r122" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "Depreciation, Depletion and Amortization, Nonproduction", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r76", "r113" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "verboseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Contract [Domain]", "terseLabel": "Derivative Contract [Domain]" } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsAdditionalInformationDetails", "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsDesignatedAsCashFlowHedgesDetails", "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsEffectOfCashFlowHedgingOnAociDetails", "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsFairValueOfDerivativeInstrumentsOnBalanceSheetDetails", "http://healthcarerealty.com/role/NotesAndBondsPayableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeFairValueOfDerivativeLiability": { "auth_ref": [ "r35", "r36", "r191", "r246" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.", "label": "Derivative Liability, Fair Value, Gross Liability", "terseLabel": "Liability derivatives" } } }, "localname": "DerivativeFairValueOfDerivativeLiability", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsFairValueOfDerivativeInstrumentsOnBalanceSheetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeFixedInterestRate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fixed interest rate related to the interest rate derivative.", "label": "Derivative, Fixed Interest Rate", "terseLabel": "Derivative, fixed interest rate (percent)" } } }, "localname": "DerivativeFixedInterestRate", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsAdditionalInformationDetails", "http://healthcarerealty.com/role/NotesAndBondsPayableDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r189", "r192", "r198", "r201" ], "lang": { "en-US": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]", "terseLabel": "Derivative Instrument [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsAdditionalInformationDetails", "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsDesignatedAsCashFlowHedgesDetails", "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsEffectOfCashFlowHedgingOnAociDetails", "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsFairValueOfDerivativeInstrumentsOnBalanceSheetDetails", "http://healthcarerealty.com/role/NotesAndBondsPayableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": { "auth_ref": [ "r210" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.", "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]", "terseLabel": "Derivative Financial Instruments" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstruments" ], "xbrltype": "textBlockItemType" }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": { "auth_ref": [ "r185", "r189", "r198" ], "lang": { "en-US": { "role": { "documentation": "Information by type of hedging relationship.", "label": "Hedging Relationship [Axis]", "terseLabel": "Hedging Relationship [Axis]" } } }, "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsAdditionalInformationDetails", "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsDesignatedAsCashFlowHedgesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": { "auth_ref": [ "r185", "r189", "r198", "r201", "r202", "r205", "r207" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.", "label": "Derivative Instruments, Gain (Loss) [Table]", "terseLabel": "Derivative Instruments, Gain (Loss) [Table]" } } }, "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative Instruments, Gain (Loss) [Line Items]", "terseLabel": "Derivative Instruments, Gain (Loss) [Line Items]" } } }, "localname": "DerivativeInstrumentsGainLossLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative [Line Items]", "terseLabel": "Derivative [Line Items]" } } }, "localname": "DerivativeLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsDesignatedAsCashFlowHedgesDetails", "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsEffectOfCashFlowHedgingOnAociDetails", "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsFairValueOfDerivativeInstrumentsOnBalanceSheetDetails", "http://healthcarerealty.com/role/FairValueOfFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeTable": { "auth_ref": [ "r86", "r180", "r182", "r183", "r185", "r187", "r194", "r198", "r203", "r204", "r207" ], "lang": { "en-US": { "role": { "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.", "label": "Derivative [Table]", "terseLabel": "Derivative [Table]" } } }, "localname": "DerivativeTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsDesignatedAsCashFlowHedgesDetails", "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsEffectOfCashFlowHedgingOnAociDetails", "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsFairValueOfDerivativeInstrumentsOnBalanceSheetDetails", "http://healthcarerealty.com/role/FairValueOfFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DesignatedAsHedgingInstrumentMember": { "auth_ref": [ "r185" ], "lang": { "en-US": { "role": { "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "label": "Designated as Hedging Instrument [Member]", "terseLabel": "Designated as Hedging Instrument" } } }, "localname": "DesignatedAsHedgingInstrumentMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsDesignatedAsCashFlowHedgesDetails", "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsFairValueOfDerivativeInstrumentsOnBalanceSheetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DevelopmentInProcess": { "auth_ref": [ "r273" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 4.0, "parentTag": "us-gaap_RealEstateInvestmentPropertyAtCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The current amount of expenditures for a real estate project that has not yet been completed.", "label": "Development in Process", "terseLabel": "Construction in progress" } } }, "localname": "DevelopmentInProcess", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DirectCostsOfLeasedAndRentedPropertyOrEquipment": { "auth_ref": [ "r61" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense incurred and directly related to generating revenue from leased and rented property or equipment.", "label": "Direct Costs of Leased and Rented Property or Equipment", "verboseLabel": "Property operating" } } }, "localname": "DirectCostsOfLeasedAndRentedPropertyOrEquipment", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]", "terseLabel": "Disaggregation of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]", "terseLabel": "Disaggregation of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r148" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Disaggregation of revenue" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": { "auth_ref": [ "r156", "r166" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of components of a stock option or other award plan under which equity-based compensation is awarded to employees, typically comprised of the amount of unearned compensation (deferred compensation cost), compensation expense, and changes in the quantity and fair value of the shares (or other type of equity) granted, exercised, forfeited, and issued and outstanding pertaining to that plan. Disclosure may also include nature and general terms of such arrangements that existed during the period and potential effects of those arrangements on shareholders, effect of compensation cost arising from equity-based payment arrangements on the income statement, method of estimating the fair value of the goods or services received, or the fair value of the equity instruments granted, during the period, cash flow effects resulting from equity-based payment arrangements and, for registrants that accelerate vesting of out of the money share options, reasons for the decision to accelerate.", "label": "Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]", "terseLabel": "Summary of the activity under the Incentive Plan" } } }, "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisposalGroupClassificationAxis": { "auth_ref": [ "r10" ], "lang": { "en-US": { "role": { "documentation": "Information by disposal group classification.", "label": "Disposal Group Classification [Axis]", "terseLabel": "Disposal Group Classification [Axis]" } } }, "localname": "DisposalGroupClassificationAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsDiscontinuedOperationsAndAssetsHeldForSaleBalanceSheetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisposalGroupClassificationDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations.", "label": "Disposal Group Classification [Domain]", "terseLabel": "Disposal Group Classification [Domain]" } } }, "localname": "DisposalGroupClassificationDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsDiscontinuedOperationsAndAssetsHeldForSaleBalanceSheetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember": { "auth_ref": [ "r10", "r121", "r125" ], "lang": { "en-US": { "role": { "documentation": "Disposal group that is classified as held-for-sale. Excludes disposals classified as discontinued operations.", "label": "Disposal Group, Held-for-sale, Not Discontinued Operations [Member]", "terseLabel": "Disposal Group, Held-for-sale, Not Discontinued Operations" } } }, "localname": "DisposalGroupHeldforsaleNotDiscontinuedOperationsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsDiscontinuedOperationsAndAssetsHeldForSaleBalanceSheetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r0", "r1", "r8", "r124" ], "calculation": { "http://healthcarerealty.com/role/RealEstateInvestmentsDiscontinuedOperationsAndAssetsHeldForSaleBalanceSheetDetails": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount classified as accounts payable and accrued liabilities attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Accounts Payable and Accrued Liabilities", "terseLabel": "Accounts payable and accrued liabilities" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsDiscontinuedOperationsAndAssetsHeldForSaleBalanceSheetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets": { "auth_ref": [ "r0", "r1", "r8", "r124" ], "calculation": { "http://healthcarerealty.com/role/RealEstateInvestmentsDiscontinuedOperationsAndAssetsHeldForSaleBalanceSheetDetails": { "order": 2.0, "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount classified as other assets attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Other Assets", "terseLabel": "Other assets, net" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationOtherAssets", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsDiscontinuedOperationsAndAssetsHeldForSaleBalanceSheetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities": { "auth_ref": [ "r0", "r1", "r8", "r124" ], "calculation": { "http://healthcarerealty.com/role/RealEstateInvestmentsDiscontinuedOperationsAndAssetsHeldForSaleBalanceSheetDetails": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount classified as other liabilities attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Other Liabilities", "terseLabel": "Other liabilities" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationOtherLiabilities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsDiscontinuedOperationsAndAssetsHeldForSaleBalanceSheetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of disposal group.", "label": "Disposal Group Name [Domain]", "terseLabel": "Disposal Group Name [Domain]" } } }, "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsDiscontinuedOperationsAndAssetsHeldForSaleBalanceSheetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DividendsCommonStockCash": { "auth_ref": [ "r144" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.", "label": "Dividends, Common Stock, Cash", "negatedTerseLabel": "Dividends to common stockholders ($0.30 per share)" } } }, "localname": "DividendsCommonStockCash", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementOfEquityUnauditedStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_DividendsShareBasedCompensation": { "auth_ref": [], "calculation": { "http://healthcarerealty.com/role/StockholdersEquityComputationOfBasicAndDilutedEarningsLossPerCommonShareDetails": { "order": 2.0, "parentTag": "hr_NetIncomeLossfromContinuingOperationsAvailabletoCommonStockholdersBasic", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared and applicable to holders of share-based compensation, for example, but not limited to, non-vested shares, stock options, or restricted stock units.", "label": "Dividends, Share-based Compensation", "negatedTerseLabel": "Dividends paid on nonvested share-based awards" } } }, "localname": "DividendsShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityComputationOfBasicAndDilutedEarningsLossPerCommonShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r56", "r90", "r96", "r97", "r98", "r99", "r102", "r260", "r277" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic earnings per common share (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited", "http://healthcarerealty.com/role/StockholdersEquityComputationOfBasicAndDilutedEarningsLossPerCommonShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r56", "r90", "r96", "r97", "r98", "r99", "r102", "r260", "r277" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted earnings per common share (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited", "http://healthcarerealty.com/role/StockholdersEquityComputationOfBasicAndDilutedEarningsLossPerCommonShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EmployeeStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.", "label": "Employee Stock [Member]", "verboseLabel": "Employee Stock Purchase Plan" } } }, "localname": "EmployeeStockMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquitySummaryOfActivityUnderEmployeeStockPurchasePlanDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r137" ], "lang": { "en-US": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementOfEquityUnauditedStatement", "http://healthcarerealty.com/role/StockholdersEquityReconciliationOfBeginningAndEndingCommonStockOutstandingDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentDividendsOrDistributions": { "auth_ref": [ "r54", "r72", "r76", "r275" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of distribution received from equity method investee for return on investment, classified as operating activities. Excludes distribution for return of investment, classified as investing activities.", "label": "Proceeds from Equity Method Investment, Distribution", "terseLabel": "Distributions from unconsolidated joint ventures" } } }, "localname": "EquityMethodInvestmentDividendsOrDistributions", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_EstimateOfFairValueFairValueDisclosureMember": { "auth_ref": [ "r215" ], "lang": { "en-US": { "role": { "documentation": "Measured as an estimate of fair value.", "label": "Estimate of Fair Value Measurement [Member]", "terseLabel": "Fair Value" } } }, "localname": "EstimateOfFairValueFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/FairValueOfFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ExtinguishmentOfDebtAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Gross amount of debt extinguished.", "label": "Extinguishment of Debt, Amount", "terseLabel": "Extinguishment of Debt, Amount" } } }, "localname": "ExtinguishmentOfDebtAmount", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/NotesAndBondsPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueByBalanceSheetGroupingTextBlock": { "auth_ref": [ "r211", "r216" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.", "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]", "terseLabel": "Fair value and carrying values for notes and bonds payable, mortgage notes receivable, and notes receivable" } } }, "localname": "FairValueByBalanceSheetGroupingTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/FairValueOfFinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByMeasurementBasisAxis": { "auth_ref": [ "r211", "r212" ], "lang": { "en-US": { "role": { "documentation": "Information by measurement basis.", "label": "Measurement Basis [Axis]", "terseLabel": "Measurement Basis [Axis]" } } }, "localname": "FairValueByMeasurementBasisAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/FairValueOfFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosureItemAmountsDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.", "label": "Fair Value Measurement [Domain]", "terseLabel": "Fair Value Measurement [Domain]" } } }, "localname": "FairValueDisclosureItemAmountsDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/FairValueOfFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r213" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "verboseLabel": "Fair Value of Financial Instruments" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/FairValueOfFinancialInstruments" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Finance Lease Liabilities, Payments, Due [Abstract]", "terseLabel": "Financing" } } }, "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinanceLeaseLiability": { "auth_ref": [ "r230", "r242" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 6.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetailsCalc2": { "order": 2.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.", "label": "Finance Lease, Liability", "terseLabel": "Financing lease liabilities", "verboseLabel": "Lease Liability" } } }, "localname": "FinanceLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails", "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsAndDispositionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r242" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.", "label": "Finance Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Future Minimum Financing Lease Payments" } } }, "localname": "FinanceLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDue": { "auth_ref": [ "r242" ], "calculation": { "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetailsCalc2": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.", "label": "Finance Lease, Liability, Payments, Due", "totalLabel": "Total undiscounted lease payments" } } }, "localname": "FinanceLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r242" ], "calculation": { "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails": { "order": 6.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due after fifth fiscal year following latest fiscal year.", "label": "Finance Lease, Liability, Payments, Due after Year Five", "terseLabel": "2024 and thereafter" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r242" ], "calculation": { "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails": { "order": 5.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in fifth fiscal year following latest fiscal year.", "label": "Finance Lease, Liability, Payments, Due Year Five", "terseLabel": "2023" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r242" ], "calculation": { "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails": { "order": 4.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in fourth fiscal year following latest fiscal year.", "label": "Finance Lease, Liability, Payments, Due Year Four", "terseLabel": "2022" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r242" ], "calculation": { "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails": { "order": 3.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in third fiscal year following latest fiscal year.", "label": "Finance Lease, Liability, Payments, Due Year Three", "terseLabel": "2021" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r242" ], "calculation": { "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails": { "order": 2.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in second fiscal year following latest fiscal year.", "label": "Finance Lease, Liability, Payments, Due Year Two", "terseLabel": "2020" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r242" ], "calculation": { "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails": { "order": 1.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in remainder of fiscal year following latest fiscal year ended.", "label": "Finance Lease, Liability, Payments, Remainder of Fiscal Year", "terseLabel": "2019" } } }, "localname": "FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r242" ], "calculation": { "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetailsCalc2": { "order": 1.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.", "label": "Finance Lease, Liability, Undiscounted Excess Amount", "negatedTerseLabel": "Discount" } } }, "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAsset": { "auth_ref": [ "r229" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's right to use underlying asset under finance lease.", "label": "Finance Lease, Right-of-Use Asset", "terseLabel": "Financing lease right-of-use assets" } } }, "localname": "FinanceLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r240", "r243" ], "lang": { "en-US": { "role": { "documentation": "Weighted average discount rate for finance lease calculated at point in time.", "label": "Finance Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted-average discount rate - finance leases (percent)" } } }, "localname": "FinanceLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesLeaseCostDetails" ], "xbrltype": "percentItemType" }, "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r239", "r243" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Finance Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted-average remaining lease term - finance leases" } } }, "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesLeaseCostDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetOffMarketLeaseFavorableGross": { "auth_ref": [ "r28" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "This element represents the identifiable intangible asset established upon acquisition based on a favorable difference between the terms of an acquired lease and the current market terms for that lease at the acquisition date.", "label": "Finite-Lived Intangible Asset, Off-market Lease, Favorable, Gross", "terseLabel": "Above-market lease intangibles" } } }, "localname": "FiniteLivedIntangibleAssetOffMarketLeaseFavorableGross", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsAndDispositionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainsLossesOnSalesOfInvestmentRealEstate": { "auth_ref": [ "r57", "r58", "r76", "r258", "r278" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": { "order": 3.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net gain (loss) resulting from sales and other disposals of real estate owned for investment purposes.", "label": "Gains (Losses) on Sales of Investment Real Estate", "terseLabel": "Gain on sales of real estate assets" } } }, "localname": "GainsLossesOnSalesOfInvestmentRealEstate", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r63" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "verboseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_GroundLeasesNet": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Net long-term land leases which are capitalized as part of real property.", "label": "Ground Leases, Net", "terseLabel": "Prepaid ground leases" } } }, "localname": "GroundLeasesNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsAndDispositionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_HedgingDesignationAxis": { "auth_ref": [ "r185", "r202" ], "lang": { "en-US": { "role": { "documentation": "Information by designation of purpose of derivative instrument.", "label": "Hedging Designation [Axis]", "terseLabel": "Hedging Designation [Axis]" } } }, "localname": "HedgingDesignationAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsDesignatedAsCashFlowHedgesDetails", "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsFairValueOfDerivativeInstrumentsOnBalanceSheetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_HedgingDesignationDomain": { "auth_ref": [ "r185" ], "lang": { "en-US": { "role": { "documentation": "Designation of purpose of derivative instrument.", "label": "Hedging Designation [Domain]", "terseLabel": "Hedging Designation [Domain]" } } }, "localname": "HedgingDesignationDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsDesignatedAsCashFlowHedgesDetails", "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsFairValueOfDerivativeInstrumentsOnBalanceSheetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_HedgingRelationshipDomain": { "auth_ref": [ "r185" ], "lang": { "en-US": { "role": { "documentation": "Nature or intent of a hedge.", "label": "Hedging Relationship [Domain]", "terseLabel": "Hedging Relationship [Domain]" } } }, "localname": "HedgingRelationshipDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsAdditionalInformationDetails", "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsDesignatedAsCashFlowHedgesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeLossFromContinuingOperations": { "auth_ref": [ "r60", "r77", "r99", "r178" ], "calculation": { "http://healthcarerealty.com/role/StockholdersEquityComputationOfBasicAndDilutedEarningsLossPerCommonShareDetails": { "order": 1.0, "parentTag": "hr_NetIncomeLossfromContinuingOperationsAvailabletoCommonStockholdersBasic", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of income (loss) from continuing operations attributable to the parent.", "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent", "terseLabel": "Net Income" } } }, "localname": "IncomeLossFromContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityComputationOfBasicAndDilutedEarningsLossPerCommonShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromEquityMethodInvestments": { "auth_ref": [ "r54", "r76", "r114", "r120", "r257", "r275" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "This item represents the entity's proportionate share for the period of the net income (loss) of its investee (such as unconsolidated subsidiaries and joint ventures) to which the equity method of accounting is applied. This item includes income or expense related to stock-based compensation based on the investor's grant of stock to employees of an equity method investee.", "label": "Income (Loss) from Equity Method Investments", "negatedTerseLabel": "Equity from unconsolidated joint ventures loss" } } }, "localname": "IncomeLossFromEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by name of disposal group.", "label": "Disposal Group Name [Axis]", "terseLabel": "Disposal Group Name [Axis]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsDiscontinuedOperationsAndAssetsHeldForSaleBalanceSheetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]", "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsDiscontinuedOperationsAndAssetsHeldForSaleBalanceSheetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": { "auth_ref": [ "r1", "r2", "r3", "r4", "r5", "r6", "r7", "r9", "r11", "r12", "r13", "r125", "r126" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.", "label": "Disposal Groups, Including Discontinued Operations [Table]", "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Table]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsDiscontinuedOperationsAndAssetsHeldForSaleBalanceSheetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r123" ], "lang": { "en-US": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsEffectOfCashFlowHedgingOnAociDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsEffectOfCashFlowHedgingOnAociDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r75" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "verboseLabel": "Accounts payable and accrued liabilities" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "verboseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingAssets": { "auth_ref": [ "r75" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in operating assets classified as other.", "label": "Increase (Decrease) in Other Operating Assets", "negatedLabel": "Other assets, including right-of-use-assets" } } }, "localname": "IncreaseDecreaseInOtherOperatingAssets", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": { "auth_ref": [ "r75" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in operating liabilities classified as other.", "label": "Increase (Decrease) in Other Operating Liabilities", "verboseLabel": "Other liabilities" } } }, "localname": "IncreaseDecreaseInOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementOfEquityUnauditedStatement" ], "xbrltype": "stringItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r53", "r112", "r219", "r222", "r261" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseMember": { "auth_ref": [ "r200" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing interest expense.", "label": "Interest Expense [Member]", "terseLabel": "Interest Expense" } } }, "localname": "InterestExpenseMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsEffectOfCashFlowHedgingOnAociDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InterestPaid": { "auth_ref": [ "r79" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities.", "label": "Interest Paid, Including Capitalized Interest, Operating and Investing Activities", "verboseLabel": "Interest paid" } } }, "localname": "InterestPaid", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidCapitalized": { "auth_ref": [ "r67", "r79" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash paid for interest capitalized, classified as investing activity.", "label": "Interest Paid, Capitalized, Investing Activities", "terseLabel": "Capitalized interest" } } }, "localname": "InterestPaidCapitalized", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet": { "auth_ref": [ "r209" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The estimated net amount of unrealized gains or losses on interest rate cash flow hedges as of the balance sheet date expected to be reclassified to earnings within the next twelve months.", "label": "Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net", "terseLabel": "Interest rate cash flow hedge gain (loss) to be reclassified to interest expense during the next 12 months" } } }, "localname": "InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestRateContractMember": { "auth_ref": [ "r152", "r199" ], "lang": { "en-US": { "role": { "documentation": "Derivative instrument whose primary underlying risk is tied to the right to receive or pay a sum of money at a given interest rate.", "label": "Interest Rate Contract [Member]", "terseLabel": "Interest Rate Products" } } }, "localname": "InterestRateContractMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsAdditionalInformationDetails", "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsEffectOfCashFlowHedgingOnAociDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InterestRateSwapMember": { "auth_ref": [ "r199" ], "lang": { "en-US": { "role": { "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.", "label": "Interest Rate Swap [Member]", "terseLabel": "Interest Rate Swap", "verboseLabel": "Settled Interest Rate Swaps" } } }, "localname": "InterestRateSwapMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsDesignatedAsCashFlowHedgesDetails", "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsEffectOfCashFlowHedgingOnAociDetails", "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsFairValueOfDerivativeInstrumentsOnBalanceSheetDetails", "http://healthcarerealty.com/role/NotesAndBondsPayableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InvestmentBuildingAndBuildingImprovements": { "auth_ref": [ "r271" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_RealEstateInvestmentPropertyAtCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Aggregate of the carrying amounts as of the balance sheet date of investments in building and building improvements.", "label": "Investment Building and Building Improvements", "terseLabel": "Investment Building and Building Improvements", "verboseLabel": "Buildings, improvements and lease intangibles" } } }, "localname": "InvestmentBuildingAndBuildingImprovements", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://healthcarerealty.com/role/RealEstateInvestmentsDiscontinuedOperationsAndAssetsHeldForSaleBalanceSheetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Land": { "auth_ref": [ "r15", "r27" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_RealEstateInvestmentPropertyAtCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated depletion of real estate held for productive use, excluding land held for sale.", "label": "Land", "verboseLabel": "Land" } } }, "localname": "Land", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://healthcarerealty.com/role/RealEstateInvestmentsDiscontinuedOperationsAndAssetsHeldForSaleBalanceSheetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LandAvailableForDevelopment": { "auth_ref": [ "r268" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 5.0, "parentTag": "us-gaap_RealEstateInvestmentPropertyAtCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Carrying amount of land available for development.", "label": "Land Available for Development", "terseLabel": "Land held for development" } } }, "localname": "LandAvailableForDevelopment", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r241", "r243" ], "calculation": { "http://healthcarerealty.com/role/LeasesLeaseCostDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "Lease, Cost", "totalLabel": "Total lease expense" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Lease, Cost [Abstract]", "terseLabel": "Lease expense" } } }, "localname": "LeaseCostAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesLeaseCostDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r241" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "terseLabel": "Lease Cost" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_LeasesOperatingAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Leases, Operating [Abstract]", "terseLabel": "Other information" } } }, "localname": "LeasesOperatingAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesLeaseCostDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessee, Lease, Description [Line Items]", "terseLabel": "Lessee, Lease, Description [Line Items]" } } }, "localname": "LesseeLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesGroundLeasesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionTable": { "auth_ref": [ "r234" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about lessee's leases.", "label": "Lessee, Lease, Description [Table]", "terseLabel": "Lessee, Lease, Description [Table]" } } }, "localname": "LesseeLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesGroundLeasesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseDiscountRate": { "auth_ref": [ "r233" ], "lang": { "en-US": { "role": { "documentation": "Discount rate used by lessee to determine present value of operating lease payments.", "label": "Lessee, Operating Lease, Discount Rate", "terseLabel": "Ground lease, discount rate (percent)" } } }, "localname": "LesseeOperatingLeaseDiscountRate", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfNewAccountingStandardDetails" ], "xbrltype": "percentItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r242" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Future Minimum Operating Lease Payments" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r242" ], "calculation": { "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Payments, Due", "totalLabel": "Total undiscounted lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r242" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due after Year Five", "terseLabel": "2024 and thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r242" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Five", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r242" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Four", "terseLabel": "2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r242" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Three", "terseLabel": "2021" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r242" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two", "terseLabel": "2020" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r242" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease having an initial or remaining lease term in excess of one year due in remainder of fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year", "terseLabel": "2019" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r242" ], "calculation": { "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedTerseLabel": "Discount" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "auth_ref": [ "r232" ], "lang": { "en-US": { "role": { "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Term of Contract", "terseLabel": "Ground lease, initial term" } } }, "localname": "LesseeOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesGroundLeasesDetails", "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfNewAccountingStandardDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Lessor, Operating Lease, Payments, Fiscal Year Maturity [Abstract]", "terseLabel": "Future Lease Payments Receivable [Abstract]" } } }, "localname": "LessorOperatingLeasePaymentsFiscalYearMaturityAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesLessorAccountingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceived": { "auth_ref": [ "r244" ], "calculation": { "http://healthcarerealty.com/role/LeasesLessorAccountingDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lease payments to be received by lessor for operating lease.", "label": "Lessor, Operating Lease, Payments to be Received", "totalLabel": "Total" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceived", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesLessorAccountingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears": { "auth_ref": [ "r244" ], "calculation": { "http://healthcarerealty.com/role/LeasesLessorAccountingDetails": { "order": 5.0, "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lease payments to be received by lessor in fifth fiscal year following latest fiscal year for operating lease. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.", "label": "Lessor, Operating Lease, Payments to be Received, Five Years", "terseLabel": "2023" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceivedFiveYears", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesLessorAccountingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears": { "auth_ref": [ "r244" ], "calculation": { "http://healthcarerealty.com/role/LeasesLessorAccountingDetails": { "order": 4.0, "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lease payments to be received by lessor in fourth year following latest fiscal year for operating lease. Excludes interim and annual periods when interim periods are reported on rolling approach, from latest statement of financial position date.", "label": "Lessor, Operating Lease, Payments to be Received, Four Years", "terseLabel": "2022" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceivedFourYears", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesLessorAccountingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock": { "auth_ref": [ "r244" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of maturity of undiscounted cash flows to be received by lessor on annual basis for operating lease.", "label": "Lessor, Operating Lease, Payments to be Received, Maturity [Table Text Block]", "terseLabel": "Future Minimum Lease Payments Receivable" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear": { "auth_ref": [ "r244" ], "calculation": { "http://healthcarerealty.com/role/LeasesLessorAccountingDetails": { "order": 1.0, "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lease payments to be received by lessor in remainder of fiscal year following latest fiscal year for operating lease. Excludes interim and annual periods when interim periods are reported on rolling approach, from latest statement of financial position date.", "label": "Lessor, Operating Lease, Payments to be Received, Remainder of Fiscal Year", "terseLabel": "2019" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesLessorAccountingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter": { "auth_ref": [ "r244" ], "calculation": { "http://healthcarerealty.com/role/LeasesLessorAccountingDetails": { "order": 6.0, "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lease payments to be received by lessor after fifth fiscal year following latest statement of financial position date for operating lease. Excludes interim and annual periods when interim periods are reported on rolling approach, from latest statement of financial position date.", "label": "Lessor, Operating Lease, Payments to be Received, Thereafter", "terseLabel": "2024 and thereafter" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceivedThereafter", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesLessorAccountingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears": { "auth_ref": [ "r244" ], "calculation": { "http://healthcarerealty.com/role/LeasesLessorAccountingDetails": { "order": 3.0, "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lease payments to be received by lessor in third fiscal year following latest fiscal year for operating lease. Excludes interim and annual periods when interim periods are reported on rolling approach, from latest statement of financial position date.", "label": "Lessor, Operating Lease, Payments to be Received, Three Years", "terseLabel": "2021" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceivedThreeYears", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesLessorAccountingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears": { "auth_ref": [ "r244" ], "calculation": { "http://healthcarerealty.com/role/LeasesLessorAccountingDetails": { "order": 2.0, "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lease payments to be received by lessor in second fiscal year following latest fiscal year for operating lease. Excludes interim and annual periods when interim periods are reported on rolling approach, from latest statement of financial position date.", "label": "Lessor, Operating Lease, Payments to be Received, Two Years", "terseLabel": "2020" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceivedTwoYears", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesLessorAccountingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r29" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities [Abstract]", "verboseLabel": "Liabilities:" } } }, "localname": "LiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r25", "r253", "r267" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders' equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities and Equity [Abstract]", "verboseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation": { "auth_ref": [ "r0", "r1", "r8", "r10", "r124" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://healthcarerealty.com/role/RealEstateInvestmentsDiscontinuedOperationsAndAssetsHeldForSaleBalanceSheetDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Liabilities", "totalLabel": "Liabilities of properties held for sale", "verboseLabel": "Liabilities of properties held for sale" } } }, "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://healthcarerealty.com/role/RealEstateInvestmentsDiscontinuedOperationsAndAssetsHeldForSaleBalanceSheetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.", "label": "Line of Credit [Member]", "terseLabel": "Line of Credit" } } }, "localname": "LineOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/NotesAndBondsPayableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r19", "r131", "r252", "r266" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt", "verboseLabel": "Notes and bonds payable" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://healthcarerealty.com/role/NotesAndBondsPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r31" ], "lang": { "en-US": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/NotesAndBondsPayableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r31", "r130" ], "lang": { "en-US": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/NotesAndBondsPayableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MediumTermNotesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt instruments with maturities ranging from five to ten years.", "label": "Medium-term Notes [Member]", "terseLabel": "Medium-term Notes" } } }, "localname": "MediumTermNotesMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/NotesAndBondsPayableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MortgagesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A loan to finance the purchase of real estate where the lender has a lien on the property as collateral for the loan.", "label": "Mortgages [Member]", "terseLabel": "Mortgages" } } }, "localname": "MortgagesMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/NotesAndBondsPayableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r73" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by (used in) financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "verboseLabel": "FINANCING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r73" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "verboseLabel": "INVESTING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r73", "r74", "r77" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "verboseLabel": "OPERATING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r46", "r49", "r55", "r77", "r101", "r259", "r276" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "NET INCOME", "totalLabel": "NET INCOME", "verboseLabel": "Net income" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementOfEquityUnauditedStatement", "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited", "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]", "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfNewAccountingStandardDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": { "auth_ref": [ "r89", "r91", "r92" ], "lang": { "en-US": { "role": { "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.", "label": "New Accounting Pronouncements or Change in Accounting Principle [Table]", "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Table]" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfNewAccountingStandardDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "New Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r64" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Total other income (expense)" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Nonoperating Income (Expense) [Abstract]", "verboseLabel": "OTHER INCOME (EXPENSE)" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NumberOfInterestRateDerivativesHeld": { "auth_ref": [ "r181", "r183" ], "lang": { "en-US": { "role": { "documentation": "Number of interest rate derivative instruments held by the entity at the reporting date.", "label": "Number of Interest Rate Derivatives Held", "terseLabel": "Number of instruments" } } }, "localname": "NumberOfInterestRateDerivativesHeld", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsAdditionalInformationDetails", "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsDesignatedAsCashFlowHedgesDetails" ], "xbrltype": "integerItemType" }, "us-gaap_NumberOfPropertiesSubjectToGroundLeases": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of separate real estate development properties located on land subject to ground leases.", "label": "Number of Properties Subject to Ground Leases", "terseLabel": "Number of properties subject to ground leases" } } }, "localname": "NumberOfPropertiesSubjectToGroundLeases", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesGroundLeasesDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total Expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Operating Expenses [Abstract]", "verboseLabel": "EXPENSES" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r235", "r243" ], "calculation": { "http://healthcarerealty.com/role/LeasesLeaseCostDetails": { "order": 1.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease, Cost", "terseLabel": "Operating lease expense" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Operating Lease Liabilities, Payments Due [Abstract]", "terseLabel": "Operating" } } }, "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r230" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 5.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Operating lease liabilities", "verboseLabel": "Lease Liability" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails", "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfNewAccountingStandardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r231", "r237" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Operating cash flows outflows related to operating leases" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r229" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfNewAccountingStandardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r240", "r243" ], "lang": { "en-US": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted-average discount rate - operating leases (percent)" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesLeaseCostDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r239", "r243" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted-average remaining lease term - operating leases" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesLeaseCostDetails", "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfNewAccountingStandardDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDue": { "auth_ref": [ "r224", "r226" ], "calculation": { "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsUnderAsc840Details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.", "label": "Operating Leases, Future Minimum Payments Due", "totalLabel": "Total" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsUnderAsc840Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent": { "auth_ref": [ "r224", "r226" ], "calculation": { "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsUnderAsc840Details": { "order": 1.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments Due, Next Twelve Months", "terseLabel": "2019" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsUnderAsc840Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears": { "auth_ref": [ "r224", "r226" ], "calculation": { "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsUnderAsc840Details": { "order": 5.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Five Years", "terseLabel": "2023" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInFiveYears", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsUnderAsc840Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears": { "auth_ref": [ "r224", "r226" ], "calculation": { "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsUnderAsc840Details": { "order": 4.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Four Years", "terseLabel": "2022" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInFourYears", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsUnderAsc840Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears": { "auth_ref": [ "r224", "r226" ], "calculation": { "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsUnderAsc840Details": { "order": 3.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Three Years", "terseLabel": "2021" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInThreeYears", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsUnderAsc840Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears": { "auth_ref": [ "r224", "r226" ], "calculation": { "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsUnderAsc840Details": { "order": 2.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Two Years", "terseLabel": "2020" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInTwoYears", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsUnderAsc840Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter": { "auth_ref": [ "r224", "r226" ], "calculation": { "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsUnderAsc840Details": { "order": 6.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due Thereafter", "terseLabel": "2024 and thereafter" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueThereafter", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsUnderAsc840Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsReceivable": { "auth_ref": [ "r227" ], "calculation": { "http://healthcarerealty.com/role/LeasesFutureLeasePaymentsReceivableUnderAsc840Details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Future minimum rental payments in aggregate as of the balance sheet date under operating leases.", "label": "Operating Leases, Future Minimum Payments Receivable", "totalLabel": "Total" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsReceivable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesFutureLeasePaymentsReceivableUnderAsc840Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsReceivableCurrent": { "auth_ref": [ "r227" ], "calculation": { "http://healthcarerealty.com/role/LeasesFutureLeasePaymentsReceivableUnderAsc840Details": { "order": 1.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsReceivable", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Future rental payments receivable within one year of the balance sheet date under an operating lease.", "label": "Operating Leases, Future Minimum Payments Receivable, Current", "terseLabel": "2019" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesFutureLeasePaymentsReceivableUnderAsc840Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsReceivableInFiveYears": { "auth_ref": [ "r227" ], "calculation": { "http://healthcarerealty.com/role/LeasesFutureLeasePaymentsReceivableUnderAsc840Details": { "order": 5.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsReceivable", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Future rental payments receivable within the fifth year from the balance sheet date under an operating lease.", "label": "Operating Leases, Future Minimum Payments Receivable, in Five Years", "terseLabel": "2023" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsReceivableInFiveYears", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesFutureLeasePaymentsReceivableUnderAsc840Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsReceivableInFourYears": { "auth_ref": [ "r227" ], "calculation": { "http://healthcarerealty.com/role/LeasesFutureLeasePaymentsReceivableUnderAsc840Details": { "order": 4.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsReceivable", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Future rental payments receivable within the fourth year from the balance sheet date under an operating lease.", "label": "Operating Leases, Future Minimum Payments Receivable, in Four Years", "terseLabel": "2022" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsReceivableInFourYears", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesFutureLeasePaymentsReceivableUnderAsc840Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsReceivableInThreeYears": { "auth_ref": [ "r227" ], "calculation": { "http://healthcarerealty.com/role/LeasesFutureLeasePaymentsReceivableUnderAsc840Details": { "order": 3.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsReceivable", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Future rental payments receivable within the third year from the balance sheet date under an operating lease.", "label": "Operating Leases, Future Minimum Payments Receivable, in Three Years", "terseLabel": "2021" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsReceivableInThreeYears", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesFutureLeasePaymentsReceivableUnderAsc840Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsReceivableInTwoYears": { "auth_ref": [ "r227" ], "calculation": { "http://healthcarerealty.com/role/LeasesFutureLeasePaymentsReceivableUnderAsc840Details": { "order": 2.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsReceivable", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Future rental payments receivable within the second year from the balance sheet date under an operating lease.", "label": "Operating Leases, Future Minimum Payments Receivable, in Two Years", "terseLabel": "2020" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsReceivableInTwoYears", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesFutureLeasePaymentsReceivableUnderAsc840Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsReceivableThereafter": { "auth_ref": [ "r227" ], "calculation": { "http://healthcarerealty.com/role/LeasesFutureLeasePaymentsReceivableUnderAsc840Details": { "order": 6.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsReceivable", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Future minimum lease payments receivable under operating leases for periods greater than five years following the balance sheet date.", "label": "Operating Leases, Future Minimum Payments Receivable, Thereafter", "terseLabel": "2024 and thereafter" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsReceivableThereafter", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesFutureLeasePaymentsReceivableUnderAsc840Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesIncomeStatementLeaseRevenue": { "auth_ref": [ "r225" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": { "order": 1.0, "parentTag": "us-gaap_Revenues", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The total amount of revenue recognized for the period from operating leases, including minimum lease revenue, contingent revenue, percentage revenue and sublease revenue.", "label": "Operating Leases, Income Statement, Lease Revenue", "terseLabel": "Rental income" } } }, "localname": "OperatingLeasesIncomeStatementLeaseRevenue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited", "http://healthcarerealty.com/role/LeasesLeaseIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAmortizationOfDeferredCharges": { "auth_ref": [ "r62", "r76" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization of other deferred costs recognized in the income statement.", "label": "Amortization of Other Deferred Charges", "terseLabel": "Other amortization" } } }, "localname": "OtherAmortizationOfDeferredCharges", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssets": { "auth_ref": [ "r16", "r249", "r264" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of assets classified as other.", "label": "Other Assets", "verboseLabel": "Other assets, net" } } }, "localname": "OtherAssets", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsMember": { "auth_ref": [ "r188", "r205" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other assets.", "label": "Other Assets [Member]", "terseLabel": "Other Assets" } } }, "localname": "OtherAssetsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfNewAccountingStandardDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherCommitmentsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Other Commitments [Line Items]", "terseLabel": "Other Commitments [Line Items]" } } }, "localname": "OtherCommitmentsLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CommitmentsAndContingenciesConstructionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OtherCommitmentsTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about obligations resulting from other commitments.", "label": "Other Commitments [Table]", "terseLabel": "Other Commitments [Table]" } } }, "localname": "OtherCommitmentsTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CommitmentsAndContingenciesConstructionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax [Abstract]", "terseLabel": "Interest rate swaps:" } } }, "localname": "OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax": { "auth_ref": [ "r37", "r41", "r190", "r195", "r206" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax", "terseLabel": "Amount of Loss Recognized in OCI on Derivative" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsEffectOfCashFlowHedgingOnAociDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax": { "auth_ref": [ "r41", "r43" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax", "negatedLabel": "Reclassification adjustments for losses included in net income (interest expense)", "terseLabel": "Amount of Loss Reclassified from OCI into Income" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited", "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsEffectOfCashFlowHedgingOnAociDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax": { "auth_ref": [ "r38", "r196" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after tax and adjustments, of gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.", "label": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), after Adjustments and Tax", "terseLabel": "Gains (losses) arising during the period on interest rate swaps" } } }, "localname": "OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementOfEquityUnauditedStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesBeforeTax": { "auth_ref": [ "r37" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before tax, after reclassification adjustments, of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).", "label": "Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, before Tax", "terseLabel": "Loss on forward starting interest rate swap agreement recognized in OCI" } } }, "localname": "OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesBeforeTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/NotesAndBondsPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r47", "r50", "r52", "r137" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Net of Tax", "totalLabel": "Total other comprehensive income (loss)" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]", "terseLabel": "Other comprehensive income:" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax": { "auth_ref": [ "r41", "r43", "r44", "r186" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of reclassification adjustment from accumulated other comprehensive income of accumulated gain (loss) realized from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's deferred hedging gain (loss).", "label": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, Net of Tax", "negatedTerseLabel": "Reclassification adjustments for losses included in net income (interest expense)" } } }, "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementOfEquityUnauditedStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax": { "auth_ref": [ "r37", "r41", "r208" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).", "label": "Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Net of Tax", "terseLabel": "(Losses) gains arising during the period on interest rate swaps" } } }, "localname": "OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilities": { "auth_ref": [ "r255" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities classified as other.", "label": "Other Liabilities", "verboseLabel": "Other liabilities" } } }, "localname": "OtherLiabilities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesMember": { "auth_ref": [ "r188", "r205" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other liabilities.", "label": "Other Liabilities [Member]", "terseLabel": "Other liabilities" } } }, "localname": "OtherLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsFairValueOfDerivativeInstrumentsOnBalanceSheetDetails", "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfNewAccountingStandardDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherNonoperatingIncome": { "auth_ref": [ "r64" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income", "verboseLabel": "Interest and other income, net" } } }, "localname": "OtherNonoperatingIncome", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForCapitalImprovements": { "auth_ref": [ "r67" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow for acquisition of or capital improvements to properties held for investment (operating, managed, leased) or for use.", "label": "Payments for Capital Improvements", "negatedTerseLabel": "Additional long-lived assets" } } }, "localname": "PaymentsForCapitalImprovements", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "auth_ref": [ "r69" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow to reacquire common stock during the period.", "label": "Payments for Repurchase of Common Stock", "negatedLabel": "Common stock redemptions" } } }, "localname": "PaymentsForRepurchaseOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "auth_ref": [ "r71" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.", "label": "Payments of Debt Issuance Costs", "negatedLabel": "Debt issuance and assumption costs" } } }, "localname": "PaymentsOfDebtIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDividendsCommonStock": { "auth_ref": [ "r69" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.", "label": "Payments of Ordinary Dividends, Common Stock", "negatedLabel": "Dividends paid" } } }, "localname": "PaymentsOfDividendsCommonStock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesGross": { "auth_ref": [ "r66", "r177" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.", "label": "Payments to Acquire Businesses, Gross", "terseLabel": "Cash consideration" } } }, "localname": "PaymentsToAcquireBusinessesGross", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsAndDispositionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireRealEstate": { "auth_ref": [ "r67" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow from the acquisition of a piece of land, anything permanently fixed to it, including buildings, structures on it and so forth; includes real estate intended to generate income for the owner; excludes real estate acquired for use by the owner.", "label": "Payments to Acquire Real Estate", "negatedTerseLabel": "Acquisitions of real estate" } } }, "localname": "PaymentsToAcquireRealEstate", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToDevelopRealEstateAssets": { "auth_ref": [ "r67" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Payments to develop real estate assets is the process of adding improvements on or to a parcel of land. Such improvements may include drainage, utilities, subdividing, access, buildings, and any combination of these elements; and are generally classified as cash flow from investing activities.", "label": "Payments to Develop Real Estate Assets", "negatedLabel": "Development of real estate" } } }, "localname": "PaymentsToDevelopRealEstateAssets", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r156", "r166" ], "lang": { "en-US": { "role": { "documentation": "Information by plan name pertaining to equity-based compensation arrangements.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquitySummaryOfActivityUnderStockBasedIncentivePlansDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the equity-based compensation arrangement plan.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquitySummaryOfActivityUnderStockBasedIncentivePlansDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PortionAtFairValueFairValueDisclosureMember": { "auth_ref": [ "r214" ], "lang": { "en-US": { "role": { "documentation": "Measured at fair value for financial reporting purposes.", "label": "Portion at Fair Value Measurement [Member]", "terseLabel": "Portion at Fair Value Measurement [Member]" } } }, "localname": "PortionAtFairValueFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/FairValueOfFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r20" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "verboseLabel": "Preferred stock, par value (dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r20" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "verboseLabel": "Preferred stock, authorized shares" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r20" ], "lang": { "en-US": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "verboseLabel": "Preferred stock, issued shares" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r20" ], "lang": { "en-US": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "verboseLabel": "Preferred stock, outstanding shares" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r20" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 6.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "verboseLabel": "Preferred stock, $.01 par value per share; 50,000 shares authorized; none issued and outstanding" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r68" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Proceeds from Issuance of Common Stock", "verboseLabel": "Net proceeds from issuance of common stock" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRepaymentsOfLinesOfCredit": { "auth_ref": [ "r87" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The net cash inflow or cash outflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with either short term or long term maturity that is collateralized (backed by pledge, mortgage or other lien in the entity's assets).", "label": "Proceeds from (Repayments of) Lines of Credit", "terseLabel": "Net (repayments) borrowings on unsecured credit facility" } } }, "localname": "ProceedsFromRepaymentsOfLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleAndCollectionOfNotesReceivable": { "auth_ref": [ "r65" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow associated with the proceeds from sale of notes receivable, as well as principal collections from a borrowing supported by a written promise to pay an obligation (note receivable).", "label": "Proceeds from Sale and Collection of Notes Receivable", "verboseLabel": "Proceeds from notes receivable repayments" } } }, "localname": "ProceedsFromSaleAndCollectionOfNotesReceivable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RealEstateHeldforsale": { "auth_ref": [ "r272" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Carrying amount as of the balance sheet date of investments in land and buildings held for sale, excluding real estate considered to be inventory of the entity.", "label": "Real Estate Held-for-sale", "terseLabel": "Net investment in property held for sale" } } }, "localname": "RealEstateHeldforsale", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAssetsHeldForSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RealEstateInvestmentPropertyAccumulatedDepreciation": { "auth_ref": [ "r270" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_RealEstateInvestmentPropertyNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cumulative amount of depreciation for real estate property held for investment purposes.", "label": "Real Estate Investment Property, Accumulated Depreciation", "negatedLabel": "Less accumulated depreciation and amortization", "negatedTerseLabel": "Accumulated depreciation" } } }, "localname": "RealEstateInvestmentPropertyAccumulatedDepreciation", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://healthcarerealty.com/role/RealEstateInvestmentsDiscontinuedOperationsAndAssetsHeldForSaleBalanceSheetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RealEstateInvestmentPropertyAtCost": { "auth_ref": [ "r271" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_RealEstateInvestmentPropertyNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of real estate investment property which may include the following: (1) land available-for-sale; (2) land available-for-development; (3) investments in building and building improvements; (4) tenant allowances; (5) developments in-process; (6) rental properties; and (7) other real estate investments.", "label": "Real Estate Investment Property, at Cost", "totalLabel": "Real estate properties, Total" } } }, "localname": "RealEstateInvestmentPropertyAtCost", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://healthcarerealty.com/role/RealEstateInvestmentsDiscontinuedOperationsAndAssetsHeldForSaleBalanceSheetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RealEstateInvestmentPropertyNet": { "auth_ref": [ "r271" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://healthcarerealty.com/role/RealEstateInvestmentsDiscontinuedOperationsAndAssetsHeldForSaleBalanceSheetDetails": { "order": 1.0, "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of real estate investment property, net of accumulated depreciation, which may include the following: (1) land available-for-sale; (2) land available-for-development; (3) investments in building and building improvements; (4) tenant allowances; (5) developments in-process; (6) rental properties; and (7) other real estate investments.", "label": "Real Estate Investment Property, Net", "totalLabel": "Total real estate properties, net" } } }, "localname": "RealEstateInvestmentPropertyNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://healthcarerealty.com/role/RealEstateInvestmentsDiscontinuedOperationsAndAssetsHeldForSaleBalanceSheetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RealEstateInvestmentPropertyNetAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Real Estate Investment Property, Net [Abstract]", "verboseLabel": "Real estate properties:" } } }, "localname": "RealEstateInvestmentPropertyNetAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_RepaymentsOfDebt": { "auth_ref": [ "r70" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.", "label": "Repayments of Debt", "negatedTerseLabel": "Repayments on notes and bonds payable" } } }, "localname": "RepaymentsOfDebt", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r100" ], "lang": { "en-US": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]", "terseLabel": "Restricted Stock" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquitySummaryOfActivityUnderStockBasedIncentivePlansDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r146", "r147", "r148" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": { "order": 2.0, "parentTag": "us-gaap_Revenues", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Other operating" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited", "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r88", "r151" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]", "terseLabel": "Revenue from Contracts with Customers (Topic 606)" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r59", "r110", "r111", "r116" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "totalLabel": "Revenues" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Revenues [Abstract]", "verboseLabel": "REVENUES" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": { "auth_ref": [ "r238", "r243" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability", "terseLabel": "Right-of-use assets obtained in exchange for new finance lease liabilities" } } }, "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r238", "r243" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Right-of-use assets obtained in exchange for new operating lease liabilities" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]", "terseLabel": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r172", "r173" ], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsAndDispositionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": { "auth_ref": [ "r172", "r173" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.", "label": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]", "terseLabel": "Summary of acquisitions" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r197" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of gain (loss) on derivative and nonderivative instruments designated and qualifying as cash flow hedge recorded in accumulated other comprehensive income (AOCI) and reclassified into earnings.", "label": "Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss)" } } }, "localname": "ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.", "label": "Schedule of Debt [Table Text Block]", "terseLabel": "Schedule of Debt" } } }, "localname": "ScheduleOfDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/NotesAndBondsPayableTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r195" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the effective portion of the gains and losses on derivative instruments designated (and non-derivative instruments) designated and qualifying in cash flow hedges and net investment hedges that was recognized in other comprehensive income (loss) during the current period.", "label": "Schedule of Derivative Instruments, Effect on Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Schedule of Derivative Instruments, Effect on Other Comprehensive Income (Loss)" } } }, "localname": "ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": { "auth_ref": [ "r194" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.", "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]", "terseLabel": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value" } } }, "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": { "auth_ref": [ "r1", "r2", "r3", "r4", "r5", "r6", "r7", "r9", "r11", "r12", "r13", "r125", "r126" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.", "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]", "terseLabel": "Assets held for sale" } } }, "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r101" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Earnings (loss) per share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r156", "r166" ], "lang": { "en-US": { "role": { "documentation": "Components of an equity-based arrangement under which compensation is awarded to employees, typically comprised of compensation expense; changes in the quantity and fair value of the shares (or other type of equity) granted, exercised, forfeited, and issued and outstanding pertaining to that plan; and cash flow effects resulting from the equity-based payment arrangement. Component disclosures are by type of award and plan name.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquitySummaryOfActivityUnderEmployeeStockPurchasePlanDetails", "http://healthcarerealty.com/role/StockholdersEquitySummaryOfActivityUnderStockBasedIncentivePlansDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock": { "auth_ref": [ "r165" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of employee stock purchase plan activity.", "label": "Schedule of Share-based Compensation, Employee Stock Purchase Plan, Activity [Table Text Block]", "terseLabel": "Summary of employee stock purchase plan activity" } } }, "localname": "ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r33", "r84", "r134", "r135", "r136", "r138", "r139", "r140", "r141", "r142", "r143", "r144" ], "lang": { "en-US": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]", "terseLabel": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityReconciliationOfBeginningAndEndingCommonStockOutstandingDetails", "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SeniorNotesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors.", "label": "Senior Notes [Member]", "terseLabel": "Senior Notes" } } }, "localname": "SeniorNotesMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/NotesAndBondsPayableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r75" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.", "label": "Share-based Compensation", "verboseLabel": "Share-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r163" ], "lang": { "en-US": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "verboseLabel": "Granted (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquitySummaryOfActivityUnderStockBasedIncentivePlansDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r162" ], "lang": { "en-US": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Share-based awards, end of period", "periodStartLabel": "Share-based awards, beginning of period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquitySummaryOfActivityUnderStockBasedIncentivePlansDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "verboseLabel": "Summary of the activity under the incentive plans" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquitySummaryOfActivityUnderStockBasedIncentivePlansDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r164" ], "lang": { "en-US": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedTerseLabel": "Vested (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquitySummaryOfActivityUnderStockBasedIncentivePlansDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquitySummaryOfActivityUnderEmployeeStockPurchasePlanDetails", "http://healthcarerealty.com/role/StockholdersEquitySummaryOfActivityUnderStockBasedIncentivePlansDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "auth_ref": [ "r161" ], "lang": { "en-US": { "role": { "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period", "negatedTerseLabel": "Expired (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquitySummaryOfActivityUnderEmployeeStockPurchasePlanDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r160" ], "lang": { "en-US": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period", "negatedTerseLabel": "Forfeited (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquitySummaryOfActivityUnderEmployeeStockPurchasePlanDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "verboseLabel": "Granted (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquitySummaryOfActivityUnderEmployeeStockPurchasePlanDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r158", "r166" ], "lang": { "en-US": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Outstanding and exercisable, end of period (shares)", "periodStartLabel": "Outstanding and exercisable, beginning of period (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquitySummaryOfActivityUnderEmployeeStockPurchasePlanDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]", "verboseLabel": "Summary of the Employee Stock Purchase Plan activity" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquitySummaryOfActivityUnderEmployeeStockPurchasePlanDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r154", "r157" ], "lang": { "en-US": { "role": { "documentation": "Equity-based compensation award.", "label": "Equity Award [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquitySummaryOfActivityUnderEmployeeStockPurchasePlanDetails", "http://healthcarerealty.com/role/StockholdersEquitySummaryOfActivityUnderStockBasedIncentivePlansDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SharesIssuedPricePerShare": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "Shares Issued, Price Per Share", "terseLabel": "Shares Issued, Price Per Share" } } }, "localname": "SharesIssuedPricePerShare", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "For net-share settlement of share-based awards when the employer settles employees' income tax withholding obligations, this element represents the number of shares the employees use to repay the employer.", "label": "Shares Paid for Tax Withholding for Share Based Compensation", "terseLabel": "Shares withheld to pay estimated withholding taxes" } } }, "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquitySummaryOfActivityUnderStockBasedIncentivePlansDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r88" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r34", "r137" ], "lang": { "en-US": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementOfEquityUnauditedStatement", "http://healthcarerealty.com/role/StockholdersEquityReconciliationOfBeginningAndEndingCommonStockOutstandingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementOfEquityUnauditedStatement" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Balance Sheet data (as of the period ended):" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsDiscontinuedOperationsAndAssetsHeldForSaleBalanceSheetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementOfEquityUnauditedStatement" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r20", "r21", "r137", "r144" ], "lang": { "en-US": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Issuance of common stock (shares)", "verboseLabel": "Issuance of common stock" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityReconciliationOfBeginningAndEndingCommonStockOutstandingDetails", "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": { "auth_ref": [ "r20", "r21", "r137", "r144" ], "lang": { "en-US": { "role": { "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures", "terseLabel": "Nonvested share-based awards, net of withheld shares" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityReconciliationOfBeginningAndEndingCommonStockOutstandingDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r20", "r21", "r137", "r144", "r159" ], "lang": { "en-US": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedTerseLabel": "Exercised (shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquitySummaryOfActivityUnderEmployeeStockPurchasePlanDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r20", "r21", "r137", "r144" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Issuance of common stock, net of issuance costs" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementOfEquityUnauditedStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchasedAndRetiredDuringPeriodValue": { "auth_ref": [ "r20", "r21", "r137", "r144" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).", "label": "Stock Repurchased and Retired During Period, Value", "negatedTerseLabel": "Common stock redemptions" } } }, "localname": "StockRepurchasedAndRetiredDuringPeriodValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementOfEquityUnauditedStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r21", "r23", "r24", "r119" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "totalLabel": "Total stockholders' equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://healthcarerealty.com/role/CondensedConsolidatedStatementOfEquityUnauditedStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]", "verboseLabel": "Stockholders' equity:" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r145" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "verboseLabel": "Stockholders' Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsAdditionalInformationDetails", "http://healthcarerealty.com/role/NotesAndBondsPayableDetails", "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsAndDispositionsDetails", "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r245" ], "lang": { "en-US": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsAdditionalInformationDetails", "http://healthcarerealty.com/role/NotesAndBondsPayableDetails", "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsAndDispositionsDetails", "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r245" ], "lang": { "en-US": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsAdditionalInformationDetails", "http://healthcarerealty.com/role/NotesAndBondsPayableDetails", "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsAndDispositionsDetails", "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]", "terseLabel": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "verboseLabel": "Supplemental Cash Flow Information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_TypeOfAdoptionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Adoption and early adoption of sources of change to generally accepted accounting principles (GAAP) in the United States. The FASB released the FASB Accounting Standards Codification as the authoritative source of literature effective for interim and annual periods ending after September 15, 2009. As part of the Codification process, the FASB issues Accounting Standards Updates to amend the Codification but otherwise the Accounting Standards Updates are not authoritative in their own right. All previous accounting standards (such as FASB Statements of Financial Accounting Standards, FASB Interpretations, FASB Staff Positions, Emerging Issues Task Force Consensuses, other pronouncements of the FASB or other designated bodies, or other forms of GAAP are considered accounting pronouncements) were superseded upon the adoption of the Codification. For an interim period, references to the superseded standards are included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.", "label": "Type of Adoption [Domain]", "terseLabel": "Type of Adoption [Domain]" } } }, "localname": "TypeOfAdoptionMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesGroundLeasesDetails", "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfNewAccountingStandardDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r103", "r104", "r105", "r106", "r107", "r108", "r109" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates in the Condensed Consolidated Financial Statements" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_VariableLeaseCost": { "auth_ref": [ "r236", "r243" ], "calculation": { "http://healthcarerealty.com/role/LeasesLeaseCostDetails": { "order": 2.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.", "label": "Variable Lease, Cost", "terseLabel": "Variable lease expense" } } }, "localname": "VariableLeaseCost", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r95", "r99" ], "calculation": { "http://healthcarerealty.com/role/StockholdersEquityComputationOfBasicAndDilutedEarningsLossPerCommonShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-US": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "totalLabel": "Weighted average Common Shares outstanding\u2014Diluted", "verboseLabel": "Weighted average common shares outstanding - diluted (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited", "http://healthcarerealty.com/role/StockholdersEquityComputationOfBasicAndDilutedEarningsLossPerCommonShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesIssuedBasic": { "auth_ref": [ "r93", "r94", "r101" ], "calculation": { "http://healthcarerealty.com/role/StockholdersEquityComputationOfBasicAndDilutedEarningsLossPerCommonShareDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "This element represents the weighted average total number of shares issued throughout the period including the first (beginning balance outstanding) and last (ending balance outstanding) day of the period before considering any reductions (for instance, shares held in treasury) to arrive at the weighted average number of shares outstanding. Weighted average relates to the portion of time within a reporting period that common shares have been issued and outstanding to the total time in that period. Such concept is used in determining the weighted average number of shares outstanding for purposes of calculating earnings per share (basic).", "label": "Weighted Average Number of Shares Issued, Basic", "verboseLabel": "Weighted average Common Shares outstanding" } } }, "localname": "WeightedAverageNumberOfSharesIssuedBasic", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityComputationOfBasicAndDilutedEarningsLossPerCommonShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]", "verboseLabel": "Weighted average Common Shares outstanding" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityComputationOfBasicAndDilutedEarningsLossPerCommonShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r93", "r99" ], "calculation": { "http://healthcarerealty.com/role/StockholdersEquityComputationOfBasicAndDilutedEarningsLossPerCommonShareDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "totalLabel": "Weighted average Common Shares\u2014Basic", "verboseLabel": "Weighted average common shares outstanding - basic (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited", "http://healthcarerealty.com/role/StockholdersEquityComputationOfBasicAndDilutedEarningsLossPerCommonShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesRestrictedStock": { "auth_ref": [ "r94" ], "calculation": { "http://healthcarerealty.com/role/StockholdersEquityComputationOfBasicAndDilutedEarningsLossPerCommonShareDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic", "weight": -1.0 } }, "lang": { "en-US": { "role": { "documentation": "Number of shares of restricted stock determined by relating the portion of time within a reporting period that restricted shares have been outstanding to the total time in that period. Restricted shares are subject to sales, contractual, regulatory or other restrictions that prevent or inhibit the holder from freely disposing of them before the restriction ends.", "label": "Weighted Average Number of Shares, Restricted Stock", "negatedTerseLabel": "Nonvested shares" } } }, "localname": "WeightedAverageNumberOfSharesRestrictedStock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityComputationOfBasicAndDilutedEarningsLossPerCommonShareDetails" ], "xbrltype": "sharesItemType" } }, "unitCount": 11 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109256448&loc=d3e4984-109258" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2599-110228" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230" }, "r127": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14326-108349" }, "r129": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6036836-161870" }, "r133": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770" }, "r145": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130539-203045" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130543-203045" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130545-203045" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=108792157&loc=SL49130690-203046-203046" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6812-107765" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=108792157&loc=SL49130690-203046-203046" }, "r151": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=79507207&loc=d3e4534-113899" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(4)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109196918&loc=d3e11149-113907" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109196918&loc=d3e11178-113907" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=84229725&loc=d3e845-128460" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=84229725&loc=d3e848-128460" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=109124213&loc=d3e6578-128477" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=109124213&loc=d3e6613-128477" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4613673-111683" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579240-113959" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579245-113959" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579245-113959" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5580258-113959" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)(ii)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41620-113959" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41620-113959" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "c", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41638-113959" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41638-113959" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "4E", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624181-113959" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41641-113959" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41678-113959" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "182", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109975725&loc=SL5629052-113961" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109974929&loc=SL110061190-113977" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "25", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109977999&loc=d3e76258-113986" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109978405&loc=d3e80720-113993" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=112277219&loc=d3e80748-113994" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "815", "URI": "http://asc.fasb.org/topic&trid=2229140" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=SL6742756-110258" }, "r213": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "820", "URI": "http://asc.fasb.org/topic&trid=2155941" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=75026489&loc=d3e13220-108610" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=109250915&loc=d3e13433-108611" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=109250915&loc=d3e13467-108611" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=109250915&loc=d3e13476-108611" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(Note 3)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=82846649&loc=d3e38371-112697" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=77902458&loc=d3e39896-112707" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=84164653&loc=d3e41551-112718" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=113997351&loc=SL77916155-209984" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888428&loc=SL77919396-209981" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=SL51823488-111719" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-10(c)(3)(ii)(A))", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=82851474&loc=d3e511914-122862" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-10(c)(7)(ii))", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=82851474&loc=d3e511914-122862" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(1),(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(13)(f))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(14)(d))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(10))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),1(d))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.1(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.1(d))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.1(f))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.10)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.15)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(10))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(3)(a))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=99384497&loc=SL65671331-158438" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.15)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=6589523&loc=d3e617274-123014" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=6590653&loc=d3e638233-123024" }, "r282": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r283": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "a", "Publisher": "SEC", "Section": "303", "Subparagraph": "5" }, "r284": { "Article": "12", "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "13", "Sentence": "Column B" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.28,29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669646-108580" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(dd)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669646-108580" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i-k)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669646-108580" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669646-108580" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=d3e637-108580" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669686-108580" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=d3e689-108580" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "17A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL34724391-108580" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "17B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL34724394-108580" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=d3e557-108580" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=109228884&loc=d3e1436-108581" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(12))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(b)(7)(c))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(b)(9)(a))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.13)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(c))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3179-108585" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3291-108585" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3291-108585" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3291-108585" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "21D", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=SL94080555-108585" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3521-108585" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3536-108585" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3044-108585" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(d),(e))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(e),(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(n)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690" }, "r88": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22580-107794" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1448-109256" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e2646-109256" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1505-109256" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1252-109256" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=SL5780133-109256" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1337-109256" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" } }, "version": "2.1" } ZIP 67 0000899749-19-000048-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000899749-19-000048-xbrl.zip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end

G&INHFN1L$M'CA=>3!NX#B+AL,7D5V$(C3H0 M4"CU9 "D]%; $T.*M\RP"W =JE5OOX]J:X]LK[?ES, MIG78=/29$-=LH1&BACH7OX\ A''&'\%D' H9]$;8.BN9?74$JI],2>:*^,E(II)Z=.1KCC6-&;O;0H>C,PE;Y=);:/; MS#7?H_/^TR"'0 ,L&-4:@?H ^PI6]:[*XZX45C%]B%].E2*K\WC@@@CK,.5<6\&! M$,A4834DF,G9D.)CI5F' %_SW,S3X^-D\?/F3DU7<32KG^N98J+.D7LRT\\,T!TNYJL4B91&N;W[5/Y_;?)S\3+]; M'Q.\X.A-WF<$BH4EWAG +/!$ $3D#D?AQ+@/ZM0FT?&#.KW"W]>*M>G@^>2: M%^V"E1P8Z! VB%D"==24L!H+(#3GS/P J70%#I3MH=]KY*<1-L^CF]^FA2HE MO)W/V.G@XX*$$$,G-'1>,"84M8I4R$)D1L;KAJPZ%&>ZKB#ZHO@+T^IL;M"! MU@$89 &'3C$&*5( ^ZJ<7&I1E=9Z;KD>%U",%L@@]&EQU"KL[^<__* (1: M.B6\YZF&,Y$,5ZBE,Y'CVMNY_OK?N\@&3_2;;^M*$;4KXW7[@0$R @RA42HN$;&LNM"G!-S@_-G'6?J;&YK-2II>'B*>K;**P MB33 B9VZBZMMG[.BZP)_0Z%G=[.ED5#?RD3Y+39<+=_--YM7ORW*92,\#/?NN*&QO6NQO16]OU>@L9J['>K] M Y\6#''0&(-AE"3C2!+/=NNIM#SGGJGZF4G_[=/AZG)]*_/%_?@VVUXEV,-\ M.?!I40\Q!+'B&B/-H:#*\MVBRD!6&:+Z>5I_SY.>\C?!YR M$4U/*K6G%:8&FISC9A>GI'5;B'>D$R57I(/+3MH?QH^;?5_G)BW? M:G(2ADH!)02UDD*%J5-PNW\$@9.PUH[QW\E)17#066 1T!0*;R$V6,D*1P3H MR,IL-"519\E)E\'?VY&0[;[OF=RD_68!VVAX"Q(1C$:# -ACSJJ1&,A[W6%_ M2UN3M1GP^G!(<_#[IM'9G*)7>0:8,LJ00QARJZDW<>V'U6APWI'K 5*IF2"/ ML*$1@ADE._9MB5-E&HZUCMZ' ]H)R2EB'ED&&2153Y64O=Y%U9^L+Q73ZTH= MV4 ..\T56.H%$Q1YX2B,=K]'HAJ+B#_^G>;2[EJ2@_Y@ @)O(,V5 .<5,43$ MNW M 7H7V>")O@D6O9O'.?VT!OYF];58?/DZF6^#Q!_*^?4T-"-S6W.E#LB.:9]WMY%W:AP ]D2PZ[19R M[./R#KFS.QD(WNN)M<&GV'9,\_YG8R,2O/V)^#+7\BKS\&47@A'1I/$(6J11 MY (L_C0B[64&0\$UZ8Y\TD2'*N"!S8 MY>]_S\)6*-!O:=J/D]EM1/++Y,<_9ZNO*6-M-K^/OSB,SKD9=>'K@D*8,6)I M--4-E]!H!%6%#)-*])*\/)R@^( F1K>2O&(>YCH<^_82*XD1F FE&5%6:Z Q MQ09SZAT1Q M8JV!OC?213\6TG$]G#[,UWC=WNKB?S5/5235/ZT;\9J]FX%XV M[AK5+Q%'_7"X-'%K[PY0$$D9LIP JQQ@3E%<(6'B?^/:2&M*@_*ZL/>VB.TV M:-QDD0:UJU\95=1L&H=H9P]/R?DX1]#,-P9 4CU,2H# !!M*H]H#6WPH\2"G MHO8 DV,R:=DOV'V1T>(V)5A2>& M?B3WF+=,WNL*H7\->WB,1^OK5N=<&FC>5CXI8&2)Q#RW0K-:63L=J9=3^-?2&K5>$)AESAB@)-*: 0.) MJ,IY1@0\RC'/!N@UM$&%UXJA"YP'-M^O?>JR[6F/.%2(OVVIFAML95M@]KHR-&[=>PQ&;3OYI_BO'/+=#W;QT7YK5BLTKCFM[^7B]7] MY+[X4*X.7M/8X"V!8&TI$M9IP+2Q7GMBJI%Q1G-\E@'1I179EGVAW(@_FUV2 MF[OG_CSW\@A93CX2O#,0&A37-2PB*-0#KJL^4T-S2J(,*!33,C/:A+01#0Y^ M\):9/V_^FJ=][:J3ZPL@CW#C\O<$;P02A"A@@&,<0V#LSB;"&.6<=KPX_-%E MNE++E.D[.(;IZN9.W9;?-MMT M'R)HNV:?TY[<9'$[-@<5,F@$$8 9+A5TF&*"UM%!B@&SOE:><#3^;_#E[F*5(9#VN_/) \-+ Z$@@ZI2V4DN/?#6OD.4\ M)SUP0,&_K@F3BVMOD9O-XKS\./F9UF0UOXV_63Q%^5S I/HO"=%E=19 9JSB M'FB,."45"B)ZH.-*E.J 79UAW1OC;O_UM UU^G)QPH(\5UKMDO<$A32PWAC" M%(*&0@!L!3=2!(_LAL'KV.5=2J0O=J;"2<]1I+.:[U#S (& 0'(<1^$Q]T8Z MZJN1 :O&EBK3C=3+UH'N>4G=BSHN__AV.UD5L3T#J.YJ>OKYX"VA@ K#3129 MEPXA6QFAV%H]LII[>>(_O(2V"G!#DRK^*GQ*^OK(:OCB[T%[ M HV&P",89Y-,J[VI^JQ,UG70 [2N^EWEE/:+-L%200E!T?K7!%H?A[MS M,S!F;B1UJ!M+K&P'MTYE/OEQ7N;[;8+SVCBB-->8 2N$LZ+B.]%6]UH\:. R MS\"M2YG_LYC=?UT5M^I[L9BX'VP9D@(804ZXUP.O"?ZS:WR/2D%[C+%VF M2K3!@C80[,NY:&KSO*]1W3;[W4%;J3P#!'')+)=8.EBA3XCSL,_2 M4E_,?E\LET5Q\ZU(%_G-[]\7DV7QI5@\WMR9;\PT$+)SBS6FACG+0* M(VFWHZ:6CNU&CAY94G8LBMXVT%YT^=6B\*E(4?O]\< 3=+ST5<%[S9RPV#H7 M5QLC/%95*(,Z('N]K'W,Y.Q8,-?4E>DT?0+LTV1U*G_NW*.!&:T)X4 (#) U MP&%8K4N4&Y>SAH\HAM2-GLP0Q'6TY*T5(%0# M+C3'"A&_&RN(7_XV'+O0?WE2N [CJFWN4V=+CCP1.#5:.6@ C18(]D1+5+ET M5$/G'VK_7B03BB-(;$6 M60&8M%"HW5R!-&?_[>*KL,?(I0Z%,;"C*Z,KEN*%I\A2ADRJDH$Y=&ASUI5) MK+1NJ]3BA\EJ73IJRXUROD'RYYDJBFS9;I;_@48/\\SZK(7A*C_!.!*,J^IUXHR96PU>@B$'Y>C MWR*W.L6Y+Y9%2_OFSBU7Z[.8IT+Q+QL&I3"V$CK%*:' VXB9KT9C:-;%L0/T MR3M@31:>?;'C4_&]F#\5/@)2A4I3Z6CS% V@QV)11PO5?450V-$X:LPEYP#[BI2O?I:\*0EF##3#,.NBU% 935R&B"<\I M/#1 -[P#[G6,^,#\H^U,2V6X8ZOU$8J1G>+7VG*%1$I24Y:3^./6).;("UCO M5'HW([6SY>3^?I'N'UH75=C*XMPA_5./!4$TQY11ZYD6 !I&.:]&:Y4;V?G5 M-L3^:]WDMM#M,HDI*J;;I^GJ9O$YE3"9GLI@/M0T &LM)49":I!G!D2(1#42 M:-7(,MS;$6K9*J8]L",5S-MV<'GT4/S)]H%##:C$7%MAD.*$.H.J,5'D1L*3 M?)'^RHUL,!N%Z#].%O^.ZO#=/-H!QU,;#S<,G,(X%;SS(!K/T:1ADN[ZAY', MB9\,4]@Y,BI;A+*1J#\EF!_6,?O?GB;IBLN?IP1^M'DZMB;PO01L+_?3*?;.YN\$5Q?K8?;1YL5&W19]9"6Q@=:86B M@JOZ2B3.F?,#BGZU+ORV &TF_-ER6CP\3.9%^72\@,#AA@$@A8Q%VH&DFA3V MR,J=9J(N9Y]^0,&I]@6>#65?T:SI:2!^/_ME\F/YJ'T0V\+RC.E,!$,2V"A ME9P#5^'"K<^YCG- UFG[-+DLMMX"] ,+<5[Y3LVVXYFI$BV% MEH8UKA@>*" M&V6!B5\LE;6R.?N/9]:\-^[\\W'1I<@XZ+&F2#"D$6*X&K^26=NU U0#;1#A M@@AG4YAK3/GM'](_?T:7Z7__Y_\!4$L#!!0 ( "*'H4X'&$/,SP@ !DZ M 4 :'(M,C Q.3,S,7AE>#,Q,2YH=&WM6VMS&CD6_9S\"@VIF7*JP#R= MV)BXRH%VF:E)G''(9O>C: E::W6+D=1@]M?OO5(##<8QCG$V[)"JX&X][U6? MN7SE6[]Z]/ 8EL+,FG+^__Z+9)H50N?ZVWR^5.KT,N>Q_^((W#2I7T M-$V,L$(E5);+P<<"*436CIKE\F0R.9S4#Y4>EGO791RJ499*&7[(+"NU\Z/W]3=O"V>M,H7_KM?L9S:S% DO11S5:%9K ME5]/1Y0Q4+C45]:JN%FMCV[G95:-?('EM[9$I1@F3;FIU?BSY1J&%E.29MK*P8BI&A\?WJY M/Z7:I!0&L8I\YB'*_-NKZIO**3"/J &Q$2>?J>[3A)O2U:WD4W(>6JRI5;;' MS>VHMUUN_ALP* ;3IPO5+9*>8HS\?D@^<,V9L%&1A XE4UA?:IO+(EO:EQP: M2)D)^*Y0*;A[,Z+A[#X38(T.W_*:Y*XYL[!DELW&FPAFHV;C&,9!!VD95F87 M9==TJ?D8U0BIS-8,/&'AVVN^O#@SZ=$V-VL-/^ECU[=ZN.(@O=#WBWCZ@(S/ M @(2T3$GFH\%GT#X9"-AR%]SHZ$Y&#J@54(NE(Y)M5+Z$SFVB6D\7:.]>U)E M!Z0]GA[[J&J[@*?WU "* "_QE-PD:B(Y&_*BAU4&)J;@424*0G;H2T5":#(E M:6)URF$F@(Z+YP%EE,1PIP659$#1N&NB8N%<@FMWIT'"0VX,Q(C8)*8WW+F) M^9@&RA@( U-*EPAD?B04&I((:)9 =Y"$<4TFD0@C8E+\6?2?@)W,!D$%8F$D MI >8<$S >H*"9@2^"F?'<4<@FF*@YAC-*^E/\\NPI\>6Z5'?:7IP,A ) !"Q MO !<$;@!S:%:Y^I%,@!C[.(XN YERF!, '4.744@A$ #/@),(IV09E(N^))! MU:Q,#91D+CLO8HM40@,@B0(DN^F,DR>D)B(#J29FQB#-A\) E@8342ST#\]NJX5GU[:C*T9W$HFE8U@*R%ZP/SVJ&J M2S#L0/P"'@7B G!&N$&,"!-A#VP6@V=![X+W3)A0*I-"/_0Y6DD/Y)%6(6=0 M;,@!X)9Q((('9W ;1C09BNH1\W?^5F">D'@"X?@$ M;7Z.5Q[G*,O&$PV6)AK 1*CG*MN@!09PS1U@T,F;_P&#WM:^CT%T%QC4X0;& M R"Y..5AE!"(Z4& M RMG-(R+PIQK48:#0!9<&78:47Q:J:3H$4$M)\0B0(,>/MS+1ZEPU>?8$)P6 M]-^-?&:G*-;?/8IM;.;O,&US![$QX8"D8\&01]2HQ(&/&N @IC%(+JK9#.A M/4'[0@K(U"%D6S@(_L;XC*:O4GN_!)MX53IOS3%=&SR<_9/^ M+!%TUH'[E0!Y3G'P/1NVRP:V"VSH>*#=!2QNCV5)@JM9RXI'^!<,T%08IAIA MF8N&UHP:*V.A'%^#P%@&UFBV-TP.[NDR 'Z!Y5]IG0D> NK=SAYN^B7I7*[7 M7JJ(FGGHB#[#\9$SYTS=>F2.;DJDN.$RV^9;:5]\\A+M"@=W:DOB:![SS\'7<> MSB4D!#"B.U 77%'*Q0<4)N%7_,=@ FG-QA/^03!150NM7%OH!5382N"W;DF70/KT(RE+S]X![LF+O,V3,]LZ:>7Q9XQ^T G 343(]5]ZMI69"B)AT-?=YR=(T#K*Y8.H%6\*'F4*OV7W5J0% M/IE;-"MQ11E_B#:%[)'TP]UR70B4E'1G>G%W<@>?HHWO^8L[7+54>W^ND:N[F'#[-&T$IROG/[-W\].".>*_-ID-GK-L\YU MN9]&WYON@HU<%SO^O^K[@4Z]W:@6W0'T'Z!Z;0/5T5O@J_QF)!A0^;G,X_-B M^F=3].^N7V9=%W0B[G4>>55Q_YY%_Q_!X;(ID]Y5I^..S ;70:?;N]SC?*_? MKN%X]=CW'L-[_78-PY\T-P*3#[=#TXX$'Y#@EH(9@7--);=JU=44D+IK^^YTC+'<V1=([V>/2>7 MW5\_DNIAL42ZBB::&RX3*CRO?94CNCPPI%TLU\EFJ>SZD$PG#C6!G[8>(][AI>.X2)O.RV1H]&8R) M-F/!WN="F9A"2&,NQO4NCYDF5VQ$;F5,DU-[3_._6+U4')A35#S@P[,&)0F- MH:^N59O-6K76:A^UCMNUVGFI]*%:;IXTV\V3=J7UH9P[:W@4_MM>DX_)S((G MK! Q-*->*A??G@YH$(#!A9XT1L;U4F7P,&TS@ITQ.:)JG,*VWO/5;VZ1M&"9GX!VA3U35VG<4S5>!O:M]JW MWNRT[X@%YVKYE6KT_P(S2#1O@5 W]Y]:EYU2?>: MW+5;MDNE6%ZT_NL-M9B<4['V7)NP@[T:N3E[4@0P0H9E4BD=;DU7'YC&U LH M>\FH,)%/%2.W^'4,CB+5AG027ZJ!5$CM[]Z(WU*J8&0Q)BVF# ^Y3]'1??=Z MWZ1*IQ0&,9+<,1]U_O%-Z;AX"B@G,B0F8N2.JAY-F"Y$&0@2*1]076>^/:YC,$B:NJ+BAO:$PP$ MA,C4?)\KYNRU'E!_#/[ MXEG1!?$AFN%3D:T<6)G[\LHO+M%$>W2Q]7+53?K<52X=+KE_I_3C*IX^H>.+ M0(%$=,B(8D/.1I 4IHJ!:P$@)^1"JIB4BH7?$-6;.*/3-=;;)^59 M(.WQ]-Q'5=X%/'V@&E $>(G'Y#Z1(\&"/LL[6&5@"B0\JD1"0@I]*4\(3<8D M38Q*&"A!3=J2(RYM8)6[D5@83Y3&O(@% DIO?,.N;I MF!K: E &IA0VS+'K/^( >+=(&A S+6 MY!?3Z1$W$1BH!Q =<'8<=P"JR0#,A$<#B](;SR_#GAY;ID=EI^G!2,@3 "!B M>0:X/' #Q V&Z-E]GH3@C&WF!-]]D08P)H!Z#EUY( 1'!SX 3"*=D&9"S/B2 M054O30V4#&SMF4>)5( D$0"DNUTVNKC4QV14,B1GC!(L3ZD$@HS)(J-3F_0 M,C]'!#U19D7;/1>VS(7J+G"ANP"<']^H,[5D>BJY5AE G,'6@WUE4 M=0BF'8A?P"-'7 #."-.($:XC[(%B,406C"YX'7#M"ZE3Z( DFZ<\C?(\IE ^3?7F73"7Z3% ;#:3RXYDJF <.M#KFVP "F6V'&P<)R% MF?E0I9B@E@)9>C2#<3X+8WB30\@!7;04/+#;E3KM:1YPJC@:P%T29X-G@B.E M&A,KZS2TS<)L:)&:@4(&0AEV&E!\6JF@&!'!+*O$+$&#'B[=F\]2X5N/H2 $ M+>B_&_7,3E&LMWL4V]C-KS!M\P"Q,>& I$,>((^HEHD%']7 02QCD%Q4!1.@ M _4X[7'!H5*'E&W=M$A[RPD+=\?8!=&Y,L@&W(?,H$$*%;\&M&**Z4/]'U@% M;$'49PEDC@)8!W?8 .F,(E#L.68![?D 8MZ>6UOFEK\+W&H/J4BMCT?@L3#$ MG=4A0$:O*2RF^>$&, M[YQ6$=73U!%CAN4C"VPPM>N1!;HQ$?R>B6R;;TD^_\U+M"LIK"V088,HZY,8Q] M(9;V)"2)>#_@H)\=Y "X!J%+8VB$OUB^31P$^S/EH+YU!FEBWX+J=_N=A__B MSD-30$$ (]I7^- 5=[1\S@"U6?HUW0$8,7J/^90K$&Q&94L;^S9GLJ_\+"YD MQ;K;!5P3$6@ '36;!H1'>9,51- %P ]U2]XE=1HR.G>2!NRUQF2!>.T._*X$ MBYWBP$YL#30A+PL5.-L\()+9$ &8MN\%,_#G75K#DZ$40X:Y34+[V>M-E445 M%@^$'#.X.XJDBR-T@5I A:TD?NN6= &DWWXP9>'96\!]\R*OGJ)["36M$$\" M>#+U0KGZO2F^K2.)[LS29EH5GW_::HM')3?D\J,JS/5?>-K%I8>-U_,3).C6 MQ>+YT*+S8<_RX5]RV$O:0ISI\\2I1U,C)PWVU*-KR3QX[?"D>%0\/BF7CV$A M3H[>GO8@:C%5\*40=*!9??)E!3RSH BH&_R/E?)/1X#W(3';^<"QN*MHZ/' M[U5JLWM/QQ>'K:4:8^F([OSUY!CO7)-;J2S4K'GR)]775NW@ZM>EP/^O M]OY*Q\Z+E/+VE/@_8'IY ],QZ.&)A'K$ R#V2SG+E\7T]V;H?]V^S+O.Z$3L M6TGRIFC_O8C]_P2'/>W9\[^7MYV[[O7-9?N6G%]_^OEC\VZ/]KU]NX;F]2?9 M]TC>V[=KN57[@?DIOG\DOW.?D1O%-,Y!M2+.0G(QK>NOW1;T4T7]TB_/ M_N4"=&VAM_1KN.W^FN\EBU3[^:KAX0\?SUXW["\RS_X&4$L#!!0 ( "*' MH4[9A[F)VP4 ##,R+FAT;>U:6W/:.!1^ M;G_%*9UVVAG -I"$ ,U,ELN&G2:DX&QG'X4M8FUERY5%"/OK]\@7 H2D)8%= MLDLF(>AZ+OK.YR/)C3>M7M/^X[(-GO(Y7%[]\KG;A%S!,+Z6FX;1LEMP9I]_ MADK1M,"6)(B88B(@W##:%SG(>4J%-<.83";%2;DHY+5A]PT]5<7@0D2TZ"HW M=_*ZH:M.7K]J>)2X^/]5XTVA "WAC'T:*' D)8JZ,(Y8< U?71I] PL*A5G/ MI@BGDEU["DJF=0Q?A?S&;DC60S'%Z4G[UF-#IAI&4D1A1BJM,13N%"(UY?13 M;B0"51@1G_%IS68^C>""3J O?!+4X[:(_45KEAFJNE;<93U6;4 MK)+YKAX2UT6#"T.AE/!K5CF\G=4I$285BMZJ N'L.JAQ.E+W=6SHFE76L<"C MDJT:,92HHZ[.5)U3.&Y;5_7*"D4+$74*6">)HVK1V/>)G&Y"^V:[;W<[W>:I MW>U=#!"R_<'5Z84-=@^L*EP5!\5F$0;MIFX&JWQ@S@K'YN&BV4^W, ;CG&[' MZQJC!\2E22)S*+B+,Z0@AG)I4YHZ&&!4;D'5,TJX\APB*?3UURGRPSA2T T< M(4,A=43OO!%-*A4;,8=H5H/+L8S&!*=48N I6SEX]3EJ5/E 4-FQ#AJ,W,'HG&,?1FF,"1PH7WK>"2XII@L^3Z+ M(NTZ_-4]7?0"X,04'3;OB\2-F2ORT,V#+5P7?BO".?9V45(>+B6-F%[<6$K3 M8W2$LE"V8C<4>B-D3_14&@FI=_-Q7YP.9VIZDD68SJ!\S/C&UYQ$^;D)?L?A M*V5T6$ "AQ'^H Q*' ^VXFJ+<:3(D-. M42O.T^CYE#-S<3D*B9.5TZ5?$6"/Y:=P/WU2&,_*S>:;,%=Y21#J5%2YNC'] M8L1=%[K?:-\YA*YP0%F&9::_3O5JID@A=%]E6<2D5391^6,7Z#W1< MP5#/)B3;HQGGC,8<";-HE/3[F$FJ]S.1!DB4LI=5_D"09218!Q_< MCS-0W<7N+&Y39%G'Y4I=Q\$*O\1K:,00VR-MW44LO02D=0-\!OE).HK/0$50 MJ LLX?$,@H3IAV"(I*G1EM?-A'/ 83@G$B8VA B_*!^/&LV(%"=TX_U[3+/8 M:\P3L(J0REAFM$2RJURV ,+GIP\+:[N9_&$;6(_H-52 M%#RHPMSX!3^:F0EI^JC+\P("'0M\\5#$3*)_+?9;X]#')_*:!8EZ9*Q$5A'O M^).:A/N.CXM5\\ \Q.3I$!U1/7A7'PKI4EEP!.FO'/5NQ?*X:?[!(C,L#NM5KQQKO= M;[>Z]MD>Z7O[_C4D/W6;O'1XM,?PWKZ7AN&?.N[<=6"GVZ>2N9EMZDZ!8&_K M]FW=*3#_UQ=UGU-O*Z?6MT]G_>[ [EV>M?O0ZEW]^OETL,?[WKZ7EI6LOD?= M(WEOWTL[L7S*S?^/+J&67F)\SEN+V[H^67JQMVX[BU+OI[[:?@\5HYNWL,N0H7 B!=G=J# MUVZ?5657;'>RLO]DT!)L,2V3"DE5V7GZ Y"22%FD;J9D7= C<4DB2.(ROV]. M3$Q,_/)_GI\&VG>>I&$<_?D,?@!G&H^Z<2^,'O]\]ON=?VZ<_9_/_^N7_^?\ M_'_LFR^:&W='3SS*-"?A0<9[VH\PZVM_Z_'T#^TAB9^TO\7)'^'WX/R\N&EX MP1%%O1[M!3CHZ8R2>]2E)N_IT#0X9'K0>;[ P'A M,>P85 =P^ >F>B!XRZ M 7OH4C9Y6/GV[OCMHU34<_QZ;5K,B8/'Q]^X ]Q\O@1FJ;Y\5F6.2L*73RDY_>]:=&'(+W/"_;"]&-^ MZ:-XA7$.X#F&DUNZLB?K;A 7:HI'67WI**LIW$OJ"_>2FL)I]^$\C'IA$LS? ME&9/'\OK-3?SL/Y-/*Q[4]@]3[.RGY[OD\&'E'<_/,;?/XXORMO@[&UA]+T; MU[\FOU3WIKBF7GECXMJ*9<-D03D7 &\>LE>%:OHQSOJ#,+BO?_'X8EU;DVRFJ:5P%1=J;DF: M!JR>%?**+VQ536MZ_+Z!'^25NBX/PFY:_Y;\4LT[^'.WW]SCDZMU?<:[Y]__ M55^]XEK-37%W^- J?Q24YL6R\5,D9HV!DD#T8@+39(OG[98^LZFIE;S^E:+,4MX,S_1RS:U"&3[T!PVH&U^L MN6W @X:7R2LU-SRG):54%#<" '[\GZ]?;KM]_A0(K99F0=3E4Q9/8QU!-G-G M/@CC>_''<8DIM =14]?EEVH)>9CPKC1+&E]C"FGK)O& ?RP+S\IXH[A-+]?( M=OHP/.\.$EY3X5PS3B[7JX6D8=#R2_4:6$I!#2N-U7!^M>;&+(S.AT%2<^/D M2B/TE\"^'O*%>?-]D>WSO=9JZO.>:$48!C5V4XZ#2HF%@@ 72$*#&-16>&P0 M+; VF@6G6J*.%[N\VT",XDK-&T?I^6,0#"5C)2_?XC!J4)OUY1;T=SIZZL># M!I7ZJE =U8V:#-91G;$AC?<&Q9I?6E#1Y;5LJ&+XW"0/4!!0- @C+B=9<^;[ M$NM]\2#-8*=N=)IT>P[D12"ONRFGFAI&+WEHD+J@#N7U?-1>V8-<-+5!:?#Q0-=HW*>XCA,G"E=>K2/3!K69U?6O-&$E MW]0-S.12/4::ZS:^6"?F43<+GIM83%Y;8OPW2\!LH9KQ>XB[3?455^J0DB7\ M<0%-B^M37N]VAWBBNU3P_&#:PZ["N$[+[&B;-E;&XTB ^Z6@X;*#PZ>4Z MQ3IZJF]V+TL^9B]#_E&4X$G8K=)1>M]D8Q07Z^>IB^W?2H&ZV4(#J]?.]B>/ M:A2@2H%:P MJPG&%YJ[8^%+9\O4=$NW6Z-#-[N2 MY,6:VX9!PPQ,7*AKC9PZ+^R_:HEF?"^- M/36>($\+SE#"(BNDF>_#NI66"=^'MIV9S6PQ/8P.I'+S9_F^:&!87ZXFY06U,KM1A(WAL M6E025Q;02YRE_<7<(DO4B4F#_=VM,[SYTS\;7#SR2LT-_2:3J%]K$4VF]@N] M,O42(:Z.'93U/3ZY6(?H48,Y,&I$XX*%R>GU^EFI *M@A;1Y9CHI4%?1IL%* M:D=KZGCJB\GN"OZI2;%%8A9W?RP1,U&BT2!?9(C7&.!-ZK)60W:3;GK?,&,M MKBT@R:73]B8.>8P;7IE?:ICG+9SCU8OWC -IN8>H>3$IE[ &A5=/4-*QQ;?%\#6W1^EK#(F)#EXHK=2JC+-[GP2#K=X-$$*+X]/)A//LS 9X9 MNL8AJQFJB199Z%JNMU;DTWNO(A>F!D-QL>257O@0=O.A;E@XFBM2YT'*^J+I MSPT4,[FZ:/:^>&F\V7;T!@ O=0_6NH>=! M/>[R^)X)RSC,ZU;?/OS6<:?LX]%4-O'_,8LS ;\\R2: M[I>/Q7?QZ(_C9_]R'_=>M#1[&8B.?1#/.7\(GL+!R\5=^,13[8K_T&[BIR#Z ME%]+PW_S"PB&V2=1OU]ZX??)G:)/AX/@1 Q9!@/,=BS&V/F//\Y7*GBF%2KFSV=")UWJZ0GDIS;,]W?0?[-G40 M,UT"+8,4M;0<:@ P;?S\\A$H+V]FI/1*:H]S=Q6]SSQ6]IM=[8-QR, M3 \;+O6A8QL03:KC6-5Z+REX]ODOK5=9=O7K"AO0M0'QB*TC;'JVZ1!GVG_ M=^&TPLL*GGV6-6BORD7_SDL&\75B P.+=S($H85]$T_DU\"^/ZWPLH)%A<\! M;D4XO$CPR(LC%_R#P674X\__S5\JU7:1:W@^9#[!4/?@?C/,$VFM]#;1;4]4?XQC!Y_3>(?6=^)GX9!5*V\87K(-T25H($067%=P!N10M\L,!3QPA.8]Q4FT),3'TQ8L*[CI6/B)>+HP.;6>,$=$)85)=([.M%$4%JT:I;VS^6;2 MO^B59O83HY28#F&[MC8,77@42'] MINXXOFN5;+JLX-EG L"D/9,&+&H06=H@MDF#7*0[ED4MT_4\,2*4VA:&#&%L M,4ALBBHLL+A@WB#0=IN,&5EW6=S]PPV_A\(HZZ63 MASA!VO\F&ER52.0C&]G$ZYA!J.#8TQ=W@V]ERKI,DE!64S M =Q2,\6(OJV9%J0Z=@W39IJ/9@7.P:7MB)'P? M>1!YKDW %% 4E"U;5E"P*2)B2K2-EJTR;G,M$X- A0E(Q?S,US$T;&JY4PPQ M5!KNRPK*EID(ZN\U9M>C3"YCRUV"535HN28V'1<0UW5\X "F^Y-:^YB4B%M6 M\+T'KKYY'F8$&(R:IN\Q8OH0&70*)(^5CIGB>-.OX?X[;] MP^7WV6649DD^H[2>P_0?_>0?=SQY^A*+%HXX @A]Y?)ATWN^Q-%C)DK(>Z4K M*;]K[Z-F" 4,%?IF-,!,2@M)2D905W;5NLW5**@(FIY?C(P&(20G0&O2E% UI. M-I<5W*%Y,=O(!2I8QPC[+K&9XV'?,H M/DUQ[E$ID@LDJD\\E!;?9P!5'<$X90^:81-A&EF4XAIB8^)194VQY M5D5;+2DH1//=AFVN50[&+M0M"!P$/1MY -E3QA!:MYR=+2NXE5:M.%;U^M4O ]!ZR^:81:.C4M:30(NC-UWV=X4F,F M>*/TZ"XI6-NTC[.K+=.8NO3S+S*J-P],>0I$4[0\3/VB7X1U)>>39>(/S])7 M4ER445>B&\*GX8"??2P>7GUB_C6-1TG^+0^'O!AW5M'>BB,B7XPJBO#6UR@V\<,_/>-)GKU0J,'W?Y(=QS]1UU%BHK&$B727[UU-%)&LV M;KA^CNCTD>,K&S9\"J>];W1UM-MHM*3'_6ZT,5E);*?1%8_K'K9[A@N,];C M:)4+*ATUG8CEAK><7GGY[G^Y9!5'XFLZ,UVS>KU0:H%@(-VXEY$3#,,L&(RG M;;OJ]&F/\D=9X_RGXK>>>//S88I)02+[SIQ&N\RY,38J?I^CQ,-<^TX& VSO%2EK5Y&.&[TB M /K)/YS1TV@09.%W/EWS.RH,]).+QB9N#P;[,L!3[=_M%IW >]UQOR&D"M8G,R]5$K$W1/^NQIN:@Q^<)G\;K:LQ M/DI:WWQE1OEFWLLWLT?BL^&,7\G.'OCUWM43H/QZ!S2T-8'9:G3?RLS?3^F>.^K[3<7'Z45 ME)BH)8+W730Z9*%0YL51"L5XJXB:/N[!]+'E#3&;#:TR%'8; /:.0ZZ4_I$/ ML)H[OOO<<5]$0=ER!SG &[A_%=;W .O[XQ96>OT !G@\-?__@J@<8SL8R,.] M;ON<9U_BXER"UTB7AZ&DWX(7F03+BGKBEV3$>U_"X#X<",N6'QC!-S5Y!N4K MMGEO9^_5XFTM_J9)]H^;('HLTJO);U^#Y_!I]/0J&YO5^^.W)([$QVX.NCF5,BYT*]/-!$DO_7W8$_66B8@!.@P9$YUR,>VBL\_R MZTP?+9*7-41XK1Z>D^O%77R Q+9 0O_&P\>^T-;6=YX$CUQ)Z@))K>TK);%[ MHXISB_.(U6Y]^TY!Q6XN#E::\NPX):':M%,0@JFOI<;."B-E9RVSLZI]I+36 M5IU%2D*5A.ZE7;6(0]5<57^[<7"Q%'_1&W>PZN>7)][#+)[Y5 M>6!/,/C"@Y3_.@H2\<:7PQ&KND;E[M3&5NVM@;>%V*AE0_\U3+M\(&QD'H\. MQ+1?..@U[3F9X384TM\'Z>^_QWH5I =1\)AK/Y\?U++I8KPWM4JA7@W]L:-^ MA:'_%B1_"+OV: :]ICTG,]PKD+P:[M,B=F6]'P6Z)[[.W$(/!EXJ8X6L[K]& M89J'7!AMB_MG+E&YX+^P& M@^N'!P%:>Q0.Y$%-E2=/0]Q^Y?%C$@S[LG3A%,V&R3]<1XGB!L[-W%FZT9@5 MG-H\:"U4K''(SS[+,;]PG=T!$1D*B"L!\?)* ?'4@'AY=8! =(\\#$"5ZG4L MCM99.JH6;SM;LANFPS@-!K\F\6CH#((T%:)9LZ-GIMQO?-![B!/Q50J9N"1? M$48CWKL6E0FJ.)[<7RS)3@>ANL]&[F&>YB&2#QO$Z2CAJ?TR\])4/&(PDC)1 M_\()]B^CH?A!O..&]X/[PU!%D\CB):-1AB!O.!QOQ-'D[;L9S)P4ZD;S -?J MYI+5*-PIW"G"NW2T-A;I#UC QVS!4B[[<'T/5^K]E1IS1?_B MCWS=#)&\NGX8^&S#S)T?LU,V/Q;FXY*8G4X^@8)7BO\$%/_LVZZWY6^FH]K9X2D[:EF<,4XU6SC[6[#+^WPZE8Z<"& MLUG#U"8N/L Q73L!\[YJG!4SF1[@$.V(1;>>?JZ>%%6V]"V"=8UIPV'F3-R? MV-E"BY.11,K$4W7+HU M-LYXVAL)V"'\BD._Q-%CQI,G>?N\]ZF\^S!H<1JQ-=<9N1.GJ3=:8LFZOJQX M5EYWY@$Z9E>4NCO1"=+'5G0R6D?DI)]M]"0?<#QB5]L=.Y&YVMX\5+F;B:2M ME;NJ,\1 M_P\S/^C*LRA?W+S/P3H2^"6,^/5#\9BC$,%5NF8GXCC?LX:E[5MI97A9O,?7N&UW-6U=81S]%:===O??Z:H>SI#T+ MNEX)<&H]^S37L_=(5N?G,6^G^+IGI+\&8?0E3E/[Y3?>>PRCQQL^*-) ]L/A MS-.=(.W[@_C'N-RKAX]_=7D:/D8U*4S'O_.>E8Z+EI4X-)2\.[MO-I)EY6J' MLJ6ZU0M")7OJOG6TK"5<2?C1S]!H) M/WK)5"*Q8]([%,'8)F4=E7@8BC'VBS$.WTPJ)V6'(A3;FG@>%5.T)Q:GPS9[ MX-'8>\)[?\E^J^=#2;:2[/U3Y6LM ?63?UC=XMKLB!UPG%PM;>8BN MVW6'^99GV8#WCME@RT.J%K3R (>YL@D#M>[ W&HDQI&'S^Z%9W2? S#V+>1V M;K-'JV+GJ:(*LE+6*-]Q)H*L;M%[/OO5*FF2%'CO6W$MI[AAJGAV]GP ML>VF:5/#=^@6[K=!$%T%3WRZ?"!;>!EU93V_F*B!N^ IR5J\ YH4E(Q.<[H0B1 M6JD76E@FV(,SNM_5&BOSVV%P&O$R^Q8,,I]_#:^7?PVWE7]M;-L)V$%S9JS# M7A@D+[?!@%\_Y+"=D-4L-@]/#FH;EA-07Z&7]I6I7H>M(;KS1;(;GF9)V,UXK^+F/%J3N,'36]L)+3RQ.3R77WFKC+4WLE0>\U-55-M)6XJB[>X;M**8;?OXK!]T^RHU-:VO4UA MI+Q-;_8V53M1268[DODW'C[V97*\[SP)'@]D2_.^2FAM9YZ$I+Y>*_.#,/EK M,!AQ^^4K#])1D@>7VT$:IK.!16D6/HD77S],[YA^<,.T.XCEO8XE&4G8Y2V M'R2\^MQ>^%T,7[5%\HZKT9,PY[*X:AF6;PK36$>07?Q^Z\Y7XC]FJC'[H,H; M7![%3V'4^([QF,CJILM>\NI9DTO3IBWLE]XT+4%==PO+NBRP9H\7E6\>Q*;& M+7[H#X'[X#'A.2P:JCQ;:,TWW(\W6C8\>[(/JAM_BA+ M^..%O+KN ^5^T*8.E=?6?-YPO)VUX9&3RVL^]8LHUE3+_-JRYWT,GR^$V,6C MI,O3XFN?!T+(Q6>!F,^_Y'^"HDM\#*CI >38@#H^H[9O6L@R&&"F0[$-S\1- MP'CZ=:?V$/_SY[#]3P!Q*'(Q\A&S3LPSB MVDS4T 2865BW3?&6=!A$&[_H\YT\5E"+'S29%$6@20!6/K#:\$KS[Y./E>^- M/3$,>A)#YUD\O-"'SY^D$C@/!N%C="'7*WA2J10$16=5GC>Y?< ?L@LPN3^, MI![.OU=?&,7)4S"8>2649<0CL[QM73X8C*_^^0R8V%F&8]3121@_#GLUP"LY[\DTROCBM<><6"4M\%".7.[_&+ M[N,LBY\F=2J^7<#ALY;&@["GY7(!P*>9$4"B-ZO=6_T^?D+UIZ(7Y"_CMXSO M>?6*V2&/13T?!O&/BW[8$\/\:3RX1#QE7E16E_CQ'?_O?T(*/DTENY#J:8=] MS.5D3MK;D6YC[2K+._*O/XIWWL>#GGC$[U>7=YZKW=Y9=][M;%,6578WE;OU MG-]O+N\NO5O-NG(U[W^FERZ27KMW=M+Z[_>N;K]JD MDL5?H9FC.,HMZ+!;V*J,$:1#2#FF^OF//\[]H)N=&ZZ)@6.[)O 1)-BR/0L5 M2MIR -.=,RT*Y(2NQ\,+-^[FB;?DVKQ@^F+Z<2-5:<7S7M>@A96'X/POTPZ> MJ?;G:I/>UD/:"&ZM9TVL_R34![3KB/V]2BPF=')#MT9)A@98:%K0T*UY? M,O5U3 [1*RW9$[,C];J5JVN)OXG'RD>G\_<\UQ@)!]2RU?7?7WZW;NZ\FR]_ MUVZ\;]N[K2[:TVH\SNALS6(M>L;#9*?>C]KU[YV]YNG533] M5,M;SIV\#$VLMVUCC7MMU4G$FI9AG:**$RWK<^U?HR 1[QB\:(572^." GH7 MV@:$W_ FP5S=?F&98MC1I'IJ[^%K:)-WZ^KKFS=54M&XHO$F&H]/A<;O;JRK MV\N/ZT " YQ :!)W '&FM^7FE)8LGU#JFTPDUQJ9/; I-W8*&8=D^$#/K M\80:>LRO3JB]?(GPAC^&J412)D/0-YA8-\S>?O.L+W>_.=:-)]A+?/R[=G?S M^^V==GGE7-\(-K/N/+>]B7=#)5J:>+>'@I^\9S%,^2!(QWS9^5J0:NF0=^5: M=$\+(RW,4JW;SPW5GS>T'>N=HT>)K(->.D;F>.%EMW;FAG!L7"XYTO&D2!AE!H+PD["1 0/(:#)_5UE; MVW4_M.9*S3-&:\)NCN4!\]H_1TF8]L)N;CO'#XT\NXNZA5$W3H9Q$A25$55, M'H,H_'?^_6>%PV,1PO(R'>K/#VC$=F!!/MS+6 ,03:WWB::5[4TZSO M/!KQ/>F178ZX$NUW4I'M2?+M*!1F&@-@3UJMQ%>)[QKB>Q6D_>_A8, [VAV/ M(IZFG&N8(8#WI!N4/)^ /+=YMQ[?Y%Z_9Y]P_M26[>^-'G^7JCC-9+REB7G^#/!;S[0:H]A /> MTX+!0)20:3)2\>^_1F$B?LQB[9Z/"X@'W_)\P;*X%6*Y5EC$/8H)FGR#N#X2 M]0V%W'K/W;[,]J19W4Q>EG&/6F\DLTKE18<)[_*<2R'2GD3[^JGVDWC>@_A_ M.NKVM;0O,W8DD\#"K!]DU6B='\%L-64=BQO'C?BYHP513_L)55IZS[GHY]'] M/T4[Y$UY>7&GK,;X87*#4YK7(J]ED&::";1>\))^:(K]^SM/ZT(!UXJL;1K6 MYV5/6T-$FNI_%6^M^G6APB<%U76!*:54".A3F&5"KH4%TLV2.)+],7C1N.B; M%^U2UBSHYAX0-\B"(IKS%63+9PQ'B!M#K.M M@TI!:&T(":$-M($PAK@6=(6=)7/("!F3LI1(G5#[JQ;%T7GMA508=N+C6*U( MH>_&3Z(%+U+[B:<)C2'MKD?M,8E_9/W)U0]"&?*\:CW^$$9YD'SNR)3S"P0^ M-54POPP_38HM+=!8O4DYB:AQV8:J3DJ&44$0$-V?HXE*K^KQ#QM-?0\H?.WL M\QWXW!;ZHNBIJ=)X#Q1-U*C"45WO>/6ZNO7>VAM3L@T[\6&!02;= MM[5F9/A0-PG+IU["Z(KB?.8T2@MC3@QUOE>];NNCL ?ENP8RX:CV(Q2OE@,6 M\1_24DSX]S#-C;@HB+IA,)"VGTQ&*@O+9(^](.FE8FH5R\2#L].VL=M%@_BG MX.=:P^QXQ6*/_6DWK^8<:9\/!E.@_B2$*#?]B]UDBRWK[<]Q%WIG#M.Y5&?? MMKXVT>+N@AUO?A1FHAB&>:S).9_SQ.X"HHH!L*DRLM5GD$9?+\TX-<,,K^?!8^ M9Q?1Z*D79^."9Y\A,CL(ZAV(R61?[J2)Y6K7AAVG%=4J4E+*%FIY$[6X;-V' MU86VRLU+=U,?\0K;@62B1-O/1#F?[')_8HP:M,),WM5^4@KG(S^_3WCPQWGP M($3Y(AC\"%Y2.03]9#;1[0II9%6BVPT2W6Z\Y>_7..L'3]H7^:A.*NST\U2T MX6%Y&,A:*1/>0H^O4]8LD?AQ@[[R7CAZJF]18ZH6F1MR)L?B8=1[@P1>;WC; M!AF]WMX[S>;->H$MK8_7 N T=>"=97_Q9'XCY_KJSKNZVRR)[JOJFNOVG[F1 M[7W01LHXQ@=_,'6"(7ICD,_R+:!P08 G]I>;H01YA'FU"9XVE*=Q#@EF7:9A[JB3_[4)7D9%?-24;S&@#N9 MV-:U([DQ;1VP#9I[QN-CEZ7=VP>B/>AQ*YD@3U?SU#"3VX-N;O0OK=/1ZW0M?-T! M:L_'P0/*T6U;UWV'6*[ON8Z'&"GQ@ M(,_AU6[[G!\UPC;O>86WP\5;.FIV,J:#8?9QM94%_/\3BN M2@.F2HTE_9"743=^XB>(K.4]CA2R#A993:/N&=!EMN4 XIE(]QPQZL4Q/M2' M1,C UC39+.J<^&F8\+X\EO4[/UT,+A\-K#!XL!@LQ]GUD$U= *FP69!O00>8 M7C'.'L1B)K$-[29AYOUK%,K#/X\66.MTL:Z@=+!0:B)0W8$$$#$-9Z8\F\XV M=*@7\3J&RZ#C[4J=!6E?\\5HGN(4;?D8$(6\@T5>.ETB&++*R[-M#;7*- :HWB@,;M:Q %CSE=3#/UN&':'14G&\G=KE84 M#%[2,%?A)KIN M(> 8OI,O"&&=&D@'N!W^T;"BG@,:LK_(#5FAL%:D=TNRB/AA,/DN26@0IR,9 M7A_QI)-@TNM\>[0* M)#T%4P8XS$0FT'7;Q0XU#,LRK5P*+2+-/5L%DI[JN'WAC\&@,&3R1(&G:,DL M[V5TDJY=4W>PZ3 +>0+ P]C1[J;1+\XPL(S]19B52JL87W83\D[Z/Z5'@U- M)E:(DU,$]O(./FY@5WJ"8=?1#=?'.M,I\1P3NW+Q"ONV2SRXP<1X[+U QPO; M[?;>[U&1QXK+M+JWP:#(]5$$#.7.A=_3?)_^6#4?,WS7Z>CC!FP3D2%D4=OR M3"A#.GS+I":%DLAT0!S"*&K)%4D_O+*QVS7@3\ITW_Z0><_]\#X\R5B,Y9V+ M6EH,/7 ?G&KK<;;U_9)YO[,_U769@X!K^P81M@)V78?I.?(109X-R2[]J;>B MGX-LE.S3SHF]"*Y\S_R]FZN7=L0/&;6*9VLYS59(5J%RFFV0T^R5>.IK$?H; M$EQ]LV[NM,L/FG]Y95TYE]87[?)*I@:S[BZOK]9/-;75ZI\U), J$^XM3X0P M(YP;-D=?J3F+DF7I]8-17=58' <]U_05MJROUO0M)]<[^_P;#P99OQLD,NVK M^/BBW26C-,MW!2;#>/'I .TE"5M1/:^[57\G2%DE@6%^]T68B;[I?I)'9C_) MI.*I3#F=]>.1N+F7=C3^W.7#3&8J+S+ :J)QP?3LRDH[9O3KWJ8[>W/"5;E MOCC/V:)<9K#YDKG179M=6NU=>S5!W;+=6,ECMU]>"K:XL58B^/]5\5IT_QX% MHUXH>.D4SYU][P'>__"1 VSH.H,ZF\YZ/M?TH:!Z8:;;W/:MIKM5"#\A87!Y ME\O#QN?EP=@K?]W&]OCK?C#K^\&ZO?5>)Q%^)R7PAO3VQ^Z7WAPA>>3!NU-N1L&ZU'?_UAD9L M4N=\>-Y:Z27G71%#IYQ@.CWORM,A=7W=,FQ;APZ#2*=6D;O%L8'+O,EY5Z/T M_#$(AA=R<&=/M?+'QUI53K0:I;WJ<5;G>'J>%5YXGA7"H(, 77:6U1KCL6[@ MS=IXKEE_.!5J5FC>#S03,D4S=J#!+->V# Q=ZC(76LX$S3Y#9$4T&W_1%9J/ M4SG;HW @WY=VM/!)'B$[SF$F WX'/$BY%D99$#V&]P.>+C')MK%O=@_PQ, 4 M3P;Q',O'2/5_MZ:"L4= M1E@'47 ,L#L!)7KL8#+,*9A*P@HSSAFQ$?VM2"S :VJU/3 MP6PZ1[(,LAY6VE$T BO45#.EO=(R,K8O2T9C<8JDLGE,>'J:DR*JEP#"%K0< MUX'(,:F./6[2=/MS7]TT,'H*)"DM,[! M@X:R*6BHYQ ?.3[2$39UY-H6\"9:Q_1LO"%H6IKGX X$[!A 7YCFF2J=,.,6\.:K*GK>]! M.)"!Z'Z<5*"WO94NO4/U-A&W;%B5&ML#-7:VT=NPU]*ZU,E@[R1#PX_3EF2H!)ENZ![VY396TP'8,YG0<),)F.?[ M_FN0R> Y+X^=*UWJ$Y>&E3EQNCT]IW< %<8E,X[!N%0H.G@4Z66L!*.6A:E- M+6$4 @0)U8M43Q)%!C.=5E#4UCJ4R022&#P&%!W1%$W,R;6@VQT]C0;Y#N > M'R9BS(+IV3'!4RQ:]N_9[,:G93O^M 21M$0DL'1?QBTQG6+==0R:GRY3&(^6 MXBOM[!]F=^E[34P6Q02J.3H*0 M;S";^9[ON";VA((=JU7;-NWM@+BE9;@.@$18J[H"\=N5-MG'K45GG^_B+!AH M2>U^HHX6\;?Z5_<5PHL1;(#2?^HB"AR/NC[R/=?R# %G,@UZ-.E!15_"P,4:A34S=\2JCI&QYQT306Q9B?HFV*HG9TE-'!QLDZ/O=2/UEIRK.T M#$Y)Q2B>\-2IXOSPJ -<8/FVT$T^$S8?I6QB][F&8U1BBXM._$WTH1\G\O@- M@3!Y,+"H01B->*\\:WR;6X+1/O\@NO9%5OG[X/>4Y!K>GI)#1 M@?I1V(!*2^TS?,8'$Q^20!T-78^3VRNZ?DW7%)=T[5!F,H,XMN-1[.HNP!:F M)O!%20.1.?=7T:=\IV0M#"&B=OTJJE94?;14?9V)EH\Y^73]/A 5(9D T"9 M+G?%FJYG6ZY.)\&DCFVZ_MR:>=Z%QV8S(QV#MAG+HKA83?9M- %\%;BV8# MS>V=#<3#PV>M%X_DT4-O";Y<(Q'X>^:S7*O]K3=WAR0S$RM@NQ#ZEDY-4S?$ MQ F8YG1_!_;=UR2S96V,.YBB#D%MQ@,L'=)6Q%-I\S:/)54T= (T5 FVT&5V M#X20XPBK!]H$>,YTFYF%_+D=T5LV_?[O^XGHWM_];\_[R^^7=WT_\Q(434$,G,Y;'.^7Y M$@;WX2!4Q]THP!Y36X]G%_A5G/$B?_Y]'/52;1B\R&0VZLR,??9&PDIJ/F!B M3"W@4!TCU]$Q]HQIOC 7S.]W^Q)'CW<\>7+Y_19C7CI8%[8Z5'G\#X#,%+#W M!]A&Z0%$'C1,RZ+4,!W=U%UL^F R]0:V-Q?=M@38;>TQQSKIF,91K,L=CQ:W MNMUX) _"&:OO(GU+MYN,>$\;E#;X:2[>">DOU:7C^)CHC/DZ@,S%ONM/'5KB MUSEU.>G9;T7'6E'/*KJU,K-Q1DG"HTQ0J?A9\;/BY^/EYV(#7WNL?*AI MK9>Q-JF>&HL$-UN$64)L/0\#,:^='GKI-VQ9JLQEMW?""NW 5@WJO3W-2!'Z M\2..5<)R;& 9OHZ("9EO^]3UF3]!'*/Z7 [=%1#7CD-(9QVZQ6T\>X2XXXVJ M+382JGF)6>(-(M/2(7" "6WL(ENWR?2$6I=B8X&C=HM1<(30#E,.HV/37P>* M%QU6]I=:S".^*XQ$1\"#V+H%X 0O$.GSQ\SN0#7!CL[T#@7D&/!R)-KG[+,3 M/SV%>4[_(DZ\6+QZY%'W9!6/CFDE:2[U9$)WY", 7&8P&TT7WFU?GYM:5;I3 M9J6N=N9JBN@Y#2^B<"":GLB\U0W(BO-'19EH41.8-B1ZI8&4!MH8.*3,W@EM M,26RL6';CN[XE@N0-ST'%C$R=U[>>L"IT4@G"YPC444U$Z';+.[^T1>?>9+^ M[_RLD>Q%[3,\^O:=S%@>C]/^6\(?>))PV0Z!V8[V7Q\ U(9!HGV7YV]H0YYH M:3](^">-@ X H/@F3,Y1UH\3\:#>)TV0,=?"-)6[&J0I&H^R-!,?1#M.4Y\2 M6-&G!!(# M>RL:4;.K",,@*4POD9W71$#E1:),2VH0RAR*=8ELW?!?YAF.4)UA:V*R;6\;1 M-A3AG(L3F4=QT(K2A8?@(W=N6^P*@&EK M30"1H]@8=#Q3.4N\38Y",! *,.R=AY'6#89A%@Q.%$=FB2-$/.H)O6.9CFG: MQ+8A,J8XYU$J)DG:($Z/=?'ZIV5 PY5MXX8-= B89WG0I,2Q$*43H#DNJDO: M,.G6/&+1J7;J923ZF'\1/>ORAS#B/9M'XD/V35Z.(RLJ[OD6IUG"LS#A( MHQ,73-'*('+>'ZTM'4<+VO21' 96CT?U.H7,22T;\4P+FW9#[U;-]UJ0,H]8GO.PQ/ .Y[%JX<'%WVLH!C M@66KTL5W<<7X'??O%K4K,'$'J'2?2FGN!Z0J'AG/Q( YNN_HT+)=W]89GH:9 M8:H;K4.J+;\G,(P./(Y,?T>IV\1+0H'5WJEN/UUFN J#= I"!R.#&,QGIN6[ MGB'^LZ9+[5\Q, MWT8.M7Q?AR:QC>G!EL0QY[RNJZ&TI0,N.X0@H0_;G!@>!TJ/-[J[V.::UL1X MGRB8EV&Y$@&#D?C&&-0AQ,0"'L/ZU.P%!IY;B*P:M5[>QUN<+1J =!AKT[3= MVTWH2H<>/^RJ<33089;O4>+HU!=_'-NO.'!LL!'LVII1,D@[5-^E!CVH&>+9TO.M6+:)-SH)IXQ#7?>"=2OH+WZ<^DHF_7:@;)B8, M.&SJY3+\17F*K:BW0^7_+@=)*^W_3GL-%9\<$)\8E?0@V/1]!WK8(H 2:%!, M@#WA$^*S1<<)K,HG!WPB]/N:-1_SU8CI[_G?2G4&8<3/^X7- !'XTVMITX6T M[:;*[U^INSZ7QV#%3^+&%[F?)I+'77:T+'[D>5#8CS#K:^*35IR#F<7Y%R>. M39_<36,QG?DK\CW;K%/J69%T4C<<<.'<9)I M FN^$&$-@O/_SL\LD;>\\"#1>"0?,NFVM=LWV0A4$/1D-]#&C^MH02+/#A.M MROACD@=XR^H_R JG7'N8=D4Z[8H/O<#0G(PM8<&.) M@*]0E?_M)Y-G#(-'?GZ?\."/\^!!5/$B&/P(7E+QIH_]9-RZ("?.U#)] Q/? MGIF-)BORT53 EU4]X3S'3+HK:6%36*E@6K-4N6%A/P.+G(R>GAX=.9 MUD\DH_YG"I@C)J(8^0C9IF<9Q+6E46@"S"RLV^9:_5?SHL]W>3"'$ ^9C4,* MP[1S@SEZ:I**1:/^B@:,Q6/^:YSU@R?MBWQ4)PVB]#P5;7B8>\!O/!AD_:X4 M]1OY\46[2T9IILD5WT3@5:)^=2+;V/X85_"I*(4L$3,[Q4 M82,Q L5R]3Y5VQ_SW#(V6OF!=T*N>6M/T[Z*'_JIYJW$P"L^MCI?CZ31,A!O MRC=PSC"TV5XKY.2_M:>MHCQ6KUH;PM@*Y(MO\NX+N2L@[(I'_F0]%2=FY@H\ M'HF;>\(PX,]=/LS*[;R:P%KP\^HM65U#O:'JOT?!J!<*#IA6K%*EF1D5F)A5 MH:20XGNUSF,9K,+?.RXFP] M?P-K\%I+W3VK2G M,N3&1G1VJ*N1-]Y?O:O?O5LEY\?>UF-OW\F,Y?$$X]\($@\&XPUFIRFUK;=O M[Q97]WWME#$=\VI:00-@ CQD0D]<,2UL8+,X6<$ E@[-)6?8IH4C=^KU+)_$1=&SJFA1QL.53@ MW\9H GN;.O-'[+T%]D:;L$=(;3+<*[NF.. RG@C(:5+<-/XB>Y,"]?\+?2H-,MD/*8)J./9#G40(!Y!/B7C',.^ MA4TZ%W+=#BK;T_P=PVSSH+6]1:5:2SJ>]FTU<W;+'@34H60+<=AK#HC2\@IF;X$9)N4N"&KX MT+--W[!\0P .F[ TO"VT#LQ:G+&C#D1M9IO=3Y@=[YJI]S_?O*M;M69ZY.ML M:BR/IZW'XUO\EDB_8O:BW(O'F@(QMV(8H!5'A:D#BSC(Q ;PB(Y=#">3!@HCH-7 MD#IX2*%R8@"H97K0URV=85TGGL,(F4!*6,UV^Y!J;?Z@PXXA@Q0/'U+'HY1_ MY1&7NVWE9JZ@]Q1&89HE>6(]Q23'R"0$E"G](:0^\6S?P\2UB U@S@N(]#^4>T6TJ8Z-#5(9OA:"]0! UIPBR@>GKCF<31HF%=;'<+:3.:[QWKW>'!T[.T[Y0 V01GETB\AT#!,9 +DZ:[E^[XYC1/% MGCT7HS[=E#9VAFUU@FOJ'=3J0:_[&;;=Z-=7CG77SWMIW$4Z:F? MVW?LD8=J+(^GKB=//YWP8*#Q/"N\%J0I5VMG1^F@,"MG MU6/?I(;)$' 9!4'93/OIV*ZE&D]!:5HO)A1*?0<&'H* M+=1\:G6NAB" I:/:Y*)'O*]>4?Y1$1V$#$)<8<8;<9: MS\O96P9,G1NO$-:(,,PJ&X@H01[33WMAI:KMZ>' ML"-4V#(^),X3GQ7Y7#M:Q#-%+JMX8(\LR1($M)QE M,T*' TP$EODXQ1MXT MX R3N0C-/'?>51Q-M[<6B16WNHYU"EF4%.R.'W9&N9)E6Z9.30]8MNMYT/29 MS=A$Y>LNGE_)6AEV[6UD-+=WAO0> 4^%I1Q/^]Z58=Y]'7W9E ."MZ7TJ>D'\MG2>3[>0DFGI^*\U2VEEO5XY M"0X$[GN!:%1Q(@!L0^8@W6:8(N )"]Z?NNET:\ZB6 ?1Z]D4*R$:=2#;97K4 M8_$[;!&]VXZON?+N)M$UI\E7:P@P%@+W=>A!;&POQBCU&>6 8T)91/FSAMA/"N86J[R;W7/3LJP\JIYYMBT M@>_:R"$ZTAUCFM88^_-QK U$-IY5S?'9#LP3A+>0='$/9UD*F2> 3+T,5_0= M2 A@.G,L#]O4L75@3I#I0:"WC\RVC0S1FI- YC&9$6[X/11([Z5RT =B^'N= MN;6ICM8;)=*0R/I<7@SC$[4D]HBCE(?Y;<3+2I/(MPSH^(0BXE@68;X'RJ!, MPZ+F:^)UL'1U>>6O['#>K:=&F4**6A2U+*46L[3I MF&>;%C,\3X<.Q#:P#6)-J$5W\9Q-MR&UK+J2I:BEWI;[F 6B,M/?\[^5Z@S" MB)_WB\UV$($_S0@BE&*WA0K?"5LKZ HS3-SX(HVO*,YXVM&R^)'G>89^A%D_ MM\BNY 7Q>_[%B:,\ECZ0KB$_C(*H*R19NY6I266BTE3F)QJ,>N)J&(WOR%^1 MYWUDGU+-BJ*1N..&#^,DDUER?2$F&@3G_RT%)K_EA0>))F13/&32I6NW3X@S MES.6@A0Q[&A2D#=^7$>3053BIE!@XU&>1CT,9/4?9(53KCU,NR*==L6'67G( M_Q1B\EH"*N/;E:>>)Z\$=DY"%C#/QA*!7HEO_K>?3)XQ%)/ \_N$!W^PGX]8%.5FEG@%=9EL.()Z)=,_!E!8K5-2'1,=4WA/,=,NB MMI85-8J6!:LU2Y;NQH,XN"D>CB33J)+P.9CC@2:I6#3JKVC 6#SFO\99/WC2 MOLA'==(@2L]3T8:'N0?\QH-!UN]*49<9A[,7[2X9I9DF-PDE J_!G)-WL^HN MT8[CZG[EO7#T5%_?X@FB6M/T[Z*'_JIYJW$QRL^-O\VWE\>23-A(-[T-4BZ_1F^-MMK MA4R@U]K35E$EJU>M#6%LA0"*;_+NBS 3K^F*1_[DQ@-A%Z:%.H]'XN9>^O/J M5=Y%%7^/@E$O%,C?J%X3A5DI/3/? 1,#+)1D4WRO/FXLOS-&&RCF"KG=IW7Y M8#"^FMO%\KNH9G?RO:8S[L(G87-=\1_:3?P4S,T.?X2]K"\^BG:,3=^N'*5A MRB\F'^9DY6SJ4YRZQ:6::_(X%J]@^I\^G/7;W8)M/[$-[],)1$[GO9- MA9NUE%5H$V_ V(@O*\[6